,Gene/Region,"HGNC/Dosage ID",Cytoband,GRCh37,GRCh38,"HI Score","Haplo Disease","Haplo Disease ID","TS Score","Triplo Disease","Triplo Disease ID",OMIM,Morbid,%HI,pLI,LOEUF,"Last Eval."
R,"16p13.12 population region (gnomAD-SV_v2.1_DEL_16_152599)",ISCA-46484,16p13.12,16:14782199-14805000,16:14688342-14711143,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"1 copy: 14q telomere; 3 copies: 14q telomere",ISCA-37477,14q32.3,14:106050000-107289540,14:105583663-106881350,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,07/31/2014
R,"1 copy: 2q telomere|3 copies: 2q telomere",ISCA-37470,2q37.3,2:242930600-243102476,2:241988449-242157305,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,04/24/2014
R,"1 copy: 6p telomere | 3 copies: 6p telomere",ISCA-37471,6p25,6:259528-339802,6:259528-339802,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,06/20/2014
R,"10p12.1 population region (DGV_Gold_Standard_June_2021_gssvL11273)",ISCA-46638,10p12.1,10:27638256-27642180,10:27349327-27353251,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10p12.33 population region (gnomAD-SV_v2.1_DEL_10_108282)",ISCA-46426,10p12.33,10:17867999-17880000,10:17826000-17838001,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10p12.33 population region (gnomAD-SV_v2.1_DEL_10_108283)",ISCA-46427,10p12.33,10:17879999-17893800,10:17838000-17851801,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10p12.33 population region (gnomAD-SV_v2.1_DEL_10_108288)",ISCA-46428,10p12.33,10:18117799-18130100,10:17828846-17841147,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10p12.33 population region (gnomAD-SV_v2.1_DEL_10_108289)",ISCA-46429,10p12.33,10:18126899-18135000,10:17837946-17846047,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10p13 population region (DGV_Gold_Standard_June_2021_gssvL10668)",ISCA-46637,10p13,10:13259247-13260742,10:13217247-13218742,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q11.2 recurrent region (LCR C-LCR D)",ISCA-37497,10q11.22-q11.23,10:49389703-51053583,10:48181660-49845537,"1 (Little Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,10/12/2022
R,"10q11.22 population region (DGV_Gold_Standard_June_2021_gssvG4512)",ISCA-46639,10q11.22,10:47531763-47597768,10:46160527-46226532,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q11.22 population region (DGV_Gold_Standard_June_2021_gssvL12105)",ISCA-46640,10q11.22,10:48664595-48872432,10:47074765-47282602,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q11.22 population region (DGV_Gold_Standard_June_2021_gssvL12112)",ISCA-46642,10q11.22,10:48902069-48986229,10:47502722-47586882,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_109954)",ISCA-46430,10q11.22,10:46310649-46325800,10:45815201-45830352,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_109958)",ISCA-46431,10q11.22,10:46338599-46375000,10:45843151-45879552,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_109998)",ISCA-46432,10q11.22,10:47171999-47177000,10:46377769-46382770,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_109999)",ISCA-46433,10q11.22,10:47177699-47182800,10:46373069-46378170,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110000)",ISCA-46434,10q11.22,10:47191199-47201400,10:48009306-48019507,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110001)",ISCA-46435,10q11.22,10:47211299-47216400,10:48029382-48034483,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110016)",ISCA-46436,10q11.22,10:47748899-47754600,10:46377639-46383340,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110019)",ISCA-46437,10q11.22,10:47896499-47919300,10:50080601-50103402,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110021)",ISCA-46438,10q11.22,10:47927849-47935000,10:50111946-50119097,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110022)",ISCA-46439,10q11.22,10:47932799-47938200,10:50116898-50122299,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110031)",ISCA-46440,10q11.22,10:48020299-48039225,10:50205831-50224757,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110040)",ISCA-46441,10q11.22,10:48197999-48248000,10:46798971-46848972,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110043)",ISCA-46442,10q11.22,10:48239999-48247800,10:47499361-47507162,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110044)",ISCA-46443,10q11.22,10:48251999-48258000,10:47487361-47493362,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.22 population region (gnomAD-SV_v2.1_DEL_10_110072)",ISCA-46444,10q11.22,10:48806124-48812000,10:46933236-46939112,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (DGV_Gold_Standard_June_2021_gssvL12109)",ISCA-46641,10q11.23,10:51861706-52000736,10:50101946-50240976,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110193)",ISCA-46445,10q11.23,10:51219499-51231000,10:73668724-73680225,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110221)",ISCA-46446,10q11.23,10:51839699-51845100,10:50079939-50085340,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110222)",ISCA-46447,10q11.23,10:51845699-51850800,10:50085939-50091040,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110223)",ISCA-46448,10q11.23,10:51851849-51857400,10:50092089-50097640,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110224)",ISCA-46449,10q11.23,10:51858299-51864600,10:50098539-50104840,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110225)",ISCA-46450,10q11.23,10:51861999-51894650,10:50102239-50134890,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110229)",ISCA-46451,10q11.23,10:51967199-51974400,10:50207439-50214640,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q11.23 population region (gnomAD-SV_v2.1_DEL_10_110230)",ISCA-46452,10q11.23,10:51973199-51981300,10:50213439-50221540,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q22.1 population region (DGV_Gold_Standard_June_2021_gssvL13247)",ISCA-46643,10q22.1,10:71280815-71291303,10:69521059-69531547,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q22.1 population region (DGV_Gold_Standard_June_2021_gssvL13249)",ISCA-46644,10q22.1,10:71282906-71291092,10:69523150-69531336,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"10q22.3 population region (gnomAD-SV_v2.1_DEL_10_112166)",ISCA-46453,10q22.3,10:81604499-81610800,10:79844743-79851044,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"10q22.3q23.2 recurrent region (includes BMPR1A)",ISCA-37424,10q22.3-q23.2,10:81682843-88739388,10:79923087-86979631,"3 (Sufficient Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,05/15/2023
R,"11p11.2 (Potocki-Shaffer syndrome) region (includes ALX4, EXT2)",ISCA-37441,11p11.2,11:43894800-46152450,11:43873250-46130899,"3 (Sufficient Evidence)","Potocki-Shaffer syndrome",MONDO:0011022,"0 (No Evidence)",'-,'-,,,‐,‐,‐,12/12/2013
R,"11p13 (WAGR syndrome) region",ISCA-37401,11p13,11:31803509-32510988,11:31781961-32489442,"3 (Sufficient Evidence)","WAGR syndrome",MONDO:0008681,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,05/24/2016
R,"11p14.1 population region (DGV_Gold_Standard_June_2021_gssvG6305)",ISCA-46659,11p14.1,11:29007150-29012087,11:28985603-28990540,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.1 population region (DGV_Gold_Standard_June_2021_gssvG6192)",ISCA-46658,11p15.1,11:18940205-18963657,11:18918658-18942110,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.1 population region (DGV_Gold_Standard_June_2021_gssvL17400)",ISCA-46651,11p15.1,11:18941859-18964598,11:18920312-18943051,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvG5919)",ISCA-46656,11p15.4,11:3239311-3360988,11:3218081-3339758,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvG5957)",ISCA-46657,11p15.4,11:4255965-4278463,11:4234735-4257233,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvL16732)",ISCA-46653,11p15.4,11:4264092-4309730,11:4242862-4288500,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvL16737)",ISCA-46654,11p15.4,11:4255449-4278126,11:4234219-4256896,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvL16784)",ISCA-46655,11p15.4,11:4968688-4980232,11:4947458-4959002,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvL16881)",ISCA-46649,11p15.4,11:5873984-5883499,11:5852754-5862269,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (DGV_Gold_Standard_June_2021_gssvL16961)",ISCA-46650,11p15.4,11:7809752-7834885,11:7788205-7813338,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11p15.4 population region (gnomAD-SV_v2.1_DEL_11_116046)",ISCA-46454,11p15.4,11:4967746-4976658,11:4946516-4955428,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"11p15.4 population region (gnomAD-SV_v2.1_DEL_11_116124)",ISCA-46455,11p15.4,11:5873988-5883493,11:5852758-5862263,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"11p15.4 population region (gnomAD-SV_v2.1_DEL_11_116241)",ISCA-46456,11p15.4,11:7811175-7833378,11:7789628-7811831,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"11p15.5 population region (DGV_Gold_Standard_June_2021_gssvL16511)",ISCA-46652,11p15.5,11:1915245-1937002,11:1894015-1915772,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11q11 population region (DGV_Gold_Standard_June_2021_gssvL19042)",ISCA-46645,11q11,11:55445709-55457776,11:55678233-55690300,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11q11 population region (DGV_Gold_Standard_June_2021_gssvL19045)",ISCA-46646,11q11,11:55434253-55443984,11:55666777-55676508,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11q11 population region (gnomAD-SV_v2.1_DEL_11_119505)",ISCA-46457,11q11,11:55031602-55038540,11:55264126-55271064,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"11q11 population region (gnomAD-SV_v2.1_DEL_11_119564)",ISCA-46458,11q11,11:55364275-55444015,11:55596799-55676539,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"11q12.2 population region (DGV_Gold_Standard_June_2021_gssvG6800)",ISCA-46660,11q12.2,11:60966146-61020399,11:61198674-61252927,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"11q13.2q13.4 recurrent region (includes SHANK2, FGFs)",ISCA-37498,11q13.2-q13.4,11:67763646-71236931,11:67996175-71525885,"2 (Emerging Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,09/27/2022
R,"11q13.4 population region (DGV_Gold_Standard_June_2021_gssvL19865)",ISCA-46647,11q13.4,11:71850646-71889330,11:72139602-72178286,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"11q14.3 population region (gnomAD-SV_v2.1_DEL_11_121860)",ISCA-46460,11q14.3,11:89762999-89783400,11:90029831-90050232,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"11q14.3 population region (gnomAD-SV_v2.1_DUP_11_33042)",ISCA-46459,11q14.3,11:89520077-89657031,11:89786909-89923863,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/09/2021
R,"11q22.2 population region (DGV_Gold_Standard_June_2021_gssvL21098)",ISCA-46648,11q22.2,11:102751106-102752862,11:102880376-102882132,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"12p11.1 population region (DGV_Gold_Standard_June_2021_gssvL24290)",ISCA-46665,12p11.1,12:34355893-34361543,12:34202958-34208608,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p11.23 population region (DGV_Gold_Standard_June_2021_gssvL23860)",ISCA-46664,12p11.23,12:27647940-27654731,12:27495007-27501798,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p11.23 population region (gnomAD-SV_v2.1_DEL_12_126677)",ISCA-46465,12p11.23,12:27648141-27655163,12:27495208-27502230,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12p13.2 population region (DGV_Gold_Standard_June_2021_gssvL23179)",ISCA-46667,12p13.2,12:10581251-10597043,12:10428652-10444444,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.2 population region (DGV_Gold_Standard_June_2021_gssvL23223)",ISCA-46661,12p13.2,12:11191681-11217625,12:11039082-11065026,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.2 population region (DGV_Gold_Standard_June_2021_gssvL23228)",ISCA-46662,12p13.2,12:11227081-11251139,12:11074482-11098540,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.2 population region (DGV_Gold_Standard_June_2021_gssvL23231)",ISCA-46663,12p13.2,12:11224984-11240896,12:11072385-11088297,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.2 population region (gnomAD-SV_v2.1_DEL_12_125567)",ISCA-46462,12p13.2,12:10581544-10597003,12:10428945-10444404,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12p13.2 population region (gnomAD-SV_v2.1_DEL_12_125568)",ISCA-46463,12p13.2,12:10581599-10587675,12:10429000-10435076,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12p13.2 population region (gnomAD-SV_v2.1_DEL_12_125610)",ISCA-46464,12p13.2,12:11225999-11250600,12:11073400-11098001,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12p13.31 population region (DGV_Gold_Standard_June_2021_gssvG7792)",ISCA-46668,12p13.31,12:8558090-8596215,12:8405494-8443619,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.31 population region (DGV_Gold_Standard_June_2021_gssvG7850)",ISCA-46669,12p13.31,12:8361522-8391789,12:8208926-8239193,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"12p13.31 population region (gnomAD-SV_v2.1_DUP_12_33971)",ISCA-46461,12p13.31,12:8361449-8390896,12:8208853-8238300,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12q12 population region (gnomAD-SV_v2.1_DEL_12_127735)",ISCA-46466,12q12,12:40874766-40876424,12:40480964-40482622,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"12q23.3 population region (DGV_Gold_Standard_June_2021_gssvL26928)",ISCA-46666,12q23.3,12:105369015-105374180,12:104975237-104980402,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"13q12.11 population region (DGV_Gold_Standard_June_2021_gssvG9718)",ISCA-46672,13q12.11,13:21534913-21541123,13:20960774-20966984,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"13q12.12 recurrent region (includes SACS, SGCG)",ISCA-46298,13q12.12,13:23544582-24881361,13:22970443-24307222,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,04/26/2021
R,"13q21.1 population region (DGV_Gold_Standard_June_2021_gssvL30434)",ISCA-46670,13q21.1,13:57768508-57786942,13:57194374-57212808,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"13q21.33 population region (DGV_Gold_Standard_June_2021_gssvL31119)",ISCA-46671,13q21.33,13:72476988-72489787,13:71902850-71915649,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvG10810)",ISCA-46675,14q11.2,14:19596713-20418095,14:19010800-19832182,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvG10817)",ISCA-46679,14q11.2,14:20190229-20426809,14:19722070-19958650,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvG10827)",ISCA-46680,14q11.2,14:20335536-20423298,14:19867377-19955139,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvG10899)",ISCA-46681,14q11.2,14:19462329-19469848,14:18685852-18693371,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvL33520)",ISCA-46678,14q11.2,14:20190699-20425231,14:19722540-19957072,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (DGV_Gold_Standard_June_2021_gssvL33589)",ISCA-46677,14q11.2,14:19462304-19469872,14:18685827-18693395,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q11.2 population region (gnomAD-SV_v2.1_DEL_14_140616)",ISCA-46467,14q11.2,14:24467999-24474000,14:23998790-24004791,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"14q11.2 region (TCRA region)",ISCA-37476,14q11.2,14:22111109-23021097,14:21642889-22552154,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,04/09/2015
R,"14q11.2 region including CHD8 and SUPT16H",ISCA-37438,14q11.2,14:21826900-21861987,14:21358741-21393828,"2 (Emerging Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,05/09/2012
R,"14q13.2 population region (DGV_Gold_Standard_June_2021_gssvL34350)",ISCA-46676,14q13.2,14:35605396-35615320,14:35136190-35146114,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32 region associated with UPD(14) phenotypes",ISCA-37449,14q32,14:100394594-101504529,14:99928257-101038192,"2 (Emerging Evidence)","paternal uniparental disomy of chromosome 14",MONDO:0011975,"0 (No Evidence)",'-,'-,,,‐,‐,‐,05/10/2012
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvG12097)",ISCA-46682,14q32.33,14:106118177-106145774,14:105651840-105679437,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvG12117)",ISCA-46683,14q32.33,14:106826451-106850917,14:106370520-106394986,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvG12133)",ISCA-46684,14q32.33,14:107147166-107164532,14:106691149-106708515,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvG12150)",ISCA-46685,14q32.33,14:106805092-106814699,14:106349168-106358775,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvL37239)",ISCA-46674,14q32.33,14:106483725-106508484,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"14q32.33 population region (DGV_Gold_Standard_June_2021_gssvL37313)",ISCA-46673,14q32.33,14:107172848-107183396,14:106717601-106728149,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"15q11.2 population region (DGV_Gold_Standard_June_2021_gssvG12224)",ISCA-46686,15q11.2,15:20388741-22207639,15:20183488-22002386,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"15q11.2 population region (DGV_Gold_Standard_June_2021_gssvG12359)",ISCA-46688,15q11.2,15:21145101-21164300,15:20939772-20958971,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"15q11.2 population region (gnomAD-SV_v2.1_DEL_15_145826)",ISCA-46468,15q11.2,15:20729174-20745525,15:20523935-20540286,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q11.2 population region (gnomAD-SV_v2.1_DEL_15_145837)",ISCA-46469,15q11.2,15:21042049-21056300,15:20836720-20850971,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q11.2 recurrent region (BP1-BP2) (includes NIPA1)",ISCA-37448,15q11.2,15:22832519-23090897,15:22782170-23040134,"3 (Sufficient Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,04/12/2021
R,"15q11.2q13 recurrent (PWS/AS) region (Class 1, BP1-BP3)",ISCA-37404,15q11.2-q13.1,15:22832519-28379874,15:22782170-28134728,"3 (Sufficient Evidence)","Prader-Willi syndrome",MONDO:0008300,"3 (Sufficient Evidence)","15q11q13 microduplication syndrome",MONDO:0012081,,,‐,‐,‐,11/26/2013
R,"15q11.2q13 recurrent (PWS/AS) region (Class 2,BP2-BP3)",ISCA-37478,15q11.2-q13.1,15:23747996-28379874,15:23465365-28134728,"3 (Sufficient Evidence)","Prader-Willi syndrome",MONDO:0008300,"3 (Sufficient Evidence)","15q11q13 microduplication syndrome",MONDO:0012081,,,‐,‐,‐,11/26/2013
R,"15q13 recurrent region (BP3-BP4) (includes APBA2)",ISCA-46285,15q13.1-q13.2,15:29156959-30368990,15:28916886-30076787,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/09/2020
R,"15q13.2 population region (DGV_Gold_Standard_June_2021_gssvG12633)",ISCA-46687,15q13.2,15:30488097-30796070,15:30195894-30503867,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"15q13.2 population region (gnomAD-SV_v2.1_DEL_15_146428)",ISCA-46470,15q13.2,15:30381948-30438500,15:30089745-30146297,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.2 population region (gnomAD-SV_v2.1_DEL_15_146452)",ISCA-46472,15q13.2,15:30692999-30725200,15:30400796-30432997,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"15q13.2 population region (gnomAD-SV_v2.1_DEL_15_146453)",ISCA-46471,15q13.2,15:30432998-30883100,15:30140795-30590897,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.2 population region (gnomAD-SV_v2.1_DEL_15_146464)",ISCA-46473,15q13.2,15:30825199-30853100,15:30532996-30560897,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"15q13.2 population region (gnomAD-SV_v2.1_DEL_15_146467)",ISCA-46474,15q13.2,15:30847949-30883100,15:30555746-30590897,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DEL_15_146609)",ISCA-46476,15q13.3,15:32692999-32698000,15:32400798-32405799,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DEL_15_146612)",ISCA-46477,15q13.3,15:32743999-32755100,15:32451798-32462899,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DEL_15_146614)",ISCA-46478,15q13.3,15:32774999-32780000,15:32482798-32487799,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DEL_15_146625)",ISCA-46479,15q13.3,15:32864999-32898000,15:32572798-32605799,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DEL_15_146627)",ISCA-46480,15q13.3,15:32886199-32898000,15:32593998-32605799,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"15q13.3 population region (gnomAD-SV_v2.1_DUP_15_39790)",ISCA-46475,15q13.3,15:32690774-32734250,15:32398573-32442049,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q13.3 recurrent region (BP4-BP5) (includes CHRNA7)",ISCA-37411,15q13,15:31192889-32445405,15:30900686-32153204,"3 (Sufficient Evidence)","chromosome 15q13.3 microdeletion syndrome",MONDO:0012774,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,04/28/2018
R,"15q13.3 recurrent region (D-CHRNA7 to BP5) (includes CHRNA7, OTUD7A)",ISCA-46295,15q13.3,15:32019621-32445405,15:31727418-32153204,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,05/10/2018
R,"15q14 population region (gnomAD-SV_v2.1_DEL_15_146738)",ISCA-46481,15q14,15:34710126-34856557,15:34417925-34564356,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q14 population region (gnomAD-SV_v2.1_DEL_15_146739)",ISCA-46482,15q14,15:34726357-34872885,15:34434156-34580684,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"15q24 recurrent region (LCR A-LCR C)",ISCA-46296,15q24.1-q24.2,15:72963715-75508312,15:72671374-75215971,"3 (Sufficient Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,01/03/2020
R,"15q24 recurrent region (LCR A-LCR D) (includes SIN3A)",ISCA-37396,15q24.1-q24.2,15:72963715-75972909,15:72671374-75680568,"3 (Sufficient Evidence)","chromosome 15q25 deletion syndrome",MONDO:0013672,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,08/31/2018
R,"15q24 recurrent region (LCR C-LCR D) (includes SIN3A)",ISCA-46300,15q24,"15: 75631787-75972909",15:75339446-75680568,"3 (Sufficient Evidence)","chromosome 15q24 deletion syndrome",MONDO:0013256,"0 (No Evidence)",'-,'-,,,‐,‐,‐,01/13/2020
R,"15q25.2 recurrent region (proximal LCR B-LCR C)",ISCA-37500,15q25.2,15:83213988-84714733,15:82534140-84045981,"3 (Sufficient Evidence)","chromosome 15q25 deletion syndrome",MONDO:0013672,"0 (No Evidence)",'-,'-,,,‐,‐,‐,10/13/2016
R,"15q25.2q25.3 recurrent region (distal, LCR C-LCR D)",ISCA-37514,15q25.2-q25.3,15:85139652-85713001,15:84596421-85169770,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,06/26/2020
R,"16p11.2 population region (gnomAD-SV_v2.1_DEL_16_153568)",ISCA-46489,16p11.2,16:28715099-28771000,16:28703778-28759679,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p11.2 population region (gnomAD-SV_v2.1_DEL_16_153573)",ISCA-46490,16p11.2,16:28764999-28772000,16:28753678-28760679,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p11.2 population region (gnomAD-SV_v2.1_DEL_16_153860)",ISCA-46492,16p11.2,16:32655999-32802000,16:32644678-32790679,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p11.2 population region (gnomAD-SV_v2.1_DUP_16_42022)",ISCA-46491,16p11.2,16:32019999-32096000,16:32008678-32084679,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p11.2 recurrent region (distal, BP2-BP3) (includes SH2B1)",ISCA-37486,16p11.2,16:28822635-29046499,16:28811314-29035178,"3 (Sufficient Evidence)","distal 16p11.2 microdeletion syndrome",MONDO:0013267,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,02/13/2024
R,"16p11.2 recurrent region (proximal, BP4-BP5) (includes TBX6)",ISCA-37400,16p11.2,16:29649997-30199852,16:29638676-30188531,"3 (Sufficient Evidence)","proximal 16p11.2 microdeletion syndrome",MONDO:0012756,"3 (Sufficient Evidence)","chromosome 16p11.2 duplication syndrome",MONDO:0013847,,,‐,‐,‐,02/09/2017
R,"16p12.1 population region (DGV_Gold_Standard_June_2021_gssvL43366)",ISCA-46689,16p12.1,16:25066146-25137378,16:25054825-25126057,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p12.2 population region (DGV_Gold_Standard_June_2021_gssvG14372)",ISCA-46691,16p12.2,16:21512076-21595577,16:21500755-21584256,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p12.2 recurrent region (distal)(includes OTOA)",ISCA-46297,16p12.2,16:21570113-21740423,16:21558792-21729102,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 22",MONDO:0011762,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,11/03/2019
R,"16p12.2 recurrent region (proximal) (includes EEF2K, CDR2)",ISCA-37409,16p12.2,16:21948445-22430804,16:21937124-22419483,"2 (Emerging Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/23/2018
R,"16p12.3 population region (gnomAD-SV_v2.1_DEL_16_152900)",ISCA-46488,16p12.3,16:18414999-18421000,16:18321142-18327143,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"16p13.11 population region (gnomAD-SV_v2.1_DEL_16_152730)",ISCA-46487,16p13.11,16:16329599-16364350,16:16235742-16270493,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/23/2021
R,"16p13.11 recurrent region (BP2-BP3) (includes MYH11)",ISCA-37415,16p13.11,16:15511711-16292265,16:15417854-16198408,"3 (Sufficient Evidence)",'-,'-,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,04/13/2021
R,"16p13.12 population region (gnomAD-SV_v2.1_DEL_16_152600)",ISCA-46485,16p13.12,16:14782999-14853150,16:14689142-14759293,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"16p13.3 population region (DGV_Gold_Standard_June_2021_gssvL41949)",ISCA-46690,16p13.3,16:1289937-1295280,16:1239936-1245279,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16p13.3 population region (gnomAD-SV_v2.1_DEL_16_151010)",ISCA-46483,16p13.3,16:59999-65000,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/09/2021
R,"16p13.3 region (includes CREBBP)",ISCA-37406,16p13.3,16:3775056-3930121,16:3725055-3880120,"3 (Sufficient Evidence)","Rubinstein-Taybi syndrome due to 16p13.3 microdeletion",MONDO:0012519,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,06/09/2016
R,"16q22.1 population region (gnomAD-SV_v2.1_DUP_16_42449)",ISCA-46493,16q22.1,16:70094243-70242956,16:70060340-70209053,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16q22.2 population region (DGV_Gold_Standard_June_2021_gssvG15245)",ISCA-46692,16q22.2,16:72088515-72116064,16:72054616-72082165,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"16q23.1 population region (DGV_Gold_Standard_June_2021_gssvG15270)",ISCA-46693,16q23.1,16:74387937-74459162,16:74354039-74425264,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvG16012)",ISCA-46702,17p11.2,17:16660760-16707833,17:16757446-16804519,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvG16017)",ISCA-46703,17p11.2,17:16711572-16724682,17:16808258-16821368,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvG16067)",ISCA-46704,17p11.2,17:18361739-18423872,17:18458425-18520558,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvG16095)",ISCA-46705,17p11.2,17:18359814-18376676,17:18456500-18473362,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvL48375)",ISCA-46699,17p11.2,17:16711606-16724681,17:16808292-16821367,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvL48476)",ISCA-46700,17p11.2,17:18418589-18465114,17:18515275-18561800,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (DGV_Gold_Standard_June_2021_gssvL48488)",ISCA-46701,17p11.2,17:18359790-18376723,17:18456476-18473409,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (gnomAD-SV_v2.1_DEL_17_159047)",ISCA-46494,17p11.2,17:18329998-18465150,17:18426684-18561836,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 population region (gnomAD-SV_v2.1_DEL_17_159095)",ISCA-46495,17p11.2,17:19014999-19054000,17:19111686-19150687,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17p11.2 recurrent (SMS/PLS) region (includes RAI1)",ISCA-37418,17p11.2,17:16810028-20213202,17:16906714-20309889,"3 (Sufficient Evidence)","Smith-Magenis syndrome",MONDO:0008434,"3 (Sufficient Evidence)","Potocki-Lupski syndrome",MONDO:0012574,,,‐,‐,‐,11/21/2013
R,"17p12 recurrent (HNPP/CMT1A) region (includes PMP22)",ISCA-37436,17p12,17:14097915-15422952,17:14194598-15519638,"3 (Sufficient Evidence)","hereditary neuropathy with liability to pressure palsies",MONDO:0008087,"3 (Sufficient Evidence)","Charcot-Marie-Tooth disease type 1A",MONDO:0007309,,,‐,‐,‐,10/13/2016
R,"17p13.3 (Miller-Dieker syndrome) region (includes YWHAE and PAFAH1B1)",ISCA-37430,17p13.3,17:1247833-2588909,17:1344539-2685615,"3 (Sufficient Evidence)","Miller-Dieker lissencephaly syndrome",MONDO:0009532,"3 (Sufficient Evidence)","chromosome 17p13.3 duplication syndrome",MONDO:0013182,,,‐,‐,‐,11/10/2016
R,"17q11.2 recurrent region (includes NF1)",ISCA-37431,17q11.2,17:29097069-30264027,17:30780079-31937008,"3 (Sufficient Evidence)","chromosome 17q11.2 deletion syndrome, 1.4Mb",MONDO:0013357,"2 (Emerging Evidence)","chromosome 17q11.2 duplication syndrome, 1.4-mb",MONDO:0030032,,,‐,‐,‐,10/12/2020
R,"17q12 population region (DGV_Gold_Standard_June_2021_gssvG16427)",ISCA-46706,17q12,17:34502940-34524192,17:36175580-36196832,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q12 population region (DGV_Gold_Standard_June_2021_gssvL49126)",ISCA-46698,17q12,17:34509779-34551554,17:36182399-36224174,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q12 recurrent (RCAD syndrome) region (includes HNF1B)",ISCA-37432,17q12,17:34815072-36192489,17:36458167-37854616,"3 (Sufficient Evidence)","chromosome 17q12 deletion syndrome",MONDO:0013797,"3 (Sufficient Evidence)","chromosome 17q12 duplication syndrome",MONDO:0013796,,,‐,‐,‐,06/16/2022
R,"17q21.2 population region (DGV_Gold_Standard_June_2021_gssvG16538)",ISCA-46707,17q21.2,17:39531718-39539732,17:41375466-41383480,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (DGV_Gold_Standard_June_2021_gssvL49379)",ISCA-46697,17q21.2,17:39383317-39396444,17:41227065-41240192,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (DGV_Gold_Standard_June_2021_gssvL49383)",ISCA-46694,17q21.2,17:39384291-39392558,17:41228039-41236306,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (DGV_Gold_Standard_June_2021_gssvL49384)",ISCA-46695,17q21.2,17:39422988-39430527,17:41266736-41274275,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (DGV_Gold_Standard_June_2021_gssvL49386)",ISCA-46696,17q21.2,17:39429150-39433594,17:41272898-41277342,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (gnomAD-SV_v2.1_DEL_17_160287)",ISCA-46496,17q21.2,17:39383999-39395000,17:41227747-41238748,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (gnomAD-SV_v2.1_DEL_17_160290)",ISCA-46497,17q21.2,17:39421793-39432145,17:41265541-41275893,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.2 population region (gnomAD-SV_v2.1_DUP_17_44064)",ISCA-46498,17q21.2,17:39531966-39539289,17:41375714-41383037,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.3 recurrent region (includes KANSL1)",ISCA-37420,17q21.3,17:43705166-44164880,17:45627800-46087514,"3 (Sufficient Evidence)","Koolen-de Vries syndrome",MONDO:0012496,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,08/10/2020
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160658)",ISCA-46499,17q21.31,17:44368999-44380000,17:46291633-46302634,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160659)",ISCA-46500,17q21.31,17:44381699-44387000,17:46304333-46309634,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160662)",ISCA-46501,17q21.31,17:44399099-44405700,17:46321733-46328334,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160663)",ISCA-46502,17q21.31,17:44401199-44418450,17:46323833-46341084,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160664)",ISCA-46503,17q21.31,17:44403899-44409900,17:46326533-46332534,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q21.31 population region (gnomAD-SV_v2.1_DEL_17_160670)",ISCA-46504,17q21.31,17:44637999-44653000,17:46560633-46575634,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"17q23.1q23.2 recurrent region (includes TBX2, TBX4)",ISCA-37501,17q23.1-q23.2,17:58113002-60275809,17:60035641-62198448,"3 (Sufficient Evidence)","chromosome 17q23.1-q23.2 deletion syndrome",MONDO:0013238,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,11/20/2018
R,"18p11.21 population region (DGV_Gold_Standard_June_2021_gssvG17388)",ISCA-46711,18p11.21,18:14432553-14565138,18:14432554-14565139,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"18p11.22 population region (DGV_Gold_Standard_June_2021_gssvL52196)",ISCA-46709,18p11.22,18:9784172-9793224,18:9784175-9793227,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"18p11.31 population region (DGV_Gold_Standard_June_2021_gssvL51911)",ISCA-46708,18p11.31,18:3568883-3571730,18:3568885-3571732,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"18q11.2 population region (DGV_Gold_Standard_June_2021_gssvL52661)",ISCA-46710,18q11.2,18:23747759-23751695,18:26167795-26171731,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"18q21.1 population region (DGV_Gold_Standard_June_2021_gssvG17872)",ISCA-46712,18q21.1,18:44542290-44558084,18:46962327-46978121,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19p12 population region (DGV_Gold_Standard_June_2021_gssvL57316)",ISCA-46716,19p12,19:20594811-20725405,19:20412004-20542598,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19p12 population region (DGV_Gold_Standard_June_2021_gssvL57428)",ISCA-46718,19p12,19:22087099-23141940,19:21904297-22959138,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19p13.12 population region (DGV_Gold_Standard_June_2021_gssvL57062)",ISCA-46715,19p13.12,19:15727731-15787718,19:15616920-15676907,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19p13.2 population region (gnomAD-SV_v2.1_DUP_19_46817)",ISCA-46505,19p13.2,19:7019174-7060500,19:7019163-7060489,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19p13.3 Critical Region 1 (CR1)",ISCA-46748,19p13.3,19:19:-19:3116922–3494377,:-,"0 (No Evidence)",'-,'-,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,,,‐,‐,‐,10/10/2023
R,"19q13.12 population region (gnomAD-SV_v2.1_DEL_19_172006)",ISCA-46506,19q13.12,19:35850999-35863275,19:35360097-35372373,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.3 region (PSG gene cluster)",ISCA-37483,19q13,19:43242796-43741310,19:42738644-43237158,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,03/13/2014
R,"19q13.31 population region (gnomAD-SV_v2.1_DEL_19_172625)",ISCA-46507,19q13.31,19:43700966-43764809,19:43196814-43260657,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.31 population region (gnomAD-SV_v2.1_DEL_19_172626)",ISCA-46508,19q13.31,19:43700999-43716000,19:43196847-43211848,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.32 population region (DGV_Gold_Standard_June_2021_gssvL58890)",ISCA-46714,19q13.32,19:46622342-46628475,19:46119085-46125218,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.41 population region (gnomAD-SV_v2.1_DEL_19_173443)",ISCA-46509,19q13.41,19:52127999-52139400,19:51624746-51636147,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.41 population region (gnomAD-SV_v2.1_DEL_19_173445)",ISCA-46510,19q13.41,19:52134299-52149000,19:51631046-51645747,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.41 population region (gnomAD-SV_v2.1_DEL_19_173549)",ISCA-46511,19q13.41,19:53316224-53323725,19:52812971-52820472,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (DGV_Gold_Standard_June_2021_gssvG19479)",ISCA-46717,19q13.42,19:56280630-56289562,19:55769264-55778196,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (DGV_Gold_Standard_June_2021_gssvL59370)",ISCA-46713,19q13.42,19:53939389-53976651,19:53436136-53473398,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173749)",ISCA-46512,19q13.42,19:54800855-54807620,19:54297004-54303769,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173800)",ISCA-46513,19q13.42,19:55245599-55250700,19:54734133-54739234,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173801)",ISCA-46514,19q13.42,19:55250753-55267130,19:54739307-54755684,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173802)",ISCA-46515,19q13.42,19:55251599-55257000,19:54740153-54745554,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173803)",ISCA-46516,19q13.42,19:55256999-55289000,19:54745547-54777548,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173805)",ISCA-46517,19q13.42,19:55274849-55281600,19:54763397-54770148,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173806)",ISCA-46518,19q13.42,19:55277999-55288000,19:54766547-54776548,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173807)",ISCA-46519,19q13.42,19:55285999-55293000,19:54774547-54781548,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173809)",ISCA-46520,19q13.42,19:55292999-55298000,19:54781547-54786548,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173811)",ISCA-46521,19q13.42,19:55301499-55324000,19:54790047-54812548,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173812)",ISCA-46522,19q13.42,19:55314899-55323600,19:54803444-54812145,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173816)",ISCA-46523,19q13.42,19:55360499-55370000,19:54849044-54858545,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"19q13.42 population region (gnomAD-SV_v2.1_DEL_19_173817)",ISCA-46524,19q13.42,19:55367999-55373100,19:54856544-54861645,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"1p13.3 population region (DGV_Gold_Standard_June_2021_gssvG1423)",ISCA-46558,1p13.3,1:108917312-109000328,1:108374690-108457706,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p13.3 population region (gnomAD-SV_v2.1_DEL_1_6959)",ISCA-46322,1p13.3,1:108923349-108996100,1:108380727-108453478,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p13.3 population region (gnomAD-SV_v2.1_DEL_1_7022)",ISCA-46323,1p13.3,1:110230194-110254581,1:109687572-109711959,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p21.1 population region (gnomAD-SV_v2.1_DUP_1_1884)",ISCA-46321,1p21.1,1:104190999-104303200,1:103648377-103760578,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p31.3 population region (DGV_Gold_Standard_June_2021_gssvL2940)",ISCA-46567,1p31.3,1:62654661-62657211,1:62188989-62191539,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p31.3 population region (DGV_Gold_Standard_June_2021_gssvL3013)",ISCA-46568,1p31.3,1:64839912-64851868,1:64374229-64386185,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36 terminal region (includes GABRD)",ISCA-37434,1p36.33-p36.31,1:834083-6289973,"1:898703 -6229913","3 (Sufficient Evidence)","chromosome 1p36 deletion syndrome",MONDO:0011929,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,05/31/2016
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1834)",ISCA-46313,1p36.11,1:24283999-24291000,1:23957509-23964510,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1937)",ISCA-46314,1p36.11,1:25592799-25651000,1:25266308-25324509,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1938)",ISCA-46315,1p36.11,1:25593699-25610200,1:25267208-25283709,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1939)",ISCA-46316,1p36.11,1:25613999-25621000,1:25287508-25294509,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1941)",ISCA-46317,1p36.11,1:25630899-25636000,1:25304408-25309509,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1943)",ISCA-46318,1p36.11,1:25639499-25650000,1:25313008-25323509,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1944)",ISCA-46319,1p36.11,1:25644399-25649500,1:25317908-25323009,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"1p36.11 population region (gnomAD-SV_v2.1_DEL_1_1945)",ISCA-46320,1p36.11,1:25654999-25661350,1:25328508-25334859,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"1p36.12 population region (DGV_Gold_Standard_June_2021_gssvL1420)",ISCA-46566,1p36.12,1:22313123-22335712,1:21986630-22009219,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.13 population region (DGV_Gold_Standard_June_2021_gssvL1195)",ISCA-46565,1p36.13,1:17009445-17012777,1:16682950-16686282,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvG371)",ISCA-46557,1p36.21,1:12897609-12922238,1:12837756-12862385,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvL1108)",ISCA-46563,1p36.21,1:16151690-16155602,1:15825195-15829107,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvL1109)",ISCA-46564,1p36.21,1:16152667-16155517,1:15826172-15829022,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvL889)",ISCA-46560,1p36.21,1:13692847-13774442,1:13366389-13447984,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvL891)",ISCA-46561,1p36.21,1:12886641-12942069,1:12826782-12882210,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (DGV_Gold_Standard_June_2021_gssvL905)",ISCA-46562,1p36.21,1:12899395-12924283,1:12839542-12864430,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (gnomAD-SV_v2.1_DEL_1_1085)",ISCA-46309,1p36.21,1:12896424-12930275,1:12836571-12870422,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (gnomAD-SV_v2.1_DEL_1_1089)",ISCA-46310,1p36.21,1:12949999-12966000,1:12890169-12906170,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (gnomAD-SV_v2.1_DEL_1_1094)",ISCA-46311,1p36.21,1:12989199-12998900,1:12929369-12939070,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (gnomAD-SV_v2.1_DEL_1_1100)",ISCA-46312,1p36.21,1:13043099-13052800,1:13040162-13049863,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.21 population region (gnomAD-SV_v2.1_DUP_1_507)",ISCA-46308,1p36.21,1:12894999-12940000,1:12835148-12880149,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.33 population region ((DGV_Gold_Standard_June_2021_gssvG23))",ISCA-46554,1p36.33,1:713039-756009,1:777659-820629,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.33 population region (DGV_Gold_Standard_June_2021_gssvG23)",ISCA-46556,1p36.33,1:713039-756009,1:777659-820629,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.33 population region (gnomAD-SV_v2.1_DEL_1_11)",ISCA-46306,1p36.33,1:363999-401750,1:455336-493087,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1p36.33 population region (gnomAD-SV_v2.1_DEL_1_195)",ISCA-46307,1p36.33,1:1640999-1647000,1:1709560-1715561,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.1 population region (gnomAD-SV_v2.1_DEL_1_7699)",ISCA-46324,1q21.1,1:146025999-146089000,1:147017931-147080932,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.1 recurrent (TAR syndrome) region (proximal, BP2-BP3) (includes RBM8A)",ISCA-37428,1q21.1,1:145386507-145748064,1:145686999-146048495,"1 (Little Evidence)","thrombocytopenia-absent radius syndrome",MONDO:0010121,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,05/18/2017
R,"1q21.1 recurrent region (BP3-BP4, distal) (includes GJA5)",ISCA-37421,1q21.1-q21.2,1:146577486-147394506,1:147105904-147917509,"3 (Sufficient Evidence)","chromosome 1q21.1 deletion syndrome",MONDO:0012914,"3 (Sufficient Evidence)","chromosome 1q21.1 duplication syndrome",MONDO:0012915,,,‐,‐,‐,04/14/2016
R,"1q21.2 population region (DGV_Gold_Standard_June_2021_gssvL5122)",ISCA-46569,1q21.2,1:147856152-147913592,1:148383996-148441436,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (DGV_Gold_Standard_June_2021_gssvL5133)",ISCA-46570,1q21.2,1:149152064-149204067,1:143657400-143709403,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (DGV_Gold_Standard_June_2021_gssvL5166)",ISCA-46571,1q21.2,1:149207851-149218151,1:143713202-143723502,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7778)",ISCA-46325,1q21.2,1:147433599-147455000,1:147961367-147982768,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7781)",ISCA-46326,1q21.2,1:147559999-147630500,1:148087722-148158223,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7795)",ISCA-46327,1q21.2,1:147931899-147982900,1:148459777-148510778,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7798)",ISCA-46328,1q21.2,1:147944999-147955500,1:120900178-120910679,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7859)",ISCA-46329,1q21.2,1:149368999-149433200,1:143874448-143938649,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 population region (gnomAD-SV_v2.1_DEL_1_7863)",ISCA-46330,1q21.2,1:149396649-149406100,1:143902073-143911524,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.2 region (polymorphic region)(non-unique; also maps to chromosomes 16, 7, and others in GRCh38)",ISCA-37469,1q21.2,1:148867551-149768855,"16:34632766 -36224317","40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,10/22/2020
R,"1q21.3 population region (DGV_Gold_Standard_June_2021_gssvG2465)",ISCA-46559,1q21.3,1:152761495-152773537,1:152789019-152801061,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.3 population region (DGV_Gold_Standard_June_2021_gssvL5433)",ISCA-46572,1q21.3,1:152554926-152575348,1:152582450-152602872,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.3 population region (gnomAD-SV_v2.1_DEL_1_8075)",ISCA-46331,1q21.3,1:152555541-152587740,1:152583065-152615264,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q21.3 population region (gnomAD-SV_v2.1_DEL_1_8087)",ISCA-46332,1q21.3,1:152760519-152771091,1:152788043-152798615,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q23.3 population region (DGV_Gold_Standard_June_2021_gssvL5778)",ISCA-46573,1q23.3,1:161570323-161598180,1:161600533-161628390,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q23.3 population region (gnomAD-SV_v2.1_DEL_1_8646)",ISCA-46333,1q23.3,1:161529258-161610923,1:161559468-161641133,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q24.2 population region (DGV_Gold_Standard_June_2021_gssvL5980)",ISCA-46574,1q24.2,1:168024558-168025732,1:168055320-168056494,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q25.2 population region (gnomAD-SV_v2.1_DEL_1_9549)",ISCA-46334,1q25.2,1:179455597-179458296,1:179486462-179489161,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q32.2 population region (gnomAD-SV_v2.1_DEL_1_11282)",ISCA-46335,1q32.2,1:207708749-207718050,1:207535404-207544705,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/16/2021
R,"1q41 population region (DGV_Gold_Standard_June_2021_gssvL7905)",ISCA-46575,1q41,1:222373208-222381462,1:222199866-222208120,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q43q44 terminal region (includes AKT3)",ISCA-37493,1q43-q44,1:243287730-245318287,1:243124428-245154985,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 22",MONDO:0012869,"0 (No Evidence)",'-,'-,,,‐,‐,‐,10/12/2016
R,"1q44 population region (DGV_Gold_Standard_June_2021_gssvL8766)",ISCA-46576,1q44,1:248756880-248797809,1:248593579-248634508,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (DGV_Gold_Standard_June_2021_gssvL8958)",ISCA-46577,1q44,1:248755655-248758478,1:248592354-248595177,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DEL_1_13885)",ISCA-46337,1q44,1:248712454-248757403,1:248549153-248594102,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DEL_1_13888)",ISCA-46338,1q44,1:248728999-248743000,1:248565698-248579699,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DEL_1_13889)",ISCA-46339,1q44,1:248730999-248798200,1:248567698-248634899,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DEL_1_13890)",ISCA-46340,1q44,1:248737999-248744000,1:248574698-248580699,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DEL_1_13898)",ISCA-46341,1q44,1:248806699-248819725,1:248643398-248656424,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"1q44 population region (gnomAD-SV_v2.1_DUP_1_3816)",ISCA-46336,1q44,1:248619999-248647000,1:248456698-248483699,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"20p11.22 population region (DGV_Gold_Standard_June_2021_gssvL71898)",ISCA-46720,20p11.22,20:21486525-21496720,20:21505887-21516082,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"20q11.21 population region (DGV_Gold_Standard_June_2021_gssvL72187)",ISCA-46719,20q11.21,20:29509040-29536079,20:30274364-30301403,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"21p11.2 population region (DGV_Gold_Standard_June_2021_gssvG23340)",ISCA-46724,21p11.2,21:10704853-10982352,21:10807602-11085101,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"21q11.2 population region (DGV_Gold_Standard_June_2021_gssvL74506)",ISCA-46723,21q11.2,21:14957505-15202003,21:13585184-13829682,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"21q11.2 population region (gnomAD-SV_v2.1_DEL_21_178681)",ISCA-46525,21q11.2,21:14980399-14986100,21:13608078-13613779,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"21q11.2 population region (gnomAD-SV_v2.1_DEL_21_178682)",ISCA-46526,21q11.2,21:14995199-15001200,21:13622878-13628879,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"21q11.2 population region (gnomAD-SV_v2.1_DEL_21_178683)",ISCA-46527,21q11.2,21:15012799-15034700,21:13640478-13662379,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"21q22.3 population region (DGV_Gold_Standard_June_2021_gssvL75982)",ISCA-46722,21q22.3,21:44969018-44974013,21:43549137-43554132,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"21q22.3 population region (DGV_Gold_Standard_June_2021_gssvL76000)",ISCA-46721,21q22.3,21:44970333-44971747,21:43550452-43551866,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/04/2021
R,"21q22.3 population region (gnomAD-SV_v2.1_DEL_21_181010)",ISCA-46528,21q22.3,21:47580927-47582908,21:46161013-46162994,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.2 recurrent (DGS/VCFS) region (proximal, A-B) (includes TBX1)",ISCA-37433,22q11.21,22:18912231-20287208,22:18924718-20299685,"3 (Sufficient Evidence)","DiGeorge syndrome",MONDO:0008564,"3 (Sufficient Evidence)","chromosome 22q11.2 microduplication syndrome",MONDO:0012020,,,‐,‐,‐,08/31/2018
R,"22q11.2 recurrent (DGS/VCFS) region (proximal, A-D) (includes TBX1)",ISCA-37446,22q11.21,22:18912231-21465672,22:18924718-21111383,"3 (Sufficient Evidence)","DiGeorge syndrome",MONDO:0008564,"3 (Sufficient Evidence)","chromosome 22q11.2 microduplication syndrome",MONDO:0012020,,,‐,‐,‐,08/31/2018
R,"22q11.2 recurrent region (central, B/C-D) (includes CRKL)",ISCA-37516,22q11.21,22:20731986-21465672,22:20377696-21111383,"2 (Emerging Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/30/2022
R,"22q11.2 recurrent region (distal type I, D-E/F)",ISCA-37397,22q11.21-q11.22,22:21917117-23649111,22:21562828-23306924,"3 (Sufficient Evidence)","chromosome 22q11.2 deletion syndrome, distal",MONDO:0012740,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,12/08/2022
R,"22q11.2 recurrent region (distal type II, E-F)",ISCA-37488,22q11.22-q11.23,22:23119414-23649111,22:22776924-23306924,"1 (Little Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,01/19/2023
R,"22q11.2 recurrent region (distal type III, D-G/H) (includes SMARCB1)",ISCA-46292,22q11.21-q11.23,22:21917117-24994433,22:21562828-24598466,"3 (Sufficient Evidence)","rhabdoid tumor predisposition syndrome 1",MONDO:0012252,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/27/2023
R,"22q11.2 recurrent region (distal type III, E/F-H) (includes SMARCB1)",ISCA-46747,22q11.22q11.23,22:23119415-24994433,22:22776925-24598466,"3 (Sufficient Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,01/25/2023
R,"22q11.2 recurrent region (distal type III, F-G) (includes SMARCB1)",ISCA-46294,22q11.23,22:23831202-24632821,22:23489015-24236853,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,09/30/2022
R,"22q11.21 population region (DGV_Gold_Standard_June_2021_gssvL76981)",ISCA-46728,22q11.21,22:20428070-20499197,22:18578203-18649330,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (DGV_Gold_Standard_June_2021_gssvL77047)",ISCA-46729,22q11.21,22:21812558-21916568,22:21458269-21562279,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (DGV_Gold_Standard_June_2021_gssvL77049)",ISCA-46730,22q11.21,22:21711480-21742055,22:21357191-21387766,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (DGV_Gold_Standard_June_2021_gssvL77050)",ISCA-46731,22q11.21,22:21866876-21909287,22:21512587-21554998,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (gnomAD-SV_v2.1_DEL_22_181316)",ISCA-46529,22q11.21,22:18738599-18747000,22:18751086-18759487,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (gnomAD-SV_v2.1_DEL_22_181446)",ISCA-46530,22q11.21,22:20366424-20371500,22:18516557-18521633,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (gnomAD-SV_v2.1_DEL_22_181452)",ISCA-46531,22q11.21,22:20451599-20457600,22:18601732-18607733,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (gnomAD-SV_v2.1_DEL_22_181459)",ISCA-46532,22q11.21,22:20693999-20699000,22:21324131-21329132,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 population region (gnomAD-SV_v2.1_DEL_22_181532)",ISCA-46533,22q11.21,22:21562199-21569400,22:21207910-21215111,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.21 recurrent (Cat eye syndrome) region (includes CECR2)",ISCA-37393,22q11.1-q11.21,22:17392953-18591860,22:16912063-18109094,"0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","cat-eye syndrome",MONDO:0007276,,,‐,‐,‐,02/27/2014
R,"22q11.22 population region (DGV_Gold_Standard_June_2021_gssvL77120)",ISCA-46727,22q11.22,22:23223448-23238992,22:22881268-22896812,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (DGV_Gold_Standard_June_2021_gssvG24415)",ISCA-46732,22q11.23,22:25703259-25785235,22:25307292-25389268,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (DGV_Gold_Standard_June_2021_gssvL77238)",ISCA-46725,22q11.23,22:24360812-24402386,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (DGV_Gold_Standard_June_2021_gssvL77244)",ISCA-46726,22q11.23,22:24314289-24334833,22:23972100-23992644,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (gnomAD-SV_v2.1_DEL_22_181670)",ISCA-46534,22q11.23,22:24274143-24311297,22:23931956-23969110,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (gnomAD-SV_v2.1_DEL_22_181679)",ISCA-46535,22q11.23,22:24315999-24323000,22:23973810-23980811,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (gnomAD-SV_v2.1_DEL_22_181680)",ISCA-46536,22q11.23,22:24324299-24334200,22:23982108-23992009,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q11.23 population region (gnomAD-SV_v2.1_DEL_22_181682)",ISCA-46537,22q11.23,22:24344399-24397000,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"22q13.1 population region (gnomAD-SV_v2.1_DEL_22_182715)",ISCA-46538,22q13.1,22:39358308-39388415,22:38962303-38992410,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64414)",ISCA-46578,2p11.2,2:90005834-90052218,2:89967024-90013408,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64418)",ISCA-46579,2p11.2,2:90044551-90102805,2:90005741-90063995,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64421)",ISCA-46580,2p11.2,2:89459244-89512939,2:89159760-89213455,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64445)",ISCA-46581,2p11.2,2:90249376-90275932,2:90210510-90237066,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64458)",ISCA-46582,2p11.2,2:90044437-90061011,2:90005627-90022201,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (DGV_Gold_Standard_June_2021_gssvL64514)",ISCA-46583,2p11.2,2:90160287-90163570,2:90121435-90124718,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p11.2 population region (gnomAD-SV_v2.1_DEL_2_19888)",ISCA-46342,2p11.2,2:87242199-87253600,2:87015076-87026477,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2p15p16.1 region (includes BCL11A)",ISCA-37408,2p15-p16.1,2:59139200-62488871,2:58912065-62261736,"3 (Sufficient Evidence)","chromosome 2p16.1-p15 deletion syndrome",MONDO:0012916,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,06/09/2016
R,"2p21 region (includes PREPL and SLC3A1)",ISCA-37440,2p21,2:44410272-44589641,2:44183133-44362502,"30 (Autosomal Recessive)","hypotonia-cystinuria syndrome",MONDO:0011669,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/21/2012
R,"2p24.3 MYCN-DDX1 duplication region",ISCA-46287,2p24.3,2:15708677-16185337,2:15568553-16045215,"Not Yet Evaluated",'-,'-,"2 (Emerging Evidence)",neuroblastoma,MONDO:0005072,,,‐,‐,‐,08/07/2017
R,"2q11.2 recurrent region (includes ARID5A, TMEM127)",ISCA-37495,2q11.2,2:96739012-97671429,2:96073264-97005692,"3 (Sufficient Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,02/21/2022
R,"2q13 recurrent region (includes BCL2L11)",ISCA-37496,2q13,2:111392193-113104742,2:110634616-112347165,"2 (Emerging Evidence)",'-,'-,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,06/23/2018
R,"2q13 recurrent region (includes NPHP1)",ISCA-37405,2q13,2:110862108-110983703,2:110104531-110228181,"30 (Autosomal Recessive)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,02/25/2016
R,"2q21.1 population region (DGV_Gold_Standard_June_2021_gssvL66075)",ISCA-46584,2q21.1,2:130793882-130823249,2:130036309-130065676,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 population region (gnomAD-SV_v2.1_DEL_2_22133)",ISCA-46343,2q21.1,2:130953999-130959000,2:130196426-130201427,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 population region (gnomAD-SV_v2.1_DEL_2_22135)",ISCA-46344,2q21.1,2:130954938-130957387,2:130197365-130199814,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 population region (gnomAD-SV_v2.1_DEL_2_22155)",ISCA-46345,2q21.1,2:131236999-131242000,2:130479426-130484427,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 population region (gnomAD-SV_v2.1_DEL_2_22156)",ISCA-46346,2q21.1,2:131248899-131254600,2:130491326-130497027,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 population region (gnomAD-SV_v2.1_DEL_2_22163)",ISCA-46347,2q21.1,2:131412799-131430000,2:130655226-130672427,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.1 recurrent region (includes ARHGEF4, GPR148)",ISCA-46288,2q21.1,2:131477509-131929693,2:130719936-131172120,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,09/30/2019
R,"2q21.2 population region (gnomAD-SV_v2.1_DEL_2_22275)",ISCA-46348,2q21.2,2:132519999-132529000,2:131762426-131771427,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q21.2 population region (gnomAD-SV_v2.1_DUP_2_6167)",ISCA-46349,2q21.2,2:132853576-133213563,2:132096003-132455990,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q37.3 population region (DGV_Gold_Standard_June_2021_gssvL70815)",ISCA-46585,2q37.3,2:242872862-243012181,2:241930711-242070030,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"2q37.3 terminal region (includes HDAC4)",ISCA-37394,2q37.3,2:239954693-242930600,2:239032997-241988449,"3 (Sufficient Evidence)","2q37 microdeletion syndrome",MONDO:0010886,"0 (No Evidence)",'-,'-,,,‐,‐,‐,06/13/2016
R,"3 copies: 15q telomere",ISCA-37480,15q26.3,15:102161480-102521392,15:101621277-101981189,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,11/26/2013
R,"3 copies: 16p centromere",ISCA-37481,16p11.1,16:34202088-35147508,16:34967717-35913137,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/01/2013
R,"3p12.3 population region (DGV_Gold_Standard_June_2021_gssvL82397)",ISCA-46590,3p12.3,3:75422907-75644624,3:75373756-75595473,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3p12.3 population region (DGV_Gold_Standard_June_2021_gssvL82434)",ISCA-46591,3p12.3,3:75567345-75581692,3:75518194-75532541,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3p12.3 population region (gnomAD-SV_v2.1_DEL_3_33722)",ISCA-46350,3p12.3,3:75767999-75796000,3:75718848-75746849,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q11.2 population region (DGV_Gold_Standard_June_2021_gssvL83303)",ISCA-46586,3q11.2,3:97878295-97923426,3:98159451-98204582,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q11.2 population region (DGV_Gold_Standard_June_2021_gssvL83307)",ISCA-46587,3q11.2,3:97887492-97919334,3:98168648-98200490,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q24 Region (includes ZIC1)",ISCA-46553,3q24,3:136403035-148341113,"3:136684193 -148623326","3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,‐,‐,‐,07/19/2021
R,"3q25.31 population region (DGV_Gold_Standard_June_2021_gssvL85294)",ISCA-46588,3q25.31,3:155478166-155498646,3:155760377-155780857,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q29 population region (DGV_Gold_Standard_June_2021_gssvG26791)",ISCA-46592,3q29,3:195376588-195493533,3:195649717-195766662,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q29 population region (DGV_Gold_Standard_June_2021_gssvL86947)",ISCA-46589,3q29,3:195380278-195469564,3:195653407-195742693,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"3q29 recurrent region (includes DLG1)",ISCA-37443,3q29,3:195756054-197344662,3:196029183-197617791,"3 (Sufficient Evidence)","chromosome 3q29 microdeletion syndrome",MONDO:0012269,"1 (Little Evidence)","chromosome 3q29 microduplication syndrome",MONDO:0012761,,,‐,‐,‐,02/18/2024
R,"4p11 population region (DGV_Gold_Standard_June_2021_gssvG27527)",ISCA-46598,4p11,4:49489242-49524812,4:49487225-49522795,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4p11 population region (DGV_Gold_Standard_June_2021_gssvL90109)",ISCA-46595,4p11,4:49177189-49249875,4:49175172-49247858,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4p16.1 population region (DGV_Gold_Standard_June_2021_gssvG27165)",ISCA-46597,4p16.1,4:9417997-9457368,4:9416271-9455642,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4p16.1 population region (DGV_Gold_Standard_June_2021_gssvL88361)",ISCA-46596,4p16.1,4:9486907-9516088,4:9485260-9514441,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4p16.3 terminal (Wolf-Hirschhorn syndrome) region",ISCA-37429,4p16.3,4:331568-2010962,"4:337779 -2009235","3 (Sufficient Evidence)","Wolf-Hirschhorn syndrome",MONDO:0008684,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,08/11/2016
R,"4q13.2 population region (DGV_Gold_Standard_June_2021_gssvL90978)",ISCA-46594,4q13.2,4:70134832-70270391,4:69269114-69404673,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4q13.2 population region (gnomAD-SV_v2.1_DEL_4_46396)",ISCA-46351,4q13.2,4:70123650-70232337,4:69257932-69366619,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4q13.2 population region (gnomAD-SV_v2.1_DEL_4_46398)",ISCA-46352,4q13.2,4:70123999-70171300,4:69258281-69305582,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4q13.2 population region (gnomAD-SV_v2.1_DEL_4_46399)",ISCA-46353,4q13.2,4:70126481-70235359,4:69260763-69369641,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"4q13.2 population region (gnomAD-SV_v2.1_DEL_4_46401)",ISCA-46354,4q13.2,4:70138063-70247165,4:69272345-69381447,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"4q13.2 population region (gnomAD-SV_v2.1_DEL_4_46404)",ISCA-46355,4q13.2,4:70152039-70261334,4:69286321-69395616,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"4q13.3 population region (DGV_Gold_Standard_June_2021_gssvL91223)",ISCA-46593,4q13.3,4:75282628-75323181,4:74416911-74457464,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"4q13.3 population region (gnomAD-SV_v2.1_DEL_4_46744)",ISCA-46356,4q13.3,4:75315999-75323000,4:74450282-74457283,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"4q13.3 population region (gnomAD-SV_v2.1_DEL_4_46753)",ISCA-46357,4q13.3,4:75483999-75493000,4:74448523-74457524,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5p15 terminal (Cri du chat syndrome) region",ISCA-37390,5p15.33-p15.2,5:37693-11347262,5:37695-11347150,"3 (Sufficient Evidence)","Cri-du-chat syndrome",MONDO:0007404,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,06/21/2016
R,"5p15.33 population region (DGV_Gold_Standard_June_2021_gssvG29169)",ISCA-46604,5p15.33,5:814446-825367,5:814331-825252,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"5q13.2 population region (DGV_Gold_Standard_June_2021_gssvG30124)",ISCA-46605,5q13.2,5:69316084-69343660,5:70020257-70047833,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"5q13.2 population region (gnomAD-SV_v2.1_DEL_5_58897)",ISCA-46359,5q13.2,5:70312999-70365100,5:71017172-71069273,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q13.2 population region (gnomAD-SV_v2.1_DEL_5_58900)",ISCA-46361,5q13.2,5:70326999-70335700,5:71031172-71039873,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q13.2 population region (gnomAD-SV_v2.1_DUP_5_15350)",ISCA-46358,5q13.2,5:69305399-69369100,5:70009572-70073273,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q13.2 population region (gnomAD-SV_v2.1_DUP_5_15442)",ISCA-46360,5q13.2,5:70324499-70404000,5:71028672-71108173,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q22.1 population region (DGV_Gold_Standard_June_2021_gssvL101506)",ISCA-46602,5q22.1,5:110905931-110911040,5:111570233-111575342,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"5q31.3 population region (DGV_Gold_Standard_June_2021_gssvG31070)",ISCA-46606,5q31.3,5:140554513-140560187,:-,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/16/2021
R,"5q31.3 population region (DGV_Gold_Standard_June_2021_gssvL102648)",ISCA-46599,5q31.3,5:140096767-140104053,5:140717182-140724468,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"5q31.3 population region (gnomAD-SV_v2.1_DEL_5_63328)",ISCA-46362,5q31.3,5:140222136-140238931,5:140842551-140859346,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q35 recurrent (Sotos syndrome) region (includes NSD1)",ISCA-37425,5q35.2-q35.3,5:175728979-177047793,5:176301976-177620792,"3 (Sufficient Evidence)","Sotos syndrome",MONDO:0019349,"3 (Sufficient Evidence)",'-,'-,,,‐,‐,‐,04/10/2014
R,"5q35.3 population region (DGV_Gold_Standard_June_2021_gssvL104164)",ISCA-46600,5q35.3,5:178348352-178353194,5:178921351-178926193,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/06/2021
R,"5q35.3 population region (DGV_Gold_Standard_June_2021_gssvL104429)",ISCA-46601,5q35.3,5:180591001-180596624,5:181164001-181169624,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"5q35.3 population region (gnomAD-SV_v2.1_DEL_5_65831)",ISCA-46363,5q35.3,5:180375131-180430626,5:180948131-181003626,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"5q35.3 population region (gnomAD-SV_v2.1_DEL_5_65880)",ISCA-46364,5q35.3,5:180787999-180857000,5:181360998-181429999,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"6p21.32 population region (DGV_Gold_Standard_June_2021_gssvL106264)",ISCA-46609,6p21.32,6:32475856-32514239,6:32508079-32546462,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6p21.32 population region (DGV_Gold_Standard_June_2021_gssvL106269)",ISCA-46610,6p21.32,6:32516836-32541693,6:32549059-32573916,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6p21.32 population region (DGV_Gold_Standard_June_2021_gssvL106271)",ISCA-46611,6p21.32,6:32627550-32648423,6:32659773-32680646,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6p22.1 population region (DGV_Gold_Standard_June_2021_gssvL105924)",ISCA-46607,6p22.1,6:29892560-29905834,6:29924783-29938057,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6p22.1 population region (DGV_Gold_Standard_June_2021_gssvL105927)",ISCA-46608,6p22.1,6:29837200-29849273,6:29869423-29881496,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6p25.3 population region (DGV_Gold_Standard_June_2021_gssvL104460)",ISCA-46612,6p25.3,6:83824-202184,6:83824-202184,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6q13 population region (DGV_Gold_Standard_June_2021_gssvG32688)",ISCA-46613,6q13,6:74707825-74718498,6:73998109-74008782,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6q13 population region (DGV_Gold_Standard_June_2021_gssvG32691)",ISCA-46614,6q13,6:74708884-74717014,6:73999168-74007298,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"6q24 region (includes PLAGL1)",ISCA-37442,6q24,"6:144243292 -144416561",6:143922155-144095424,"1 (Little Evidence)",'-,'-,"3 (Sufficient Evidence)","diabetes mellitus, transient neonatal, 1",MONDO:0011073,,,‐,‐,‐,05/24/2016
R,"7p11.2 population region (DGV_Gold_Standard_June_2021_gssvL115697)",ISCA-46617,7p11.2,7:57062764-57088685,7:56995057-57020978,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7p14.1 population region (DGV_Gold_Standard_June_2021_gssvL115094)",ISCA-46616,7p14.1,7:38386563-38397743,7:38346962-38358142,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7p22.1 population region (DGV_Gold_Standard_June_2021_gssvL113541)",ISCA-46615,7p22.1,7:6900773-6923243,7:6861142-6883612,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7p22.1 population region (gnomAD-SV_v2.1_DEL_7_77765)",ISCA-46365,7p22.1,7:5940999-5953000,7:5901368-5913369,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7p22.1 population region (gnomAD-SV_v2.1_DEL_7_77769)",ISCA-46366,7p22.1,7:5976999-5982000,7:5937368-5942369,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7p22.1 population region (gnomAD-SV_v2.1_DEL_7_77893)",ISCA-46367,7p22.1,7:6818999-6827200,7:6779368-6787569,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7p22.1 region (includes ACTB)",ISCA-46742,7p22.1,7:5536848-5799722,7:5497217-5760091,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,,,‐,‐,‐,02/08/2022
R,"7q11.21 population region (DGV_Gold_Standard_June_2021_gssvL115987)",ISCA-46618,7q11.21,7:62687315-62723648,7:63226937-63263270,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q11.21 population region (DGV_Gold_Standard_June_2021_gssvL116036)",ISCA-46619,7q11.21,7:62963166-62979392,7:63502788-63519014,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q11.21 population region (gnomAD-SV_v2.1_DEL_7_81890)",ISCA-46368,7q11.21,7:65110999-65144000,7:65646085-65679086,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q11.23 population region (DGV_Gold_Standard_June_2021_gssvL116711)",ISCA-46620,7q11.23,7:74378312-74480711,7:74963584-75065983,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q11.23 population region (gnomAD-SV_v2.1_DEL_7_82621)",ISCA-46369,7q11.23,7:74223499-74230000,7:74809162-74815663,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q11.23 population region (gnomAD-SV_v2.1_DEL_7_82636)",ISCA-46370,7q11.23,7:74420999-74428000,7:75006833-75013834,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q11.23 population region (gnomAD-SV_v2.1_DEL_7_82637)",ISCA-46371,7q11.23,7:74452999-74459200,7:75038895-75045096,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q11.23 population region (gnomAD-SV_v2.1_DEL_7_82638)",ISCA-46372,7q11.23,7:74468999-74476300,7:75054892-75062193,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q11.23 recurrent (Williams-Beuren syndrome) region (includes ELN)",ISCA-37392,7q11.23,7:72744455-74142510,7:73330452-74728172,"3 (Sufficient Evidence)","Williams syndrome",MONDO:0008678,"3 (Sufficient Evidence)","7q11.23 microduplication syndrome",MONDO:0012342,,,‐,‐,‐,08/06/2015
R,"7q11.23 recurrent distal region (includes HIP1, YWHAG)",ISCA-46291,7q11.23,7:75158048-76063176,7:75528718-76433859,"2 (Emerging Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,‐,‐,‐,04/20/2023
R,"7q22.1 population region (DGV_Gold_Standard_June_2021_gssvL117874)",ISCA-46625,7q22.1,7:101968967-102022209,7:102328550-102381792,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q22.1 population region (gnomAD-SV_v2.1_DEL_7_84190)",ISCA-46373,7q22.1,7:99461390-99463562,7:99863767-99865939,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q22.1 population region (gnomAD-SV_v2.1_DEL_7_84412)",ISCA-46374,7q22.1,7:102300999-102331000,7:102660552-102690553,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/12/2021
R,"7q34 population region (DGV_Gold_Standard_June_2021_gssvL119360)",ISCA-46621,7q34,7:142133273-142170344,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q34 population region (DGV_Gold_Standard_June_2021_gssvL119369)",ISCA-46622,7q34,7:142099063-142108894,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q34 population region (DGV_Gold_Standard_June_2021_gssvL119380)",ISCA-46623,7q34,7:142460176-142482236,7:142752325-142774385,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q34 population region (DGV_Gold_Standard_June_2021_gssvL119381)",ISCA-46624,7q34,7:142461276-142474923,7:142753425-142767072,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q34 population region (gnomAD-SV_v2.1_DEL_7_87015)",ISCA-46375,7q34,7:141754993-141780979,7:142055193-142081179,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"7q34 population region (gnomAD-SV_v2.1_DEL_7_87016)",ISCA-46376,7q34,7:141765424-141794499,7:142065624-142094699,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"7q35 population region (DGV_Gold_Standard_June_2021_gssvG35898)",ISCA-46626,7q35,7:143884211-143930465,7:144187118-144233372,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q35 population region (DGV_Gold_Standard_June_2021_gssvL119429)",ISCA-46627,7q35,7:143880615-144075919,7:144183522-144378826,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q35 population region (gnomAD-SV_v2.1_DEL_7_87112)",ISCA-46377,7q35,7:143408999-143417500,7:143711906-143720407,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"7q36.1 population region (DGV_Gold_Standard_June_2021_gssvL119849)",ISCA-46628,7q36.1,7:150286146-150307909,7:150589058-150610821,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"7q36.3 ZRS (SHH cis-regulatory) duplication region (within LMBR1 intron 5)",ISCA-37467,7q36.3,7:156583796-156584568,7:156791102-156791874,"0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","polydactyly of a triphalangeal thumb",MONDO:0008270,,,‐,‐,‐,02/15/2018
R,"8p23.1 population region (DGV_Gold_Standard_June_2021_gssvG36607)",ISCA-46629,8p23.1,8:7110945-7157807,8:7253423-7300285,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"8p23.1 population region (DGV_Gold_Standard_June_2021_gssvG36608)",ISCA-46630,8p23.1,8:6828736-6878156,8:6971214-7020634,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"8p23.1 population region (DGV_Gold_Standard_June_2021_gssvG36644)",ISCA-46631,8p23.1,8:7212582-7227421,8:7355060-7369899,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89353)",ISCA-46380,8p23.1,8:7736499-7764500,8:7878977-7906978,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89355)",ISCA-46382,8p23.1,8:7744999-7754100,8:7887477-7896578,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89356)",ISCA-46383,8p23.1,8:7798999-7824100,8:7941477-7966578,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89357)",ISCA-46384,8p23.1,8:7806249-7812100,8:7948727-7954578,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89703)",ISCA-46385,8p23.1,8:11903999-11926000,8:12046490-12068491,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89706)",ISCA-46386,8p23.1,8:11961999-11968000,8:12104490-12110491,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DEL_8_89725)",ISCA-46388,8p23.1,8:12291199-12311050,8:12433690-12453541,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DUP_8_23708)",ISCA-46381,8p23.1,8:7736999-7743100,8:7879477-7885578,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/17/2021
R,"8p23.1 population region (gnomAD-SV_v2.1_DUP_8_23819)",ISCA-46387,8p23.1,8:12251799-12297400,8:12394290-12439891,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.1 recurrent region (includes GATA4)",ISCA-37423,8p23.1,8:8100064-11766329,8:8242542-11908820,"3 (Sufficient Evidence)",'-,'-,"2 (Emerging Evidence)",'-,'-,,,‐,‐,‐,06/10/2022
R,"8p23.1 region (DEFB gene cluster)",ISCA-37472,8p23.1,8:7053186-8130689,8:7195664-8273167,"40 (Dosage Sensitivity Unlikely)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,03/12/2014
R,"8p23.3 population region (gnomAD-SV_v2.1_DEL_8_88399)",ISCA-46378,8p23.3,8:25899-33100,8:75899-83100,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8p23.3 population region (gnomAD-SV_v2.1_DEL_8_88408)",ISCA-46379,8p23.3,8:116099-129200,8:166099-179200,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8q24.3 population region (gnomAD-SV_v2.1_DEL_8_98283)",ISCA-46389,8q24.3,8:145312849-145332400,8:144257946-144277497,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"8q24.3 population region (gnomAD-SV_v2.1_DEL_8_98285)",ISCA-46390,8q24.3,8:145479999-145502750,8:144256043-144278794,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.1 population region (gnomAD-SV_v2.1_DEL_9_102297)",ISCA-46416,9p11.1,9:47307099-47317679,9:41901558-41912138,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (DGV_Gold_Standard_June_2021_gssvG38779)",ISCA-46635,9p11.2,9:44283472-44840754,9:42606667-43163949,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102024)",ISCA-46396,9p11.2,9:43622999-43708000,9:61197782-61282783,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102025)",ISCA-46397,9p11.2,9:43623999-43631000,9:61196784-61203785,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102027)",ISCA-46398,9p11.2,9:43628499-43647400,9:61192272-61211173,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102032)",ISCA-46399,9p11.2,9:43708999-43728000,9:67082041-67101042,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102035)",ISCA-46400,9p11.2,9:43723999-43739000,9:67097078-67112079,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102036)",ISCA-46401,9p11.2,9:43733799-43739000,9:67106870-67112071,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102042)",ISCA-46402,9p11.2,9:43795899-43804300,9:67168889-67177290,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102043)",ISCA-46403,9p11.2,9:43800749-43849800,9:67173745-67222796,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102046)",ISCA-46404,9p11.2,9:43870599-43876000,9:61087440-61092841,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102047)",ISCA-46405,9p11.2,9:43870599-43899100,9:61087440-61115941,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102048)",ISCA-46406,9p11.2,9:43902774-43914325,9:61055297-61066848,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102049)",ISCA-46407,9p11.2,9:43915599-43920850,9:67288703-67293954,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102085)",ISCA-46408,9p11.2,9:44313499-44331000,9:42657618-42675119,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102096)",ISCA-46409,9p11.2,9:44388999-44470300,9:42712222-42793523,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102097)",ISCA-46410,9p11.2,9:44391999-44411000,9:42579118-42598119,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102099)",ISCA-46411,9p11.2,9:44399899-44405000,9:42571218-42576319,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102187)",ISCA-46412,9p11.2,9:45728849-45746725,9:67724915-67742791,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102236)",ISCA-46413,9p11.2,9:46366999-46389000,9:67701487-67723488,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102294)",ISCA-46414,9p11.2,9:47281174-47300125,9:41875633-41894584,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p11.2 population region (gnomAD-SV_v2.1_DEL_9_102296)",ISCA-46415,9p11.2,9:47298999-47304000,9:41893458-41898459,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p12 population region (DGV_Gold_Standard_June_2021_gssvL130619)",ISCA-46633,9p12,9:43584760-43755000,9:66946498-67116738,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"9p12 population region (DGV_Gold_Standard_June_2021_gssvL130637)",ISCA-46634,9p12,9:43589946-43694171,9:61230528-61334753,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"9p12 population region (gnomAD-SV_v2.1_DEL_9_101915)",ISCA-46393,9p12,9:41322999-41329000,9:42187993-42193994,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p12 population region (gnomAD-SV_v2.1_DEL_9_101925)",ISCA-46394,9p12,9:41499999-41507000,9:60913727-60920728,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p12 population region (gnomAD-SV_v2.1_DEL_9_101967)",ISCA-46395,9p12,9:42363999-42374800,9:40218981-40229782,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p13.1 population region (gnomAD-SV_v2.1_DEL_9_101840)",ISCA-46392,9p13.1,9:40024899-40031800,9:67289628-67296529,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p24.3 population region (gnomAD-SV_v2.1_DUP_9_26178)",ISCA-46391,9p24.3,9:111999-126000,9:111999-126000,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9p24.3 Region (includes DMRT1)",ISCA-46741,9p24.3,9:1-1982069,9:883300-918342,"2 (Emerging Evidence)","disorder of sexual differentiation",MONDO:0002145,"'-5 (Not yet evaluated)",'-,'-,,,‐,‐,‐,11/10/2023
R,"9q12 population region (gnomAD-SV_v2.1_DEL_9_102303)",ISCA-46417,9q12,9:65496999-65509000,9:39368304-39380305,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/11/2021
R,"9q13 population region (gnomAD-SV_v2.1_DEL_9_102391)",ISCA-46418,9q13,9:67954499-67986500,9:67887053-67919054,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q21.11 population region (gnomAD-SV_v2.1_DEL_9_102459)",ISCA-46419,9q21.11,9:69375499-69388225,9:64363081-64375807,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q21.11 population region (gnomAD-SV_v2.1_DEL_9_102460)",ISCA-46420,9q21.11,9:69398749-69405200,9:64386331-64392782,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q21.11 population region (gnomAD-SV_v2.1_DEL_9_102461)",ISCA-46421,9q21.11,9:69418924-69435100,9:64406506-64422682,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q21.11 population region (gnomAD-SV_v2.1_DUP_9_27460)",ISCA-46422,9q21.11,9:70557057-70693525,9:41447948-41584416,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q21.11 population region (gnomAD-SV_v2.1_DUP_9_27462)",ISCA-46423,9q21.11,9:70631499-70655275,9:41373825-41397601,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/17/2021
R,"9q31.1 population region (DGV_Gold_Standard_June_2021_gssvL132495)",ISCA-46632,9q31.1,9:107362715-107368622,9:104600434-104606341,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/05/2021
R,"9q31.2 population region (gnomAD-SV_v2.1_DEL_9_104809)",ISCA-46424,9q31.2,9:110537534-110540595,9:107775253-107778314,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
R,"9q32 population region (DGV_Gold_Standard_June_2021_gssvG40321)",ISCA-46636,9q32,9:117078800-117098147,9:114316520-114335867,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/05/2021
R,"9q34.3 population region (gnomAD-SV_v2.1_DEL_9_106704)",ISCA-46425,9q34.3,9:138936849-138944500,9:136045003-136052654,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/10/2021
G,A4GALT,HGNC:18149,22q13.2,22:43088127-43117307,22:42692121-42721301,"30 (Autosomal Recessive)",'-,'-,"0 (No Evidence)",'-,'-,,,73.08,0,1.65,12/11/2014
G,AAGAB,HGNC:25662,15q23,15:67493005-67547536,15:67200667-67255198,"3 (Sufficient Evidence)","palmoplantar keratoderma, punctate type 1A",MONDO:0007858,"0 (No Evidence)",'-,'-,,,50.94,0,1.04,02/28/2013
G,AARS1,HGNC:20,16q22.1,16:70286201-70323409,16:70252298-70289506,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.74,0,0.62,01/11/2018
G,AARS2,HGNC:21022,6p21.1,6:44266468-44281084,6:44298731-44313347,"30 (Autosomal Recessive)","leukoencephalopathy, progressive, with ovarian failure",MONDO:0014387,"Not Yet Evaluated",'-,'-,,,53.33,0,0.84,08/22/2016
G,AASS,HGNC:17366,7q31.32,7:121713603-121784303,7:122073549-122144249,"30 (Autosomal Recessive)",hyperlysinemia,MONDO:0009388,"Not Yet Evaluated",'-,'-,,,45.6,0,0.81,08/22/2016
G,ABAT,HGNC:23,16p13.2,16:8768474-8878427,16:8674617-8784570,"30 (Autosomal Recessive)","GABA aminotransaminase deficiency",MONDO:0013166,"Not Yet Evaluated",'-,'-,,,41.04,0.01,0.57,08/22/2016
G,ABCB11,HGNC:42,2q31.1,2:169777291-169887834,2:168915390-169031324,"30 (Autosomal Recessive)","progressive familial intrahepatic cholestasis type 2",MONDO:0011156,"0 (No Evidence)",'-,'-,,,30.88,0,0.64,07/08/2020
G,ABCC8,HGNC:59,11p15.1,11:17414045-17498392,11:17392498-17476845,"30 (Autosomal Recessive)","hyperinsulinemic hypoglycemia, familial, 1",MONDO:0009734,"0 (No Evidence)",'-,'-,,,1.79,0,0.77,02/24/2012
G,ABCD1,HGNC:61,Xq28,X:152990311-153010209,X:153724856-153744755,"3 (Sufficient Evidence)",adrenoleukodystrophy,MONDO:0018544,"0 (No Evidence)",'-,'-,,,59.98,1,0.15,12/02/2020
G,ABCG5,HGNC:13886,2p21,2:44039611-44065978,2:43806211-43839231,"30 (Autosomal Recessive)","sitosterolemia 1",MONDO:0020747,"Not Yet Evaluated",'-,'-,,,36.56,0,1.39,08/22/2016
G,ABCG8,HGNC:13887,2p21,2:44066110-44110127,2:43838971-43882988,"30 (Autosomal Recessive)","sitosterolemia 1",MONDO:0020747,"0 (No Evidence)",'-,'-,,,39.74,0,1.37,08/22/2016
G,ABHD12,HGNC:15868,20p11.21,20:25275379-25371471,20:25294743-25390835,"30 (Autosomal Recessive)","PHARC syndrome",MONDO:0012984,"0 (No Evidence)",'-,'-,,,52.8,0,0.76,12/11/2014
G,ABR,HGNC:81,17p13.3,17:906759-1133016,17:1003519-1229722,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,10.64,0.63,0.36,09/05/2012
G,ABRAXAS1,HGNC:25829,4q21.23,4:84380670-84406253,4:83459517-83485100,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,64,0,1.01,07/18/2023
G,ACAD8,HGNC:87,11q25,11:134123462-134135749,11:134253568-134265855,"30 (Autosomal Recessive)","isobutyryl-CoA dehydrogenase deficiency",MONDO:0012648,"0 (No Evidence)",'-,'-,,,52.61,0,1.27,12/11/2014
G,ACADM,HGNC:89,1p31.1,1:76190394-76229364,1:75724709-75763679,"30 (Autosomal Recessive)","medium chain acyl-CoA dehydrogenase deficiency",MONDO:0008721,"0 (No Evidence)",'-,'-,,,29.48,0,1.15,08/22/2016
G,ACADSB,HGNC:91,10q26.13,10:124768522-124817806,10:123009006-123058290,"30 (Autosomal Recessive)","2-methylbutyryl-CoA dehydrogenase deficiency",MONDO:0012392,"Not Yet Evaluated",'-,'-,,,65.42,0,1.17,08/22/2016
G,ACADVL,HGNC:92,17p13.1,17:7120444-7128585,17:7217125-7225266,"30 (Autosomal Recessive)","very long chain acyl-CoA dehydrogenase deficiency",MONDO:0008723,"0 (No Evidence)",'-,'-,,,33.28,0,1.05,08/22/2016
G,ACD,HGNC:25070,16q22.1,16:67691415-67694163,16:67657512-67660260,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,81.12,0,1.19,10/09/2019
G,ACOX1,HGNC:119,17q25.1,17:73937588-73975247,17:75941507-75979166,"30 (Autosomal Recessive)","peroxisomal acyl-CoA oxidase deficiency",MONDO:0009919,"0 (No Evidence)",'-,'-,,,38.86,0.06,0.46,11/20/2014
G,ACP5,HGNC:124,19p13.2,19:11685475-11689790,19:11574660-11578975,"30 (Autosomal Recessive)","Spondyloenchondrodysplasia with immune dysregulation",MONDO:0011939,"0 (No Evidence)",'-,'-,,,66.32,0.08,0.72,08/22/2016
G,ACSF3,HGNC:27288,16q24.3,16:89160260-89222641,16:89093852-89156233,"30 (Autosomal Recessive)","combined malonic and methylmalonic acidemia",MONDO:0013661,"0 (No Evidence)",'-,'-,,,79.2,0,1.77,08/22/2016
G,ACSL4,HGNC:3571,Xq23,X:108884564-108976486,X:109641335-109733257,"1 (Little Evidence)","intellectual disability, X-linked 63",MONDO:0010313,"0 (No Evidence)",'-,'-,,,15.6,0.98,0.31,04/28/2021
G,ACTA2,HGNC:130,10q23.31,10:90694831-90751154,10:88935074-88991337,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,2.61,0.93,0.36,09/28/2022
G,ACTB,HGNC:132,7p22.1,7:5566779-5570232,7:5527148-5530601,"0 (No Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,1.03,0.99,0.23,02/08/2022
G,ACTC1,HGNC:143,15q14,15:35082431-35087750,15:34790230-34795549,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.59,0.74,0.48,11/17/2015
G,ACTL6B,HGNC:160,7q22.1,7:100240720-100254071,7:100643097-100656448,"30 (Autosomal Recessive)","developmental and epileptic encephalopathy",MONDO:0100062,"Not Yet Evaluated",'-,'-,,,15.91,0,0.65,11/23/2022
G,ACVRL1,HGNC:175,12q13.13,12:52301288-52317145,12:51906944-51923361,"3 (Sufficient Evidence)","telangiectasia, hereditary hemorrhagic, type 2",MONDO:0010880,"0 (No Evidence)",'-,'-,,,49.42,0,0.69,11/10/2016
G,ADA2,HGNC:1839,22q11.1,22:17659680-17702738,22:17178790-17221848,"30 (Autosomal Recessive)","vasculitis due to ADA2 deficiency",MONDO:0014306,"Not Yet Evaluated",'-,'-,,,85.15,0,1.07,08/22/2016
G,ADAM9,HGNC:216,8p11.22,8:38854492-38962780,8:38996973-39105261,"30 (Autosomal Recessive)","cone-rod dystrophy 9",MONDO:0013002,"0 (No Evidence)",'-,'-,,,58.29,0.03,0.42,12/11/2014
G,ADAMTS13,HGNC:1366,9q34.2,9:136279457-136324508,9:133414337-133459386,"30 (Autosomal Recessive)","congenital thrombotic thrombocytopenic purpura",MONDO:0010122,"Not Yet Evaluated",'-,'-,,,81.4,0,0.68,08/22/2016
G,ADAMTS17,HGNC:17109,15q26.3,15:100511642-100882180,15:99971437-100341975,"30 (Autosomal Recessive)","Weill-Marchesani 4 syndrome, recessive",MONDO:0013176,"0 (No Evidence)",'-,'-,,,44.61,0,0.73,08/22/2016
G,ADAMTS18,HGNC:17110,16q23.1,16:77316025-77468931,16:77282128-77435034,"30 (Autosomal Recessive)","microcornea-myopic chorioretinal atrophy",MONDO:0014195,"0 (No Evidence)",'-,'-,,,48.75,0,0.93,08/22/2016
G,ADAMTS2,HGNC:218,5q35.3,5:178537854-178772462,5:179110853-179345461,"30 (Autosomal Recessive)","Ehlers-Danlos syndrome, dermatosparaxis type",MONDO:0009161,"0 (No Evidence)",'-,'-,,,25.76,0.97,0.31,08/22/2016
G,ADAMTSL2,HGNC:14631,9q34.2,9:136397286-136440641,9:133532164-133575519,"30 (Autosomal Recessive)","geleophysic dysplasia 1",MONDO:0009269,"0 (No Evidence)",'-,'-,,,62.46,0,0.74,08/22/2016
G,ADGRG1,HGNC:4512,16q21,16:57653650-57699479,16:57619738-57665567,"30 (Autosomal Recessive)","bilateral frontoparietal polymicrogyria",MONDO:0011738,"0 (No Evidence)",'-,'-,,,82.05,0,0.89,05/17/2012
G,ADGRV1,HGNC:17416,5q14.3,5:89854614-90460254,5:90558797-91164437,"30 (Autosomal Recessive)","Usher syndrome type 2",MONDO:0016484,"0 (No Evidence)",'-,'-,,,25.58,0,0.52,08/23/2021
G,ADNP,HGNC:15766,20q13.13,20:49505455-49547974,20:50888918-50931437,"3 (Sufficient Evidence)","ADNP-related multiple congenital anomalies - intellectual disability - autism spectrum disorder",MONDO:0014379,"0 (No Evidence)",'-,'-,,,9.79,1,0.12,11/22/2017
G,ADSL,HGNC:291,22q13.1,22:40742504-40783531,22:40346500-40387527,"30 (Autosomal Recessive)","adenylosuccinate lyase deficiency",MONDO:0007068,"0 (No Evidence)",'-,'-,,,4.7,0,1.07,11/06/2015
G,AFF2,HGNC:3776,Xq28,X:147582137-148082193,X:148500617-149000663,"3 (Sufficient Evidence)","FRAXE intellectual disability",MONDO:0010659,"0 (No Evidence)",'-,'-,,,2.76,1,0.28,12/08/2020
G,AGA,HGNC:318,4q34.3,4:178351928-178363591,4:177430774-177442437,"30 (Autosomal Recessive)",aspartylglucosaminuria,MONDO:0008830,"Not Yet Evaluated",'-,'-,,,51.89,0,1.04,08/22/2016
G,AGK,HGNC:21869,7q34,7:141251210-141355044,7:141551410-141655244,"30 (Autosomal Recessive)","Sengers syndrome",MONDO:0008922,"0 (No Evidence)",'-,'-,,,51.17,0,0.88,11/20/2014
G,AGPAT2,HGNC:325,9q34.3,9:139567595-139581909,9:136673143-136687457,"30 (Autosomal Recessive)","congenital generalized lipodystrophy type 1",MONDO:0012071,"0 (No Evidence)",'-,'-,,,74.8,0,1.54,08/22/2016
G,AGRN,HGNC:329,1p36.33,1:955500-991496,1:1020120-1056116,"30 (Autosomal Recessive)","congenital myasthenic syndrome 8",MONDO:0014052,"0 (No Evidence)",'-,'-,,,71.13,0,0.44,08/22/2016
G,AGT,HGNC:333,1q42.2,1:230838269-230881329,1:230702523-230745583,"30 (Autosomal Recessive)","renal tubular dysgenesis of genetic origin",MONDO:0009970,"0 (No Evidence)",'-,'-,,,59.54,0,1.45,11/13/2014
G,AGTR2,HGNC:338,Xq23,X:115301997-115306227,X:116170744-116174974,"0 (No Evidence)","intellectual disability, X-linked 88",MONDO:0010454,"0 (No Evidence)",'-,'-,,,25.02,0.01,1.31,05/10/2012
G,AGXT,HGNC:341,2q37.3,2:241808241-241819917,2:240868824-240880500,"30 (Autosomal Recessive)","primary hyperoxaluria type 1",MONDO:0009823,"Not Yet Evaluated",'-,'-,,,70.08,0,1.03,08/22/2016
G,AHCY,HGNC:343,20q11.22,20:32868074-32899608,20:34231981-34311836,"30 (Autosomal Recessive)","hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase",MONDO:0013404,"0 (No Evidence)",'-,'-,,,18.88,0.04,0.62,06/08/2016
G,AHDC1,HGNC:25230,1p36.11-p35.3,1:27860756-27930655,1:27534245-27604227,"3 (Sufficient Evidence)","AHDC1-related intellectual disability - obstructive sleep apnea - mild dysmorphism syndrome",MONDO:0014358,"0 (No Evidence)",'-,'-,,,18.42,1,0.08,02/28/2018
G,AHI1,HGNC:21575,6q23.3,6:135604670-135818878,6:135283532-135497740,"30 (Autosomal Recessive)","Joubert syndrome 3",MONDO:0012078,"0 (No Evidence)",'-,'-,,,32.57,0,0.95,09/06/2012
G,AICDA,HGNC:13203,12p13.31,12:8754766-8765455,12:8602170-8612859,"30 (Autosomal Recessive)","hyper-IgM syndrome type 2",MONDO:0011528,"Not Yet Evaluated",'-,'-,,,24.45,0,1.33,08/22/2016
G,AIMP1,HGNC:10648,4q24,4:107236701-107270613,4:106315544-106349456,"30 (Autosomal Recessive)","hypomyelinating leukodystrophy 3",MONDO:0009843,"0 (No Evidence)",'-,'-,,,22.3,0,1.22,08/22/2016
G,AKT1,HGNC:391,14q32.33,14:105235686-105262085,14:104769349-104795748,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.05,0.98,0.32,01/25/2022
G,AKT2,HGNC:392,19q13.2,19:40736224-40791252,19:40230317-40285345,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.88,0.64,0.42,05/07/2015
G,AKT3,HGNC:393,1q43-q44,1:243651535-244014381,1:243488233-243851079,"1 (Little Evidence)",microcephaly,MONDO:0001149,"0 (No Evidence)",'-,'-,,,2.71,1,0.18,05/09/2023
G,ALAD,HGNC:395,9q32,9:116148592-116163564,9:113386312-113401284,"30 (Autosomal Recessive)","porphyria due to ALA dehydratase deficiency",MONDO:0013000,"Not Yet Evaluated",'-,'-,,,32.28,0,0.87,08/22/2016
G,ALDH1A3,HGNC:409,15q26.3,15:101420036-101456831,15:100879831-100916626,"30 (Autosomal Recessive)","isolated microphthalmia 8",MONDO:0014050,"0 (No Evidence)",'-,'-,,,34.78,0.14,0.51,08/22/2016
G,ALDH3A2,HGNC:403,17p11.2,17:19551449-19580909,17:19648136-19677596,"30 (Autosomal Recessive)","Sjogren-Larsson syndrome",MONDO:0010031,"Not Yet Evaluated",'-,'-,,,53.41,0,0.83,08/22/2016
G,ALDH4A1,HGNC:406,1p36.13,1:19197924-19229049,1:18871430-18902555,"30 (Autosomal Recessive)","hyperprolinemia type 2",MONDO:0009401,"0 (No Evidence)",'-,'-,,,47.22,0,0.71,04/09/2015
G,ALDH5A1,HGNC:408,6p22.3,6:24495197-24537435,6:24494969-24537207,"30 (Autosomal Recessive)","succinic semialdehyde dehydrogenase deficiency",MONDO:0010083,"0 (No Evidence)",'-,'-,,,66.91,0,0.94,08/22/2016
G,ALDOA,HGNC:414,16p11.2,16:30075600-30081741,16:30064279-30070420,"30 (Autosomal Recessive)","glycogen storage disease due to aldolase A deficiency",MONDO:0012747,"Not Yet Evaluated",'-,'-,,,11.28,0,0.76,08/22/2016
G,ALG1,HGNC:18294,16p13.3,16:5121844-5137380,16:5071843-5087379,"30 (Autosomal Recessive)","ALG1-congenital disorder of glycosylation",MONDO:0012052,"Not Yet Evaluated",'-,'-,,,67.9,0,1.5,08/22/2016
G,ALG12,HGNC:19358,22q13.33,22:50293877-50312086,22:49859311-49918438,"30 (Autosomal Recessive)","ALG12-congenital disorder of glycosylation",MONDO:0011783,"0 (No Evidence)",'-,'-,,,85.41,0,1.03,08/22/2016
G,ALG2,HGNC:23159,9q22.33,9:101978707-101984224,9:99216425-99221942,"30 (Autosomal Recessive)","congenital myasthenic syndrome 14",MONDO:0014543,"Not Yet Evaluated",'-,'-,,,54.65,0,1.18,08/22/2016
G,ALG6,HGNC:23157,1p31.3,1:63833298-63904224,1:63367627-63438553,"30 (Autosomal Recessive)","ALG6-congenital disorder of glycosylation 1C",MONDO:0011291,"Not Yet Evaluated",'-,'-,,,35.38,0,0.64,08/22/2016
G,ALK,HGNC:427,2p23.2-p23.1,2:29415640-30144452,2:29192774-29921586,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.47,0,0.45,12/20/2019
G,ALMS1,HGNC:428,2p13.1,2:73612886-73837046,2:73385758-73609919,"30 (Autosomal Recessive)","Alstrom syndrome",MONDO:0008763,"0 (No Evidence)",'-,'-,,,78.65,0,0.87,08/22/2016
G,ALS2,HGNC:443,2q33.1,2:202564990-202645656,2:201700267-201780933,"30 (Autosomal Recessive)","Alstrom syndrome",MONDO:0008763,"0 (No Evidence)",'-,'-,,,15.08,0,0.52,08/22/2016
G,ALX4,HGNC:450,11p11.2,11:44281990-44331689,11:44260440-44310139,"3 (Sufficient Evidence)","parietal foramina 2",MONDO:0012309,"0 (No Evidence)",'-,'-,,,8.75,0.36,0.52,07/22/2020
G,AMH,HGNC:464,19p13.3,19:2249322-2252072,19:2249323-2252073,"30 (Autosomal Recessive)","persistent Mullerian duct syndrome",MONDO:0009857,"Not Yet Evaluated",'-,'-,,,59.26,0,1.77,08/22/2016
G,AMN,HGNC:14604,14q32.32,14:103389000-103397179,14:102922663-102930842,"30 (Autosomal Recessive)","Imerslund-Grasbeck syndrome type 1",MONDO:0100156,"0 (No Evidence)",'-,'-,,,83.83,0,0.82,08/22/2016
G,ANGPTL3,HGNC:491,1p31.3,1:63063191-63071984,1:62597520-62606313,"30 (Autosomal Recessive)","familial hypobetalipoproteinemia 2",MONDO:0011505,"Not Yet Evaluated",'-,'-,,,48.8,0,1.3,08/22/2016
G,ANK2,HGNC:493,4q25-q26,4:113626778-114304892,4:112705622-113383736,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,24.11,1,0.11,05/22/2019
G,ANKH,HGNC:15492,5p15.2,5:14704909-14871887,5:14704800-14871778,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,40.3,0.28,0.5,02/23/2022
G,ANKRD11,HGNC:21316,16q24.3,16:89334038-89556969,16:89267630-89490561,"3 (Sufficient Evidence)","KBG syndrome",MONDO:0007846,"0 (No Evidence)",'-,'-,,,75.55,1,0.11,06/14/2022
G,ANKRD17,HGNC:23575,4q13.3,4:73939093-74124515,4:73073376-73258798,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,12.36,1,0.06,04/11/2023
G,ANKRD26,HGNC:29186,10p12.1,10:27293045-27389423,10:26947582-27100494,"0 (No Evidence)","thrombocytopenia 2",MONDO:0008555,"0 (No Evidence)","thrombocytopenia 2",MONDO:0008555,,,88.32,0,0.73,10/10/2023
G,ANKS6,HGNC:26724,9q22.33,9:101494291-101558837,9:98732009-98796555,"30 (Autosomal Recessive)","nephronophthisis 16",MONDO:0014158,"Not Yet Evaluated",'-,'-,,,50.29,0,0.69,08/22/2016
G,ANOS1,HGNC:6211,Xp22.31,X:8496915-8700178,X:8528874-8732137,"3 (Sufficient Evidence)","hypogonadotropic hypogonadism 1 with or without anosmia",MONDO:0010635,"0 (No Evidence)",'-,'-,,,60.51,1,0.25,05/26/2021
G,ANTXR2,HGNC:21732,4q21.21,4:80822300-80994626,4:79901146-80073472,"30 (Autosomal Recessive)","hyaline fibromatosis syndrome",MONDO:0009229,"0 (No Evidence)",'-,'-,,,4.33,0.09,0.5,08/22/2016
G,AP1S2,HGNC:560,Xp22.2,X:15843929-15872936,X:15825806-15854813,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability 5",MONDO:0010574,"0 (No Evidence)",'-,'-,,,10.13,0.87,0.45,04/28/2021
G,AP4B1,HGNC:572,1p13.2,1:114436816-114447650,1:113894194-113905028,"30 (Autosomal Recessive)","hereditary spastic paraplegia 47",MONDO:0013551,"0 (No Evidence)",'-,'-,,,41.21,0,0.83,08/22/2016
G,AP4S1,HGNC:575,14q12,14:31494312-31565656,14:31025106-31096450,"30 (Autosomal Recessive)","hereditary spastic paraplegia 52",MONDO:0013552,"0 (No Evidence)",'-,'-,,,19.1,0,1.63,08/22/2016
G,APC,HGNC:583,5q22.2,5:112043195-112181936,5:112707498-112846239,"3 (Sufficient Evidence)","familial adenomatous polyposis 1",MONDO:0021056,"0 (No Evidence)",'-,'-,,,2.19,1,0.16,07/19/2021
G,APOB,HGNC:603,2p24.1,2:21224301-21266945,2:21001429-21044073,"3 (Sufficient Evidence)","familial hypobetalipoproteinemia 1",MONDO:0014252,"0 (No Evidence)",'-,'-,,,12.78,0,0.46,04/09/2020
G,APOC2,HGNC:609,19q13.32,19:45449308-45452822,19:44946051-44949565,"30 (Autosomal Recessive)","familial apolipoprotein C-II deficiency",MONDO:0008810,"Not Yet Evaluated",'-,'-,,,88.9,0.4,0.94,08/22/2016
G,APP,HGNC:620,21q21.3,21:27252861-27543446,21:25880550-26171128,"0 (No Evidence)",'-,'-,"2 (Emerging Evidence)",'-,'-,,,0.94,0.05,0.42,07/06/2012
G,AR,HGNC:644,Xq12,X:66763863-66950461,X:67544021-67730619,"3 (Sufficient Evidence)","androgen insensitivity syndrome",MONDO:0019154,"0 (No Evidence)",'-,'-,,,0.35,0.99,0.29,12/08/2020
G,ARCN1,HGNC:649,11q23.3,11:118443124-118473748,11:118572409-118603033,"3 (Sufficient Evidence)","short stature, rhizomelic, with microcephaly, micrognathia, and developmental delay",MONDO:0014948,"0 (No Evidence)",'-,'-,,,9.21,1,0.1,05/10/2022
G,ARFGEF2,HGNC:15853,20q13.13,20:47538248-47653230,20:48921711-49036693,"30 (Autosomal Recessive)","periventricular heterotopia with microcephaly, autosomal recessive",MONDO:0011966,"0 (No Evidence)",'-,'-,,,27.35,1,0.25,08/22/2016
G,ARG1,HGNC:663,6q23.2,6:131894366-131905469,6:131573226-131584329,"30 (Autosomal Recessive)",hyperargininemia,MONDO:0008814,"0 (No Evidence)",'-,'-,,,33.51,0,0.92,08/22/2016
G,ARHGAP11B,HGNC:15782,15q13.2,15:30918331-30941432,15:30626128-30649229,"0 (No Evidence)",'-,'-,"Not Yet Evaluated",'-,'-,,,81.2,0,1.56,03/28/2023
G,ARHGAP31,HGNC:29216,3q13.32-q13.33,3:119013230-119139561,3:119294383-119420714,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,37.14,1,0.19,06/13/2023
G,ARHGEF4,HGNC:684,2q21.1,2:131594487-131804826,2:130836914-131047253,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,65.32,0,0.55,04/05/2018
G,ARHGEF6,HGNC:685,Xq26.3,X:135747709-135863091,X:136665550-136780932,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,14.42,1,0.14,04/25/2012
G,ARHGEF9,HGNC:14561,Xq11.1,X:62854847-63005094,X:63634967-63785214,"3 (Sufficient Evidence)","X-linked complex neurodevelopmental disorder",MONDO:0100148,"0 (No Evidence)",'-,'-,,,10.55,1,0.15,11/25/2021
G,ARID1A,HGNC:11110,1p36.11,1:27022506-27108595,1:26696015-26782104,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 14",MONDO:0013819,"0 (No Evidence)",'-,'-,,,9.63,1,0.07,05/27/2020
G,ARID1B,HGNC:18040,6q25.3,6:157097160-157531913,6:156776026-157210779,"3 (Sufficient Evidence)","Coffin-Siris syndrome 1",MONDO:0007617,"0 (No Evidence)",'-,'-,,,14.17,1,0.1,05/26/2021
G,ARID2,HGNC:18037,12q12,12:46123489-46301820,12:45729706-45908037,"3 (Sufficient Evidence)","Coffin-Siris syndrome 6",MONDO:0033492,"0 (No Evidence)",'-,'-,,,11.02,1,0.1,06/26/2019
G,ARL6,HGNC:13210,3q11.2,3:97483365-97520086,3:97764521-97801242,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 3",MONDO:0010832,"0 (No Evidence)",'-,'-,,,10.16,0.01,0.92,08/22/2016
G,ARL6IP1,HGNC:697,16p12.3,16:18802989-18812871,16:18791667-18801549,"30 (Autosomal Recessive)","hereditary spastic paraplegia 61",MONDO:0014304,"Not Yet Evaluated",'-,'-,,,17.4,0.02,0.78,08/22/2016
G,ARSA,HGNC:713,22q13.33,22:51061182-51066580,22:50622754-50628152,"30 (Autosomal Recessive)","metachromatic leukodystrophy, juvenile form",MONDO:0009591,"0 (No Evidence)",'-,'-,,,63.58,0,1.34,09/05/2012
G,ARSD,HGNC:717,Xp22.33,X:2822013-2847380,X:2903972-2929339,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,92.29,0,0.86,07/21/2016
G,ARSL,HGNC:719,Xp22.33,X:2852562-2886286,X:2934521-2968245,"3 (Sufficient Evidence)","X-linked chondrodysplasia punctata 1",MONDO:0010555,"0 (No Evidence)",'-,'-,,,89.33,0.59,0.49,07/12/2012
G,ARX,HGNC:18060,Xp21.3,X:25021811-25034082,X:25003694-25015965,"3 (Sufficient Evidence)","X-linked lissencephaly with abnormal genitalia",MONDO:0010268,"0 (No Evidence)",'-,'-,,,20.25,0.91,0.39,12/05/2019
G,ASAH1,HGNC:735,8p22,8:17913501-17942470,8:18055992-18084961,"30 (Autosomal Recessive)","Farber lipogranulomatosis",MONDO:0009218,"0 (No Evidence)",'-,'-,,,65.81,0,1.18,09/12/2017
G,ASH1L,HGNC:19088,1q22,1:155305059-155532594,1:155335268-155563202,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,23.94,1,0.06,12/27/2017
G,ASL,HGNC:746,7q11.21,7:65540806-65558563,7:66075819-66093576,"30 (Autosomal Recessive)","argininosuccinic aciduria",MONDO:0008815,"Not Yet Evaluated",'-,'-,,,18.56,0,0.94,08/22/2016
G,ASPA,HGNC:756,17p13.2,17:3377404-3406699,17:3474110-3503405,"30 (Autosomal Recessive)","Canavan disease",MONDO:0010079,"0 (No Evidence)",'-,'-,,,37.65,0,1.1,08/22/2016
G,ASPH,HGNC:757,8q12.3,8:62413115-62627151,8:61500556-61714592,"30 (Autosomal Recessive)","facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome",MONDO:0011106,"Not Yet Evaluated",'-,'-,,,46.75,0,0.82,08/22/2016
G,ASPM,HGNC:19048,1q31.3,1:197053257-197115799,1:197084127-197146669,"30 (Autosomal Recessive)","microcephaly 5, primary, autosomal recessive",MONDO:0012106,"0 (No Evidence)",'-,'-,,,41.31,0,0.74,08/22/2016
G,ASTN2,HGNC:17021,9q33.1,9:119185391-120177335,9:116423112-117415057,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,2.19,1,0.25,03/09/2021
G,ASXL1,HGNC:18318,20q11.21,20:30946134-31027122,20:32358331-32439319,"3 (Sufficient Evidence)","Bohring-Opitz syndrome",MONDO:0011510,"0 (No Evidence)",'-,'-,,,20.78,0,0.79,03/14/2013
G,ASXL2,HGNC:23805,2p23.3,2:25956622-26101356,2:25733753-25878487,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,43.83,1,0.15,06/28/2018
G,ASXL3,HGNC:29357,18q12.1,18:31158183-31331159,18:33578219-33751195,"3 (Sufficient Evidence)","severe feeding difficulties-failure to thrive-microcephaly due to ASXL3 deficiency syndrome",MONDO:0014205,"0 (No Evidence)",'-,'-,,,13.78,1,0.2,11/22/2017
G,ATCAY,HGNC:779,19p13.3,19:3880683-3928080,19:3880685-3928082,"30 (Autosomal Recessive)","Cayman type cerebellar ataxia",MONDO:0011025,"Not Yet Evaluated",'-,'-,,,64.83,0.62,0.45,08/22/2016
G,ATF6,HGNC:791,1q23.3,1:161736110-161933860,1:161766320-161964070,"30 (Autosomal Recessive)","achromatopsia 7",MONDO:0014677,"0 (No Evidence)",'-,'-,,,26.14,0,0.7,01/12/2017
G,ATM,HGNC:795,11q22.3,11:108093794-108239829,11:108223067-108369102,"3 (Sufficient Evidence)","ataxia telangiectasia",MONDO:0008840,"0 (No Evidence)",'-,'-,,,0.97,0,0.71,04/08/2020
G,ATP10A,HGNC:13542,15q12,15:25923859-26108349,15:25672237-25865088,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,68.57,0,0.43,04/25/2012
G,ATP13A2,HGNC:30213,1p36.13,1:17312453-17338423,1:16985958-17011928,"30 (Autosomal Recessive)","Kufor-Rakeb syndrome",MONDO:0011706,"Not Yet Evaluated",'-,'-,,,35.38,0,0.58,08/22/2016
G,ATP2A1,HGNC:811,16p11.2,16:28889809-28915787,16:28878488-28904466,"30 (Autosomal Recessive)","Brody myopathy",MONDO:0010977,"0 (No Evidence)",'-,'-,,,24.7,0,0.83,08/22/2016
G,ATP2C2,HGNC:29103,16q24.1,16:84402144-84497793,16:84368538-84464187,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,70.21,0,1.84,09/17/2018
G,ATP6AP2,HGNC:18305,Xp11.4,X:40440222-40466100,X:40580970-40606848,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,35.15,0.87,0.43,10/31/2012
G,ATP6V0A2,HGNC:18481,12q24.31,12:124196900-124246302,12:123712353-123761755,"30 (Autosomal Recessive)","autosomal recessive cutis laxa type 2A",MONDO:0018163,"0 (No Evidence)",'-,'-,,,46.77,0,0.75,08/22/2016
G,ATP6V0A4,HGNC:866,7q34,7:138391039-138482941,7:138706294-138798196,"30 (Autosomal Recessive)","renal tubular acidosis, distal, 3, with or without sensorineural hearing loss",MONDO:0011268,"Not Yet Evaluated",'-,'-,,,54.41,0,1,08/22/2016
G,ATP6V1E1,HGNC:857,22q11.21,22:18074902-18111588,22:17592136-17628822,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,39.36,0.53,0.51,04/26/2012
G,ATP7A,HGNC:869,Xq21.1,X:77166190-77305892,X:77910693-78050395,"3 (Sufficient Evidence)","Menkes disease",MONDO:0010651,"0 (No Evidence)",'-,'-,,,30.07,1,0.22,03/24/2021
G,ATP7B,HGNC:870,13q14.3,13:52506805-52585586,13:51932669-52012132,"30 (Autosomal Recessive)","Wilson disease",MONDO:0010200,"0 (No Evidence)",'-,'-,,,64.5,0,1.19,01/12/2017
G,ATP8A2,HGNC:13533,13q12.13,13:25946112-26599989,13:25371974-26025851,"30 (Autosomal Recessive)","cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4",MONDO:0014104,"0 (No Evidence)",'-,'-,,,24.95,0,0.6,03/28/2023
G,ATPAF2,HGNC:18802,17p11.2,17:17921335-17942482,17:18015059-18039168,"30 (Autosomal Recessive)","mitochondrial complex V (ATP synthase) deficiency, nuclear type 1",MONDO:0011421,"0 (No Evidence)",'-,'-,,,45.43,0,1.44,08/22/2016
G,ATR,HGNC:882,3q23,3:142168077-142297575,3:142449235-142578733,"1 (Little Evidence)","familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome",MONDO:0013806,"0 (No Evidence)",'-,'-,,,8.61,0,0.4,06/05/2020
G,ATRX,HGNC:886,Xq21.1,X:76760358-77041702,X:77504880-77786216,"3 (Sufficient Evidence)","alpha thalassemia-X-linked intellectual disability syndrome",MONDO:0010519,"0 (No Evidence)",'-,'-,,,6.65,1,0.12,07/31/2012
G,AUTS2,HGNC:14262,7q11.22,7:69063461-70258492,7:69598475-70793506,"3 (Sufficient Evidence)","autism spectrum disorder due to AUTS2 deficiency",MONDO:0014361,"0 (No Evidence)",'-,'-,,,0.51,1,0.25,06/24/2020
G,AVPR2,HGNC:897,Xq28,X:153168079-153172620,X:153902625-153907166,"3 (Sufficient Evidence)","diabetes insipidus, nephrogenic, X-linked",MONDO:0010581,"0 (No Evidence)",'-,'-,,,12.7,0.56,0.72,02/01/2021
G,AXIN2,HGNC:904,17q24.1,17:63524681-63557766,17:65528563-65561648,"3 (Sufficient Evidence)","oligodontia-cancer predisposition syndrome",MONDO:0012075,"0 (No Evidence)",'-,'-,,,4.92,0.57,0.4,12/08/2021
G,B3GALNT2,HGNC:28596,1q42.3,1:235610505-235667752,1:235439796-235504452,"30 (Autosomal Recessive)","muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11",MONDO:0014071,"Not Yet Evaluated",'-,'-,,,60.43,0,0.84,08/22/2016
G,B3GALT6,HGNC:17978,1p36.33,1:1167617-1170421,1:1232237-1235041,"30 (Autosomal Recessive)","spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures",MONDO:0010075,"0 (No Evidence)",'-,'-,,,73.2,0.02,1.43,08/22/2016
G,B4GALT1,HGNC:924,9p21.1,9:33104075-33167334,9:33104077-33185089,"30 (Autosomal Recessive)","B4GALT1-congenital disorder of glycosylation",MONDO:0011772,"0 (No Evidence)",'-,'-,,,58.79,0.04,0.7,08/22/2016
G,B4GALT7,HGNC:930,5q35.3,5:177027133-177037331,5:177600132-177610330,"30 (Autosomal Recessive)","Ehlers-Danlos syndrome, spondylodysplastic type, 1",MONDO:0020682,"0 (No Evidence)",'-,'-,,,41.46,0,1.11,08/22/2016
G,B9D1,HGNC:24123,17p11.2,17:19238008-19281226,17:19334695-19377913,"30 (Autosomal Recessive)","Joubert syndrome 27",MONDO:0014927,"0 (No Evidence)",'-,'-,,,54.99,0,0.95,08/22/2016
G,BAG3,HGNC:939,10q26.11,10:121410892-121437331,10:119651380-119677819,"3 (Sufficient Evidence)","dilated cardiomyopathy 1HH",MONDO:0013479,"0 (No Evidence)",'-,'-,,,55.47,0.62,0.45,02/12/2015
G,BAP1,HGNC:950,3p21.1,3:52435024-52444024,3:52401008-52410008,"3 (Sufficient Evidence)","BAP1-related tumor predisposition syndrome",MONDO:0013692,"0 (No Evidence)",'-,'-,,,18.49,0.99,0.28,12/27/2019
G,BARD1,HGNC:952,2q35,2:215590370-215674407,2:214725646-214809683,"3 (Sufficient Evidence)","hereditary breast carcinoma",MONDO:0016419,"0 (No Evidence)",'-,'-,,,33.35,0,1.36,05/01/2020
G,BBS12,HGNC:26648,4q27,4:123653859-123666094,4:122700442-122744939,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 12",MONDO:0014440,"0 (No Evidence)",'-,'-,,,80.48,0,0.96,08/22/2016
G,BBS5,HGNC:970,2q31.1,2:170336004-170363165,2:169479494-169506655,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 5",MONDO:0014434,"0 (No Evidence)",'-,'-,,,9.97,0,0.89,10/12/2015
G,BBS7,HGNC:18758,4q27,4:122745484-122791629,4:121824329-121870474,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 7",MONDO:0014435,"Not Yet Evaluated",'-,'-,,,20.8,0,0.74,08/22/2016
G,BCAP31,HGNC:16695,Xq28,X:152965947-152989842,X:153700492-153724387,"3 (Sufficient Evidence)","severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome",MONDO:0010334,"0 (No Evidence)",'-,'-,,,31.87,0.43,0.65,08/08/2023
G,BCHE,HGNC:983,3q26.1,3:165490692-165555211,3:165772904-165837423,"30 (Autosomal Recessive)","butyrylcholinesterase deficiency",MONDO:0015270,"Not Yet Evaluated",'-,'-,,,14.36,0,1.33,08/22/2016
G,BCKDHB,HGNC:987,6q14.1,6:80816327-81055987,6:80106610-80466676,"30 (Autosomal Recessive)","maple syrup urine disease",MONDO:0009563,"Not Yet Evaluated",'-,'-,,,21.83,0,1.1,08/22/2016
G,BCKDK,HGNC:16902,16p11.2,16:31119707-31124159,16:31108386-31117640,"30 (Autosomal Recessive)","branched-chain keto acid dehydrogenase kinase deficiency",MONDO:0013970,"Not Yet Evaluated",'-,'-,,,35.16,0,0.87,08/22/2016
G,BCL11A,HGNC:13221,2p16.1,2:60677655-60780789,2:60450520-60553924,"3 (Sufficient Evidence)","Dias-Logan syndrome",MONDO:0014914,"0 (No Evidence)",'-,'-,,,0.61,0.97,0.32,04/13/2017
G,BCL2L11,HGNC:994,2q13,2:111878491-111926022,2:111120914-111168445,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,38.11,0.89,0.42,06/21/2018
G,BCLAF1,HGNC:16863,6q23.3,6:136577765-136610984,6:136256627-136289846,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.44,0,0.93,06/28/2018
G,BCOR,HGNC:20893,Xp11.4,X:39910499-40036582,X:40051246-40177329,"3 (Sufficient Evidence)","microphthalmia, syndromic 2",MONDO:0010261,"0 (No Evidence)",'-,'-,,,16.71,1,0.14,10/04/2012
G,BCR,HGNC:1014,22q11.23,22:23522696-23660224,22:23180509-23318037,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.65,0.99,0.3,07/10/2012
G,BCS1L,HGNC:1020,2q35,2:219524406-219528166,2:218658743-218663443,"30 (Autosomal Recessive)","Bjornstad syndrome",MONDO:0009872,"0 (No Evidence)",'-,'-,,,13.17,0,1.24,08/22/2016
G,BIN1,HGNC:1052,2q14.3,2:127805599-127864730,2:127048023-127107154,"30 (Autosomal Recessive)","myopathy, centronuclear, 2",MONDO:0009709,"Not Yet Evaluated",'-,'-,,,41.75,0.78,0.37,08/22/2016
G,BLM,HGNC:1058,15q26.1,15:91260577-91359396,15:90717346-90816166,"30 (Autosomal Recessive)","Bloom syndrome",MONDO:0008876,"0 (No Evidence)",'-,'-,,,37.81,0,0.75,02/09/2022
G,BLNK,HGNC:14211,10q24.1,10:97948927-98031326,10:96189171-96271569,"30 (Autosomal Recessive)","agammaglobulinemia 4, autosomal recessive",MONDO:0013289,"0 (No Evidence)",'-,'-,,,35.7,0.61,0.39,08/22/2016
G,BMP4,HGNC:1071,14q22.2,14:54416454-54423609,14:53949736-53956891,"2 (Emerging Evidence)","microphthalmia with brain and digit anomalies",MONDO:0011936,"0 (No Evidence)",'-,'-,,,0.22,0.96,0.33,11/09/2021
G,BMPER,HGNC:24154,7p14.3,7:33944527-34196039,7:33904915-34156427,"30 (Autosomal Recessive)",diaphanospondylodysostosis,MONDO:0011946,"Not Yet Evaluated",'-,'-,,,15,0,0.66,08/22/2016
G,BMPR1A,HGNC:1076,10q23.2,10:88516376-88687726,10:86755763-86932844,"3 (Sufficient Evidence)","juvenile polyposis syndrome",MONDO:0017380,"0 (No Evidence)",'-,'-,,,30.17,0.9,0.36,06/24/2020
G,BMPR2,HGNC:1078,2q33.1-q33.2,2:203241050-203432472,2:202376327-202567749,"3 (Sufficient Evidence)","pulmonary hypertension, primary, 1",MONDO:0024533,"0 (No Evidence)",'-,'-,,,1.48,1,0.19,08/26/2020
G,BPHL,HGNC:1094,6p25.2,6:3118610-3153812,6:3118376-3153578,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,69.92,0,1.35,02/02/2021
G,BPNT2,HGNC:26019,8q12.1,8:57870490-57906426,8:56957931-56993867,"30 (Autosomal Recessive)","chondrodysplasia with joint dislocations, gPAPP type",MONDO:0013561,"Not Yet Evaluated",'-,'-,,,43.21,0.02,0.84,08/22/2016
G,BPTF,HGNC:3581,17q24.2,17:65821619-65980494,17:67825503-67984378,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,36.79,1,0.1,07/12/2022
G,BPY2,HGNC:13508,Yq11.223,Y:25130410-25151612,Y:22984263-23005465,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,94.47,‐,‐,08/22/2012
G,BRAF,HGNC:1097,7q34,7:140413128-140624729,7:140713328-140924929,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,8.98,1,0.21,08/04/2014
G,BRAT1,HGNC:21701,7p22.3,7:2577444-2595158,7:2537810-2555524,"30 (Autosomal Recessive)","neonatal-onset encephalopathy with rigidity and seizures",MONDO:0013784,"0 (No Evidence)",'-,'-,,,81.22,0,1,08/22/2016
G,BRCA1,HGNC:1100,17q21.31,17:41196312-41277381,17:43044295-43170327,"3 (Sufficient Evidence)","breast-ovarian cancer, familial, susceptibility to, 1",MONDO:0011450,"0 (No Evidence)",'-,'-,,,1.2,0,0.92,09/23/2021
G,BRCA2,HGNC:1101,13q13.1,13:32889645-32974405,13:32315508-32400268,"3 (Sufficient Evidence)","breast-ovarian cancer, familial, susceptibility to, 2",MONDO:0012933,"0 (No Evidence)",'-,'-,,,13.3,0,0.64,07/14/2021
G,BRIP1,HGNC:20473,17q23.2,17:59756500-59940889,17:61679139-61863528,"3 (Sufficient Evidence)","hereditary breast carcinoma",MONDO:0016419,"0 (No Evidence)",'-,'-,,,17.47,0,0.79,02/15/2019
G,BRPF1,HGNC:14255,3p25.3,3:9773419-9789699,3:9731735-9748015,"3 (Sufficient Evidence)","intellectual developmental disorder with dysmorphic facies and ptosis",MONDO:0015022,"0 (No Evidence)",'-,'-,,,15.78,1,0.18,08/23/2023
G,BRWD3,HGNC:17342,Xq21.1,X:79925002-80065376,X:80669503-80809877,"3 (Sufficient Evidence)","X-linked intellectual disability",MONDO:0100284,"0 (No Evidence)",'-,'-,,,28.63,1,0.08,08/24/2022
G,BSND,HGNC:16512,1p32.3,1:55464606-55482845,1:54998933-55017172,"30 (Autosomal Recessive)","Bartter disease type 4A",MONDO:0011242,"0 (No Evidence)",'-,'-,,,78.77,0,1.78,05/17/2012
G,BTD,HGNC:1122,3p25.1,3:15642859-15764023,3:15601361-15722516,"30 (Autosomal Recessive)","biotinidase deficiency",MONDO:0009665,"0 (No Evidence)",'-,'-,,,76.15,0,1.3,05/21/2015
G,BTK,HGNC:1133,Xq22.1,X:100604438-100645784,X:101349450-101390796,"3 (Sufficient Evidence)","Bruton-type agammaglobulinemia",MONDO:0010421,"0 (No Evidence)",'-,'-,,,4.3,1,0.1,03/24/2021
G,BUB1B,HGNC:1149,15q15.1,15:40453270-40513324,15:40161069-40221123,"30 (Autosomal Recessive)","mosaic variegated aneuploidy syndrome 1",MONDO:0009759,"0 (No Evidence)",'-,'-,,,14.21,0,0.58,02/02/2022
G,C19orf12,HGNC:25443,19q12,19:30189793-30206696,19:29698886-29715789,"30 (Autosomal Recessive)","neurodegeneration with brain iron accumulation 4",MONDO:0013674,"0 (No Evidence)",'-,'-,,,77.08,0.34,1.06,08/22/2016
G,C1QB,HGNC:1242,1p36.12,1:22979729-22988130,1:22653236-22661637,"30 (Autosomal Recessive)","C1Q deficiency",MONDO:0013343,"0 (No Evidence)",'-,'-,,,69.46,0.15,1.04,01/17/2017
G,CA12,HGNC:1371,15q22.2,15:63613577-63674045,15:63321378-63381846,"30 (Autosomal Recessive)","isolated hyperchlorhidrosis",MONDO:0007747,"Not Yet Evaluated",'-,'-,,,56.48,0,1.33,08/22/2016
G,CA5A,HGNC:1377,16q24.2,16:87915155-87970135,16:87881549-87936529,"30 (Autosomal Recessive)","hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency",MONDO:0014332,"0 (No Evidence)",'-,'-,,,88.4,0,0.97,08/22/2016
G,CA8,HGNC:1382,8q12.1,8:61097971-61193959,8:60185412-60281400,"30 (Autosomal Recessive)","cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 3",MONDO:0013188,"0 (No Evidence)",'-,'-,,,10.02,0.01,0.67,08/22/2016
G,CABP2,HGNC:1385,11q13.2,11:67286383-67290917,11:67518912-67523446,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 93",MONDO:0013963,"0 (No Evidence)",'-,'-,,,58.19,0,0.97,08/20/2021
G,CABP4,HGNC:1386,11q13.2,11:67219874-67229223,11:67452403-67461752,"30 (Autosomal Recessive)","cone-rod synaptic disorder, congenital nonprogressive",MONDO:0012490,"0 (No Evidence)",'-,'-,,,71.95,0,1.54,08/22/2016
G,CACNA1A,HGNC:1388,19p13.13,19:13317256-13617293,19:13206442-13506479,"3 (Sufficient Evidence)","episodic ataxia type 2",MONDO:0007163,"0 (No Evidence)",'-,'-,,,35.52,1,0.13,05/21/2017
G,CACNA1C,HGNC:1390,12p13.33,12:2162153-2807116,12:1970780-2697950,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,8.42,1,0.1,03/24/2016
G,CACNA1S,HGNC:1397,1q32.1,1:201008640-201081554,1:201039512-201112426,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,25.88,0,0.52,01/18/2016
G,CADPS2,HGNC:16018,7q31.32,7:121958465-122526514,7:122318411-122886460,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.53,0.37,0.34,07/10/2012
G,CALM1,HGNC:1442,14q32.11,14:90862846-90874612,14:90396502-90408268,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.15,0.94,0.33,12/12/2023
G,CAMK2A,HGNC:1460,5q32,5:149599054-149669693,5:150219491-150290130,"1 (Little Evidence)","intellectual disability, autosomal dominant 53",MONDO:0030919,"0 (No Evidence)",'-,'-,,,5.97,1,0.25,05/24/2023
G,CAMK2B,HGNC:1461,7p13,7:44256753-44365193,7:44217154-44326013,"1 (Little Evidence)","intellectual disability, autosomal dominant 54",MONDO:0030920,"0 (No Evidence)",'-,'-,,,16.28,0.74,0.36,01/25/2023
G,CAMTA1,HGNC:18806,1p36.31-p36.23,1:6845514-7829766,1:6785454-7769706,"3 (Sufficient Evidence)","cerebellar dysfunction with variable cognitive and behavioral abnormalities",MONDO:0013886,"0 (No Evidence)",'-,'-,,,2.22,1,0.17,12/14/2017
G,CANT1,HGNC:19721,17q25.3,17:76987798-77005846,17:78991716-79009764,"30 (Autosomal Recessive)","Desbuquois dysplasia 1",MONDO:0009629,"Not Yet Evaluated",'-,'-,,,65.38,0,1.31,08/22/2016
G,CAPN3,HGNC:1480,15q15.1,15:42651699-42704515,15:42359501-42412317,"30 (Autosomal Recessive)","autosomal recessive limb-girdle muscular dystrophy type 2A",MONDO:0009675,"0 (No Evidence)",'-,'-,,,21.69,0,0.97,08/22/2016
G,CARD14,HGNC:16446,17q25.3,17:78143829-78183130,17:80170030-80209331,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,75.93,0,1,08/01/2013
G,CASK,HGNC:1497,Xp11.4,X:41374187-41782807,X:41514934-41923554,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Najm type",MONDO:0010417,"0 (No Evidence)",'-,'-,,,3.08,1,0.07,06/28/2012
G,CASP10,HGNC:1500,2q33.1,2:202047864-202094129,2:201183141-201229406,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,89.09,0,1.29,04/10/2020
G,CASQ2,HGNC:1513,1p13.1,1:116242642-116311335,1:115700021-115768714,"30 (Autosomal Recessive)","catecholaminergic polymorphic ventricular tachycardia 2",MONDO:0012762,"Not Yet Evaluated",'-,'-,,,18.61,0,1.38,08/22/2016
G,CASR,HGNC:1514,3q13.33-q21.1,3:121902515-122010476,3:122183668-122291629,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,3.37,0.05,0.45,03/02/2012
G,CASZ1,HGNC:26002,1p36.22,1:10696661-10856703,1:10636604-10796646,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.36,1,0.15,04/25/2019
G,CATSPER2,HGNC:18810,15q15.3,15:43920701-43941082,15:43628503-43648884,"30 (Autosomal Recessive)",'-,'-,"0 (No Evidence)",'-,'-,,,73.76,0,1.22,09/20/2012
G,CBFB,HGNC:1539,16q22.1,16:67063052-67134961,16:67029149-67101058,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.25,0.96,0.33,02/22/2012
G,CBL,HGNC:1541,11q23.3,11:119077049-119178859,11:119206339-119308149,"0 (No Evidence)","CBL-related disorder",MONDO:0013308,"0 (No Evidence)",'-,'-,,,3.6,0,0.5,02/14/2024
G,CBS,HGNC:1550,21q22.3,21:44473301-44496983,21:43053191-43076873,"30 (Autosomal Recessive)","classic homocystinuria",MONDO:0009352,"0 (No Evidence)",'-,'-,,,40.28,0,0.73,08/22/2016
G,CBY2,HGNC:30720,13q14.13,13:46276455-46288694,13:45702320-45714559,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,62.14,0,1.09,02/03/2021
G,CC2D2A,HGNC:29253,4p15.32,4:15471489-15603180,4:15469865-15601557,"30 (Autosomal Recessive)","Joubert syndrome and related disorders",MONDO:0015369,"0 (No Evidence)",'-,'-,,,79.39,0,0.78,07/17/2013
G,CCBE1,HGNC:29426,18q21.32,18:57098171-57364655,18:59430939-59697721,"30 (Autosomal Recessive)","Hennekam lymphangiectasia-lymphedema syndrome 1",MONDO:0009337,"Not Yet Evaluated",'-,'-,,,44.75,0,1.01,08/22/2016
G,CCDC103,HGNC:32700,17q21.31,17:42977097-42982758,17:44899729-44905390,"30 (Autosomal Recessive)","primary ciliary dyskinesia 17",MONDO:0013854,"Not Yet Evaluated",'-,'-,,,67.25,0,1.36,08/22/2016
G,CCDC39,HGNC:25244,3q26.33,3:180331796-180397277,3:180614008-180679489,"30 (Autosomal Recessive)","primary ciliary dyskinesia 14",MONDO:0013434,"0 (No Evidence)",'-,'-,,,54.04,0,0.75,08/22/2016
G,CCDC40,HGNC:26090,17q25.3,17:78010441-78074412,17:80036642-80100613,"30 (Autosomal Recessive)","primary ciliary dyskinesia 15",MONDO:0013435,"Not Yet Evaluated",'-,'-,,,95.52,0,0.85,08/22/2016
G,CCDC8,HGNC:25367,19q13.32,19:46913586-46916821,19:46410329-46413564,"30 (Autosomal Recessive)","3M syndrome 3",MONDO:0013627,"0 (No Evidence)",'-,'-,,,90.02,0.25,0.83,08/22/2016
G,CCN6,HGNC:12771,6q21,6:112375307-112390889,6:112052813-112069686,"30 (Autosomal Recessive)","progressive pseudorheumatoid arthropathy of childhood",MONDO:0008827,"Not Yet Evaluated",'-,'-,,,48.76,0,0.84,08/22/2016
G,CCNQ,HGNC:28434,Xq28,X:152853383-152864595,X:153587925-153599139,"2 (Emerging Evidence)","syndactyly-telecanthus-anogenital and renal malformations syndrome",MONDO:0010408,"0 (No Evidence)",'-,'-,,,61.79,0.9,0.4,12/01/2021
G,CCT5,HGNC:1618,5p15.2,5:10250033-10266524,5:10249921-10266412,"30 (Autosomal Recessive)","hereditary sensory and autonomic neuropathy with spastic paraplegia",MONDO:0009748,"0 (No Evidence)",'-,'-,,,23.05,1,0.19,08/22/2016
G,CD19,HGNC:1633,16p11.2,16:28943292-28950663,16:28931971-28939342,"30 (Autosomal Recessive)","immunodeficiency, common variable, 3",MONDO:0013283,"Not Yet Evaluated",'-,'-,,,36.07,0.9,0.36,08/22/2016
G,CD27,HGNC:11922,12p13.31,12:6554121-6560879,12:6443892-6451713,"30 (Autosomal Recessive)","lymphoproliferative syndrome 2",MONDO:0014054,"Not Yet Evaluated",'-,'-,,,67.27,0.01,0.92,07/28/2023
G,CD36,HGNC:1663,7q21.11,7:80231523-80308593,7:80602207-80679274,"30 (Autosomal Recessive)","platelet-type bleeding disorder 10",MONDO:0012031,"Not Yet Evaluated",'-,'-,,,15.69,0,2,08/22/2016
G,CD3D,HGNC:1673,11q23.3,11:118209669-118213420,11:118338954-118342705,"30 (Autosomal Recessive)","immunodeficiency 19",MONDO:0014280,"Not Yet Evaluated",'-,'-,,,84.89,0,1.46,08/22/2016
G,CD3E,HGNC:1674,11q23.3,11:118175445-118186888,11:118304730-118316173,"30 (Autosomal Recessive)","immunodeficiency 18",MONDO:0014278,"0 (No Evidence)",'-,'-,,,86.63,0,0.92,05/09/2017
G,CD3G,HGNC:1675,11q23.3,11:118215059-118225876,11:118344344-118355161,"30 (Autosomal Recessive)","combined immunodeficiency due to CD3gamma deficiency",MONDO:0014276,"Not Yet Evaluated",'-,'-,,,82.39,0,1.22,08/22/2016
G,CD40LG,HGNC:11935,Xq26.3,X:135730317-135742549,X:136648158-136660390,"3 (Sufficient Evidence)","hyper-IgM syndrome type 1",MONDO:0010626,"0 (No Evidence)",'-,'-,,,8.39,0.72,0.56,04/08/2020
G,CD59,HGNC:1689,11p13,11:33724556-33758025,11:33703010-33736479,"30 (Autosomal Recessive)","primary CD59 deficiency",MONDO:0012858,"Not Yet Evaluated",'-,'-,,,97.5,0.61,1,08/22/2016
G,CD8A,HGNC:1706,2p11.2,2:87011728-87035519,2:86784605-86808396,"30 (Autosomal Recessive)","susceptibility to respiratory infections associated with CD8alpha chain mutation",MONDO:0012161,"0 (No Evidence)",'-,'-,,,84.5,0,1.5,08/22/2016
G,CDAN1,HGNC:1713,15q15.2,15:43015742-43029326,15:42723544-42737128,"30 (Autosomal Recessive)","anemia, congenital dyserythropoietic, type 1a",MONDO:0009135,"0 (No Evidence)",'-,'-,,,40.71,0,0.68,08/22/2016
G,CDC42BPB,HGNC:1738,14q32.32,14:103398717-103523886,14:102932380-103057549,"1 (Little Evidence)","autism spectrum disorder",MONDO:0005258,"0 (No Evidence)",'-,'-,,,65.08,1,0.12,10/24/2018
G,CDC73,HGNC:16783,1q31.2,1:193091161-193223945,1:193122031-193254815,"3 (Sufficient Evidence)","hyperparathyroidism 2 with jaw tumors",MONDO:0007768,"0 (No Evidence)",'-,'-,,,11.74,1,0.19,04/13/2022
G,CDH1,HGNC:1748,16q22.1,16:68771195-68869440,16:68737292-68835537,"3 (Sufficient Evidence)","hereditary diffuse gastric adenocarcinoma",MONDO:0007648,"0 (No Evidence)",'-,'-,,,0.51,0.15,0.43,04/10/2020
G,CDH15,HGNC:1754,16q24.3,16:89238156-89261900,16:89171748-89195492,"0 (No Evidence)","intellectual disability, autosomal dominant 3",MONDO:0012946,"0 (No Evidence)",'-,'-,,,74.65,0,1.11,08/08/2013
G,CDH23,HGNC:13733,10q22.1,10:73156677-73575704,10:71396920-71815947,"30 (Autosomal Recessive)","inherited auditory system disease",MONDO:0037940,"Not Yet Evaluated",'-,'-,,,15.83,0,0.57,08/22/2016
G,CDHR1,HGNC:14550,10q23.1,10:85954293-85979377,10:84194537-84219621,"30 (Autosomal Recessive)","cone-rod dystrophy 15",MONDO:0013348,"Not Yet Evaluated",'-,'-,,,54.74,0,1.31,08/22/2016
G,CDIN1,HGNC:26929,15q14,15:36871827-37102445,15:36579626-36810244,"30 (Autosomal Recessive)","congenital dyserythropoietic anemia type type 1B",MONDO:0014285,"Not Yet Evaluated",'-,'-,,,2.88,0,1.06,08/22/2016
G,CDK13,HGNC:1733,7p14.1,7:39989855-40139179,7:39950256-40099580,"2 (Emerging Evidence)","syndromic intellectual disability",MONDO:0000508,"Not Yet Evaluated",'-,'-,,,11.16,0.91,0.32,02/23/2022
G,CDK4,HGNC:1773,12q14.1,12:58141510-58146093,12:57747727-57752310,"0 (No Evidence)","melanoma, cutaneous malignant, susceptibility to, 3",MONDO:0012183,"0 (No Evidence)",'-,'-,,,1.03,0.06,0.64,09/02/2020
G,CDK5RAP2,HGNC:18672,9q33.2,9:123151153-123342445,9:120388875-120580167,"30 (Autosomal Recessive)","microcephaly 3, primary, autosomal recessive",MONDO:0011488,"Not Yet Evaluated",'-,'-,,,55.08,0,0.66,08/22/2016
G,CDK6,HGNC:1777,7q21.2,7:92234235-92465887,7:92604921-92836573,"30 (Autosomal Recessive)","microcephaly 12, primary, autosomal recessive",MONDO:0014484,"Not Yet Evaluated",'-,'-,,,1.6,0.98,0.28,08/22/2016
G,CDKL5,HGNC:11411,Xp22.13,X:18443728-18671749,X:18425608-18653629,"3 (Sufficient Evidence)","developmental and epileptic encephalopathy, 2",MONDO:0010396,"0 (No Evidence)",'-,'-,,,13.18,1,0.23,07/12/2012
G,CDKN1B,HGNC:1785,12p13.1,12:12870302-12875303,12:12717368-12722369,"3 (Sufficient Evidence)","multiple endocrine neoplasia type 4",MONDO:0012552,"0 (No Evidence)",'-,'-,,,1.36,0.62,0.65,07/08/2020
G,CDKN1C,HGNC:1786,11p15.4,11:2904448-2907005,11:2883218-2885775,"3 (Sufficient Evidence)","Beckwith-Wiedemann syndrome",MONDO:0007534,"0 (No Evidence)",'-,'-,,,24.52,0.82,0.53,09/25/2020
G,CDKN2A,HGNC:1787,9p21.3,9:21967751-21995323,9:21967752-21995324,"3 (Sufficient Evidence)","melanoma, cutaneous malignant, susceptibility to, 2",MONDO:0007964,"0 (No Evidence)",'-,'-,,,0.81,0.39,0.95,03/18/2022
G,CDT1,HGNC:24576,16q24.3,16:88870197-88875666,16:88803789-88809258,"30 (Autosomal Recessive)","Meier-Gorlin syndrome 4",MONDO:0013431,"Not Yet Evaluated",'-,'-,,,45.26,0,1.22,08/22/2016
G,CDY1,HGNC:1809,Yq11.23,Y:27768264-27771049,Y:25622115-25625511,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,93.18,‐,‐,08/22/2012
G,CEBPA,HGNC:1833,19q13.11,19:33790840-33793470,19:33299934-33302534,"0 (No Evidence)","acute myeloid leukemia",MONDO:0018874,"0 (No Evidence)",'-,'-,,,47.24,0.55,1.18,06/09/2022
G,CEBPE,HGNC:1836,14q11.2,14:23586515-23588464,14:23117306-23119255,"30 (Autosomal Recessive)","specific granule deficiency 1",MONDO:0044207,"Not Yet Evaluated",'-,'-,,,30.23,0.01,1,08/22/2016
G,CELF4,HGNC:14015,18q12.2,18:34823003-35145761,18:37242844-37565798,"1 (Little Evidence)","intellectual disability",MONDO:0001071,"0 (No Evidence)",'-,'-,,,4.37,1,0.23,12/07/2022
G,CENPJ,HGNC:17272,13q12.12-q12.13,13:25456417-25496999,13:24882279-24934000,"30 (Autosomal Recessive)","microcephaly 6, primary, autosomal recessive",MONDO:0012029,"Not Yet Evaluated",'-,'-,,,54.37,0,0.97,08/22/2016
G,CENPP,HGNC:32933,9q22.31,9:95087750-95382811,9:92325468-92620529,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,76.86,0.05,0.68,09/19/2012
G,CEP164,HGNC:29182,11q23.3,11:117192494-117283982,11:117321778-117413266,"30 (Autosomal Recessive)","nephronophthisis 15",MONDO:0013917,"0 (No Evidence)",'-,'-,,,29.41,0,0.84,08/22/2016
G,CEP290,HGNC:29021,12q21.32,12:88442793-88535865,12:88049016-88142088,"30 (Autosomal Recessive)","Joubert syndrome and related disorders",MONDO:0015369,"0 (No Evidence)",'-,'-,,,13.34,0,0.99,08/22/2012
G,CEP78,HGNC:25740,9q21.2,9:80850991-80894606,9:78236075-78279690,"30 (Autosomal Recessive)","cone-rod dystrophy and hearing loss 1",MONDO:0020778,"0 (No Evidence)",'-,'-,,,49.15,0,1.02,10/23/2017
G,CERS3,HGNC:23752,15q26.3,15:100940600-101084888,15:100400395-100544683,"30 (Autosomal Recessive)","autosomal recessive congenital ichthyosis 9",MONDO:0014010,"Not Yet Evaluated",'-,'-,,,62.26,0.01,0.63,08/22/2016
G,CERT1,HGNC:2205,5q13.3,5:74664311-74807806,5:75368486-75511981,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,14.73,0.67,0.36,01/25/2023
G,CFAP418,HGNC:27232,8q22.1,8:96257141-96281429,8:95244913-95269201,"30 (Autosomal Recessive)","cone-rod dystrophy 16",MONDO:0013786,"0 (No Evidence)",'-,'-,,,54.96,0,1.42,08/22/2016
G,CFAP53,HGNC:26530,18q21.1,18:47753563-47792865,18:50227193-50266495,"30 (Autosomal Recessive)","heterotaxy, visceral, 6, autosomal",MONDO:0013887,"0 (No Evidence)",'-,'-,,,72.99,0,1.34,08/22/2016
G,CFC1,HGNC:18292,2q21.1,2:131349738-131357148,2:130592165-130599575,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,88.86,0.11,1.25,09/22/2021
G,CFD,HGNC:2771,19p13.3,19:859664-863641,19:859664-863641,"30 (Autosomal Recessive)","recurrent Neisseria infections due to factor D deficiency",MONDO:0013487,"0 (No Evidence)",'-,'-,,,76.28,0,1.68,08/22/2016
G,CFL2,HGNC:1875,14q13.1,14:35178319-35183799,14:34709113-34714593,"30 (Autosomal Recessive)","nemaline myopathy 7",MONDO:0012538,"Not Yet Evaluated",'-,'-,,,4.83,0,1.53,08/22/2016
G,CFTR,HGNC:1884,7q31.2,7:117120079-117308719,7:117480025-117668665,"30 (Autosomal Recessive)","cystic fibrosis",MONDO:0009061,"Not Yet Evaluated",'-,'-,,,2.33,0,1.31,08/22/2016
G,CHAMP1,HGNC:20311,13q34,13:115079978-115092797,13:114314503-114327322,"2 (Emerging Evidence)","intellectual disability, autosomal dominant 40",MONDO:0014699,"0 (No Evidence)",'-,'-,,,52.86,0.99,0.27,03/25/2020
G,CHAT,HGNC:1912,10q11.23,10:50817141-50875988,10:49609095-49667942,"30 (Autosomal Recessive)","congenital myasthenic syndrome 6",MONDO:0009689,"Not Yet Evaluated",'-,'-,,,10,0,0.88,08/22/2016
G,CHD1L,HGNC:1916,1q21.1,1:146644326-146767443,1:147172747-147295762,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,45.36,0,1.3,08/30/2018
G,CHD2,HGNC:1917,15q26.1,15:93443554-93571226,15:92900324-93027996,"3 (Sufficient Evidence)","developmental and epileptic encephalopathy 94",MONDO:0014150,"0 (No Evidence)",'-,'-,,,20.62,1,0.07,10/23/2019
G,CHD4,HGNC:1919,12p13.31,12:6679248-6716545,12:6570082-6607379,"1 (Little Evidence)","Sifrim-Hitz-Weiss syndrome",MONDO:0014946,"0 (No Evidence)",'-,'-,,,9.88,1,0.16,11/30/2022
G,CHD5,HGNC:16816,1p36.31,1:6161847-6240381,1:6101787-6180321,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"Not Yet Evaluated",'-,'-,,,47.85,1,0.16,09/27/2022
G,CHD7,HGNC:20626,8q12.2,8:61591299-61780587,8:60678740-60868028,"3 (Sufficient Evidence)","CHARGE syndrome",MONDO:0008965,"0 (No Evidence)",'-,'-,,,2.4,1,0.08,04/11/2023
G,CHD8,HGNC:20153,14q11.2,14:21853358-21924282,14:21385199-21456123,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,11.24,1,0.08,04/25/2018
G,CHEK1,HGNC:1925,11q24.2,11:125495031-125546150,11:125625136-125681124,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,3.14,0,0.93,11/10/2021
G,CHEK2,HGNC:16627,22q12.1,22:29083731-29137822,22:28687743-28741834,"3 (Sufficient Evidence)","hereditary breast carcinoma",MONDO:0016419,"0 (No Evidence)",'-,'-,,,6.9,0,1.53,01/08/2020
G,CHKB,HGNC:1938,22q13.33,22:51017392-51021278,22:50578963-50582849,"30 (Autosomal Recessive)","megaconial type congenital muscular dystrophy",MONDO:0011246,"0 (No Evidence)",'-,'-,,,60.19,0,0.92,08/22/2016
G,CHL1,HGNC:1939,3p26.3,3:238446-451100,3:196763-409417,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,45.34,0,0.64,12/12/2023
G,CHM,HGNC:1940,Xq21.2,X:85116185-85302562,X:85861180-86047558,"3 (Sufficient Evidence)",choroideremia,MONDO:0010557,"0 (No Evidence)",'-,'-,,,25.28,1,0.19,03/24/2021
G,CHMP1A,HGNC:8740,16q24.3,16:89710843-89724116,16:89644435-89657708,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 8",MONDO:0013990,"0 (No Evidence)",'-,'-,,,33.54,0,1.18,08/22/2016
G,CHMP7,HGNC:28439,8p21.3,8:23101150-23119512,8:23243637-23261999,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,23,0.86,0.38,09/27/2022
G,CHRDL1,HGNC:29861,Xq23,X:109917084-110039045,X:110673856-110795817,"3 (Sufficient Evidence)","isolated congenital megalocornea",MONDO:0010649,"0 (No Evidence)",'-,'-,,,24.72,0.22,0.52,12/08/2016
G,CHRM3,HGNC:1952,1q43,1:239549868-240078750,1:239386568-239915450,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,33.36,0.99,0.25,11/16/2023
G,CHRNA7,HGNC:1960,15q13.3,15:32322686-32465219,15:32030483-32173018,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,40.52,0,0.77,05/10/2018
G,CHST6,HGNC:6938,16q23.1,16:75505940-75529339,16:75472042-75495441,"30 (Autosomal Recessive)","macular corneal dystrophy",MONDO:0009020,"0 (No Evidence)",'-,'-,,,57.77,0,1.82,08/22/2016
G,CHSY1,HGNC:17198,15q26.3,15:101715932-101792253,15:101175727-101252048,"30 (Autosomal Recessive)","temtamy preaxial brachydactyly syndrome",MONDO:0011533,"0 (No Evidence)",'-,'-,,,54.01,0.71,0.41,08/22/2016
G,CIC,HGNC:14214,19q13.2,19:42772682-42799948,19:42268530-42295796,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,37.93,1,0.18,11/08/2022
G,CIDEC,HGNC:24229,3p25.3,3:9908394-9921937,3:9866710-9880253,"30 (Autosomal Recessive)","CIDEC-related familial partial lipodystrophy",MONDO:0014098,"0 (No Evidence)",'-,'-,,,62.02,0.01,0.94,08/22/2016
G,CITED2,HGNC:1987,6q24.1,6:139692944-139695785,6:139371807-139374648,"0 (No Evidence)","congenital heart defects, multiple types",MONDO:0000119,"0 (No Evidence)",'-,'-,,,3.47,0.76,0.63,11/29/2023
G,CLASP1,HGNC:17088,2q14.2-q14.3,2:122095352-122407038,2:121337776-121649462,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,18.65,1,0.18,12/13/2022
G,CLCF1,HGNC:17412,11q13.2,11:67131639-67141648,11:67364168-67374177,"30 (Autosomal Recessive)","cold-induced sweating syndrome 2",MONDO:0012467,"Not Yet Evaluated",'-,'-,,,30.27,0.95,0.32,08/22/2016
G,CLCN4,HGNC:2022,Xp22.2,X:10125015-10205700,X:10156975-10237660,"1 (Little Evidence)","intellectual disability, X-linked 49",MONDO:0010250,"0 (No Evidence)",'-,'-,,,28.47,1,0.15,07/27/2022
G,CLCN5,HGNC:2023,Xp11.23,X:49687206-49863887,X:49922596-50099230,"3 (Sufficient Evidence)","Dent disease type 1",MONDO:0010225,"0 (No Evidence)",'-,'-,,,13.07,0.99,0.28,10/18/2012
G,CLCNKA,HGNC:2026,1p36.13,1:16348531-16360545,1:16022036-16034050,"30 (Autosomal Recessive)","Bartter disease type 4B",MONDO:0000909,"0 (No Evidence)",'-,'-,,,75.9,0,1.12,05/17/2012
G,CLCNKB,HGNC:2027,1p36.13,1:16370277-16383821,1:16043782-16057326,"30 (Autosomal Recessive)","Bartter disease type 3",MONDO:0011822,"0 (No Evidence)",'-,'-,,,71.85,0,1.24,11/17/2011
G,CLDN14,HGNC:2035,21q22.13,21:37832919-37948867,21:36460621-36576569,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 29",MONDO:0013537,"0 (No Evidence)",'-,'-,,,39.29,0,1.75,08/22/2016
G,CLMP,HGNC:24039,11q24.1,11:122940580-123065956,11:123069872-123195248,"30 (Autosomal Recessive)","congenital short bowel syndrome, autosomal recessive",MONDO:0020718,"0 (No Evidence)",'-,'-,,,26.76,0,1,08/22/2016
G,CLN3,HGNC:2074,16p12.1,16:28477974-28503403,16:28466653-28492082,"30 (Autosomal Recessive)","neuronal ceroid lipofuscinosis 3",MONDO:0008767,"Not Yet Evaluated",'-,'-,,,55,0,0.91,08/22/2016
G,CLN8,HGNC:2079,8p23.3,8:1711955-1734736,8:1753059-1786570,"30 (Autosomal Recessive)","neuronal ceroid lipofuscinosis 8",MONDO:0010830,"Not Yet Evaluated",'-,'-,,,76.78,0,1.17,08/22/2016
G,CLNK,HGNC:17438,4p16.1,4:10488019-10686392,4:10486395-10734846,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,84.67,0,1.77,06/02/2016
G,CLPP,HGNC:2084,19p13.3,19:6361542-6370253,19:6361531-6370242,"30 (Autosomal Recessive)","Perrault syndrome 3",MONDO:0013588,"0 (No Evidence)",'-,'-,,,37.05,0.57,0.57,03/06/2018
G,CLRN1,HGNC:12605,3q25.1,3:150643950-150690786,3:150926163-150972999,"30 (Autosomal Recessive)","Usher syndrome type 3A",MONDO:0010170,"0 (No Evidence)",'-,'-,,,42.65,0,1.81,08/22/2016
G,CLTC,HGNC:2092,17q23.1,17:57697256-57774317,17:59619895-59696956,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,4.77,1,0.1,09/27/2022
G,CNGB1,HGNC:2151,16q21,16:57916244-58005032,16:57882340-57971128,"30 (Autosomal Recessive)","retinitis pigmentosa 45",MONDO:0013413,"Not Yet Evaluated",'-,'-,,,68.86,0,1.15,08/22/2016
G,CNKSR2,HGNC:19701,Xp22.12,X:21392536-21672807,X:21374418-21654689,"3 (Sufficient Evidence)","intellectual disability, X-linked, syndromic, Houge type",MONDO:0030909,"0 (No Evidence)",'-,'-,,,7.56,1,0.19,01/12/2021
G,CNNM4,HGNC:105,2q11.2,2:97426639-97477611,2:96760902-96811874,"30 (Autosomal Recessive)","Jalili syndrome",MONDO:0009007,"Not Yet Evaluated",'-,'-,,,64.14,0,0.94,08/22/2016
G,CNOT1,HGNC:7877,16q21,16:58553855-58663730,16:58519951-58629826,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,4.66,1,0.04,12/13/2022
G,CNOT2,HGNC:7878,12q15,12:70636798-70748773,12:70243018-70354993,"1 (Little Evidence)","intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies",MONDO:0032832,"0 (No Evidence)",'-,'-,,,4.39,1,0.19,11/08/2022
G,CNOT3,HGNC:7879,19q13.42,19:54641478-54659419,19:54137762-54155681,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,49.76,1,0.08,06/27/2018
G,CNTN1,HGNC:2171,12q12,12:41086241-41466217,12:40692439-41072415,"30 (Autosomal Recessive)","Compton-North congenital myopathy",MONDO:0012929,"Not Yet Evaluated",'-,'-,,,22.29,0.15,0.37,08/22/2016
G,CNTN2,HGNC:2172,1q32.1,1:205012077-205047417,1:205042949-205078289,"30 (Autosomal Recessive)","epilepsy, familial adult myoclonic, 5",MONDO:0014167,"0 (No Evidence)",'-,'-,,,20.14,0,0.44,08/22/2016
G,CNTN4,HGNC:2174,3p26.3-p26.2,3:2140550-3099643,3:2098866-3057959,"0 (No Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,6.9,0,0.52,06/14/2022
G,CNTN6,HGNC:2176,3p26.3,3:1134708-1445901,3:1093024-1404217,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,39.69,0,1.15,09/28/2022
G,CNTNAP2,HGNC:13830,7q35-q36.1,7:145813893-148118090,7:146116801-148420998,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.94,0,0.55,10/23/2019
G,COG1,HGNC:6545,17q25.1,17:71189194-71204646,17:73193055-73208507,"30 (Autosomal Recessive)","COG1-congenital disorder of glycosylation",MONDO:0012637,"Not Yet Evaluated",'-,'-,,,67.93,0,0.65,08/22/2016
G,COG4,HGNC:18620,16q22.1,16:70514470-70557457,16:70480567-70523554,"30 (Autosomal Recessive)","COG4-congenital disorder of glycosylation",MONDO:0013281,"Not Yet Evaluated",'-,'-,,,21.66,0,0.71,08/22/2016
G,COG7,HGNC:18622,16p12.2,16:23399814-23464510,16:23388493-23453189,"30 (Autosomal Recessive)","COG7-congenital disorder of glycosylation",MONDO:0012118,"0 (No Evidence)",'-,'-,,,68.01,0,0.66,04/09/2015
G,COG8,HGNC:18623,16q22.1,16:69360331-69373467,16:69326428-69339564,"30 (Autosomal Recessive)","COG8-congenital disorder of glycosylation",MONDO:0012635,"0 (No Evidence)",'-,'-,,,32.72,0,1.13,03/25/2015
G,COL11A1,HGNC:2186,1p21.1,1:103342029-103574078,1:102876473-103108522,"1 (Little Evidence)","Stickler syndrome type 2",MONDO:0011493,"0 (No Evidence)",'-,'-,,,8.57,1,0.22,10/19/2011
G,COL16A1,HGNC:2193,1p35.2,1:32117864-32169618,1:31652263-31704017,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,41.54,0,0.63,02/01/2021
G,COL1A1,HGNC:2197,17q21.33,17:48261462-48278992,17:50184101-50201631,"3 (Sufficient Evidence)","osteogenesis imperfecta type 1",MONDO:0008146,"0 (No Evidence)",'-,'-,,,7.09,1,0.11,08/23/2012
G,COL1A2,HGNC:2198,7q21.3,7:94024207-94060539,7:94394895-94431227,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.09,1,0.2,10/12/2012
G,COL2A1,HGNC:2200,12q13.11,12:48366750-48398259,12:47972967-48006212,"3 (Sufficient Evidence)","Stickler syndrome type 1",MONDO:0007160,"0 (No Evidence)",'-,'-,,,2.04,1,0.13,07/29/2020
G,COL3A1,HGNC:2201,2q32.2,2:189839099-189877472,2:188974373-189012746,"3 (Sufficient Evidence)","autosomal dominant Ehlers-Danlos syndrome, vascular type",MONDO:0007524,"0 (No Evidence)",'-,'-,,,14.75,1,0.1,01/12/2017
G,COL4A3,HGNC:2204,2q36.3,2:228029340-228179508,2:227164624-227314792,"30 (Autosomal Recessive)","autosomal recessive Alport syndrome",MONDO:0008762,"0 (No Evidence)",'-,'-,,,47.51,0,0.52,05/22/2013
G,COL4A5,HGNC:2207,Xq22.3,X:107683068-107940775,X:108439838-108697545,"3 (Sufficient Evidence)","X-linked Alport syndrome",MONDO:0010520,"0 (No Evidence)",'-,'-,,,8.97,1,0.19,09/08/2020
G,COL5A1,HGNC:2209,9q34.3,9:137533649-137736689,9:134641803-134844843,"3 (Sufficient Evidence)","Ehlers-Danlos syndrome, classic type, 1",MONDO:0019567,"0 (No Evidence)",'-,'-,,,35.85,1,0.06,12/14/2017
G,COL6A5,HGNC:26674,3q22.1,3:130064359-130203690,3:130345672-130484846,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,76.88,0,0.92,02/02/2021
G,COL7A1,HGNC:2214,3p21.31,3:48601506-48632762,3:48564073-48595329,"30 (Autosomal Recessive)",'-,'-,"Not Yet Evaluated",'-,'-,,,45.68,0,0.6,02/08/2023
G,COL9A1,HGNC:2217,6q13,6:70924764-71012787,6:70215061-70303084,"0 (No Evidence)","epiphyseal dysplasia, multiple, 6",MONDO:0013591,"0 (No Evidence)",'-,'-,,,23.89,0,0.81,11/06/2013
G,COL9A2,HGNC:2218,1p34.2,1:40766161-40782958,1:40300489-40317286,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,42.16,0,0.64,10/09/2013
G,COLEC11,HGNC:17213,2p25.3,2:3642702-3692234,2:3595112-3644644,"30 (Autosomal Recessive)","3MC syndrome 2",MONDO:0009927,"0 (No Evidence)",'-,'-,,,55.58,0.02,0.82,08/22/2016
G,COLQ,HGNC:2226,3p25.1,3:15491640-15563213,3:15450133-15521706,"30 (Autosomal Recessive)","congenital myasthenic syndrome 5",MONDO:0011281,"0 (No Evidence)",'-,'-,,,5.64,0,1.1,08/22/2016
G,COQ2,HGNC:25223,4q21.23,4:84184977-84206287,4:83263824-83285134,"30 (Autosomal Recessive)","coenzyme Q10 deficiency, primary, 1",MONDO:0011829,"0 (No Evidence)",'-,'-,,,68.33,0,0.89,08/22/2016
G,CORO1A,HGNC:2252,16p11.2,16:30194923-30200397,16:30183602-30189076,"30 (Autosomal Recessive)","severe combined immunodeficiency due to CORO1A deficiency",MONDO:0014168,"0 (No Evidence)",'-,'-,,,26.02,0.97,0.32,08/22/2016
G,COX10,HGNC:2260,17p12,17:13972821-14111994,17:14069504-14208677,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"Not Yet Evaluated",'-,'-,,,60.22,0.08,0.61,08/22/2016
G,COX14,HGNC:28216,12q13.12,12:50506019-50514236,12:50112236-50120453,"30 (Autosomal Recessive)","cytochrome-c oxidase deficiency disease",MONDO:0009068,"0 (No Evidence)",'-,'-,,,44.4,0.36,1.8,08/22/2016
G,COX15,HGNC:2263,10q24.2,10:101454050-101491884,10:99694293-99732127,"30 (Autosomal Recessive)","cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2",MONDO:0014051,"0 (No Evidence)",'-,'-,,,39.87,0,1.33,08/22/2016
G,COX20,HGNC:26970,1q44,1:244998608-245008365,1:244835306-244845063,"30 (Autosomal Recessive)","cytochrome-c oxidase deficiency disease",MONDO:0009068,"Not Yet Evaluated",'-,'-,,,46.76,0.02,1.48,08/22/2016
G,COX6B1,HGNC:2280,19q13.12,19:36139225-36149684,19:35648323-35658782,"30 (Autosomal Recessive)","cytochrome-c oxidase deficiency disease",MONDO:0009068,"0 (No Evidence)",'-,'-,,,28.4,0.12,1.17,08/22/2016
G,CP,HGNC:2295,3q24-q25.1,3:148880201-148939616,3:149162414-149221829,"30 (Autosomal Recessive)",aceruloplasminemia,MONDO:0011426,"Not Yet Evaluated",'-,'-,,,46.99,0,0.65,08/22/2016
G,CPA4,HGNC:15740,7q32.2,7:129933001-129964020,7:130293161-130324180,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,54.59,0,1.4,07/25/2012
G,CPA6,HGNC:17245,8q13.2,8:68334273-68658595,8:67422038-67746360,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,29.99,0,1.24,09/04/2019
G,CPLANE1,HGNC:25801,5p13.2,5:37106337-37249478,5:37075669-37249376,"30 (Autosomal Recessive)","Joubert syndrome 17",MONDO:0013824,"0 (No Evidence)",'-,'-,,,76.94,0,0.67,08/22/2016
G,CPN1,HGNC:2312,10q24.2,10:101801950-101841626,10:100042193-100081869,"30 (Autosomal Recessive)","carboxypeptidase N deficiency",MONDO:0008910,"0 (No Evidence)",'-,'-,,,57.42,0,1.06,08/22/2016
G,CPS1,HGNC:2323,2q34,2:211342409-211543831,2:210477685-210679107,"30 (Autosomal Recessive)","carbamoyl phosphate synthetase I deficiency disease",MONDO:0009376,"Not Yet Evaluated",'-,'-,,,5.16,0,0.52,08/22/2016
G,CPT1A,HGNC:2328,11q13.3,11:68522088-68609384,11:68754620-68844277,"30 (Autosomal Recessive)","carnitine palmitoyl transferase 1A deficiency",MONDO:0009705,"0 (No Evidence)",'-,'-,,,54.76,0,0.66,08/22/2016
G,CRADD,HGNC:2340,12q22,12:94071151-94288616,12:93677375-93894840,"30 (Autosomal Recessive)","intellectual disability, autosomal recessive 34",MONDO:0013785,"0 (No Evidence)",'-,'-,,,41.34,0.88,0.44,08/22/2016
G,CREBBP,HGNC:2348,16p13.3,16:3775055-3930714,16:3725054-3880713,"3 (Sufficient Evidence)","Rubinstein-Taybi syndrome due to CREBBP mutations",MONDO:0008393,"0 (No Evidence)",'-,'-,,,0.62,1,0.07,10/23/2019
G,CRHR1,HGNC:2357,17q21.31,17:43861686-43913194,17:45784320-45835828,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.8,0,0.71,07/06/2012
G,CRIPT,HGNC:14312,2p21,2:46844354-46857315,2:46617215-46630176,"30 (Autosomal Recessive)","short stature with microcephaly and distinctive facies",MONDO:0014347,"0 (No Evidence)",'-,'-,,,13.94,0,1.58,08/22/2016
G,CRIPTO,HGNC:11701,3p21.31,3:46616025-46623947,3:46574535-46582457,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,77.65,0,1.92,12/27/2011
G,CRKL,HGNC:2363,22q11.21,22:21271695-21308035,22:20917407-20953747,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.35,0.45,0.64,04/13/2020
G,CRPPA,HGNC:37276,7p21.2,7:16127150-16461163,7:16087525-16421538,"30 (Autosomal Recessive)","muscular dystrophy-dystroglycanopathy",MONDO:0018276,"Not Yet Evaluated",'-,'-,,,58.01,0,0.82,08/22/2016
G,CRTAP,HGNC:2379,3p22.3,3:33155506-33189265,3:33114014-33147773,"30 (Autosomal Recessive)","osteogenesis imperfecta type 7",MONDO:0012536,"0 (No Evidence)",'-,'-,,,44.18,0,0.86,08/22/2016
G,CRYBA1,HGNC:2394,17q11.2,17:27573877-27581512,17:29246859-29254494,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,8.17,0,1,06/06/2013
G,CRYBB2,HGNC:2398,22q11.23,22:25615606-25627836,22:25211661-25231869,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.55,0.39,0.57,01/10/2023
G,CRYGC,HGNC:2410,2q33.3,2:208992861-208994552,2:208128137-208129828,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,31.55,0,1.31,05/22/2013
G,CSF2RA,HGNC:2435,"Xp22.32 and Yp11.3",Y:1337707-1394111,Y:1268814-1325218,"30 (Autosomal Recessive)","hereditary pulmonary alveolar proteinosis",MONDO:0012580,"0 (No Evidence)",'-,'-,,,91.07,0,1.12,08/23/2021
G,CSF2RB,HGNC:2436,22q12.3,22:37309670-37336481,22:36913628-36940439,"30 (Autosomal Recessive)","surfactant metabolism dysfunction, pulmonary, 5",MONDO:0013712,"Not Yet Evaluated",'-,'-,,,89.46,0.18,0.44,08/22/2016
G,CSMD1,HGNC:14026,8p23.2,8:2792883-4852436,8:2935361-4994914,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,47.53,1,0.21,10/24/2018
G,CSNK2A1,HGNC:2457,20p13,20:453142-524434,20:472498-543790,"2 (Emerging Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,2.89,0.99,0.3,09/27/2022
G,CSPP1,HGNC:26193,8q13.1-q13.2,8:67976603-68108849,8:67064368-67196614,"30 (Autosomal Recessive)","Joubert syndrome 21",MONDO:0014288,"0 (No Evidence)",'-,'-,,,45.84,0,0.93,08/22/2016
G,CSTB,HGNC:2482,21q22.3,21:45193831-45196189,21:43773950-43776308,"30 (Autosomal Recessive)","Unverricht-Lundborg syndrome",MONDO:0009698,"0 (No Evidence)",'-,'-,,,86.14,0.01,1.85,08/22/2016
G,CTC1,HGNC:26169,17p13.1,17:8128133-8151374,17:8224815-8248056,"30 (Autosomal Recessive)","cerebroretinal microangiopathy with calcifications and cysts 1",MONDO:0024564,"0 (No Evidence)",'-,'-,,,69.4,0,0.63,10/08/2019
G,CTCF,HGNC:13723,16q22.1,16:67596429-67673088,16:67562526-67639185,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,2.59,1,0.15,09/22/2021
G,CTDP1,HGNC:2498,18q23,18:77439803-77516625,18:79676768-79756625,"30 (Autosomal Recessive)","congenital cataracts-facial dysmorphism-neuropathy syndrome",MONDO:0011402,"Not Yet Evaluated",'-,'-,,,76.13,0,0.53,08/22/2016
G,CTH,HGNC:2501,1p31.1,1:70876951-70905534,1:70411268-70439851,"30 (Autosomal Recessive)",cystathioninuria,MONDO:0009058,"0 (No Evidence)",'-,'-,,,52.82,0,0.96,08/22/2016
G,CTNNA1,HGNC:2509,5q31.2,5:138089114-138270723,5:138753425-138935034,"3 (Sufficient Evidence)","hereditary gastric cancer",MONDO:0018502,"0 (No Evidence)",'-,'-,,,2.28,0.97,0.31,10/12/2022
G,CTNNA3,HGNC:2511,10q21.3,10:67672281-69455953,10:65912523-67763594,"0 (No Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,2.58,0,0.85,10/24/2018
G,CTNNB1,HGNC:2514,3p22.1,3:41240996-41281934,3:41199505-41240443,"3 (Sufficient Evidence)","severe intellectual disability-progressive spastic diplegia syndrome",MONDO:0014035,"0 (No Evidence)",'-,'-,,,0.18,1,0.13,11/22/2017
G,CTNND2,HGNC:2516,5p15.2,5:10971948-11904558,5:10971836-11904446,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,5.83,1,0.1,10/12/2021
G,CTNS,HGNC:2518,17p13.2,17:3539753-3566397,17:3636459-3663103,"30 (Autosomal Recessive)","nephropathic cystinosis",MONDO:0100151,"0 (No Evidence)",'-,'-,,,58.83,0,0.8,08/22/2012
G,CTSB,HGNC:2527,8p23.1,8:11700033-11725596,8:11842524-11868087,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,36.44,0,1.33,02/08/2012
G,CUBN,HGNC:2548,10p13,10:16865965-17171810,10:16823966-17129811,"30 (Autosomal Recessive)","Imerslund-Grasbeck syndrome type 1",MONDO:0100156,"0 (No Evidence)",'-,'-,,,67.86,0,0.65,08/22/2016
G,CUL3,HGNC:2553,2q36.2,2:225334867-225450080,2:224470150-224585363,"3 (Sufficient Evidence)","neurodevelopmental disorder with or without autism or seizures",MONDO:0030994,"0 (No Evidence)",'-,'-,,,4.57,1,0.23,01/24/2018
G,CUL4B,HGNC:2555,Xq24,X:119657713-119709387,X:120523858-120575532,"3 (Sufficient Evidence)","X-linked intellectual disability, Cabezas type",MONDO:0010306,"0 (No Evidence)",'-,'-,,,8.31,1,0.09,02/09/2021
G,CYB5A,HGNC:2570,18q22.3,18:71918081-71959198,18:74250846-74291963,"30 (Autosomal Recessive)","methemoglobinemia type 4",MONDO:0009605,"0 (No Evidence)",'-,'-,,,56.3,0,1.43,08/22/2016
G,CYBB,HGNC:2578,Xp21.1-p11.4,X:37639312-37672714,X:37780059-37813461,"3 (Sufficient Evidence)","granulomatous disease, chronic, X-linked",MONDO:0010600,"0 (No Evidence)",'-,'-,,,10.63,1,0.19,05/27/2020
G,CYLD,HGNC:2584,16q12.1,16:50775997-50835846,16:50742086-50801935,"3 (Sufficient Evidence)","Brooke-Spiegler syndrome",MONDO:0011512,"0 (No Evidence)",'-,'-,,,2.21,1,0.2,02/10/2021
G,CYP21A2,HGNC:2600,6p21.33,6:32006192-32009421,6:32038415-32041644,"30 (Autosomal Recessive)","classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",MONDO:0008728,"0 (No Evidence)",'-,'-,,,65.79,0,0.82,07/06/2012
G,CYP24A1,HGNC:2602,20q13.2,20:52769985-52790525,20:54143538-54173986,"30 (Autosomal Recessive)","hypercalcemia, infantile, 1",MONDO:0020739,"Not Yet Evaluated",'-,'-,,,56.17,0,1.54,08/22/2016
G,CYP27A1,HGNC:2605,2q35,2:219646870-219680016,2:218782147-218815293,"30 (Autosomal Recessive)","cerebrotendinous xanthomatosis",MONDO:0008948,"Not Yet Evaluated",'-,'-,,,64.32,0,1.38,08/22/2016
G,CYP3A43,HGNC:17450,7q22.1,7:99425636-99463716,7:99828013-99866093,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,35.98,0,1.11,02/02/2021
G,CYP4F22,HGNC:26820,19p13.12,19:15619336-15663128,19:15508525-15552317,"30 (Autosomal Recessive)","autosomal recessive congenital ichthyosis 5",MONDO:0011485,"Not Yet Evaluated",'-,'-,,,70.99,0,0.78,08/22/2016
G,CYP4V2,HGNC:23198,4q35.1-q35.2,4:187112721-187134617,4:186191567-186213463,"30 (Autosomal Recessive)","Bietti crystalline corneoretinal dystrophy",MONDO:0008865,"Not Yet Evaluated",'-,'-,,,70.46,0,1.03,08/22/2016
G,D2HGDH,HGNC:28358,2q37.3,2:242674045-242708226,2:241734630-241768811,"30 (Autosomal Recessive)","D-2-hydroxyglutaric aciduria 1",MONDO:0024554,"Not Yet Evaluated",'-,'-,,,73.35,0.05,0.58,08/22/2016
G,DARS2,HGNC:25538,1q25.1,1:173793811-173827684,1:173824673-173858546,"30 (Autosomal Recessive)","leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome",MONDO:0012622,"0 (No Evidence)",'-,'-,,,28.68,0,0.92,08/22/2016
G,DAZ1,HGNC:2682,Yq11.223,Y:25275502-25345241,Y:23129355-23199094,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,76.54,‐,‐,10/17/2012
G,DBH,HGNC:2689,9q34.2,9:136501485-136524451,9:133636363-133659329,"30 (Autosomal Recessive)","orthostatic hypotension 1",MONDO:0009123,"0 (No Evidence)",'-,'-,,,53.24,0,1.01,08/22/2016
G,DBT,HGNC:2698,1p21.2,1:100652475-100715390,1:100186919-100249834,"30 (Autosomal Recessive)","maple syrup urine disease",MONDO:0009563,"Not Yet Evaluated",'-,'-,,,14.95,0,0.82,08/22/2016
G,DCHS1,HGNC:13681,11p15.4,11:6642561-6677040,11:6621330-6655809,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,44.76,1,0.24,08/31/2018
G,DCLRE1C,HGNC:17642,10p13,10:14939358-14996431,10:14897359-14954432,"30 (Autosomal Recessive)","severe combined immunodeficiency due to DCLRE1C deficiency",MONDO:0011225,"0 (No Evidence)",'-,'-,,,58.59,0,0.71,08/22/2016
G,DCX,HGNC:2714,Xq23,X:110537007-110655420,X:111293779-111412192,"3 (Sufficient Evidence)","lissencephaly type 1 due to doublecortin gene mutation",MONDO:0010239,"0 (No Evidence)",'-,'-,,,1.65,0.3,0.62,07/06/2012
G,DCXR,HGNC:18985,17q25.3,17:79993734-79995573,17:82035858-82037697,"30 (Autosomal Recessive)",pentosuria,MONDO:0009846,"0 (No Evidence)",'-,'-,,,66.61,0,1.49,08/22/2016
G,DDB2,HGNC:2718,11p11.2,11:47236525-47260768,11:47214454-47239217,"30 (Autosomal Recessive)","xeroderma pigmentosum group E",MONDO:0010213,"0 (No Evidence)",'-,'-,,,26.33,0,0.85,08/22/2016
G,DDHD1,HGNC:19714,14q22.1,14:53503473-53620041,14:53036755-53153323,"30 (Autosomal Recessive)","hereditary spastic paraplegia 28",MONDO:0012256,"0 (No Evidence)",'-,'-,,,40.86,0.9,0.34,09/25/2014
G,DDOST,HGNC:2728,1p36.12,1:20978270-20987862,1:20651777-20661369,"30 (Autosomal Recessive)","DDOST-congenital disorder of glycosylation",MONDO:0013789,"0 (No Evidence)",'-,'-,,,29.71,0,0.73,08/22/2016
G,DDX3X,HGNC:2745,Xp11.4,X:41192561-41223725,X:41333308-41364472,"3 (Sufficient Evidence)","intellectual disability, X-linked 102",MONDO:0010497,"0 (No Evidence)",'-,'-,,,12.73,1,0.12,11/22/2017
G,DDX41,HGNC:18674,5q35.3,5:176938578-176943962,5:177511577-177516961,"3 (Sufficient Evidence)","DDX41-related hematologic malignancy predisposition syndrome",MONDO:0014809,"0 (No Evidence)",'-,'-,,,25.66,0,0.74,02/09/2022
G,DGKE,HGNC:2852,17q22,17:54911512-54946928,17:56834151-56869567,"30 (Autosomal Recessive)","immunoglobulin-mediated membranoproliferative glomerulonephritis",MONDO:0014005,"0 (No Evidence)",'-,'-,,,44.28,0,0.71,08/22/2016
G,DGUOK,HGNC:2858,2p13.1,2:74154007-74186073,2:73926880-73958946,"30 (Autosomal Recessive)","mitochondrial DNA depletion syndrome 3 (hepatocerebral type)",MONDO:0009636,"Not Yet Evaluated",'-,'-,,,54.68,0,1.19,08/22/2016
G,DHCR7,HGNC:2860,11q13.4,11:71145457-71159439,11:71434411-71448393,"30 (Autosomal Recessive)","Smith-Lemli-Opitz syndrome",MONDO:0010035,"0 (No Evidence)",'-,'-,,,54.8,0,1.35,04/04/2012
G,DHODH,HGNC:2867,16q22.2,16:72042643-72061558,16:72008744-72027659,"30 (Autosomal Recessive)","postaxial acrofacial dysostosis",MONDO:0009903,"0 (No Evidence)",'-,'-,,,25.78,0,0.78,08/22/2016
G,DHX57,HGNC:20086,2p22.1,2:39024871-39103075,2:38797729-38875934,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,46.62,0,0.68,06/28/2018
G,DICER1,HGNC:17098,14q32.13,14:95552565-95624347,14:95086228-95158010,"3 (Sufficient Evidence)","DICER1-related tumor predisposition",MONDO:0100216,"0 (No Evidence)",'-,'-,,,1.99,1,0.17,02/09/2022
G,DIP2A,HGNC:17217,21q22.3,21:47878804-47991139,21:46458891-46583871,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,58.86,0.11,0.35,01/23/2019
G,DIRAS3,HGNC:687,1p31.3,1:68511569-68517314,1:68045962-68050627,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,90.89,0,0,10/19/2011
G,DIS3L2,HGNC:28648,2q37.1,2:232826423-233209060,2:231961713-232344350,"1 (Little Evidence)","Perlman syndrome",MONDO:0009965,"0 (No Evidence)",'-,'-,,,37.78,0.94,0.33,10/14/2020
G,DISC1,HGNC:2888,1q42.2,1:231762536-232177018,1:231626790-232041272,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,81.6,0,0.79,03/06/2012
G,DISP1,HGNC:19711,1q41,1:222988381-223179337,1:222815039-223005995,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,49.82,0,0.6,07/06/2012
G,DKC1,HGNC:2890,Xq28,X:153991139-154005964,X:154762864-154777689,"1 (Little Evidence)","DKC1-related disorder",MONDO:0100152,"0 (No Evidence)",'-,'-,,,6.32,1,0.19,06/14/2023
G,DLG2,HGNC:2901,11q14.1,11:83166055-85339417,11:83455012-85628373,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.29,0.71,0.34,11/28/2018
G,DLG3,HGNC:2902,Xq13.1,X:69664685-69725340,X:70444835-70505490,"2 (Emerging Evidence)","intellectual disability, X-linked 90",MONDO:0010452,"0 (No Evidence)",'-,'-,,,14.46,1,0.09,11/21/2019
G,DLG4,HGNC:2903,17p13.1,17:7090506-7123369,17:7187187-7220050,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,27.2,1,0.24,10/10/2023
G,DLGAP2,HGNC:2906,8p23.3,8:687628-1656642,8:737628-1708476,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,58.64,1,0.2,03/22/2012
G,DLK1,HGNC:2907,14q32.2,14:101193229-101204561,14:100726892-100738224,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.61,0.03,0.71,04/28/2012
R,"DLK1-MEG3 Intergenic DMR",ISCA-37447,14q32.2,14:101191391-101294616,14:100725054-100828279,"1 (Little Evidence)","paternal uniparental disomy of chromosome 14",MONDO:0011975,"0 (No Evidence)",'-,'-,,,‐,‐,‐,05/10/2012
G,DLL1,HGNC:2908,6q27,6:170591294-170600166,6:170282206-170291078,"3 (Sufficient Evidence)","neurodevelopmental disorder with nonspecific brain abnormalities and with or without seizures",MONDO:0032877,"0 (No Evidence)",'-,'-,,,4.66,1,0.1,03/09/2021
G,DLX1,HGNC:2914,2q31.1,2:172950235-172954402,2:172085507-172089674,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.08,0.96,0.29,03/30/2012
G,DLX2,HGNC:2915,2q31.1,2:172964166-172967628,2:172099438-172102900,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,19.55,0.98,0.25,01/19/2012
G,DLX5,HGNC:2918,7q21.3,7:96649708-96654143,7:97020396-97024831,"0 (No Evidence)","split hand-foot malformation 1 with sensorineural hearing loss",MONDO:0009080,"0 (No Evidence)",'-,'-,,,0.99,0.22,0.68,05/14/2012
G,DLX6,HGNC:2919,7q21.3,7:96634865-96640352,7:97005553-97011040,"0 (No Evidence)","split hand-foot malformation 1 with sensorineural hearing loss",MONDO:0009080,"0 (No Evidence)",'-,'-,,,3.97,0.92,0.38,05/14/2012
G,DMD,HGNC:2928,Xp21.2-p21.1,X:31137339-33357505,X:31119222-33339388,"3 (Sufficient Evidence)","Duchenne muscular dystrophy",MONDO:0010679,"0 (No Evidence)",'-,'-,,,0.27,1,0.15,11/20/2019
G,DMP1,HGNC:2932,4q22.1,4:88571432-88585509,4:87650280-87664357,"30 (Autosomal Recessive)","hypophosphatemic rickets, autosomal recessive, 1",MONDO:0009430,"Not Yet Evaluated",'-,'-,,,81.24,0,1.14,08/22/2016
G,DMRT1,HGNC:2934,9p24.3,9:841697-969090,9:841697-969090,"1 (Little Evidence)","disorder of sexual differentiation",MONDO:0002145,"0 (No Evidence)",'-,'-,,,18.6,0.74,0.48,11/10/2023
G,DMRT2,HGNC:2935,9p24.3,9:1050357-1057552,9:1050357-1057552,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,53.86,0.01,0.76,08/22/2012
G,DMXL2,HGNC:2938,15q21.2,15:51739988-51914968,15:51447791-51622771,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,41.6,1,0.16,04/04/2012
G,DNAAF1,HGNC:30539,16q24.1,16:84178913-84211526,16:84145308-84177920,"30 (Autosomal Recessive)","primary ciliary dyskinesia 13",MONDO:0013174,"0 (No Evidence)",'-,'-,,,98.51,0,1,08/22/2016
G,DNAAF11,HGNC:16725,8q24.22,8:133582664-133687791,8:132570416-132702913,"30 (Autosomal Recessive)","primary ciliary dyskinesia 19",MONDO:0013979,"Not Yet Evaluated",'-,'-,,,66.48,0,1.08,08/22/2016
G,DNAH11,HGNC:2942,7p15.3,7:21582657-21941457,7:21543039-21901839,"30 (Autosomal Recessive)","primary ciliary dyskinesia 7",MONDO:0012748,"0 (No Evidence)",'-,'-,,,21.9,0,0.67,08/22/2016
G,DNAH5,HGNC:2950,5p15.2,5:13690437-13944797,5:13690328-14011818,"30 (Autosomal Recessive)","primary ciliary dyskinesia 3",MONDO:0012085,"0 (No Evidence)",'-,'-,,,32.91,0,0.7,08/22/2016
G,DNAI1,HGNC:2954,9p13.3,9:34458803-34520982,9:34458805-34520984,"30 (Autosomal Recessive)","primary ciliary dyskinesia 1",MONDO:0009484,"0 (No Evidence)",'-,'-,,,11.63,0,0.73,08/22/2016
G,DNAI2,HGNC:18744,17q25.1,17:72270373-72311023,17:74274234-74314884,"30 (Autosomal Recessive)","primary ciliary dyskinesia 9",MONDO:0012906,"0 (No Evidence)",'-,'-,,,64.18,0,0.98,08/22/2016
G,DNAJB6,HGNC:14888,7q36.3,7:157129698-157210133,7:157337004-157417439,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,47.78,0.85,0.4,10/29/2012
G,DNAJC21,HGNC:27030,5p13.2,5:34929664-34959069,5:34929559-34958964,"1 (Little Evidence)","bone marrow failure syndrome 3",MONDO:0014887,"0 (No Evidence)",'-,'-,,,49.28,0,0.72,10/14/2020
G,DNAJC28,HGNC:1297,21q22.11,21:34860362-34864023,21:33488055-33491716,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,63.77,0,1.39,02/02/2021
G,DNAJC6,HGNC:15469,1p31.3,1:65730432-65881554,1:65264749-65415871,"30 (Autosomal Recessive)","juvenile onset Parkinson disease 19A",MONDO:0014231,"0 (No Evidence)",'-,'-,,,34.73,1,0.22,08/22/2016
G,DNASE1,HGNC:2956,16p13.3,16:3661761-3715462,16:3611760-3665461,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,65.82,0,1.95,02/22/2012
G,DNM1,HGNC:2972,9q34.11,9:130965658-131017523,9:128203379-128255244,"30 (Autosomal Recessive)","developmental and epileptic encephalopathy",MONDO:0100062,"0 (No Evidence)",'-,'-,,,13.49,1,0.25,08/08/2023
G,DNMT3A,HGNC:2978,2p23.3,2:25450743-25565459,2:25227874-25342590,"1 (Little Evidence)","Tatton-Brown-Rahman overgrowth syndrome",MONDO:0014382,"0 (No Evidence)",'-,'-,,,3.99,0,1.58,04/29/2018
G,DOCK7,HGNC:19190,1p31.3,1:62920397-63154057,1:62454726-62688386,"30 (Autosomal Recessive)","developmental and epileptic encephalopathy, 23",MONDO:0014371,"0 (No Evidence)",'-,'-,,,28.59,0,0.38,08/22/2016
G,DOCK8,HGNC:19191,9p24.3,9:214865-465255,9:211257-465255,"30 (Autosomal Recessive)","combined immunodeficiency due to DOCK8 deficiency",MONDO:0009478,"0 (No Evidence)",'-,'-,,,35.69,0,0.48,06/14/2023
G,DOK7,HGNC:26594,4p16.3,4:3465033-3503209,4:3463306-3501482,"30 (Autosomal Recessive)","congenital myasthenic syndrome 10",MONDO:0009690,"Not Yet Evaluated",'-,'-,,,75.35,0,0.93,08/22/2016
G,DPAGT1,HGNC:2995,11q23.3,11:118967220-118972563,11:119093874-119101853,"30 (Autosomal Recessive)","congenital disorder of glycosylation",MONDO:0015286,"0 (No Evidence)",'-,'-,,,14.87,0,1.08,08/22/2016
G,DPM1,HGNC:3005,20q13.13,20:49551392-49575101,20:50934855-50958564,"30 (Autosomal Recessive)","congenital disorder of glycosylation type 1E",MONDO:0012123,"0 (No Evidence)",'-,'-,,,19.24,0,0.87,08/22/2016
G,DPM3,HGNC:3007,1q22,1:155112367-155113007,1:155139891-155140531,"30 (Autosomal Recessive)","DPM3-congenital disorder of glycosylation",MONDO:0013049,"0 (No Evidence)",'-,'-,,,53.99,0.23,1.4,04/09/2015
G,DPP6,HGNC:3010,7q36.2,7:153445218-154685995,7:153748133-154894285,"1 (Little Evidence)","intellectual disability, autosomal dominant 33",MONDO:0014580,"0 (No Evidence)",'-,'-,,,42.27,0.34,0.38,06/26/2019
G,DPYD,HGNC:3012,1p21.3,1:97543299-98386615,1:97077743-97921059,"30 (Autosomal Recessive)","dihydropyrimidine dehydrogenase deficiency",MONDO:0010130,"0 (No Evidence)",'-,'-,,,1.82,0,1.01,01/24/2018
G,DPYS,HGNC:3013,8q22.3,8:105391659-105479283,8:104379431-104467055,"30 (Autosomal Recessive)",dihydropyrimidinuria,MONDO:0009111,"Not Yet Evaluated",'-,'-,,,50.47,0,1.17,08/22/2016
G,DRD5,HGNC:3026,4p16.1,4:9783258-9785633,4:9781634-9784009,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.72,0,1.94,05/15/2012
G,DSC2,HGNC:3036,18q12.1,18:28638806-28682384,18:31058840-31102421,"2 (Emerging Evidence)","arrhythmogenic right ventricular dysplasia 11",MONDO:0012506,"0 (No Evidence)",'-,'-,,,70.44,0,0.69,01/14/2016
G,DSC3,HGNC:3037,18q12.1,18:28569331-28622708,18:30989365-31042742,"30 (Autosomal Recessive)","hereditary hypotrichosis with recurrent skin vesicles",MONDO:0013136,"Not Yet Evaluated",'-,'-,,,29.87,0,1.2,08/22/2016
G,DSCAM,HGNC:3039,21q22.2,21:41382926-42219084,21:40010999-40847158,"2 (Emerging Evidence)","autism spectrum disorder",MONDO:0005258,"0 (No Evidence)",'-,'-,,,11.07,1,0.19,10/10/2023
G,DSE,HGNC:21144,6q22.1,6:116575334-116766024,6:116254171-116444861,"30 (Autosomal Recessive)","Ehlers-Danlos syndrome, musculocontractural type 2",MONDO:0014236,"Not Yet Evaluated",'-,'-,,,5.23,0.63,0.38,08/22/2016
G,DSG2,HGNC:3049,18q12.1,18:29078140-29128971,18:31498177-31549008,"2 (Emerging Evidence)","arrhythmogenic right ventricular dysplasia 10",MONDO:0012434,"0 (No Evidence)",'-,'-,,,62.78,0,0.79,12/13/2022
G,DSG4,HGNC:21307,18q12.1,18:28956740-28994872,18:31376777-31414909,"30 (Autosomal Recessive)","hypotrichosis 6",MONDO:0011932,"0 (No Evidence)",'-,'-,,,47.44,0,0.82,08/22/2016
G,DSP,HGNC:3052,6p24.3,6:7541904-7586947,6:7541671-7586714,"3 (Sufficient Evidence)","dilated cardiomyopathy",MONDO:0005021,"0 (No Evidence)",'-,'-,,,12.87,1,0.26,10/12/2021
G,DSPP,HGNC:3054,4q22.1,4:88529681-88538025,4:87608529-87616873,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,61.42,0,1.17,03/27/2013
G,DYM,HGNC:21317,18q21.1,18:46562757-46987015,18:49036387-49460645,"30 (Autosomal Recessive)","spondyloepiphyseal dysplasia",MONDO:0016761,"0 (No Evidence)",'-,'-,,,20.38,0,0.91,02/23/2012
G,DYNC1H1,HGNC:2961,14q32.31,14:102430910-102522780,14:101964573-102056443,"0 (No Evidence)","distal hereditary motor neuropathy",MONDO:0018894,"0 (No Evidence)",'-,'-,,,28.69,1,0.08,11/14/2023
G,DYNC2H1,HGNC:2962,11q22.3,11:102980155-103350591,11:103109426-103479863,"30 (Autosomal Recessive)","asphyxiating thoracic dystrophy 3",MONDO:0013127,"Not Yet Evaluated",'-,'-,,,29.66,0,0.58,08/22/2016
G,DYNC2I1,HGNC:21862,7q36.3,7:158631936-158738880,7:158839245-158958698,"30 (Autosomal Recessive)","short-rib thoracic dysplasia 8 with or without polydactyly",MONDO:0014214,"Not Yet Evaluated",'-,'-,,,89.69,0,0.67,08/22/2016
G,DYRK1A,HGNC:3091,21q22.13,21:38737875-38898660,21:37365573-37526358,"3 (Sufficient Evidence)","DYRK1A-related intellectual disability syndrome",MONDO:0013578,"0 (No Evidence)",'-,'-,,,3.69,1,0.21,12/16/2020
G,EARS2,HGNC:29419,16p12.2,16:23532075-23568696,16:23520754-23557375,"30 (Autosomal Recessive)","leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome",MONDO:0013971,"0 (No Evidence)",'-,'-,,,49.25,0,1.02,08/22/2016
G,EBF3,HGNC:19087,10q26.3,10:131633497-131762538,10:129835233-129964274,"3 (Sufficient Evidence)","hypotonia, ataxia, and delayed development syndrome",MONDO:0015021,"0 (No Evidence)",'-,'-,,,3.89,1,0.15,12/06/2023
G,EBP,HGNC:3133,Xp11.23,X:48380196-48387104,X:48521808-48528716,"3 (Sufficient Evidence)","X-linked chondrodysplasia punctata 2",MONDO:0020603,"0 (No Evidence)",'-,'-,,,58.58,0.94,0.34,01/22/2020
G,EDA,HGNC:3157,Xq13.1,X:68835957-69259322,X:69616113-70039472,"3 (Sufficient Evidence)","X-linked hypohidrotic ectodermal dysplasia",MONDO:0010585,"0 (No Evidence)",'-,'-,,,2.43,0.97,0.27,01/25/2023
G,EDNRB,HGNC:3180,13q22.3,13:78469616-78549662,13:77895481-77975527,"1 (Little Evidence)","Waardenburg syndrome type 4A",MONDO:0010192,"0 (No Evidence)",'-,'-,,,5.87,0.01,0.59,02/07/2022
G,EEF1A2,HGNC:3192,20q13.33,20:62119367-62130436,20:63488014-63499083,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,36.29,1,0.19,06/13/2023
G,EFCAB13,HGNC:26864,17q21.32,17:45401321-45518678,17:47323955-47441312,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,86.7,0,1.37,02/02/2021
G,EFL1,HGNC:25789,15q25.2,15:82422574-82555075,15:82130233-82262734,"30 (Autosomal Recessive)","Shwachman-Diamond syndrome",MONDO:0009833,"Not Yet Evaluated",'-,'-,,,67.96,0,0.56,04/13/2022
G,EFNB1,HGNC:3226,Xq13.1,X:68048864-68062003,X:68829021-68842160,"3 (Sufficient Evidence)","craniofrontonasal syndrome",MONDO:0010570,"1 (Little Evidence)",'-,'-,,,5.79,0.93,0.35,07/26/2012
G,EFTUD2,HGNC:30858,17q21.31,17:42927316-42976813,17:44849948-44899445,"3 (Sufficient Evidence)","mandibulofacial dysostosis-microcephaly syndrome",MONDO:0012516,"0 (No Evidence)",'-,'-,,,24.19,1,0.09,05/23/2013
G,EGFR,HGNC:3236,7p11.2,7:55086710-55279321,7:55019017-55211628,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.3,0.37,0.35,05/11/2022
G,EGR2,HGNC:3239,10q21.3,10:64571756-64578927,10:62811996-62819167,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.85,0.5,0.6,11/28/2011
G,EHMT1,HGNC:24650,9q34.3,9:140513457-140730579,9:137619005-137836127,"3 (Sufficient Evidence)","Kleefstra syndrome 1",MONDO:0027407,"1 (Little Evidence)",'-,'-,,,62.96,1,0.07,07/06/2012
G,EIF2AK3,HGNC:3255,2p11.2,2:88856259-88926982,2:88556741-88628145,"30 (Autosomal Recessive)","Wolcott-Rallison syndrome",MONDO:0009192,"Not Yet Evaluated",'-,'-,,,4.63,0,0.45,08/22/2016
G,EIF2B1,HGNC:3257,12q24.31,12:124104953-124118233,12:123620406-123633686,"30 (Autosomal Recessive)","syndromic complex neurodevelopmental disorder",MONDO:0800439,"Not Yet Evaluated",'-,'-,,,49.37,0,0.98,08/22/2016
G,EIF2B3,HGNC:3259,1p34.1,1:45316194-45452267,1:44850522-44986595,"30 (Autosomal Recessive)","syndromic complex neurodevelopmental disorder",MONDO:0800439,"0 (No Evidence)",'-,'-,,,14.41,0.57,0.43,08/22/2016
G,EIF4A3,HGNC:18683,17q25.3,17:78108168-78120927,17:80134369-80147128,"30 (Autosomal Recessive)","Richieri Costa-Pereira syndrome",MONDO:0009998,"0 (No Evidence)",'-,'-,,,31.52,1,0.12,08/22/2016
G,ELANE,HGNC:3309,19p13.3,19:852303-856243,19:852303-856243,"1 (Little Evidence)","severe congenital neutropenia",MONDO:0018542,"0 (No Evidence)",'-,'-,,,34.42,0,1.13,07/13/2022
G,ELAVL2,HGNC:3313,9p21.3,9:23690102-23850599,9:23690104-23850601,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.24,1,0.19,11/28/2018
G,ELK1,HGNC:3321,Xp11.23,X:47494919-47510003,X:47635520-47650604,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,43.41,0.94,0.34,09/26/2012
G,ELN,HGNC:3327,7q11.23,7:73442503-73484237,7:74028173-74069907,"3 (Sufficient Evidence)","supravalvular aortic stenosis",MONDO:0008504,"0 (No Evidence)",'-,'-,,,8.62,0,0.87,07/10/2012
G,ELOA3P,HGNC:24617,"18q21.1 not on reference assembly",18:44554573-44556449,,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,98.17,0,0,02/22/2012
G,EMX2,HGNC:3341,10q26.11,10:119302257-119309057,10:117542746-117549546,"1 (Little Evidence)",schizencephaly,MONDO:0010011,"0 (No Evidence)",'-,'-,,,7.32,0.95,0.32,11/09/2021
G,EN2,HGNC:3343,7q36.3,7:155250824-155257526,7:155458129-155464831,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,23.56,0.63,0.63,08/26/2012
G,ENG,HGNC:3349,9q34.11,9:130577291-130617052,9:127815016-127854658,"3 (Sufficient Evidence)","telangiectasia, hereditary hemorrhagic, type 1",MONDO:0008535,"0 (No Evidence)",'-,'-,,,23.71,1,0.24,01/11/2024
G,ENO3,HGNC:3354,17p13.2,17:4853847-4860424,17:4948710-4957129,"30 (Autosomal Recessive)","glycogen storage disease due to muscle beta-enolase deficiency",MONDO:0013046,"Not Yet Evaluated",'-,'-,,,4.38,0,1.69,08/22/2016
G,ENPP1,HGNC:3356,6q23.2,6:132129160-132216295,6:131808020-131895155,"30 (Autosomal Recessive)","hypophosphatemic rickets, autosomal recessive, 2",MONDO:0013219,"0 (No Evidence)",'-,'-,,,20.17,0,0.59,08/22/2016
G,EP300,HGNC:3373,22q13.2,22:41488596-41576081,22:41092592-41180077,"3 (Sufficient Evidence)","Rubinstein-Taybi syndrome due to EP300 haploinsufficiency",MONDO:0013364,"0 (No Evidence)",'-,'-,,,0.67,1,0.1,03/14/2013
G,EPB42,HGNC:3381,15q15.2,15:43489425-43513216,15:43197227-43225737,"30 (Autosomal Recessive)","hereditary spherocytosis type 5",MONDO:0012985,"0 (No Evidence)",'-,'-,,,67.14,0,0.77,08/22/2016
G,EPCAM,HGNC:11529,2p21,2:47596450-47614159,2:47369311-47387020,"30 (Autosomal Recessive)","congenital diarrhea 5 with tufting enteropathy",MONDO:0013184,"0 (No Evidence)",'-,'-,,,60.55,0,1.16,10/08/2019
G,EPM2A,HGNC:3413,6q24.3,6:145946441-146057159,6:145383353-145736023,"30 (Autosomal Recessive)","Lafora disease",MONDO:0009697,"0 (No Evidence)",'-,'-,,,38.74,0,1.34,08/22/2016
G,EPS8,HGNC:3420,12p12.3,12:15773068-15942322,12:15620134-15789388,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 102",MONDO:0014428,"0 (No Evidence)",'-,'-,,,19.96,0.97,0.31,02/07/2018
G,ERCC1,HGNC:3433,19q13.32,19:45910592-45954805,19:45407334-45451547,"30 (Autosomal Recessive)","cerebrooculofacioskeletal syndrome 4",MONDO:0012554,"Not Yet Evaluated",'-,'-,,,39.74,0,1.3,08/22/2016
G,ERCC2,HGNC:3434,19q13.32,19:45853095-45873831,19:45349837-45370573,"30 (Autosomal Recessive)","xeroderma pigmentosum group D",MONDO:0010212,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,16.33,0,1.09,06/13/2023
G,ERCC3,HGNC:3435,2q14.3,2:128014866-128051720,2:127257290-127294144,"30 (Autosomal Recessive)","xeroderma pigmentosum group B",MONDO:0012531,"0 (No Evidence)",'-,'-,,,16.21,0,0.79,06/30/2020
G,ERCC4,HGNC:3436,16p13.12,16:14014011-14046205,16:13920154-13952348,"30 (Autosomal Recessive)",'-,'-,"0 (No Evidence)",'-,'-,,,31.43,0,0.9,08/09/2023
G,ERCC5,HGNC:3437,13q33.1,13:103498382-103528345,13:102846032-102875995,"30 (Autosomal Recessive)","xeroderma pigmentosum group G",MONDO:0010216,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,52.57,0,0.81,08/22/2016
G,ERCC6L2,HGNC:26922,9q22.32,9:98637973-98803374,9:95875691-96041092,"30 (Autosomal Recessive)","pancytopenia-developmental delay syndrome",MONDO:0014317,"0 (No Evidence)",'-,'-,,,62.16,0,0.68,08/22/2016
G,ERCC8,HGNC:3439,5q12.1,5:60162281-60240897,5:60866454-60945070,"30 (Autosomal Recessive)","Cockayne syndrome type 1",MONDO:0019569,"0 (No Evidence)",'-,'-,,,17.24,0,1.36,08/22/2016
G,ERF,HGNC:3444,19q13.2,19:42751721-42759280,19:42247569-42255128,"3 (Sufficient Evidence)","craniosynostosis 4",MONDO:0010929,"0 (No Evidence)",'-,'-,,,36.32,0.99,0.26,06/08/2021
G,ERMARD,HGNC:21056,6q27,6:170151718-170181696,6:169751306-169781600,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,84.87,0,1.02,11/13/2013
G,ESCO2,HGNC:27230,8p21.1,8:27632071-27662833,8:27771974-27819660,"30 (Autosomal Recessive)","Roberts-SC phocomelia syndrome",MONDO:0100253,"Not Yet Evaluated",'-,'-,,,44.83,0,0.83,08/22/2016
G,ESPN,HGNC:13281,1p36.31,1:6484836-6521004,1:6424776-6461370,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 36",MONDO:0012170,"0 (No Evidence)",'-,'-,,,46.09,0,0.93,02/07/2018
G,ETFB,HGNC:3482,19q13.41,19:51848409-51869642,19:51345155-51366388,"30 (Autosomal Recessive)","multiple acyl-CoA dehydrogenase deficiency",MONDO:0009282,"0 (No Evidence)",'-,'-,,,44.88,0.02,0.83,08/22/2016
G,ETFDH,HGNC:3483,4q32.1,4:159593448-159630775,4:158672296-158709623,"30 (Autosomal Recessive)","multiple acyl-CoA dehydrogenase deficiency",MONDO:0009282,"Not Yet Evaluated",'-,'-,,,46.5,0,1.04,08/22/2016
G,ETV6,HGNC:3495,12p13.2,12:11802608-12048311,12:11649674-11895377,"3 (Sufficient Evidence)","thrombocytopenia 5",MONDO:0014536,"0 (No Evidence)",'-,'-,,,1.55,0.97,0.32,01/11/2023
G,EVC2,HGNC:19747,4p16.2,4:5564166-5711275,4:5529011-5709548,"30 (Autosomal Recessive)","Ellis-van Creveld syndrome",MONDO:0009162,"0 (No Evidence)",'-,'-,,,74.81,0,1.06,07/18/2013
G,EVX2,HGNC:3507,2q31.1,2:176944835-176948690,2:176077472-176083962,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,19.69,0.4,0.68,04/04/2012
G,EXO5,HGNC:26115,1p34.2,1:40974439-40981710,1:40508767-40516038,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,64.2,0,1.43,02/02/2021
G,EXOSC3,HGNC:17944,9p13.2,9:37779711-37785089,9:37779714-37785092,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 1B",MONDO:0013853,"0 (No Evidence)",'-,'-,,,29.34,0,1.21,08/22/2016
G,EXPH5,HGNC:30578,11q22.3,11:108376162-108464495,11:108505435-108607536,"30 (Autosomal Recessive)","epidermolysis bullosa simplex 4, localized or generalized intermediate, autosomal recessive",MONDO:0014014,"0 (No Evidence)",'-,'-,,,83.2,0,0.94,08/22/2016
G,EXT1,HGNC:3512,8q24.11,8:118806729-119124065,8:117794490-118111826,"3 (Sufficient Evidence)","exostoses, multiple, type 1",MONDO:0007585,"0 (No Evidence)",'-,'-,,,1.49,1,0.26,06/17/2020
G,EXT2,HGNC:3513,11p11.2,11:44117228-44273512,11:44095678-44251962,"3 (Sufficient Evidence)","exostoses, multiple, type 2",MONDO:0007586,"0 (No Evidence)",'-,'-,,,14.77,0,0.77,06/23/2020
G,EYA1,HGNC:3519,8q13.3,8:72109668-72460329,8:71197433-71548094,"3 (Sufficient Evidence)","branchiootorenal syndrome 1",MONDO:0007236,"0 (No Evidence)",'-,'-,,,1.33,0.95,0.33,08/26/2020
G,EYA4,HGNC:3522,6q23.2,6:133562495-133853266,6:133240593-133532128,"3 (Sufficient Evidence)","autosomal dominant nonsyndromic hearing loss 10",MONDO:0011031,"0 (No Evidence)",'-,'-,,,3.86,0.05,0.45,01/22/2020
G,EYS,HGNC:21555,6q12,6:64429876-66417119,6:63719980-65707226,"30 (Autosomal Recessive)","retinitis pigmentosa 25",MONDO:0011272,"Not Yet Evaluated",'-,'-,,,25.63,0,0.83,08/22/2016
G,F10,HGNC:3528,13q34,13:113777113-113803843,13:113122799-113149529,"30 (Autosomal Recessive)","congenital factor X deficiency",MONDO:0009212,"Not Yet Evaluated",'-,'-,,,72.12,0,0.97,08/22/2016
G,F13A1,HGNC:3531,6p25.1,6:6144317-6320895,6:6144084-6320662,"30 (Autosomal Recessive)","factor XIII, A subunit, deficiency of",MONDO:0013187,"0 (No Evidence)",'-,'-,,,36.61,0,0.74,08/22/2016
G,F13B,HGNC:3534,1q31.3,1:197007871-197036390,1:197038741-197067260,"30 (Autosomal Recessive)","factor XIII, b subunit, deficiency of",MONDO:0013190,"0 (No Evidence)",'-,'-,,,74.15,0,0.85,08/22/2016
G,F5,HGNC:3542,1q24.2,1:169481189-169555719,1:169511951-169586481,"30 (Autosomal Recessive)","congenital factor V deficiency",MONDO:0009210,"0 (No Evidence)",'-,'-,,,66.18,0,0.56,01/11/2018
G,F7,HGNC:3544,13q34,13:113760102-113774999,13:113105788-113120685,"30 (Autosomal Recessive)","congenital factor VII deficiency",MONDO:0009211,"Not Yet Evaluated",'-,'-,,,80.84,0,0.9,08/22/2016
G,F8,HGNC:3546,Xq28,X:154064067-154250998,X:154835792-155022723,"3 (Sufficient Evidence)","hemophilia A",MONDO:0010602,"0 (No Evidence)",'-,'-,,,30.72,1,0.09,10/13/2020
G,F9,HGNC:3551,Xq27.1,X:138612898-138645618,X:139530739-139563459,"3 (Sufficient Evidence)","hemophilia B",MONDO:0010604,"0 (No Evidence)",'-,'-,,,40.27,1,0.17,01/12/2021
G,FA2H,HGNC:21197,16q23.1,16:74746867-74808718,16:74712969-74774820,"30 (Autosomal Recessive)","hereditary spastic paraplegia 35",MONDO:0012866,"Not Yet Evaluated",'-,'-,,,59.01,0.15,0.56,08/22/2016
G,FADD,HGNC:3573,11q13.3,11:70049402-70053496,11:70203296-70207390,"30 (Autosomal Recessive)","FADD-related immunodeficiency",MONDO:0013408,"0 (No Evidence)",'-,'-,,,68.73,0.53,1.28,08/22/2016
G,FAH,HGNC:3579,15q25.1,15:80445131-80479291,15:80152789-80186949,"30 (Autosomal Recessive)","tyrosinemia type I",MONDO:0010161,"0 (No Evidence)",'-,'-,,,64.92,0,1.41,09/02/2020
G,FAM161A,HGNC:25808,2p15,2:62051983-62081195,2:61800240-61854060,"30 (Autosomal Recessive)","retinitis pigmentosa 28",MONDO:0011630,"0 (No Evidence)",'-,'-,,,75.75,0,1.01,08/22/2016
G,FAM20C,HGNC:22140,7p22.3,7:192571-300738,7:192571-260772,"30 (Autosomal Recessive)","lethal osteosclerotic bone dysplasia",MONDO:0009821,"Not Yet Evaluated",'-,'-,,,39.39,0.31,0.49,08/22/2016
G,FAN1,HGNC:29170,15q13.3,15:31196055-31235311,15:30903852-30943108,"30 (Autosomal Recessive)","karyomegalic interstitial nephritis",MONDO:0013898,"0 (No Evidence)",'-,'-,,,86.96,0,1.12,08/22/2016
G,FANCA,HGNC:3582,16q24.3,16:89803957-89883055,16:89737549-89816647,"30 (Autosomal Recessive)","Fanconi anemia complementation group A",MONDO:0009215,"0 (No Evidence)",'-,'-,,,82.85,0,1.37,10/11/2023
G,FANCB,HGNC:3583,Xp22.2,X:14861527-14891191,X:14689524-14873069,"3 (Sufficient Evidence)","Fanconi anemia complementation group B",MONDO:0010351,"0 (No Evidence)",'-,'-,,,57.28,1,0.23,06/23/2021
G,FANCC,HGNC:3584,9q22.32,9:97861336-98079991,9:95099054-95317709,"30 (Autosomal Recessive)","Fanconi anemia complementation group C",MONDO:0009213,"0 (No Evidence)",'-,'-,,,43.39,0,1.04,08/22/2016
G,FANCD2,HGNC:3585,3p25.3,3:10068121-10143616,3:10026437-10101932,"30 (Autosomal Recessive)","Fanconi anemia complementation group D2",MONDO:0009214,"0 (No Evidence)",'-,'-,,,32.01,0,0.89,08/09/2023
G,FANCE,HGNC:3586,6p21.31,6:35420115-35434879,6:35452338-35467102,"30 (Autosomal Recessive)","Fanconi anemia complementation group E",MONDO:0010953,"0 (No Evidence)",'-,'-,,,62.05,0,0.89,06/12/2020
G,FANCF,HGNC:3587,11p14.3,11:22644079-22647369,11:22622533-22625823,"30 (Autosomal Recessive)","Fanconi anemia complementation group F",MONDO:0011325,"0 (No Evidence)",'-,'-,,,79.88,0.46,1.53,08/22/2016
G,FANCG,HGNC:3588,9p13.3,9:35073836-35079939,9:35073839-35079942,"30 (Autosomal Recessive)","Fanconi anemia complementation group G",MONDO:0013565,"0 (No Evidence)",'-,'-,,,50.76,0,1.09,11/15/2020
G,FANCI,HGNC:25568,15q26.1,15:89787210-89860490,15:89243979-89317259,"30 (Autosomal Recessive)","Fanconi anemia complementation group I",MONDO:0012186,"Not Yet Evaluated",'-,'-,,,23.8,0,1.02,08/22/2016
G,FANCL,HGNC:20748,2p16.1,2:58386378-58468515,2:58159243-58241380,"30 (Autosomal Recessive)",'-,'-,"30 (Autosomal Recessive)",'-,'-,,,9.14,0,1.61,10/21/2023
G,FARS2,HGNC:21062,6p25.1,6:5261240-5771816,6:5249934-5771583,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,44.7,0,1.15,08/22/2016
G,FAS,HGNC:11920,10q23.31,10:90750555-90776816,10:88964050-89017059,"1 (Little Evidence)","autoimmune lymphoproliferative syndrome",MONDO:0017979,"0 (No Evidence)",'-,'-,,,93.15,0.81,0.44,02/08/2022
G,FASLG,HGNC:11936,1q24.3,1:172628243-172636016,1:172659103-172666876,"30 (Autosomal Recessive)","autoimmune lymphoproliferative syndrome type 1",MONDO:0011158,"30 (Autosomal Recessive)",'-,'-,,,7.98,0.18,0.72,10/11/2023
G,FBN1,HGNC:3603,15q21.1,15:48700510-48937906,15:48408313-48645709,"3 (Sufficient Evidence)","Marfan syndrome",MONDO:0007947,"0 (No Evidence)",'-,'-,,,2.53,1,0.05,12/04/2019
G,FBP1,HGNC:3606,9q22.32,9:97365415-97402545,9:94603133-94640263,"30 (Autosomal Recessive)","fructose-1,6-bisphosphatase deficiency",MONDO:0009251,"0 (No Evidence)",'-,'-,,,36.83,0.08,0.72,08/22/2016
G,FBXO7,HGNC:13586,22q12.3,22:32870798-32894816,22:32474811-32498829,"30 (Autosomal Recessive)","parkinsonian-pyramidal syndrome",MONDO:0009830,"Not Yet Evaluated",'-,'-,,,38.24,0,0.88,08/22/2016
G,FBXW11,HGNC:13607,5q35.1,5:171288553-171433642,5:171861549-172006638,"0 (No Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,10.37,0.98,0.31,12/07/2011
G,FBXW4,HGNC:10847,10q24.32,10:103370423-103455052,10:101610666-101695295,"0 (No Evidence)",'-,'-,"0 (No Evidence)","split hand-foot malformation 3",MONDO:0009525,,,16.23,0,0.72,10/08/2014
G,FGD1,HGNC:3663,Xp11.22,X:54471887-54522667,X:54445454-54496234,"3 (Sufficient Evidence)","Aarskog-Scott syndrome, X-linked",MONDO:0010589,"0 (No Evidence)",'-,'-,,,18.2,1,0.2,05/26/2021
G,FGD4,HGNC:19125,12p11.21,12:32552492-32798984,12:32399558-32646050,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 4H",MONDO:0012250,"0 (No Evidence)",'-,'-,,,50.19,0.01,0.46,08/22/2016
G,FGF10,HGNC:3666,5p12,5:44300349-44389522,5:44300247-44389420,"3 (Sufficient Evidence)","LADD syndrome",MONDO:0007872,"0 (No Evidence)",'-,'-,,,0.55,0.94,0.34,02/23/2022
G,FGF12,HGNC:3668,3q28-q29,3:191857179-192445330,3:192139390-192727541,"0 (No Evidence)",'-,'-,"1 (Little Evidence)","developmental and epileptic encephalopathy",MONDO:0100062,,,3.96,0.62,0.54,12/01/2021
G,FGF3,HGNC:3681,11q13.3,11:69624736-69634184,11:69809968-69819416,"30 (Autosomal Recessive)","deafness with labyrinthine aplasia, microtia, and microdontia",MONDO:0012541,"Not Yet Evaluated",'-,'-,,,57.44,0,1.78,08/22/2016
G,FGFR1,HGNC:3688,8p11.23,8:38268661-38326153,8:38411143-38468635,"3 (Sufficient Evidence)","hypogonadotropic hypogonadism 2 with or without anosmia",MONDO:0007844,"0 (No Evidence)",'-,'-,,,0.42,1,0.22,04/05/2021
G,FGFR3,HGNC:3690,4p16.3,4:1795020-1810594,4:1793293-1808867,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.4,0,0.6,11/09/2011
G,FGFRL1,HGNC:3693,4p16.3,4:1005414-1020686,4:1010212-1026898,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,61.34,0.01,0.73,08/01/2013
G,FH,HGNC:3700,1q43,1:241660903-241683055,1:241497603-241519755,"3 (Sufficient Evidence)","hereditary leiomyomatosis and renal cell cancer",MONDO:0007888,"0 (No Evidence)",'-,'-,,,15.21,0.09,0.54,07/06/2020
G,FHIT,HGNC:3701,3p14.2,3:59733003-61237126,3:59747277-61251452,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.43,0.01,1.45,10/24/2018
G,FKBP14,HGNC:18625,7p14.3,7:30050203-30066318,7:30005923-30026702,"30 (Autosomal Recessive)","Ehlers-Danlos syndrome, kyphoscoliotic and deafness type",MONDO:0013800,"0 (No Evidence)",'-,'-,,,24.26,0,1.66,08/22/2016
G,FLCN,HGNC:27310,17p11.2,17:17115526-17140482,17:17212212-17237330,"3 (Sufficient Evidence)",'-,MONDO:0800444,"0 (No Evidence)",'-,'-,,,46.02,0.79,0.39,01/11/2023
G,FLG,HGNC:3748,1q21.3,1:152274641-152297715,1:152302165-152325239,"3 (Sufficient Evidence)","inherited ichthyosis",MONDO:0015947,"0 (No Evidence)",'-,'-,,,99.71,0,1.96,02/26/2020
G,FLNA,HGNC:3754,Xq28,X:153576899-153603002,X:154348531-154374634,"3 (Sufficient Evidence)","heterotopia, periventricular, X-linked dominant",MONDO:0010233,"0 (No Evidence)",'-,'-,,,8.01,1,0.08,12/02/2020
G,FLNB,HGNC:3755,3p14.3,3:57994149-58157978,3:58008422-58172251,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.25,0,0.44,07/25/2013
G,FLNC,HGNC:3756,7q32.1,7:128470460-128499326,7:128830406-128859272,"3 (Sufficient Evidence)","dilated cardiomyopathy",MONDO:0005021,"0 (No Evidence)",'-,'-,,,21.56,1,0.25,07/13/2021
G,FLVCR2,HGNC:20105,14q24.3,14:76044963-76114510,14:75578620-75648167,"30 (Autosomal Recessive)","Fowler syndrome",MONDO:0009168,"0 (No Evidence)",'-,'-,,,46.63,0,0.93,08/22/2016
G,FMO2,HGNC:3770,1q24.3,1:171154347-171181825,1:171185208-171212686,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,56.93,0,1.06,02/02/2021
G,FMR1,HGNC:3775,Xq27.3,X:146993437-147032645,X:147911919-147951125,"3 (Sufficient Evidence)","fragile X syndrome",MONDO:0010383,"0 (No Evidence)",'-,'-,,,2.45,0.65,0.42,12/16/2020
G,FOLR1,HGNC:3791,11q13.4,11:71900753-71907367,11:72189709-72196323,"30 (Autosomal Recessive)","neurodegenerative syndrome due to cerebral folate transport deficiency",MONDO:0013110,"0 (No Evidence)",'-,'-,,,71.28,0.13,0.65,06/25/2019
G,FOXC1,HGNC:3800,6p25.3,6:1610150-1614132,6:1609915-1613897,"3 (Sufficient Evidence)","Axenfeld-Rieger syndrome type 3",MONDO:0011233,"0 (No Evidence)",'-,'-,,,9.01,0.95,0.31,07/29/2020
G,FOXC2,HGNC:3801,16q24.1,16:86600435-86603334,16:86566829-86569728,"3 (Sufficient Evidence)","lymphedema-distichiasis syndrome",MONDO:0007922,"0 (No Evidence)",'-,'-,,,5.65,0.13,0.79,11/26/2013
G,FOXE1,HGNC:3806,9q22.33,9:100615508-100618999,9:97853226-97856717,"30 (Autosomal Recessive)","Bamforth-Lazarus syndrome",MONDO:0009437,"Not Yet Evaluated",'-,'-,,,37.73,0.79,0.58,08/22/2016
G,FOXE3,HGNC:3808,1p33,1:47881957-47883724,1:47416285-47418052,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,68.36,0.18,1.61,12/13/2017
G,FOXF1,HGNC:3809,16q24.1,16:86544133-86549028,16:86510527-86515422,"3 (Sufficient Evidence)","alveolar capillary dysplasia with misalignment of pulmonary veins",MONDO:0009934,"0 (No Evidence)",'-,'-,,,15.93,0.96,0.3,06/20/2013
G,FOXG1,HGNC:3811,14q12,14:29235993-29239483,14:28766787-28770277,"3 (Sufficient Evidence)","FOXG1 disorder",MONDO:0100040,"0 (No Evidence)",'-,'-,,,3.12,0.94,0.33,03/09/2021
G,FOXL2,HGNC:1092,3q22.3,3:138663066-138665979,3:138944224-138947137,"3 (Sufficient Evidence)","blepharophimosis, ptosis, and epicanthus inversus syndrome",MONDO:0007201,"0 (No Evidence)",'-,'-,,,21.55,0.88,0.44,02/09/2021
G,FOXP1,HGNC:3823,3p13,3:71003859-71633129,3:70954708-71583978,"3 (Sufficient Evidence)","intellectual disability-severe speech delay-mild dysmorphism syndrome",MONDO:0013352,"0 (No Evidence)",'-,'-,,,0.14,1,0.18,01/22/2020
G,FOXP2,HGNC:13875,7q31.1,7:113726382-114333820,7:114086327-114693765,"1 (Little Evidence)","specific language disorder",MONDO:0016226,"0 (No Evidence)",'-,'-,,,0.09,1,0.22,09/19/2012
G,FOXRED1,HGNC:26927,11q24.2,11:126139049-126148021,11:126269154-126278126,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,55.38,0,1.32,08/22/2016
G,FREM1,HGNC:23399,9p22.3,9:14737150-14910993,9:14737152-14910995,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,26.81,0,1.12,06/06/2013
G,FRMD7,HGNC:8079,Xq26.2,X:131211018-131262048,X:132076990-132128020,"3 (Sufficient Evidence)","nystagmus 1, congenital, X-linked",MONDO:0010693,"0 (No Evidence)",'-,'-,,,28.47,0.73,0.42,04/09/2020
G,FSHB,HGNC:3964,11p14.1,11:30252561-30256741,11:30231014-30235194,"30 (Autosomal Recessive)","hypogonadotropic hypogonadism 24 without anosmia",MONDO:0009239,"Not Yet Evaluated",'-,'-,,,15.77,0.34,1.06,08/22/2016
G,FTCD,HGNC:3974,21q22.3,21:47556176-47575493,21:46136262-46155579,"30 (Autosomal Recessive)","formiminoglutamic aciduria",MONDO:0009240,"0 (No Evidence)",'-,'-,,,71.26,0,1.23,08/22/2016
G,FTL,HGNC:3999,19q13.33,19:49468566-49470136,19:48965309-48966879,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,16.73,0,1.95,08/22/2013
G,FTSJ1,HGNC:13254,Xp11.23,X:48334409-48344752,X:48476021-48486364,"2 (Emerging Evidence)","non-syndromic X-linked intellectual disability",MONDO:0019181,"0 (No Evidence)",'-,'-,,,52.75,0.99,0.2,03/22/2023
G,FXN,HGNC:3951,9q21.11,9:71650668-71693992,9:69035752-69079076,"30 (Autosomal Recessive)","Friedreich ataxia 1",MONDO:0100340,"0 (No Evidence)",'-,'-,,,66.77,0.34,0.72,08/22/2016
G,FYCO1,HGNC:14673,3p21.31,3:45959395-46037316,3:45917903-45995824,"30 (Autosomal Recessive)","cataract 18",MONDO:0012395,"0 (No Evidence)",'-,'-,,,61.49,0,0.91,05/20/2015
G,FZD4,HGNC:4042,11q14.2,11:86656721-86666437,11:86945679-86955395,"3 (Sufficient Evidence)","exudative vitreoretinopathy 1",MONDO:0007589,"0 (No Evidence)",'-,'-,,,22.13,0.97,0.31,01/25/2023
G,G6PC3,HGNC:24861,17q21.31,17:42148041-42153712,17:44070673-44076344,"30 (Autosomal Recessive)","autosomal recessive severe congenital neutropenia due to G6PC3 deficiency",MONDO:0012930,"0 (No Evidence)",'-,'-,,,43.93,0,1.03,04/30/2020
G,GAA,HGNC:4065,17q25.3,17:78075380-78093680,17:80101581-80119881,"30 (Autosomal Recessive)","glycogen storage disease II",MONDO:0009290,"Not Yet Evaluated",'-,'-,,,75.35,0,0.98,08/22/2016
G,GAB4,HGNC:18325,22q11.1,22:17442826-17489112,22:16961936-17008222,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,87.14,0,1.22,02/02/2021
G,GABRA1,HGNC:4075,5q34,5:161274197-161326977,5:161847191-161899971,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,9.56,0.91,0.37,11/09/2021
G,GABRB3,HGNC:4083,15q12,15:26788699-27018910,15:26543552-26773763,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,8.38,0.95,0.34,04/25/2012
G,GABRG2,HGNC:4087,5q34,5:161494471-161582545,5:162067465-162155539,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,11.88,0.74,0.4,09/25/2018
G,GALC,HGNC:4115,14q31.3,14:88399358-88460009,14:87933014-87993667,"30 (Autosomal Recessive)","Krabbe disease",MONDO:0009499,"Not Yet Evaluated",'-,'-,,,47.35,0,0.94,08/22/2016
G,GALK1,HGNC:4118,17q25.1,17:73747550-73761273,17:75751469-75765192,"30 (Autosomal Recessive)","galactokinase deficiency",MONDO:0009255,"0 (No Evidence)",'-,'-,,,28.42,0,1.09,08/22/2016
G,GALNS,HGNC:4122,16q24.3,16:88880142-88923355,16:88813734-88856947,"30 (Autosomal Recessive)","mucopolysaccharidosis type 4A",MONDO:0009659,"0 (No Evidence)",'-,'-,,,65.94,0,1.01,08/22/2016
G,GALNT12,HGNC:19877,9q22.33,9:101569952-101612363,9:98807670-98850081,"1 (Little Evidence)","colorectal cancer, susceptibility to, 1",MONDO:0012132,"0 (No Evidence)",'-,'-,,,59.91,0,0.94,09/09/2019
G,GALNT3,HGNC:4125,2q24.3,2:166604098-166650757,2:165747588-165794692,"30 (Autosomal Recessive)","tumoral calcinosis, hyperphosphatemic, familial, 1",MONDO:0100252,"0 (No Evidence)",'-,'-,,,17.53,0,0.86,08/22/2016
G,GALR1,HGNC:4132,18q23,18:74961804-74989856,18:77249848-77277900,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,59.63,0,1.35,07/06/2012
G,GALT,HGNC:4135,9p13.3,9:34646672-34651032,9:34646675-34651035,"30 (Autosomal Recessive)","classic galactosemia",MONDO:0009258,"Not Yet Evaluated",'-,'-,,,30.87,0,0.96,08/22/2016
G,GAMT,HGNC:4136,19p13.3,19:1397025-1401541,19:1397026-1401542,"30 (Autosomal Recessive)","guanidinoacetate methyltransferase deficiency",MONDO:0012999,"0 (No Evidence)",'-,'-,,,62.39,0.01,1.26,08/22/2016
G,GAN,HGNC:4137,16q23.2,16:81348567-81424414,16:81314962-81390809,"30 (Autosomal Recessive)","giant axonal neuropathy 1",MONDO:0009749,"Not Yet Evaluated",'-,'-,,,44.7,0.02,0.5,08/22/2016
G,GATA1,HGNC:4170,Xp11.23,X:48644998-48652718,X:48786590-48794311,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,45.59,0.95,0.32,10/14/2020
G,GATA2,HGNC:4171,3q21.3,3:128198265-128212044,3:128479422-128493201,"3 (Sufficient Evidence)","deafness-lymphedema-leukemia syndrome",MONDO:0013540,"0 (No Evidence)",'-,'-,,,1.46,0.98,0.29,04/12/2023
G,GATA3,HGNC:4172,10p14,10:8096651-8117161,10:8045333-8075198,"3 (Sufficient Evidence)","hypoparathyroidism-deafness-renal disease syndrome",MONDO:0007797,"0 (No Evidence)",'-,'-,,,2.99,0.9,0.39,06/24/2020
G,GATA4,HGNC:4173,8p23.1,8:11534444-11617511,8:11676935-11760002,"3 (Sufficient Evidence)","atrial septal defect 2",MONDO:0011938,"0 (No Evidence)",'-,'-,,,0.87,0.49,0.53,02/08/2017
G,GATA6,HGNC:4174,18q11.2,18:19749550-19782491,18:22169589-22202528,"3 (Sufficient Evidence)","pancreatic hypoplasia-diabetes-congenital heart disease syndrome",MONDO:0010802,"0 (No Evidence)",'-,'-,,,4.26,1,0.17,06/20/2013
G,GATAD1,HGNC:29941,7q21.2,7:92076796-92089389,7:92447482-92495769,"30 (Autosomal Recessive)","dilated cardiomyopathy 2B",MONDO:0013848,"Not Yet Evaluated",'-,'-,,,37.42,0.43,0.65,08/22/2016
G,GATAD2B,HGNC:30778,1q21.3,1:153777201-153895448,1:153804725-153922972,"3 (Sufficient Evidence)","severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome",MONDO:0014034,"0 (No Evidence)",'-,'-,,,10.42,1,0.1,12/27/2017
G,GBA1,HGNC:4177,1q22,1:155204243-155214418,1:155234452-155244627,"30 (Autosomal Recessive)","Gaucher disease",MONDO:0018150,"0 (No Evidence)",'-,'-,,,52.28,0,0.8,08/22/2016
G,GBA2,HGNC:18986,9p13.3,9:35736863-35749225,9:35736866-35749228,"30 (Autosomal Recessive)","hereditary spastic paraplegia 46",MONDO:0013737,"Not Yet Evaluated",'-,'-,,,39.8,0,0.94,08/22/2016
G,GBE1,HGNC:4180,3p12.2,3:81538854-81810796,3:81489703-81761645,"30 (Autosomal Recessive)","glycogen storage disease due to glycogen branching enzyme deficiency",MONDO:0009292,"0 (No Evidence)",'-,'-,,,9.2,0,0.97,08/22/2016
G,GCDH,HGNC:4189,19p13.13,19:13001943-13010813,19:12891129-12899999,"30 (Autosomal Recessive)","glutaryl-CoA dehydrogenase deficiency",MONDO:0009281,"Not Yet Evaluated",'-,'-,,,60.73,0,0.64,08/22/2016
G,GCH1,HGNC:4193,14q22.2,14:55308735-55369544,14:54842017-54902826,"3 (Sufficient Evidence)","dystonia 5",MONDO:0007495,"0 (No Evidence)",'-,'-,,,28.56,0.9,0.4,02/14/2023
G,GCSH,HGNC:4208,16q23.2,16:81115550-81130000,16:81081945-81096395,"30 (Autosomal Recessive)","glycine encephalopathy",MONDO:0011612,"Not Yet Evaluated",'-,'-,,,36.73,0,1.42,08/22/2016
G,GDF2,HGNC:4217,10q11.22,10:48411774-48416908,10:47322454-47327588,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,35.53,0,0.98,10/13/2016
G,GDF5,HGNC:4220,20q11.22,20:34021145-34042571,20:35433347-35454749,"3 (Sufficient Evidence)","brachydactyly type C",MONDO:0007221,"0 (No Evidence)",'-,'-,,,5.52,0.67,0.47,02/24/2021
G,GDI1,HGNC:4226,Xq28,X:153665500-153671814,X:154437154-154443467,"1 (Little Evidence)","intellectual disability, X-linked 41",MONDO:0010451,"0 (No Evidence)",'-,'-,,,30.35,0.99,0.19,06/22/2022
G,GEN1,HGNC:26881,2p24.2,2:17935136-17970213,2:17753278-17788946,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,58.31,0,0.95,02/02/2021
G,GFER,HGNC:4236,16p13.3,16:2034194-2037750,16:1984193-1987749,"30 (Autosomal Recessive)","congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome",MONDO:0013116,"0 (No Evidence)",'-,'-,,,41.65,0,1.65,08/22/2016
G,GFM1,HGNC:13780,3q25.32,3:158362316-158413370,3:158644527-158695581,"30 (Autosomal Recessive)","hepatoencephalopathy due to combined oxidative phosphorylation defect type 1",MONDO:0012191,"0 (No Evidence)",'-,'-,,,31.6,0,0.8,08/22/2016
G,GIGYF2,HGNC:11960,2q37.1,2:233562041-233725315,2:232697331-232860605,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,14.01,1,0.08,08/24/2022
G,GIPC3,HGNC:18183,19p13.3,19:3585476-3593539,19:3585478-3593541,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 15",MONDO:0011160,"0 (No Evidence)",'-,'-,,,63.46,0.01,0.93,08/22/2016
G,GJA1,HGNC:4274,6q22.31,6:121756792-121770873,6:121435646-121449727,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.17,0.16,0.62,11/20/2013
G,GJA5,HGNC:4279,1q21.2,1:147228332-147245455,1:147756199-147773351,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,8.62,0.02,0.81,02/23/2012
G,GJA8,HGNC:4281,1q21.2,1:147374921-147381396,1:147902795-147914486,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,52.92,0,1,02/23/2012
G,GJB2,HGNC:4284,13q12.11,13:20761609-20767077,13:20187470-20192938,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,20.16,0,1.98,05/10/2012
G,GJB6,HGNC:4288,13q12.11,13:20796101-20806458,13:20221962-20232319,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,21.27,0,1.74,01/30/2014
G,GK,HGNC:4289,Xp21.2,X:30671540-30749579,X:30653423-30731462,"3 (Sufficient Evidence)","inborn glycerol kinase deficiency",MONDO:0010613,"0 (No Evidence)",'-,'-,,,11.79,0.99,0.29,09/06/2012
G,GLA,HGNC:4296,Xq22.1,X:100652791-100662913,X:101397803-101407925,"3 (Sufficient Evidence)","Fabry disease",MONDO:0010526,"0 (No Evidence)",'-,'-,,,42.34,1,0.18,03/24/2021
G,GLB1,HGNC:4298,3p22.3,3:33038109-33138638,3:32961108-33097146,"30 (Autosomal Recessive)","GM1 gangliosidosis",MONDO:0018149,"0 (No Evidence)",'-,'-,,,44.88,0,0.86,03/25/2015
G,GLDC,HGNC:4313,9p24.1,9:6532467-6645729,9:6532467-6645729,"30 (Autosomal Recessive)","glycine encephalopathy",MONDO:0011612,"0 (No Evidence)",'-,'-,,,30.92,0,1.11,06/10/2016
G,GLI2,HGNC:4318,2q14.2,2:121493444-121750229,2:120735868-120992653,"3 (Sufficient Evidence)","holoprosencephaly 9",MONDO:0012563,"0 (No Evidence)",'-,'-,,,4.89,0.97,0.31,01/11/2021
G,GLI3,HGNC:4319,7p14.1,7:42000547-42276808,7:41960949-42264268,"3 (Sufficient Evidence)","Greig cephalopolysyndactyly syndrome",MONDO:0008287,"0 (No Evidence)",'-,'-,,,20.82,1,0.2,01/12/2021
G,GLIS3,HGNC:28510,9p24.2,9:3824127-4300068,9:3824127-4490465,"30 (Autosomal Recessive)","neonatal diabetes mellitus with congenital hypothyroidism",MONDO:0012436,"0 (No Evidence)",'-,'-,,,2.6,0,0.74,08/22/2016
G,GLMN,HGNC:14373,1p22.1,1:92711959-92764544,1:92246402-92370844,"3 (Sufficient Evidence)","glomuvenous malformation",MONDO:0007672,"0 (No Evidence)",'-,'-,,,14.69,0,0.91,07/18/2013
G,GLRB,HGNC:4329,4q32.1,4:157997302-158093242,4:157076150-157172090,"30 (Autosomal Recessive)","hyperekplexia 2",MONDO:0013828,"0 (No Evidence)",'-,'-,,,35.64,0,0.66,08/22/2016
G,GLUL,HGNC:4341,1q25.3,1:182347233-182360925,1:182378098-182391790,"30 (Autosomal Recessive)","congenital brain dysgenesis due to glutamine synthetase deficiency",MONDO:0012393,"0 (No Evidence)",'-,'-,,,9.54,1,0.19,06/04/2015
G,GMPPA,HGNC:22923,2q35,2:220363613-220371711,2:219498891-219506989,"30 (Autosomal Recessive)","alacrima, achalasia, and intellectual disability syndrome",MONDO:0014219,"0 (No Evidence)",'-,'-,,,42.18,0,0.94,08/22/2016
G,GNAI1,HGNC:4384,7q21.11,7:79764147-79855497,7:80134831-80226181,"0 (No Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.38,0.91,0.38,03/28/2023
G,GNAI3,HGNC:4387,1p13.3,1:110091237-110142817,1:109548615-109600195,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.51,0.04,0.61,07/18/2013
G,GNAO1,HGNC:4389,16q13,16:56225401-56391356,16:56191489-56357444,"1 (Little Evidence)","developmental and epileptic encephalopathy",MONDO:0100062,"0 (No Evidence)",'-,'-,,,7.72,0.99,0.26,05/10/2022
G,GNAS,HGNC:4392,20q13.32,20:57414803-57486247,20:58839748-58911192,"3 (Sufficient Evidence)",pseudopseudohypoparathyroidism,MONDO:0012912,"0 (No Evidence)",'-,'-,,,8.83,0.68,0.37,01/12/2021
G,GNB1,HGNC:4396,1p36.33,1:1716725-1822526,1:1785286-1891087,"1 (Little Evidence)","intellectual disability, autosomal dominant 42",MONDO:0014855,"0 (No Evidence)",'-,'-,,,22.4,1,0.15,01/23/2019
G,GNPAT,HGNC:4416,1q42.2,1:231376958-231413719,1:231241212-231277973,"30 (Autosomal Recessive)","rhizomelic chondrodysplasia punctata type 2",MONDO:0009112,"Not Yet Evaluated",'-,'-,,,57.89,0.3,0.42,08/22/2016
G,GNRH1,HGNC:4419,8p21.2,8:25276774-25282556,8:25419258-25425040,"30 (Autosomal Recessive)","hypogonadotropic hypogonadism 12 with or without anosmia",MONDO:0013914,"0 (No Evidence)",'-,'-,,,8.16,0.15,1.05,08/22/2016
G,GNS,HGNC:4422,12q14.3,12:65107229-65153186,12:64713449-64759406,"30 (Autosomal Recessive)","mucopolysaccharidosis type 3D",MONDO:0009658,"Not Yet Evaluated",'-,'-,,,30.08,0,0.61,08/22/2016
G,GOLGA2P2Y,HGNC:16479,Yq11.23,Y:26356114-26360978,,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/22/2012
G,GORAB,HGNC:25676,1q24.2,1:170501307-170522975,1:170532166-170553834,"30 (Autosomal Recessive)","geroderma osteodysplastica",MONDO:0009271,"0 (No Evidence)",'-,'-,,,57.49,0,0.99,08/22/2016
G,GP1BB,HGNC:4440,22q11.21,22:19711062-19712294,22:19723539-19724771,"30 (Autosomal Recessive)","Bernard-Soulier syndrome",MONDO:0009276,"Not Yet Evaluated",'-,'-,,,78.01,0.51,1.33,08/22/2016
G,GP6,HGNC:14388,19q13.42,19:55525073-55549632,19:55013705-55038264,"30 (Autosomal Recessive)","platelet-type bleeding disorder 11",MONDO:0013623,"0 (No Evidence)",'-,'-,,,92.98,0,1.61,08/22/2016
G,GPC3,HGNC:4451,Xq26.2,X:132669773-133119621,X:133535745-133985594,"3 (Sufficient Evidence)","Simpson-Golabi-Behmel syndrome type 1",MONDO:0020602,"0 (No Evidence)",'-,'-,,,1.17,1,0.16,01/27/2021
G,GPC5,HGNC:4453,13q31.3,13:92050875-93519490,13:91398621-92867237,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,10.35,0,1.08,03/09/2012
G,GPC6,HGNC:4454,13q31.3-q32.1,13:93879060-95060274,13:93216529-94408020,"30 (Autosomal Recessive)","autosomal recessive omodysplasia",MONDO:0009779,"0 (No Evidence)",'-,'-,,,1.28,0.14,0.51,11/17/2011
G,GPD1,HGNC:4455,12q13.12,12:50497791-50505096,12:50104008-50111313,"30 (Autosomal Recessive)","transient infantile hypertriglyceridemia and hepatosteatosis",MONDO:0013771,"0 (No Evidence)",'-,'-,,,31.74,0.01,0.83,08/22/2016
G,GPHN,HGNC:15465,14q23.3,14:66974865-67648520,14:66508147-67735355,"2 (Emerging Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,2.69,1,0.18,06/22/2022
G,GPIHBP1,HGNC:24945,8q24.3,8:144295093-144299044,8:143213218-143217170,"30 (Autosomal Recessive)","hyperlipoproteinemia, type 1D",MONDO:0014412,"Not Yet Evaluated",'-,'-,,,96.22,0.14,1.1,08/22/2016
G,GPR148,HGNC:23623,2q21.1,2:131486643-131487909,2:130729070-130730336,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,87.6,0,1.84,04/05/2018
G,GPR179,HGNC:31371,17q12,17:36480454-36499839,17:38324571-38343956,"30 (Autosomal Recessive)","congenital stationary night blindness 1E",MONDO:0013807,"0 (No Evidence)",'-,'-,,,79.16,0,0.82,08/22/2016
G,GPSM2,HGNC:29501,1p13.3,1:109419607-109477167,1:108876985-108934545,"30 (Autosomal Recessive)","Chudley-McCullough syndrome",MONDO:0011411,"0 (No Evidence)",'-,'-,,,21.15,0,0.86,08/22/2016
G,GPX4,HGNC:4556,19p13.3,19:1103993-1106778,19:1103994-1106779,"30 (Autosomal Recessive)","spondylometaphyseal dysplasia, Sedaghatian type",MONDO:0009593,"0 (No Evidence)",'-,'-,,,34.09,0,1.28,08/22/2016
G,GRB10,HGNC:4564,7p12.1,7:50657765-50861150,7:50590068-50793453,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.48,0.94,0.34,03/23/2012
G,GREM1,HGNC:2001,15q13.3,15:33010205-33037307,15:32718004-32745106,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,2.63,0.47,0.82,08/20/2020
G,GRHPR,HGNC:4570,9p13.2,9:37422693-37436987,9:37422435-37439494,"30 (Autosomal Recessive)","primary hyperoxaluria type 2",MONDO:0009824,"0 (No Evidence)",'-,'-,,,51.6,0,1.17,08/22/2016
G,GRIA3,HGNC:4573,Xq25,X:122318131-122624766,X:123184278-123490915,"2 (Emerging Evidence)","syndromic X-linked intellectual disability 94",MONDO:0010402,"0 (No Evidence)",'-,'-,,,2.64,1,0.19,10/23/2019
G,GRID1,HGNC:4575,10q23.1-q23.2,10:87359309-88126552,10:85599552-86366795,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,13.06,1,0.24,12/21/2011
G,GRIK2,HGNC:4580,6q16.3,6:101841584-102517958,6:101393708-102070083,"30 (Autosomal Recessive)","intellectual disability, autosomal recessive 6",MONDO:0012614,"0 (No Evidence)",'-,'-,,,2.34,1,0.26,09/05/2012
G,GRIN2A,HGNC:4585,16p13.2,16:9847261-10276765,16:9753404-10182908,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,13.34,1,0.19,04/27/2022
G,GRIN2B,HGNC:4586,12p13.1,12:13690271-14134536,12:13537337-13982134,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 6",MONDO:0013509,"0 (No Evidence)",'-,'-,,,10.82,1,0.06,09/25/2019
G,GRIN3B,HGNC:16768,19p13.3,19:1000418-1009731,19:1000419-1009732,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,80.29,0,0.98,02/02/2021
G,GRIP1,HGNC:18708,12q14.3,12:66741211-67463118,12:66347431-67069338,"30 (Autosomal Recessive)","Fraser syndrome 1",MONDO:0054737,"0 (No Evidence)",'-,'-,,,18.89,0.51,0.36,07/10/2012
G,GRM1,HGNC:4593,6q24.3,6:146348843-146758737,6:146027707-146437601,"30 (Autosomal Recessive)","autosomal recessive spinocerebellar ataxia 13",MONDO:0013905,"Not Yet Evaluated",'-,'-,,,7.83,0.14,0.42,08/22/2016
G,GRM6,HGNC:4598,5q35.3,5:178405328-178422321,5:178978327-178995320,"30 (Autosomal Recessive)","congenital stationary night blindness 1B",MONDO:0009758,"0 (No Evidence)",'-,'-,,,55.3,0,1.17,08/22/2016
G,GRXCR1,HGNC:31673,4p13,4:42894730-43032675,4:42892713-43030658,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 25",MONDO:0013210,"0 (No Evidence)",'-,'-,,,33.66,0,1.7,03/06/2018
G,GTF2H5,HGNC:21157,6q25.3,6:158589382-158620376,6:158168350-158199344,"30 (Autosomal Recessive)","trichothiodystrophy 3, photosensitive",MONDO:0014619,"0 (No Evidence)",'-,'-,,,30.21,0.05,1.71,08/22/2016
G,GTF2I,HGNC:4659,7q11.23,7:74072044-74175022,7:74657718-74760692,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,33.5,1,0.27,08/08/2012
G,GTF2IRD1,HGNC:4661,7q11.23,7:73868236-74016931,7:74453906-74602605,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,47.51,0.9,0.33,10/10/2012
G,GTF2IRD2,HGNC:30775,7q11.23,7:74210490-74267901,7:74796151-74851605,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,85.33,0,1.17,12/04/2013
G,GUCA1C,HGNC:4680,3q13.13,3:108626639-108672726,3:108907792-108955195,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,74.3,0,1.88,02/02/2021
G,GUCY2C,HGNC:4688,12p12.3,12:14765566-14849533,12:14612632-14696599,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,27.06,0,1.08,09/18/2013
G,GUSB,HGNC:4696,7q11.21,7:65425671-65447200,7:65960684-65982213,"30 (Autosomal Recessive)","mucopolysaccharidosis type 7",MONDO:0009662,"0 (No Evidence)",'-,'-,,,64.3,0,0.75,10/12/2015
G,GYS2,HGNC:4707,12p12.1,12:21689041-21757781,12:21532577-21604847,"30 (Autosomal Recessive)","glycogen storage disorder due to hepatic glycogen synthase deficiency",MONDO:0009414,"0 (No Evidence)",'-,'-,,,41.21,0,1.13,08/22/2016
G,H1-4,HGNC:4718,6p22.2,6:26156557-26157343,6:26156329-26157115,"0 (No Evidence)","Rahman syndrome",MONDO:0044323,"0 (No Evidence)",'-,'-,,,49.38,0.19,1.59,07/27/2022
G,H19,HGNC:4713,11p15.5,11:2016406-2022696,11:1995176-2001466,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/22/2012
G,H6PD,HGNC:4795,1p36.22,1:9294833-9331396,1:9234774-9271337,"30 (Autosomal Recessive)","cortisone reductase deficiency 1",MONDO:0011503,"0 (No Evidence)",'-,'-,,,46.01,0,0.94,08/22/2016
G,HBA1,HGNC:4823,16p13.3,16:226679-227521,16:176680-177522,"30 (Autosomal Recessive)","alpha thalassemia",MONDO:0011399,"0 (No Evidence)",'-,'-,,,69.88,0.01,1.85,04/19/2012
G,HBA2,HGNC:4824,16p13.3,16:222875-223709,16:172876-173710,"30 (Autosomal Recessive)","alpha thalassemia",MONDO:0011399,"0 (No Evidence)",'-,'-,,,60.06,0,1.93,07/06/2012
G,HCCS,HGNC:4837,Xp22.2,X:11129452-11141206,X:11111332-11123086,"3 (Sufficient Evidence)","linear skin defects with multiple congenital anomalies 1",MONDO:0024552,"0 (No Evidence)",'-,'-,,,40.92,0.89,0.41,05/10/2012
G,HDAC4,HGNC:14063,2q37.3,2:239969864-240323343,2:239048168-239401649,"1 (Little Evidence)","2q37 microdeletion syndrome",MONDO:0010886,"0 (No Evidence)",'-,'-,,,7.56,1,0.05,11/07/2011
G,HDAC8,HGNC:13315,Xq13.1,X:71549366-71792693,X:72329516-72572843,"3 (Sufficient Evidence)","Cornelia de Lange syndrome 5",MONDO:0010471,"0 (No Evidence)",'-,'-,,,15.01,0.98,0.3,03/28/2018
G,HEXB,HGNC:4879,5q13.3,5:73935848-74017113,5:74640023-74721288,"30 (Autosomal Recessive)","Sandhoff disease",MONDO:0010006,"Not Yet Evaluated",'-,'-,,,73.45,0,0.92,08/22/2016
G,HFE,HGNC:4886,6p22.2,6:26087657-26098571,6:26087429-26098343,"30 (Autosomal Recessive)","hemochromatosis type 1",MONDO:0021001,"0 (No Evidence)",'-,'-,,,74.41,0,1.19,11/10/2016
G,HFM1,HGNC:20193,1p22.2,1:91726323-91870394,1:91260766-91408007,"30 (Autosomal Recessive)","premature ovarian failure 9",MONDO:0014322,"0 (No Evidence)",'-,'-,,,42.61,0,0.93,08/22/2016
G,HGF,HGNC:4893,7q21.11,7:81328326-81399363,7:81699010-81770047,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 39",MONDO:0012003,"Not Yet Evaluated",'-,'-,,,0.6,1,0.25,08/22/2016
G,HGSNAT,HGNC:26527,8p11.21-p11.1,8:42995607-43057998,8:43140464-43202855,"30 (Autosomal Recessive)","mucopolysaccharidosis type 3C",MONDO:0009657,"Not Yet Evaluated",'-,'-,,,68.49,0,0.73,08/22/2016
G,HIRA,HGNC:4916,22q11.21,22:19318221-19419256,22:19330698-19431733,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,19.48,1,0.14,08/28/2012
G,HIVEP2,HGNC:4921,6q24.2,6:143072606-143266313,6:142751469-142946365,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 43",MONDO:0014858,"0 (No Evidence)",'-,'-,,,13.96,1,0.08,04/25/2018
G,HIVEP3,HGNC:13561,1p34.2,1:41972036-42501605,1:41506365-42035934,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,41.45,0.91,0.31,01/23/2019
G,HJV,HGNC:4887,1q21.1,1:145413278-145417543,1:146017470-146021735,"30 (Autosomal Recessive)","hemochromatosis type 2A",MONDO:0011216,"Not Yet Evaluated",'-,'-,,,43.91,0,0.88,08/22/2016
G,HLCS,HGNC:4976,21q22.13,21:38120926-38362511,21:36748625-36990211,"30 (Autosomal Recessive)","holocarboxylase synthetase deficiency",MONDO:0009666,"0 (No Evidence)",'-,'-,,,90.61,0,0.88,08/22/2016
G,HMBS,HGNC:4982,11q23.3,11:118955591-118964259,11:119084881-119093549,"3 (Sufficient Evidence)","acute intermittent porphyria",MONDO:0008294,"0 (No Evidence)",'-,'-,,,5.34,0.95,0.34,01/08/2020
G,HMGA2,HGNC:5009,12q14.3,12:66218240-66360071,12:65824460-65966291,"1 (Little Evidence)","Silver-Russell syndrome 5",MONDO:0020795,"0 (No Evidence)",'-,'-,,,1.82,0.87,0.45,09/14/2021
G,HNF1A,HGNC:11621,12q24.31,12:121416346-121440315,12:120978543-121002512,"3 (Sufficient Evidence)","maturity-onset diabetes of the young type 3",MONDO:0010894,"0 (No Evidence)",'-,'-,,,35.48,0.96,0.33,12/13/2023
G,HNF1B,HGNC:11630,17q12,17:36046434-36105050,17:37686431-37745059,"3 (Sufficient Evidence)","renal cysts and diabetes syndrome",MONDO:0007669,"0 (No Evidence)",'-,'-,,,0.76,1,0.17,12/21/2020
G,HNRNPC,HGNC:5035,14q11.2,14:21677306-21737601,14:21209147-21269442,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,3.15,0.98,0.3,11/29/2023
G,HNRNPK,HGNC:5044,9q21.32,9:86582998-86595530,9:83968083-83980615,"3 (Sufficient Evidence)","neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-hip dysplasia syndrome",MONDO:0018681,"0 (No Evidence)",'-,'-,,,2.97,1,0.1,08/23/2023
G,HOXD13,HGNC:5136,2q31.1,2:176957449-176960672,2:176087487-176095944,"3 (Sufficient Evidence)","synpolydactyly type 1",MONDO:0008513,"0 (No Evidence)",'-,'-,,,2.62,0.01,0.95,09/23/2020
G,HOXD9,HGNC:5140,2q31.1,2:176987447-176989665,2:176122719-176124937,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,2.67,0.02,1.07,02/22/2012
G,HPGD,HGNC:5154,4q34.1,4:175411326-175444044,4:174490175-174522893,"30 (Autosomal Recessive)","hypertrophic osteoarthropathy, primary, autosomal recessive, 1",MONDO:0024546,"0 (No Evidence)",'-,'-,,,47,0,1.25,08/22/2016
G,HPRT1,HGNC:5157,Xq26.2-q26.3,X:133594195-133634698,X:134460165-134500668,"3 (Sufficient Evidence)","Lesch-Nyhan syndrome",MONDO:0010298,"0 (No Evidence)",'-,'-,,,8.48,0.94,0.34,01/13/2021
G,HPS1,HGNC:5163,10q24.2,10:100175955-100206692,10:98413948-98446935,"30 (Autosomal Recessive)","Hermansky-Pudlak syndrome 1",MONDO:0008748,"Not Yet Evaluated",'-,'-,,,60.85,0,0.69,08/22/2016
G,HPS3,HGNC:15597,3q24,3:148847425-148891519,3:149129638-149173732,"30 (Autosomal Recessive)","Hermansky-Pudlak syndrome 3",MONDO:0013555,"Not Yet Evaluated",'-,'-,,,44.42,0,1.02,08/22/2016
G,HPSE2,HGNC:18374,10q24.2,10:100216834-100995632,10:98457077-99315951,"30 (Autosomal Recessive)","urofacial syndrome type 1",MONDO:0009368,"0 (No Evidence)",'-,'-,,,3.52,0,0.69,03/12/2015
G,HRAS,HGNC:5173,11p15.5,11:532242-535576,11:532242-535576,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.08,0.08,0.93,10/15/2015
G,HSD17B10,HGNC:4800,Xp11.22,X:53458206-53461323,X:53431258-53434376,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,21.63,0.94,0.34,09/06/2012
G,HSD17B13,HGNC:18685,4q22.1,4:88224946-88244034,4:87303794-87322882,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,70.24,0,1.14,02/02/2021
G,HSD17B3,HGNC:5212,9q22.32,9:98997588-99064458,9:96235306-96302176,"30 (Autosomal Recessive)","46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",MONDO:0009916,"Not Yet Evaluated",'-,'-,,,73.59,0,1.09,08/22/2016
G,HSD17B4,HGNC:5213,5q23.1,5:118788192-118878027,5:119452497-119542332,"30 (Autosomal Recessive)","Perrault syndrome 1",MONDO:0009300,"0 (No Evidence)",'-,'-,,,44.64,0,0.75,03/06/2018
G,HSD3B7,HGNC:18324,16p11.2,16:30996528-31000468,16:30985207-30989147,"30 (Autosomal Recessive)","congenital bile acid synthesis defect 1",MONDO:0011906,"0 (No Evidence)",'-,'-,,,53.14,0,1.33,08/22/2016
G,HSPG2,HGNC:5273,1p36.12,1:22148737-22263803,1:21822244-21937310,"30 (Autosomal Recessive)","Schwartz-Jampel syndrome",MONDO:0009717,"0 (No Evidence)",'-,'-,,,49.81,0,0.41,06/02/2016
G,HTN3,HGNC:5284,4q13.3,4:70894176-70902255,4:70028459-70036538,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,90.63,0,1.89,02/02/2021
G,HUWE1,HGNC:30892,Xp11.22,X:53559057-53713664,X:53532096-53686719,"0 (No Evidence)","intellectual disability, X-linked syndromic, Turner type",MONDO:0010407,"0 (No Evidence)","intellectual disability, X-linked syndromic, Turner type",MONDO:0010407,,,10.58,1,0.06,09/26/2018
G,HYLS1,HGNC:26558,11q24.2,11:125753509-125770541,11:125883614-125900646,"30 (Autosomal Recessive)","hydrolethalus syndrome 1",MONDO:0009365,"Not Yet Evaluated",'-,'-,,,36.27,0,1.43,08/22/2016
G,HYMAI,HGNC:5326,6q24.2,6:144326053-144329867,6:144004916-144008259,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,09/06/2012
G,IDS,HGNC:5389,Xq28,X:148558519-148586836,X:149476988-149505306,"3 (Sufficient Evidence)","mucopolysaccharidosis type 2",MONDO:0010674,"0 (No Evidence)",'-,'-,,,14.02,0.95,0.32,11/10/2020
G,IDUA,HGNC:5391,4p16.3,4:980785-998352,4:986997-1008351,"30 (Autosomal Recessive)","mucopolysaccharidosis type 1",MONDO:0001586,"Not Yet Evaluated",'-,'-,,,69.73,0,1.17,08/22/2016
G,IFT140,HGNC:29077,16p13.3,16:1560428-1662073,16:1510427-1612072,"30 (Autosomal Recessive)","short-rib thoracic dysplasia 9 with or without polydactyly",MONDO:0009964,"Not Yet Evaluated",'-,'-,,,69.24,0,0.82,08/22/2016
G,IFT27,HGNC:18626,22q12.3,22:37154255-37172163,22:36758211-36776119,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 19",MONDO:0014447,"0 (No Evidence)",'-,'-,,,55.96,0,1.41,08/22/2016
G,IFT43,HGNC:29669,14q24.3,14:76452106-76550416,14:75985763-76084073,"30 (Autosomal Recessive)","cranioectodermal dysplasia 3",MONDO:0013573,"Not Yet Evaluated",'-,'-,,,67.39,0,1.6,08/22/2016
G,IGF1R,HGNC:5465,15q26.3,15:99191768-99507759,15:98648539-98964530,"3 (Sufficient Evidence)","growth delay due to insulin-like growth factor I resistance",MONDO:0010038,"0 (No Evidence)",'-,'-,,,1.29,0.97,0.31,11/08/2022
G,IGF2,HGNC:5466,11p15.5,11:2150342-2170833,11:2129117-2149566,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,79.01,0.04,1.13,03/22/2012
G,IGF2R,HGNC:5467,6q25.3,6:160390114-160532536,6:159969082-160111504,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,53.96,1,0.21,06/07/2012
G,IGHMBP2,HGNC:5542,11q13.3,11:68671359-68708069,11:68903891-68940601,"30 (Autosomal Recessive)","autosomal recessive distal spinal muscular atrophy 1",MONDO:0011436,"0 (No Evidence)",'-,'-,,,80.78,0,0.95,08/22/2016
G,IGLL1,HGNC:5870,22q11.23,22:23915312-23922477,22:23573125-23580290,"30 (Autosomal Recessive)","agammaglobulinemia 2, autosomal recessive",MONDO:0013287,"0 (No Evidence)",'-,'-,,,81.01,0.01,1.64,08/22/2016
G,IKBKG,HGNC:5961,Xq28,X:153769453-153793261,X:154541238-154565046,"3 (Sufficient Evidence)","incontinentia pigmenti",MONDO:0010631,"0 (No Evidence)",'-,'-,,,41.6,0.08,1.37,11/10/2020
G,IL10RA,HGNC:5964,11q23.3,11:117857109-117873752,11:117986394-118003037,"30 (Autosomal Recessive)","inflammatory bowel disease 28",MONDO:0013153,"0 (No Evidence)",'-,'-,,,81.79,0.02,0.69,08/22/2016
G,IL17RA,HGNC:5985,22q11.1,22:17565890-17596583,22:17085000-17115693,"30 (Autosomal Recessive)","immunodeficiency 51",MONDO:0013500,"Not Yet Evaluated",'-,'-,,,84.96,0,0.63,08/22/2016
G,IL1RAPL1,HGNC:5996,Xp21.3-p21.2,X:28605563-29974835,X:28587446-29956718,"3 (Sufficient Evidence)","intellectual disability, X-linked 21",MONDO:0010256,"0 (No Evidence)",'-,'-,,,1.75,1,0.2,11/14/2023
G,IL21R,HGNC:6006,16p12.1,16:27413495-27463363,16:27402174-27452042,"30 (Autosomal Recessive)","cryptosporidiosis-chronic cholangitis-liver disease syndrome",MONDO:0014082,"0 (No Evidence)",'-,'-,,,84.41,1,0.21,08/22/2016
G,IL2RA,HGNC:6008,10p15.1,10:6052652-6104330,10:6010689-6062367,"30 (Autosomal Recessive)","immunodeficiency due to CD25 deficiency",MONDO:0011664,"Not Yet Evaluated",'-,'-,,,67.75,0.05,0.66,08/22/2016
G,IMMP2L,HGNC:14598,7q31.1,7:110302700-111202548,7:110662644-111562492,"40 (Dosage Sensitivity Unlikely)","Tourette syndrome",MONDO:0007661,"0 (No Evidence)",'-,'-,,,4.25,0.01,1.2,04/12/2022
G,IMPA1,HGNC:6050,8q21.13,8:82569149-82598560,8:81656914-81686325,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,39.68,0,0.88,02/08/2012
G,INPP5E,HGNC:21474,9q34.3,9:139323071-139334297,9:136428619-136439845,"30 (Autosomal Recessive)","Joubert syndrome 1",MONDO:0008944,"0 (No Evidence)",'-,'-,,,77.32,0,0.68,08/22/2016
G,INS,HGNC:6081,11p15.5,11:2181009-2182439,11:2159779-2161209,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,80.96,0.3,1.17,03/22/2012
G,IQSEC2,HGNC:29059,Xp11.22,X:53262058-53350548,X:53225813-53321350,"3 (Sufficient Evidence)","intellectual disability, X-linked 1",MONDO:0010656,"0 (No Evidence)",'-,'-,,,26.16,1,0.13,04/07/2020
G,IRAK4,HGNC:17967,12q12,12:44152754-44183344,12:43758951-43789541,"30 (Autosomal Recessive)","immunodeficiency 67",MONDO:0011888,"0 (No Evidence)",'-,'-,,,45.48,0,1.05,08/22/2016
G,IRF6,HGNC:6121,1q32.2,1:209958962-209979487,1:209785617-209806142,"3 (Sufficient Evidence)","van der Woude syndrome 1",MONDO:0007333,"0 (No Evidence)",'-,'-,,,2.03,1,0.13,07/06/2012
G,ITCH,HGNC:13890,20q11.22,20:32951079-33099578,20:34363273-34511773,"30 (Autosomal Recessive)","syndromic multisystem autoimmune disease due to ITCH deficiency",MONDO:0013245,"Not Yet Evaluated",'-,'-,,,7.04,1,0.22,08/22/2016
G,ITGA3,HGNC:6139,17q21.33,17:48133474-48167845,17:50056110-50090481,"30 (Autosomal Recessive)","pidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome",MONDO:0013881,"0 (No Evidence)",'-,'-,,,25.55,0,0.53,08/22/2016
G,ITGB2,HGNC:6155,21q22.3,21:46305868-46348730,21:44885953-44928815,"30 (Autosomal Recessive)","leukocyte adhesion deficiency 1",MONDO:0007293,"Not Yet Evaluated",'-,'-,,,59.06,0,0.99,08/22/2016
G,ITGB3,HGNC:6156,17q21.32,17:45331193-45391109,17:47253827-47313743,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,35.78,0,0.52,08/27/2012
G,ITK,HGNC:6171,5q33.3,5:156607851-156682195,5:157180840-157255185,"30 (Autosomal Recessive)","lymphoproliferative syndrome 1",MONDO:0013081,"0 (No Evidence)",'-,'-,,,25.39,0,0.71,08/22/2016
G,ITPR1,HGNC:6180,3p26.1,3:4535032-4889190,3:4493348-4847506,"1 (Little Evidence)","autosomal dominant cerebellar ataxia",MONDO:0020380,"0 (No Evidence)",'-,'-,,,9.28,1,0.13,10/12/2023
G,ITSN1,HGNC:6183,21q22.11,21:35014807-35272165,21:33642501-33899861,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.18,1,0.22,06/27/2018
G,IYD,HGNC:21071,6q25.1,6:150690148-150727105,6:150369012-150405969,"30 (Autosomal Recessive)","thyroid dyshormonogenesis 4",MONDO:0010136,"0 (No Evidence)",'-,'-,,,67.58,0,0.88,08/22/2016
G,JAG1,HGNC:6188,20p12.2,20:10618332-10654647,20:10637684-10673999,"3 (Sufficient Evidence)","Alagille syndrome due to a JAG1 point mutation",MONDO:0016862,"0 (No Evidence)",'-,'-,,,1.06,1,0.15,10/19/2020
G,JAM3,HGNC:15532,11q25,11:133938967-134021896,11:134069072-134152001,"30 (Autosomal Recessive)","porencephaly-microcephaly-bilateral congenital cataract syndrome",MONDO:0013394,"0 (No Evidence)",'-,'-,,,47.11,0,0.84,06/11/2015
G,JARID2,HGNC:6196,6p22.3,6:15246300-15522273,6:15246069-15522042,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.14,1,0.19,11/07/2013
G,KANK1,HGNC:19309,9p24.3,9:470295-746103,9:470295-746103,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,49.74,0,0.95,04/28/2016
G,KANSL1,HGNC:24565,17q21.31,17:44107282-44302733,17:46029916-46225367,"3 (Sufficient Evidence)","Koolen-de Vries syndrome",MONDO:0012496,"0 (No Evidence)",'-,'-,,,16.23,1,0.24,04/11/2013
G,KARS1,HGNC:6215,16q23.1,16:75661622-75681563,16:75627724-75647665,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 89",MONDO:0013489,"0 (No Evidence)",'-,'-,,,2.51,0,0.91,08/22/2016
G,KAT6A,HGNC:13013,8p11.21,8:41786997-41909505,8:41929479-42051987,"3 (Sufficient Evidence)","autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome",MONDO:0014558,"0 (No Evidence)",'-,'-,,,19,1,0.07,03/28/2018
G,KAT6B,HGNC:17582,10q22.2,10:76585013-76792382,10:74824936-75032624,"3 (Sufficient Evidence)","blepharophimosis - intellectual disability syndrome, SBBYS type",MONDO:0011365,"0 (No Evidence)",'-,'-,,,7.97,1,0.13,04/25/2018
G,KATNAL2,HGNC:25387,18q21.1,18:44497557-44628614,18:46917594-47102243,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,41.98,0,0.82,11/28/2018
G,KCNH1,HGNC:6250,1q32.2,1:210851656-211307490,1:210678314-211134148,"0 (No Evidence)","KCNH1 associated disorder",MONDO:0100485,"0 (No Evidence)",'-,'-,,,22.54,0.55,0.39,06/28/2023
G,KCNH2,HGNC:6251,7q36.1,7:150642049-150675409,7:150944961-150978321,"3 (Sufficient Evidence)","long QT syndrome 2",MONDO:0013367,"0 (No Evidence)",'-,'-,,,8.87,1,0.27,02/26/2020
G,KCNJ1,HGNC:6255,11q24.3,11:128707915-128737191,11:128838020-128867296,"30 (Autosomal Recessive)","Bartter disease type 2",MONDO:0009424,"0 (No Evidence)",'-,'-,,,21.79,0,1.29,03/22/2012
G,KCNK9,HGNC:6283,8q24.3,8:140613081-140715366,8:139600838-139703123,"0 (No Evidence)","Birk-Barel syndrome",MONDO:0012856,"0 (No Evidence)",'-,'-,,,43.67,0.96,0.31,02/29/2012
G,KCNQ1,HGNC:6294,11p15.5-p15.4,11:2466238-2870340,11:2445008-2849105,"3 (Sufficient Evidence)","long QT syndrome 1",MONDO:0100316,"0 (No Evidence)",'-,'-,,,23.28,0,0.81,10/13/2020
G,KCNQ1OT1,HGNC:6295,11p15.5,11:2629558-2721228,11:2608328-2699994,"1 (Little Evidence)","Silver-Russell syndrome",MONDO:0008394,"0 (No Evidence)",'-,'-,,,‐,‐,‐,12/06/2023
G,KCNQ2,HGNC:6296,20q13.33,20:62031561-62104008,20:63400208-63472655,"3 (Sufficient Evidence)","seizures, benign familial neonatal, 1",MONDO:0007365,"0 (No Evidence)",'-,'-,,,39.78,1,0.16,07/18/2013
G,KCNV2,HGNC:19698,9p24.2,9:2717510-2730037,9:2717510-2730037,"30 (Autosomal Recessive)","cone dystrophy with supernormal rod response",MONDO:0012475,"Not Yet Evaluated",'-,'-,,,44.67,0,1.97,08/22/2016
G,KCTD7,HGNC:21957,7q11.21,7:66093868-66108216,7:66628881-66643229,"30 (Autosomal Recessive)","progressive myoclonus epilepsy",MONDO:0020074,"Not Yet Evaluated",'-,'-,,,35.12,0,0.65,08/22/2016
G,KDM5B,HGNC:18039,1q32.1,1:202693623-202778598,1:202724495-202808421,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,28,0,0.57,01/04/2018
G,KDM5C,HGNC:11114,Xp11.22,X:53205459-53254389,X:53176277-53225207,"3 (Sufficient Evidence)","X-linked syndromic intellectual disability",MONDO:0020119,"0 (No Evidence)",'-,'-,,,11.71,1,0.17,07/27/2023
G,KDM6A,HGNC:12637,Xp11.3,X:44732434-44972024,X:44873188-45112779,"3 (Sufficient Evidence)","Kabuki syndrome 2",MONDO:0010465,"0 (No Evidence)",'-,'-,,,4.72,1,0.16,07/18/2013
G,KDM6B,HGNC:29012,17p13.1,17:7737535-7758114,17:7834217-7854796,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,40.32,1,0.14,11/28/2018
G,KERA,HGNC:6309,12q21.33,12:91444268-91451801,12:91050491-91058024,"30 (Autosomal Recessive)","cornea plana 2",MONDO:0009014,"Not Yet Evaluated",'-,'-,,,28.54,0,1.49,08/22/2016
G,KHDC3L,HGNC:33699,6q13,6:74072381-74073894,6:73362658-73364171,"30 (Autosomal Recessive)","hydatidiform mole, recurrent, 2",MONDO:0013671,"Not Yet Evaluated",'-,'-,,,94.36,0.12,1.16,08/22/2016
G,KIF11,HGNC:6388,10q23.33,10:94352887-94415152,10:92593130-92655395,"3 (Sufficient Evidence)","microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability",MONDO:0007918,"0 (No Evidence)",'-,'-,,,9.02,1,0.12,08/01/2013
G,KIF1A,HGNC:888,2q37.3,2:241653184-241760820,2:240713767-240821403,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,50.62,1,0.14,08/08/2013
G,KIF1C,HGNC:6317,17p13.2,17:4901245-4931696,17:4997950-5028401,"30 (Autosomal Recessive)","spastic ataxia 2",MONDO:0012651,"0 (No Evidence)",'-,'-,,,44.84,0.72,0.34,08/22/2016
G,KIF7,HGNC:30497,15q26.1,15:90171208-90198698,15:89617309-89663049,"30 (Autosomal Recessive)","acrocallosal syndrome",MONDO:0008708,"0 (No Evidence)",'-,'-,,,45.81,0,0.93,08/22/2016
G,KIFBP,HGNC:23419,10q22.1,10:70748559-70776738,10:68988803-69016982,"30 (Autosomal Recessive)","Goldberg-Shprintzen megacolon syndrome",MONDO:0012280,"Not Yet Evaluated",'-,'-,,,14.57,0.08,0.51,08/22/2016
G,KISS1,HGNC:6341,1q32.1,1:204159469-204165619,1:204190341-204196491,"30 (Autosomal Recessive)","hypogonadotropic hypogonadism 13 with or without anosmia",MONDO:0013915,"Not Yet Evaluated",'-,'-,,,85.61,0.49,1.41,08/22/2016
G,KLF14,HGNC:23025,7q32.2,7:130415525-130418967,7:130730697-130734207,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,82.59,0.02,1.59,04/28/2012
G,KLF8,HGNC:6351,Xp11.21,X:55934556-56317964,X:55908123-56291531,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,60.52,0,1.31,10/12/2012
G,KLK12,HGNC:6360,19q13.41,19:51532350-51538258,19:51029094-51035002,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,83.13,0,1.36,02/02/2021
G,KMT2A,HGNC:7132,11q23.3,11:118307207-118397547,11:118436492-118526832,"3 (Sufficient Evidence)","Wiedemann-Steiner syndrome",MONDO:0011518,"0 (No Evidence)",'-,'-,,,17.01,1,0.07,05/23/2018
G,KMT2B,HGNC:15840,19q13.12,19:36208905-36229779,19:35718003-35738878,"3 (Sufficient Evidence)","dystonia 28, childhood-onset",MONDO:0015004,"0 (No Evidence)",'-,'-,,,‐,1,0.07,05/11/2017
G,KMT2C,HGNC:13726,7q36.1,7:151832010-152133088,7:152134925-152436003,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,53.58,1,0.12,01/24/2018
G,KMT2D,HGNC:7133,12q13.12,12:49412761-49454577,12:49018978-49060794,"3 (Sufficient Evidence)","Kabuki syndrome 1",MONDO:0007843,"0 (No Evidence)",'-,'-,,,17.49,1,0.1,01/23/2020
G,KMT2E,HGNC:18541,7q22.3,7:104654652-104755466,7:105014205-105115019,"3 (Sufficient Evidence)","O'Donnell-Luria-Rodan syndrome",MONDO:0032793,"0 (No Evidence)",'-,'-,,,19.81,1,0.06,12/29/2021
G,KMT5B,HGNC:24283,11q13.2,11:67922330-67981115,11:68154863-68213648,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,20.8,1,0.08,06/13/2023
G,KRAS,HGNC:6407,12p12.1,12:25358180-25403863,12:25205246-25250929,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.47,0,1.24,10/08/2015
G,KRT24,HGNC:18527,17q21.2,17:38854243-38860004,17:40697991-40703752,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,66.8,0,1.45,02/02/2021
G,KRT37,HGNC:6455,17q21.2,17:39576799-39580837,17:41420547-41424585,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,74.92,0,1.31,02/02/2021
G,L1CAM,HGNC:6470,Xq28,X:153126969-153151627,X:153861514-153886173,"3 (Sufficient Evidence)","X-linked hydrocephalus with stenosis of the aqueduct of Sylvius",MONDO:0010611,"0 (No Evidence)",'-,'-,,,15.59,1,0.13,12/02/2020
G,L3MBTL1,HGNC:15905,20q13.12,20:42136337-42179594,20:43507697-43550954,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,47.47,0,0.78,08/29/2012
G,LAMA1,HGNC:6481,18p11.31,18:6941741-7117796,18:6941742-7117797,"30 (Autosomal Recessive)","ataxia - intellectual disability - oculomotor apraxia - cerebellar cysts syndrome",MONDO:0014419,"0 (No Evidence)",'-,'-,,,60.73,0,0.62,08/22/2016
G,LAMA2,HGNC:6482,6q22.33,6:129204283-129837711,6:128883138-129516566,"30 (Autosomal Recessive)","LAMA2-related muscular dystrophy",MONDO:0100228,"0 (No Evidence)",'-,'-,,,4.68,0,0.73,11/28/2018
G,LAMA3,HGNC:6483,18q11.2,18:21269417-21535030,18:23689453-23955066,"30 (Autosomal Recessive)","junctional epidermolysis bullosa",MONDO:0017612,"Not Yet Evaluated",'-,'-,,,64.13,0,0.69,08/22/2016
G,LAMC2,HGNC:6493,1q25.3,1:183155399-183214262,1:183186264-183258968,"30 (Autosomal Recessive)","junctional epidermolysis bullosa",MONDO:0017612,"Not Yet Evaluated",'-,'-,,,41.89,0,0.65,08/22/2016
G,LAMP2,HGNC:6501,Xq24,X:119560003-119603204,X:120426148-120469349,"3 (Sufficient Evidence)","Danon disease",MONDO:0010281,"0 (No Evidence)",'-,'-,,,54.6,0.27,0.64,02/09/2021
G,LARGE1,HGNC:6511,22q12.3,22:33668495-34318812,22:33066663-33922824,"30 (Autosomal Recessive)","muscular dystrophy-dystroglycanopathy",MONDO:0018276,"0 (No Evidence)",'-,'-,,,4.11,0.99,0.3,08/22/2016
G,LBR,HGNC:6518,1q42.12,1:225589204-225616523,1:225401502-225428821,"30 (Autosomal Recessive)","Greenberg dysplasia",MONDO:0008974,"0 (No Evidence)",'-,'-,,,28.92,0.18,0.42,02/23/2015
G,LBX1,HGNC:16960,10q24.32,10:102986751-102989220,10:101226994-101229463,"0 (No Evidence)",'-,'-,"0 (No Evidence)","split hand-foot malformation 3",MONDO:0009525,,,1.88,0.68,0.59,08/21/2014
G,LCA5,HGNC:31923,6q14.1,6:80194708-80247147,6:79484991-79538782,"30 (Autosomal Recessive)","Leber congenital amaurosis 5",MONDO:0011473,"Not Yet Evaluated",'-,'-,,,45.14,0,0.65,08/22/2016
G,LCT,HGNC:6530,2q21.3,2:136545420-136594754,2:135787850-135837184,"30 (Autosomal Recessive)","congenital lactase deficiency",MONDO:0009115,"0 (No Evidence)",'-,'-,,,10.47,0.06,0.36,08/22/2016
G,LDLR,HGNC:6547,19p13.2,19:11200139-11244496,19:11089463-11133820,"3 (Sufficient Evidence)","hypercholesterolemia, familial, 1",MONDO:0007750,"0 (No Evidence)",'-,'-,,,17.35,0,1.13,10/27/2021
G,LEMD3,HGNC:28887,12q14.3,12:65563363-65642135,12:65169583-65248355,"3 (Sufficient Evidence)","Buschke-Ollendorff syndrome",MONDO:0008157,"0 (No Evidence)",'-,'-,,,36.92,1,0.25,10/19/2020
G,LEPR,HGNC:6554,1p31.3,1:65886335-66107242,1:65420652-65641559,"30 (Autosomal Recessive)","obesity due to leptin receptor gene deficiency",MONDO:0013992,"Not Yet Evaluated",'-,'-,,,18.82,0.99,0.28,08/22/2016
G,LETM1,HGNC:6556,4p16.3,4:1813206-1857883,4:1811479-1856156,"0 (No Evidence)","Wolf-Hirschhorn syndrome",MONDO:0008684,"0 (No Evidence)",'-,'-,,,63.78,0,0.74,02/03/2012
G,LFNG,HGNC:6560,7p22.3,7:2552163-2568811,7:2512529-2529177,"30 (Autosomal Recessive)","spondylocostal dysostosis 3, autosomal recessive",MONDO:0012349,"Not Yet Evaluated",'-,'-,,,18.77,0.1,0.69,08/22/2016
G,LHX3,HGNC:6595,9q34.3,9:139088096-139096974,9:136196250-136205128,"30 (Autosomal Recessive)","non-acquired combined pituitary hormone deficiency with spine abnormalities",MONDO:0009091,"Not Yet Evaluated",'-,'-,,,23.38,0.01,0.74,08/22/2016
G,LHX4,HGNC:21734,1q25.2,1:180199399-180248119,1:180228375-180278984,"1 (Little Evidence)","short stature-pituitary and cerebellar defects-small sella turcica syndrome",MONDO:0009880,"0 (No Evidence)",'-,'-,,,6.37,0.02,0.69,04/25/2022
G,LIG4,HGNC:6601,13q33.3,13:108859790-108870697,13:108207442-108218349,"30 (Autosomal Recessive)","DNA ligase IV deficiency",MONDO:0011686,"0 (No Evidence)",'-,'-,,,23.18,0,0.8,08/22/2016
G,LIMK1,HGNC:6613,7q11.23,7:73498134-73536855,7:74083804-74122525,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,19.66,1,0.23,08/22/2012
G,LINS1,HGNC:30922,15q26.3,15:101107129-101142389,15:100566924-100602184,"30 (Autosomal Recessive)","intellectual disability, autosomal recessive 27",MONDO:0013702,"0 (No Evidence)",'-,'-,,,71.81,0,0.96,08/22/2016
G,LIPA,HGNC:6617,10q23.31,10:90973329-91011532,10:89213572-89251775,"30 (Autosomal Recessive)","lysosomal acid lipase deficiency",MONDO:0010204,"Not Yet Evaluated",'-,'-,,,78.66,0,1,08/22/2016
G,LITAF,HGNC:16841,16p13.13,16:11641578-11681322,16:11547722-11640317,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,51.7,0.03,1.28,10/21/2016
G,LMAN1,HGNC:6631,18q21.32,18:56995055-57026497,18:59327823-59359265,"30 (Autosomal Recessive)","factor V and factor VIII, combined deficiency of, type 1",MONDO:0009206,"Not Yet Evaluated",'-,'-,,,36.45,0,0.55,08/22/2016
G,LMBR1,HGNC:13243,7q36.3,7:156461706-156685877,7:156669012-156893183,"30 (Autosomal Recessive)",acheiropody,MONDO:0008700,"0 (No Evidence)",'-,'-,,,24.09,0,0.83,10/18/2012
G,LMNA,HGNC:6636,1q22,1:156052364-156109872,1:156082573-156140081,"3 (Sufficient Evidence)","dilated cardiomyopathy 1A",MONDO:0007269,"0 (No Evidence)",'-,'-,,,1.72,1,0.21,12/14/2023
G,LMNB1,HGNC:6637,5q23.2,5:126112315-126172712,5:126776623-126837020,"0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","adult-onset autosomal dominant demyelinating leukodystrophy",MONDO:0008215,,,11.52,0.55,0.41,10/25/2023
G,LMTK3,HGNC:19295,19q13.33,19:48988528-49016446,19:48485271-48513680,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,70.62,1,0.18,07/25/2018
G,LMX1B,HGNC:6654,9q33.3,9:129376207-129463311,9:126613928-126701032,"3 (Sufficient Evidence)","nail-patella syndrome",MONDO:0008061,"0 (No Evidence)",'-,'-,,,2.11,0.75,0.42,11/10/2020
G,LOXHD1,HGNC:26521,18q21.1,18:44056924-44237183,18:46476961-46657220,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 77",MONDO:0013119,"0 (No Evidence)",'-,'-,,,33.62,0,1.01,08/22/2016
G,LPAR6,HGNC:15520,13q14.2,13:48985274-49018805,13:48389571-48444669,"30 (Autosomal Recessive)","hypotrichosis 8",MONDO:0010206,"Not Yet Evaluated",'-,'-,,,22.74,0,1.27,08/22/2016
G,LPIN2,HGNC:14450,18p11.31,18:2916992-3013142,18:2916994-3013144,"30 (Autosomal Recessive)","Majeed syndrome",MONDO:0012316,"0 (No Evidence)",'-,'-,,,38.45,0,0.51,08/22/2016
G,LRAT,HGNC:6685,4q32.1,4:155661990-155674272,4:154740838-154753120,"30 (Autosomal Recessive)","Leber congenital amaurosis 14",MONDO:0013231,"Not Yet Evaluated",'-,'-,,,31.39,0.03,1.32,08/22/2016
G,LRBA,HGNC:1742,4q31.3,4:151185587-151936879,4:150264435-151015727,"30 (Autosomal Recessive)","combined immunodeficiency due to LRBA deficiency",MONDO:0013863,"Not Yet Evaluated",'-,'-,,,1.79,0,0.42,08/22/2016
G,LRP2,HGNC:6694,2q31.1,2:169983619-170219044,2:169127109-169362534,"30 (Autosomal Recessive)","Donnai-Barrow syndrome",MONDO:0009104,"0 (No Evidence)",'-,'-,,,39.5,1,0.25,04/24/2019
G,LRP5,HGNC:6697,11q13.2,11:68080059-68216743,11:68298412-68449275,"2 (Emerging Evidence)","exudative vitreoretinopathy 4",MONDO:0011151,"0 (No Evidence)",'-,'-,,,8.86,0.51,0.34,12/20/2021
G,LRPAP1,HGNC:6701,4p16.3,4:3505339-3534149,4:3503612-3532422,"30 (Autosomal Recessive)","myopia 23, autosomal recessive",MONDO:0014183,"Not Yet Evaluated",'-,'-,,,81.97,0,1.17,08/22/2016
G,LRPPRC,HGNC:15714,2p21,2:44113363-44223128,2:43886224-43996265,"30 (Autosomal Recessive)","congenital lactic acidosis, Saguenay-Lac-Saint-Jean type",MONDO:0009069,"0 (No Evidence)",'-,'-,,,34.01,0,0.53,03/20/2017
G,LSS,HGNC:6708,21q22.3,21:47608360-47648688,21:46188446-46228774,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.39,0,0.6,09/06/2012
G,LYRM7,HGNC:28072,5q23.3-q31.1,5:130506637-130541121,5:131170944-131205428,"30 (Autosomal Recessive)","mitochondrial complex III deficiency nuclear type 8",MONDO:0014364,"0 (No Evidence)",'-,'-,,,31.96,0.02,1.44,08/22/2016
G,LYST,HGNC:1968,1q42.3,1:235824331-236047013,1:235661031-235883713,"30 (Autosomal Recessive)","Chediak-Higashi syndrome",MONDO:0008963,"0 (No Evidence)",'-,'-,,,53.08,0.02,0.31,08/22/2016
G,MAD2L2,HGNC:6764,1p36.22,1:11734537-11751616,1:11674480-11691830,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.39,0.08,0.72,10/20/2023
G,MAFB,HGNC:6408,20q12,20:39314488-39317876,20:40685848-40689236,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.59,0.9,0.4,05/21/2015
G,MAGEL2,HGNC:6814,15q11.2,15:23888696-23893014,15:23643549-23647867,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,84.66,0.98,0.31,05/22/2018
G,MAGT1,HGNC:28880,Xq21.1,X:77081244-77151065,X:77825747-77895568,"3 (Sufficient Evidence)","X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia",MONDO:0010455,"0 (No Evidence)",'-,'-,,,34.31,0.96,0.33,09/22/2021
G,MALT1,HGNC:6819,18q21.32,18:56338697-56421709,18:58671465-58754477,"30 (Autosomal Recessive)","combined immunodeficiency due to MALT1 deficiency",MONDO:0014197,"0 (No Evidence)",'-,'-,,,37.84,0.99,0.3,08/22/2016
G,MAN2B1,HGNC:6826,19p13.13,19:12757326-12777556,19:12646512-12666742,"30 (Autosomal Recessive)",alpha-mannosidosis,MONDO:0009561,"0 (No Evidence)",'-,'-,,,76.46,0,0.97,08/22/2016
G,MAOA,HGNC:6833,Xp11.3,X:43514254-43606064,X:43655006-43746817,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,43.16,1,0.14,09/26/2012
G,MAP2K1,HGNC:6840,15q22.31,15:66679250-66783882,15:66386912-66491544,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.71,0.9,0.38,10/13/2015
G,MAP2K2,HGNC:6842,19p13.3,19:4090319-4124119,19:4090321-4124122,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,38.94,0.97,0.33,05/27/2015
G,MAP3K1,HGNC:6848,5q11.2,5:56111376-56191979,5:56815549-56896152,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,13.53,1,0.21,08/22/2013
G,MAPT,HGNC:6893,17q21.31,17:43971920-44105700,17:45894554-46028334,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,2.65,0.01,0.57,05/08/2012
G,MARVELD2,HGNC:26401,5q13.2,5:68710943-68740157,5:69415116-69444330,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 49",MONDO:0012420,"0 (No Evidence)",'-,'-,,,51.8,0,1.18,08/22/2016
G,MASP2,HGNC:6902,1p36.22,1:11086580-11107296,1:11026523-11047239,"30 (Autosomal Recessive)","immunodeficiency due to MASP-2 deficiency",MONDO:0013423,"Not Yet Evaluated",'-,'-,,,72.87,0,1.15,08/22/2016
G,MATN3,HGNC:6909,2p24.1,2:20191813-20212429,2:19992052-20012668,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,62.15,0,1.25,03/12/2014
G,MAX,HGNC:6913,14q23.3,14:65472819-65569413,14:65006101-65102695,"3 (Sufficient Evidence)",pheochromocytoma,MONDO:0008233,"0 (No Evidence)",'-,'-,,,2.06,0.83,0.46,07/20/2021
G,MBD5,HGNC:20444,2q23.2,2:148778580-149274540,2:148020927-148516971,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 1",MONDO:0007974,"1 (Little Evidence)",'-,'-,,,8.24,1,0.14,08/11/2016
G,MC2R,HGNC:6930,18p11.2,18:13882043-13915706,18:13882044-13915707,"30 (Autosomal Recessive)","glucocorticoid deficiency 1",MONDO:0024536,"Not Yet Evaluated",'-,'-,,,63.21,0,1.85,08/22/2016
G,MCCC1,HGNC:6936,3q27.1,3:182733006-182817375,3:183015218-183116196,"30 (Autosomal Recessive)","3-methylcrotonyl-CoA carboxylase 1 deficiency",MONDO:0008861,"0 (No Evidence)",'-,'-,,,46.37,0,0.9,08/22/2016
G,MCEE,HGNC:16732,2p13.3,2:71336817-71357359,2:71109687-71130229,"30 (Autosomal Recessive)","methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency",MONDO:0009615,"0 (No Evidence)",'-,'-,,,63.92,0.03,1.34,03/25/2015
G,MCFD2,HGNC:18451,2p21,2:47129009-47168994,2:46901870-46941855,"30 (Autosomal Recessive)","factor 5 and Factor VIII, combined deficiency of, 2",MONDO:0013331,"0 (No Evidence)",'-,'-,,,48.72,0.1,1.28,08/22/2016
G,MCPH1,HGNC:6954,8p23.1,8:6264148-6506029,8:6406627-6648508,"30 (Autosomal Recessive)","microcephaly 1, primary, autosomal recessive",MONDO:0009617,"Not Yet Evaluated",'-,'-,,,94.1,0,1.44,08/22/2016
G,MECP2,HGNC:6990,Xq28,X:153287024-153363174,X:154021573-154097717,"3 (Sufficient Evidence)","Rett syndrome",MONDO:0010726,"0 (No Evidence)","syndromic X-linked intellectual disability Lubs type",MONDO:0010283,,,1.39,0.89,0.41,02/22/2021
G,MED12,HGNC:11957,Xq13.1,X:70338446-70362300,X:71118596-71142450,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.34,1,0.07,08/22/2018
G,MED13L,HGNC:22962,12q24.21,12:116396381-116715498,12:115958576-116277693,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,7.11,1,0.06,08/08/2023
G,MEF2C,HGNC:6996,5q14.3,5:88012934-88199922,5:88717117-88904105,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 20",MONDO:0013266,"1 (Little Evidence)",'-,'-,,,0.26,0.02,0.61,02/26/2020
G,MEFV,HGNC:6998,16p13.3,16:3292027-3306633,16:3242027-3256633,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,81.61,0,1.13,08/16/2018
G,MEG3,HGNC:14575,14q32.2,14:101292445-101327363,14:100826108-100861026,"1 (Little Evidence)","paternal uniparental disomy of chromosome 14",MONDO:0011975,"0 (No Evidence)",'-,'-,,,‐,‐,‐,04/25/2012
G,MEIS2,HGNC:7001,15q14,15:37181405-37393512,15:36889204-37101311,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,0.69,1,0.18,09/14/2021
G,MEN1,HGNC:7010,11q13,11:64570986-64578766,11:64803516-64811294,"3 (Sufficient Evidence)","multiple endocrine neoplasia type 1",MONDO:0007540,"0 (No Evidence)",'-,'-,,,9.63,1,0.17,01/12/2022
G,MEST,HGNC:7028,7q32.2,7:130126016-130146306,7:130486175-130506465,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,7.94,0.4,0.47,04/04/2012
G,MET,HGNC:7029,7q31,7:116312250-116438431,7:116672196-116798377,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.18,0.97,0.31,09/06/2012
G,METTL23,HGNC:26988,17q25.2,17:74722123-74729963,17:76726041-76733881,"30 (Autosomal Recessive)","intellectual disability, autosomal recessive 44",MONDO:0014409,"0 (No Evidence)",'-,'-,,,47.56,0,1.77,08/22/2016
G,MFHAS1,HGNC:16982,8p23.1,8:8640864-8751140,8:8783354-8893630,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,42.49,0,0.82,02/08/2012
G,MFN2,HGNC:16877,1p36.22,1:12040501-12073565,1:11980444-12013508,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.08,0.99,0.28,02/02/2017
G,MFRP,HGNC:18121,11q23.3,11:119209652-119217415,11:119338942-119346705,"30 (Autosomal Recessive)","isolated microphthalmia 5",MONDO:0012605,"0 (No Evidence)",'-,'-,,,61.74,0,1.22,08/22/2016
G,MFSD8,HGNC:28486,4q28.2,4:128838887-128887118,4:127917732-127965963,"30 (Autosomal Recessive)","neuronal ceroid lipofuscinosis 7",MONDO:0012588,"0 (No Evidence)",'-,'-,,,58.39,0,1.07,08/22/2016
G,MGP,HGNC:7060,12p12.3,12:15033798-15038788,12:14880864-14885854,"30 (Autosomal Recessive)","Keutel syndrome",MONDO:0009495,"0 (No Evidence)",'-,'-,,,8.46,0,1.66,02/08/2021
G,MID1,HGNC:7095,Xp22,X:10413350-10851802,X:10445310-10833683,"3 (Sufficient Evidence)","X-linked Opitz G/BBB syndrome",MONDO:0010222,"0 (No Evidence)",'-,'-,,,5.13,0.98,0.3,08/23/2021
G,MID2,HGNC:7096,Xq22.3,X:107068965-107174867,X:107825735-107931637,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.45,0.18,0.5,07/25/2012
G,MITF,HGNC:7105,3p13,3:69788615-70017483,3:69739464-69968332,"3 (Sufficient Evidence)","Waardenburg syndrome type 2A",MONDO:0008671,"0 (No Evidence)",'-,'-,,,0.98,0.98,0.31,04/13/2021
G,MKKS,HGNC:7108,20p12.2,20:10381657-10414870,20:10401009-10434222,"30 (Autosomal Recessive)","Bardet-Biedl syndrome",MONDO:0015229,"Not Yet Evaluated",'-,'-,,,38.61,0,1.29,08/22/2016
G,MKRN3,HGNC:7114,15q11.2,15:23810821-23813191,15:23565674-23568044,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,87.91,0.28,0.63,04/25/2012
G,MKS1,HGNC:7121,17q22,17:56282797-56296966,17:58205441-58219255,"30 (Autosomal Recessive)",'-,'-,"0 (No Evidence)",'-,'-,,,34.89,0,1.04,08/22/2016
G,MLC1,HGNC:17082,22q13.33,22:50497820-50524304,22:50059391-50085875,"30 (Autosomal Recessive)","megalencephalic leukoencephalopathy with subcortical cysts 1",MONDO:0024555,"Not Yet Evaluated",'-,'-,,,68.71,0,1.16,08/22/2016
G,MLH1,HGNC:7127,3p22.2,3:37035009-37092337,3:36993466-37050846,"3 (Sufficient Evidence)","Lynch syndrome 2",MONDO:0012249,"0 (No Evidence)",'-,'-,,,3.18,0,0.58,10/13/2021
G,MLPH,HGNC:29643,2q37.3,2:238395053-238463965,2:237486410-237555322,"30 (Autosomal Recessive)","Griscelli syndrome type 3",MONDO:0012220,"Not Yet Evaluated",'-,'-,,,85.56,0,0.9,08/22/2016
G,MLYCD,HGNC:7150,16q23.3,16:83932720-83960636,16:83899115-83927031,"30 (Autosomal Recessive)","malonic aciduria",MONDO:0009556,"0 (No Evidence)",'-,'-,,,65.55,0,0.84,08/22/2016
G,MMAA,HGNC:18871,4q31.21,4:146540537-146581185,4:145619385-145660033,"30 (Autosomal Recessive)","methylmalonic aciduria, cblA type",MONDO:0009613,"0 (No Evidence)",'-,'-,,,51.43,0,1.29,08/22/2016
G,MMAB,HGNC:19331,12q24.11,12:109991520-110011309,12:109553715-109573504,"30 (Autosomal Recessive)","methylmalonic aciduria, cblB type",MONDO:0009614,"0 (No Evidence)",'-,'-,,,67.13,0,0.88,06/30/2017
G,MMACHC,HGNC:24525,1p34.1,1:45965972-45979054,1:45500300-45513382,"30 (Autosomal Recessive)","methylmalonic aciduria and homocystinuria type cblC",MONDO:0010184,"Not Yet Evaluated",'-,'-,,,53.83,0,1.76,08/22/2016
G,MMADHC,HGNC:25221,2q23.2,2:150426151-150444289,2:149569637-149587775,"30 (Autosomal Recessive)","methylmalonic aciduria and homocystinuria type cblD",MONDO:0010185,"0 (No Evidence)",'-,'-,,,11.87,0,0.99,07/21/2016
G,MMUT,HGNC:7526,6p12.3,6:49398073-49430966,6:49430360-49463253,"30 (Autosomal Recessive)","methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency",MONDO:0009612,"0 (No Evidence)",'-,'-,,,1.8,0,1.23,08/25/2016
G,MNX1,HGNC:4979,7q36.3,7:156797548-156803357,7:157004854-157010663,"3 (Sufficient Evidence)","Currarino triad",MONDO:0008305,"0 (No Evidence)",'-,'-,,,0.84,0.79,0.5,10/04/2012
G,MOCS2,HGNC:7193,5q11.2,5:52391509-52405587,5:53095679-53109757,"30 (Autosomal Recessive)","sulfite oxidase deficiency due to molybdenum cofactor deficiency type B",MONDO:0009644,"0 (No Evidence)",'-,'-,,,38.56,0,1.39,08/22/2016
G,MOV10,HGNC:7200,1p13.2,1:113216934-113243368,1:112674439-112700739,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,45.41,0.81,0.34,03/12/2019
G,MPDZ,HGNC:7208,9p23,9:13105706-13279691,9:13105707-13279692,"30 (Autosomal Recessive)","hydrocephalus, nonsyndromic, autosomal recessive 2",MONDO:0014085,"0 (No Evidence)",'-,'-,,,33.44,0,0.89,08/22/2016
G,MPLKIP,HGNC:16002,7p14.1,7:40165626-40174221,7:40126027-40134622,"30 (Autosomal Recessive)","trichothiodystrophy 4, nonphotosensitive",MONDO:0021013,"Not Yet Evaluated",'-,'-,,,22.22,0,1.67,08/22/2016
G,MRE11,HGNC:7230,11q21,11:94148736-94227010,11:94415570-94512412,"30 (Autosomal Recessive)",'-,'-,"30 (Autosomal Recessive)",'-,'-,,,5.55,0,0.84,12/19/2023
G,MSH2,HGNC:7325,2p21-p16.3,2:47630206-47710367,2:47403067-47709830,"3 (Sufficient Evidence)","Lynch syndrome",MONDO:0005835,"0 (No Evidence)",'-,'-,,,1.57,0.9,0.33,10/13/2021
G,MSH3,HGNC:7326,5q14.1,5:79950471-80172634,5:80654652-80876815,"30 (Autosomal Recessive)","familial adenomatous polyposis 4",MONDO:0044300,"0 (No Evidence)",'-,'-,,,18.27,0,1.16,05/08/2020
G,MSH6,HGNC:7329,2p16.3,2:48010284-48034092,2:47783145-47810101,"3 (Sufficient Evidence)","Lynch syndrome 5",MONDO:0013710,"0 (No Evidence)",'-,'-,,,6.24,0,0.5,10/13/2021
G,MSL3,HGNC:7370,Xp22.2,X:11776278-11793891,X:11758159-11775772,"3 (Sufficient Evidence)","Basilicata-Akhtar syndrome",MONDO:0026730,"0 (No Evidence)",'-,'-,,,43.72,1,0.18,08/23/2023
G,MSRB3,HGNC:27375,12q14.3,12:65672463-65860687,12:65278683-65466907,"30 (Autosomal Recessive)","nonsyndromic genetic hearing loss",MONDO:0019497,"0 (No Evidence)",'-,'-,,,15.61,0,1.16,08/23/2021
G,MSX1,HGNC:7391,4p16.2,4:4861392-4865663,4:4859665-4863936,"3 (Sufficient Evidence)","tooth agenesis, selective, 1",MONDO:0007129,"0 (No Evidence)",'-,'-,,,1.21,0.17,1.01,01/12/2021
G,MSX2,HGNC:7392,5q35.2,5:174151585-174157899,5:174724582-174730896,"1 (Little Evidence)","parietal foramina 1",MONDO:0008197,"0 (No Evidence)",'-,'-,,,1.48,0.26,0.82,06/28/2023
G,MTAP,HGNC:7413,9p21.3,9:21802635-21867080,9:21802636-21941115,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,38.31,0,1.39,10/12/2022
G,MTFMT,HGNC:29666,15q22.31,15:65293850-65321977,15:65001512-65029639,"30 (Autosomal Recessive)","combined oxidative phosphorylation defect type 15",MONDO:0013987,"0 (No Evidence)",'-,'-,,,64.66,0,1.01,08/22/2016
G,MTHFR,HGNC:7436,1p36.22,1:11845780-11866021,1:11785723-11805964,"30 (Autosomal Recessive)","homocystinuria due to methylene tetrahydrofolate reductase deficiency",MONDO:0009353,"Not Yet Evaluated",'-,'-,,,7.44,0,0.92,08/22/2016
G,MTM1,HGNC:7448,Xq28,X:149737071-149841616,X:150562653-150673143,"3 (Sufficient Evidence)","X-linked centronuclear myopathy",MONDO:0010683,"0 (No Evidence)",'-,'-,,,12.54,1,0.18,01/11/2021
G,MTMR2,HGNC:7450,11q21,11:95566044-95657271,11:95832880-95924107,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 4B1",MONDO:0011066,"Not Yet Evaluated",'-,'-,,,23.95,0,0.65,08/22/2016
G,MTO1,HGNC:19261,6q13,6:74171460-74218959,6:73461737-73509236,"30 (Autosomal Recessive)","mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency",MONDO:0013865,"0 (No Evidence)",'-,'-,,,39.12,0,0.64,08/22/2016
G,MTR,HGNC:7468,1q43,1:236958581-237067281,1:236795281-236903981,"30 (Autosomal Recessive)","methylcobalamin deficiency type cblG",MONDO:0009609,"0 (No Evidence)",'-,'-,,,8.44,0,0.63,08/22/2016
G,MTRR,HGNC:7473,5p15.31,5:7869261-7901226,5:7850859-7901113,"30 (Autosomal Recessive)","methylcobalamin deficiency type cblE",MONDO:0009354,"0 (No Evidence)",'-,'-,,,73.75,0,0.98,08/22/2016
G,MTTP,HGNC:7467,4q23,4:100485287-100545154,4:99564130-99623997,"30 (Autosomal Recessive)",abetalipoproteinemia,MONDO:0008692,"0 (No Evidence)",'-,'-,,,40.96,0,0.59,08/22/2016
G,MUTYH,HGNC:7527,1p34.1,1:45794914-45806112,1:45329242-45340440,"30 (Autosomal Recessive)","familial adenomatous polyposis 2",MONDO:0012041,"0 (No Evidence)",'-,'-,,,44.32,0,1.19,11/11/2015
G,MYBPC3,HGNC:7551,11p11.2,11:47352957-47374253,11:47331406-47352702,"3 (Sufficient Evidence)","hypertrophic cardiomyopathy 4",MONDO:0007268,"0 (No Evidence)",'-,'-,,,41.39,0,0.59,01/10/2023
G,MYCN,HGNC:7559,2p24.3,2:16080672-16087126,2:15940550-15947004,"3 (Sufficient Evidence)","Feingold syndrome type 1",MONDO:0008115,"0 (No Evidence)",'-,'-,,,6.93,0.89,0.41,07/12/2017
G,MYH10,HGNC:7568,17p13.1,17:8377530-8534043,17:8474212-8630725,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,34.06,1,0.17,01/23/2019
G,MYH11,HGNC:7569,16p13.11,16:15796992-15950885,16:15703135-15857028,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,7.87,0.77,0.31,11/12/2015
G,MYH7,HGNC:7577,14q11.2,14:23881949-23904869,14:23412740-23435660,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,14.41,0,0.58,11/16/2015
G,MYL2,HGNC:7583,12q24.11,12:111348649-111358383,12:110910845-110921449,"30 (Autosomal Recessive)","hypertrophic cardiomyopathy 10",MONDO:0012112,"0 (No Evidence)",'-,'-,,,18.05,0,1.75,11/20/2015
G,MYL3,HGNC:7584,3p21.31,3:46899362-46904934,3:46857872-46882182,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.58,0.09,0.9,11/18/2015
G,MYLK,HGNC:7590,3q21.1,3:123328896-123603179,3:123610049-123884332,"1 (Little Evidence)","aortic aneurysm, familial thoracic 7",MONDO:0013418,"0 (No Evidence)",'-,'-,,,15.7,0,0.53,01/14/2016
G,MYO15A,HGNC:7594,17p11.2,17:18012070-18083114,17:18108756-18179800,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 3",MONDO:0010860,"Not Yet Evaluated",'-,'-,,,39.27,0,0.8,08/22/2016
G,MYO1E,HGNC:7599,15q22.2,15:59424633-59665070,15:59132434-59372871,"30 (Autosomal Recessive)","focal segmental glomerulosclerosis 6",MONDO:0013589,"0 (No Evidence)",'-,'-,,,26.13,0,0.44,08/22/2016
G,MYO3A,HGNC:7601,10p12.1,10:26223158-26501461,10:25934229-26212532,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 30",MONDO:0011774,"0 (No Evidence)",'-,'-,,,26.3,0,1.04,03/06/2018
G,MYO5A,HGNC:7602,15q21.2,15:52599480-52821247,15:52307283-52529050,"30 (Autosomal Recessive)","Griscelli syndrome type 1",MONDO:0008962,"0 (No Evidence)",'-,'-,,,15.8,0.94,0.3,08/22/2016
G,MYO5B,HGNC:7603,18q21.1,18:47349159-47721517,18:49822789-50195147,"30 (Autosomal Recessive)","microvillus inclusion disease",MONDO:0009635,"0 (No Evidence)",'-,'-,,,46.86,0,0.69,04/09/2015
G,MYT1L,HGNC:7623,2p25.3,2:1792885-2335047,2:1789113-2331275,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 39",MONDO:0014678,"0 (No Evidence)",'-,'-,,,21.8,1,0.09,03/09/2017
G,NAA10,HGNC:18704,Xq28,X:153194678-153200490,X:153929225-153935037,"1 (Little Evidence)","NAA10-related syndrome",MONDO:0100124,"0 (No Evidence)",'-,'-,,,34.08,0.76,0.52,08/09/2022
G,NAA15,HGNC:30782,4q31.1,4:140222659-140312538,4:139301505-139391384,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,7.58,1,0.28,04/13/2021
G,NAALADL2,HGNC:23219,3q26.31,3:174577124-175528336,3:174440982-175810548,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.95,0,0.71,01/07/2016
G,NAT8L,HGNC:26742,4p16.3,4:2061054-2070816,4:2059327-2069089,"30 (Autosomal Recessive)","N-acetylaspartate deficiency",MONDO:0013549,"0 (No Evidence)",'-,'-,,,40.87,0.86,0.46,08/22/2016
G,NBAS,HGNC:15625,2p24.3,2:15307040-15701458,2:14778909-15561334,"30 (Autosomal Recessive)","short stature-optic atrophy-Pelger-HuC+t anomaly syndrome",MONDO:0013889,"Not Yet Evaluated",'-,'-,,,58.54,0,0.78,08/22/2016
G,NBEA,HGNC:7648,13q13.3,13:35516407-36246873,13:34942270-35672736,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,6.83,1,0.07,06/26/2019
G,NBN,HGNC:7652,8q21.3,8:90945559-90996895,8:89933331-89984667,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,19.03,0,1.01,08/21/2020
G,NCF1,HGNC:7660,7q11.23,7:74188309-74203720,7:74774011-74789315,"30 (Autosomal Recessive)","granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 1",MONDO:0009309,"0 (No Evidence)",'-,'-,,,67.53,0,1.13,10/10/2012
G,NCF2,HGNC:7661,1q25.3,1:183524697-183560049,1:183555562-183601849,"30 (Autosomal Recessive)","granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 2",MONDO:0009310,"0 (No Evidence)",'-,'-,,,43.31,0,0.74,08/22/2016
G,NCF4,HGNC:7662,22q12.3,22:37257048-37274057,22:36861006-36878015,"30 (Autosomal Recessive)","granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3",MONDO:0013507,"Not Yet Evaluated",'-,'-,,,74.45,0,1.2,08/22/2016
G,NCKAP1,HGNC:7666,2q32.1,2:183773843-183903185,2:182909115-183038457,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,9.37,1,0.04,12/27/2017
G,NDE1,HGNC:17619,16p13.11,16:15737239-15820210,16:15643382-15726353,"30 (Autosomal Recessive)","lissencephaly 4",MONDO:0013527,"0 (No Evidence)",'-,'-,,,35.66,0.01,0.69,04/29/2016
G,NDN,HGNC:7675,15q11.2,15:23930547-23932452,15:23685400-23687305,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,32.94,0.67,0.6,04/27/2012
G,NDP,HGNC:7678,Xp11.3,X:43808022-43832636,X:43948776-43973390,"3 (Sufficient Evidence)","Norrie disease",MONDO:0010691,"0 (No Evidence)",'-,'-,,,3.81,0.65,0.88,06/14/2012
G,NDRG1,HGNC:7679,8q24.22,8:134249418-134309495,8:133237175-133297252,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 4D",MONDO:0011085,"Not Yet Evaluated",'-,'-,,,26.62,0.01,0.58,08/22/2016
G,NDUFA1,HGNC:7683,Xq24,X:119005795-119010625,X:119871832-119876662,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,60.85,0.55,1.18,07/25/2012
G,NDUFA10,HGNC:7684,2q37.3,2:240831859-240964759,2:239892442-240025342,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,85.89,0,1.1,08/22/2016
G,NDUFAF1,HGNC:18828,15q15.1,15:41679551-41694694,15:41387353-41403026,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"0 (No Evidence)",'-,'-,,,69.41,0,0.91,08/22/2016
G,NDUFAF2,HGNC:28086,5q12.1,5:60241032-60448853,5:60945205-61153026,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,53.74,0,1.6,08/22/2016
G,NDUFAF5,HGNC:15899,20p12.1,20:13765674-13802226,20:13785028-13821580,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"0 (No Evidence)",'-,'-,,,44.44,0,1.2,08/22/2016
G,NDUFB3,HGNC:7698,2q33.1,2:201936724-201950473,2:201072001-201085750,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"Not Yet Evaluated",'-,'-,,,50.55,0,1.94,08/22/2016
G,NDUFS4,HGNC:7711,5q11.2,5:52856469-52979168,5:53560639-53683338,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"Not Yet Evaluated",'-,'-,,,12.79,0,1.16,08/22/2016
G,NDUFS6,HGNC:7713,5p15.33,5:1801521-1816162,5:1801407-1816048,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"0 (No Evidence)",'-,'-,,,81.82,0.1,1.3,08/22/2016
G,NDUFS7,HGNC:7714,19p13.3,19:1383906-1395583,19:1383907-1395584,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,69.79,0.91,0.39,08/22/2016
G,NDUFS8,HGNC:7715,11q13.2,11:67798148-67804111,11:68030681-68036644,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"0 (No Evidence)",'-,'-,,,51.99,0.17,0.74,08/22/2016
G,NDUFV1,HGNC:7716,11q13.2,11:67374407-67380025,11:67606936-67612554,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"0 (No Evidence)",'-,'-,,,37.98,0,1.21,03/22/2012
G,NDUFV2,HGNC:7717,18p11.22,18:9102697-9134339,18:9102699-9134341,"30 (Autosomal Recessive)","mitochondrial complex I deficiency, nuclear type 1",MONDO:0100224,"0 (No Evidence)",'-,'-,,,15.31,0.01,0.83,08/22/2016
G,NEBL,HGNC:16932,10p12.31,10:21068902-21581979,10:20779973-21293050,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,21.79,0,1.86,12/21/2011
G,NEDD9,HGNC:7733,6p24.2,6:11183531-11382581,6:11183298-11382348,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,29.54,0.13,0.44,02/27/2019
G,NEFL,HGNC:7739,8p21.2,8:24808468-24814126,8:24950955-24956612,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,09/17/2018
G,NEK1,HGNC:7744,4q33,4:170313960-170533734,4:169392809-169612583,"30 (Autosomal Recessive)","short-rib thoracic dysplasia 6 with or without polydactyly",MONDO:0009894,"0 (No Evidence)",'-,'-,,,39.72,0,0.86,08/01/2013
G,NELFA,HGNC:12768,4p16.3,4:1984450-2010701,4:1982723-2008974,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,62.86,0.13,0.51,09/06/2012
G,NEXMIF,HGNC:29433,Xq13.3,X:73952691-74145287,X:74732856-74925452,"3 (Sufficient Evidence)","X-linked intellectual disability, Cantagrel type",MONDO:0010483,"0 (No Evidence)",'-,'-,,,29.47,1,0.2,06/26/2019
G,NF1,HGNC:7765,17q11.2,17:29421945-29704695,17:31094927-31377677,"3 (Sufficient Evidence)","neurofibromatosis type 1",MONDO:0018975,"0 (No Evidence)",'-,'-,,,0.88,0.9,0.29,02/12/2023
G,NF2,HGNC:7773,22q12.2,22:29999545-30094589,22:29603556-29698600,"3 (Sufficient Evidence)","neurofibromatosis type 2",MONDO:0007039,"0 (No Evidence)",'-,'-,,,2.2,1,0.09,09/08/2020
G,NFIA,HGNC:7784,1p31.3,1:61542899-61928460,1:61077227-61462788,"3 (Sufficient Evidence)","chromosome 1p32-p31 deletion syndrome",MONDO:0013396,"0 (No Evidence)",'-,'-,,,0.28,1,0.2,01/12/2017
G,NFIX,HGNC:7788,19p13.13,19:13106289-13209610,19:12995475-13098796,"3 (Sufficient Evidence)","Malan overgrowth syndrome",MONDO:0013885,"0 (No Evidence)",'-,'-,,,1.34,1,0.15,04/12/2022
G,NGLY1,HGNC:17646,3p24.2,3:25760435-25831530,3:25718944-25790039,"30 (Autosomal Recessive)","congenital disorder of deglycosylation 1",MONDO:0800044,"0 (No Evidence)",'-,'-,,,49.52,0,0.95,02/18/2015
G,NHP2,HGNC:14377,5q35.3,5:177576464-177580886,5:178149463-178153885,"30 (Autosomal Recessive)","dyskeratosis congenita, autosomal recessive 2",MONDO:0013519,"0 (No Evidence)",'-,'-,,,32.86,0.05,1.08,03/04/2015
G,NHS,HGNC:7820,Xp22.2-p22.13,X:17393323-17754114,X:17375200-17735994,"3 (Sufficient Evidence)","Nance-Horan syndrome",MONDO:0010545,"0 (No Evidence)",'-,'-,,,3.57,1,0.09,04/28/2021
G,NIPA1,HGNC:17043,15q11.2,15:23043279-23086843,15:22786225-22829789,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,22,0.01,1.04,04/04/2012
G,NIPA2,HGNC:17044,15q11.2,15:23004684-23034402,15:22838666-22868384,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,33.48,0.92,0.38,04/04/2012
G,NIPBL,HGNC:28862,5p13.2,5:36876871-37066515,5:36876769-37066413,"3 (Sufficient Evidence)","Cornelia de Lange syndrome 1",MONDO:0007387,"1 (Little Evidence)",'-,'-,,,3.01,1,0.03,08/26/2020
G,NKX2-5,HGNC:2488,5q34,5:172659112-172662209,5:173232109-173235206,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.67,0.95,0.33,07/22/2020
G,NKX3-2,HGNC:951,4p15.33,4:13542454-13546132,4:13540830-13547744,"30 (Autosomal Recessive)","spondylo-megaepiphyseal-metaphyseal dysplasia",MONDO:0013228,"Not Yet Evaluated",'-,'-,,,53.62,0.64,0.63,08/22/2016
G,NLGN1,HGNC:14291,3q26.31,3:173113742-174012162,3:173395952-174294372,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.37,0.85,0.37,03/25/2016
G,NLGN3,HGNC:14289,Xq13.1,X:70364691-70391051,X:71144841-71175307,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,10.65,0.98,0.31,07/25/2012
G,NNAT,HGNC:7860,20q11.23,20:36149652-36152092,20:37521250-37523690,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,21.87,0.4,0.94,04/28/2012
G,NODAL,HGNC:7865,10q22.1,10:72191692-72207707,10:70431936-70447951,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,31.54,0.97,0.31,08/08/2013
G,NOG,HGNC:7866,17q22,17:54671060-54672972,17:56593699-56595611,"3 (Sufficient Evidence)","multiple synostoses syndrome 1",MONDO:0008519,"0 (No Evidence)",'-,'-,,,0.85,0.89,0.42,01/12/2021
G,NOTCH2,HGNC:7882,1p12,1:120454176-120612276,1:119911553-120069662,"0 (No Evidence)","Alagille syndrome due to a NOTCH2 point mutation",MONDO:0012439,"0 (No Evidence)",'-,'-,,,3.21,1,0.12,07/17/2014
G,NPC1,HGNC:7897,18q11.2,18:21111406-21166470,18:23506184-23586506,"30 (Autosomal Recessive)","Niemann-Pick disease, type C1",MONDO:0009757,"Not Yet Evaluated",'-,'-,,,44.18,0,0.49,08/22/2016
G,NPHP1,HGNC:7905,2q13,2:110880925-110962590,2:110123348-110205013,"30 (Autosomal Recessive)","Joubert syndrome and related disorders",MONDO:0015369,"0 (No Evidence)",'-,'-,,,60.82,0,0.98,10/10/2012
G,NPHP4,HGNC:19104,1p36.31,1:5922871-6052485,1:5862811-5992425,"30 (Autosomal Recessive)","Senior-Loken syndrome 4",MONDO:0011756,"Not Yet Evaluated",'-,'-,,,68.34,0,0.98,08/22/2016
G,NPHS1,HGNC:7908,19q13.12,19:36316274-36343406,19:35825372-35852504,"30 (Autosomal Recessive)","congenital nephrotic syndrome, Finnish type",MONDO:0009732,"0 (No Evidence)",'-,'-,,,44.89,0,0.7,08/22/2016
G,NPRL3,HGNC:14124,16p13.3,16:135385-188672,16:85386-138673,"3 (Sufficient Evidence)","focal epilepsy",MONDO:0005384,"0 (No Evidence)",'-,'-,,,37.31,0.19,0.49,12/12/2023
G,NPTX2,HGNC:7953,7q22.1,7:98246597-98259181,7:98617285-98629869,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,40.45,0.03,0.73,10/10/2012
G,NR0B1,HGNC:7960,Xp21.2,X:30322323-30327507,X:30304206-30309390,"3 (Sufficient Evidence)","X-linked adrenal hypoplasia congenita",MONDO:0010264,"0 (No Evidence)",'-,'-,,,15.44,0.97,0.28,05/06/2020
G,NR2F1,HGNC:7975,5q15,5:92918928-92930317,5:93583222-93594611,"3 (Sufficient Evidence)","Bosch-Boonstra-Schaaf optic atrophy syndrome",MONDO:0014320,"0 (No Evidence)",'-,'-,,,2.69,0.99,0.19,08/09/2022
G,NR2F2,HGNC:7976,15q26.2,15:96869275-96883492,15:96326046-96340263,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.61,0.99,0.22,07/10/2012
G,NR3C2,HGNC:7979,4q31,4:148999915-149365850,4:148078764-148445508,"3 (Sufficient Evidence)","autosomal dominant pseudohypoaldosteronism type 1",MONDO:0008329,"0 (No Evidence)",'-,'-,,,4.63,0.84,0.35,04/06/2020
G,NR4A2,HGNC:7981,2q22-q23,2:157180949-157189233,2:156324437-156332721,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.28,1,0.13,09/27/2022
G,NR5A1,HGNC:7983,9q33.3,9:127243515-127269678,9:124481236-124507399,"3 (Sufficient Evidence)","46,XY sex reversal 3",MONDO:0013066,"0 (No Evidence)",'-,'-,,,5.31,0.99,0.26,02/24/2021
G,NRG3,HGNC:7999,10q23.1,10:83634950-84746935,10:81875194-82987179,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,10.48,0.11,0.46,12/21/2011
G,NRXN1,HGNC:8008,2p16.3,2:50145641-51259270,2:49918503-51032132,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,0.81,1,0.25,06/08/2021
G,NSD1,HGNC:14234,5q35.3,5:176560016-176727214,5:177131798-177300213,"3 (Sufficient Evidence)","Sotos syndrome",MONDO:0019349,"0 (No Evidence)",'-,'-,,,29.19,1,0.1,07/27/2020
G,NSD2,HGNC:12766,4p16.3,4:1873120-1983919,4:1871393-1982192,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,37.85,1,0.12,10/25/2023
G,NSDHL,HGNC:13398,Xq28,X:151999607-152038273,X:152831063-152869729,"3 (Sufficient Evidence)","CHILD syndrome",MONDO:0010621,"0 (No Evidence)",'-,'-,,,64.89,0.96,0.29,09/25/2019
G,NTAN1,HGNC:29909,16p13.11,16:15131714-15149931,16:15037857-15056074,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,40.72,0,1.1,09/17/2018
G,NTHL1,HGNC:8028,16p13.3,16:2089821-2097835,16:2039820-2047834,"30 (Autosomal Recessive)","familial adenomatous polyposis 3",MONDO:0014630,"0 (No Evidence)",'-,'-,,,66.04,0,1.6,07/06/2020
G,NUDT13,HGNC:18827,10q22.2,10:74870213-74891581,10:73110455-73131823,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,47.18,0,1.38,02/02/2021
G,NUS1,HGNC:21042,6q22.1,6:117996632-118031890,6:117675469-117710727,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,18.4,0.98,0.25,09/27/2022
G,NXF5,HGNC:8075,Xq22.1,X:101087085-101112549,X:101832112-101857577,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,89.99,0,1.69,05/17/2012
G,NYX,HGNC:8082,Xp11.4,X:41306596-41334905,X:41447343-41475652,"3 (Sufficient Evidence)","congenital stationary night blindness 1A",MONDO:0010690,"0 (No Evidence)",'-,'-,,,58.33,0.13,1.13,01/22/2020
G,OAT,HGNC:8091,10q26.13,10:126085872-126107492,10:124397303-124418923,"30 (Autosomal Recessive)","ornithine aminotransferase deficiency",MONDO:0009796,"Not Yet Evaluated",'-,'-,,,31.64,0,0.96,08/22/2016
G,OBSL1,HGNC:29092,2q35,2:220415450-220436261,2:219547206-219571539,"30 (Autosomal Recessive)","3M syndrome 2",MONDO:0013039,"0 (No Evidence)",'-,'-,,,60.26,0,0.88,08/22/2016
G,OCA2,HGNC:8101,15q12-q13.1,15:28000021-28344461,15:27719008-28099315,"30 (Autosomal Recessive)","oculocutaneous albinism type 2",MONDO:0008746,"0 (No Evidence)",'-,'-,,,62.33,0,0.86,04/28/2012
G,OCLN,HGNC:8104,5q13.2,5:68788374-68853931,5:69492547-69558104,"30 (Autosomal Recessive)","pseudo-TORCH syndrome 1",MONDO:0020789,"Not Yet Evaluated",'-,'-,,,18.94,0,0.95,08/22/2016
G,OCRL,HGNC:8108,Xq26.1,X:128674236-128726533,X:129540259-129592556,"3 (Sufficient Evidence)","oculocerebrorenal syndrome",MONDO:0010645,"0 (No Evidence)",'-,'-,,,14.52,1,0.16,01/12/2021
G,OFD1,HGNC:2567,Xp22.2,X:13752867-13787476,X:13714505-13773738,"3 (Sufficient Evidence)","orofaciodigital syndrome I",MONDO:0010702,"0 (No Evidence)",'-,'-,,,70.25,0.96,0.32,04/13/2021
G,OPHN1,HGNC:8148,Xq12,X:67262186-67653337,X:68042344-68433841,"3 (Sufficient Evidence)","X-linked intellectual disability-cerebellar hypoplasia syndrome",MONDO:0010337,"0 (No Evidence)",'-,'-,,,35.46,1,0.16,03/22/2023
G,OR5AU1,HGNC:15362,14q11.2,14:21623024-21624222,14:21154865-21156063,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,78.44,0,1.89,03/11/2015
G,ORC4,HGNC:8490,2q23.1,2:148687965-148779120,2:147930396-148021551,"30 (Autosomal Recessive)","Meier-Gorlin syndrome 2",MONDO:0013428,"0 (No Evidence)",'-,'-,,,6.12,0,1.13,11/06/2015
G,ORC6,HGNC:17151,16q11.2,16:46723571-46732306,16:46689659-46698394,"30 (Autosomal Recessive)","Meier-Gorlin syndrome 3",MONDO:0013430,"Not Yet Evaluated",'-,'-,,,41.77,0,1.39,08/22/2016
G,OSBPL5,HGNC:16392,11p15.4,11:3108337-3186540,11:3087107-3165310,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,75.98,0,0.56,09/06/2012
G,OSTM1,HGNC:21652,6q21,6:108362613-108395945,6:108041409-108074741,"30 (Autosomal Recessive)","autosomal recessive osteopetrosis 5",MONDO:0009817,"0 (No Evidence)",'-,'-,,,33.37,0.01,0.74,08/22/2016
G,OTC,HGNC:8512,Xp11.4,X:38211857-38280699,X:38327684-38422928,"3 (Sufficient Evidence)","ornithine carbamoyltransferase deficiency",MONDO:0010703,"0 (No Evidence)",'-,'-,,,3.31,0.87,0.41,06/28/2012
G,OTOA,HGNC:16378,16p12.2,16:21675289-21772050,16:21663968-21760729,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 22",MONDO:0011762,"0 (No Evidence)",'-,'-,,,64.09,0,0.69,08/22/2016
G,OTOF,HGNC:8515,2p23.3,2:26680071-26781624,2:26457203-26558756,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 9",MONDO:0010986,"Not Yet Evaluated",'-,'-,,,29.35,0,0.88,08/22/2016
G,OTOGL,HGNC:26901,12q21.31,12:80493317-80774660,12:80099537-80380880,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 84B",MONDO:0013984,"0 (No Evidence)",'-,'-,,,42.95,0,0.9,08/22/2016
G,OTUD7A,HGNC:20718,15q13.3,15:31767601-32162876,15:31475398-31870673,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,56.07,0.95,0.33,04/27/2018
G,OTX2,HGNC:8522,14q22.3,14:57266623-57277197,14:56799905-56810479,"3 (Sufficient Evidence)","syndromic microphthalmia type 5",MONDO:0012413,"0 (No Evidence)",'-,'-,,,0.72,0.92,0.38,09/08/2020
G,OXCT1,HGNC:8527,5p13.1,5:41730167-41870527,5:41730065-41870425,"30 (Autosomal Recessive)","succinyl-CoA:3-ketoacid CoA transferase deficiency",MONDO:0009492,"Not Yet Evaluated",'-,'-,,,26.58,0,0.54,08/22/2016
G,P3H1,HGNC:19316,1p34.2,1:43212045-43232699,1:42746374-42767028,"30 (Autosomal Recessive)","osteogenesis imperfecta type 8",MONDO:0012581,"0 (No Evidence)",'-,'-,,,48.37,0,1.23,03/12/2015
G,PACS1,HGNC:30032,11q13.1-q13.2,11:65837743-66012215,11:66070272-66244744,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,38.02,1,0.19,12/14/2021
G,PAFAH1B1,HGNC:8574,17p13.3,17:2496948-2588909,17:2593183-2685615,"3 (Sufficient Evidence)","classic lissencephaly",MONDO:0015146,"0 (No Evidence)",'-,'-,,,2.21,1,0.11,10/13/2020
G,PAH,HGNC:8582,12q23.2,12:103230667-103352219,12:102836889-102958441,"30 (Autosomal Recessive)",phenylketonuria,MONDO:0009861,"0 (No Evidence)",'-,'-,,,20.97,0,1.5,08/28/2014
G,PAK2,HGNC:8591,3q29,3:196466728-196559518,3:196739857-196832647,"1 (Little Evidence)",'-,'-,"1 (Little Evidence)",'-,'-,,,16.98,0.97,0.32,12/27/2011
G,PAK3,HGNC:8592,Xq23,X:110187625-110470589,X:110944397-111227361,"2 (Emerging Evidence)","intellectual disability, X-linked 30",MONDO:0010361,"0 (No Evidence)",'-,'-,,,5.06,0.99,0.29,12/09/2019
G,PARK7,HGNC:16369,1p36.23,1:8021771-8045565,1:7961711-7985505,"30 (Autosomal Recessive)","autosomal recessive early-onset Parkinson disease 7",MONDO:0011658,"0 (No Evidence)",'-,'-,,,10.87,0.75,0.53,08/22/2016
G,PAX1,HGNC:8615,20p11.22,20:21686302-21699119,20:21705664-21718481,"30 (Autosomal Recessive)","otofaciocervical syndrome 2",MONDO:0014254,"0 (No Evidence)",'-,'-,,,38.4,0.7,0.5,08/22/2016
G,PAX2,HGNC:8616,10q24.31,10:102495153-102589701,10:100735396-100829944,"3 (Sufficient Evidence)","renal coloboma syndrome",MONDO:0007352,"0 (No Evidence)",'-,'-,,,0.24,0.67,0.43,02/26/2020
G,PAX3,HGNC:8617,2q36.1,2:223064606-223163717,2:222199887-222298998,"3 (Sufficient Evidence)","Waardenburg syndrome type 1",MONDO:0008670,"0 (No Evidence)",'-,'-,,,0.54,0.24,0.48,05/27/2020
G,PAX5,HGNC:8619,9p13.2,9:36833266-37034265,9:36833269-37034268,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.77,1,0.17,05/24/2022
G,PAX6,HGNC:8620,11p13,11:31810574-31839509,11:31789026-31817961,"3 (Sufficient Evidence)","aniridia 1",MONDO:0024507,"1 (Little Evidence)",'-,'-,,,0.78,1,0.17,11/05/2015
G,PAX8,HGNC:8622,2q14.1,2:113973574-114036498,2:113215997-113278921,"1 (Little Evidence)","congenital hypothyroidism",MONDO:0018612,"0 (No Evidence)",'-,'-,,,7.48,1,0.2,11/09/2021
G,PAX9,HGNC:8623,14q13.3,14:37126773-37148567,14:36657568-36679362,"3 (Sufficient Evidence)","tooth agenesis, selective, 3",MONDO:0011477,"0 (No Evidence)",'-,'-,,,1.94,0.31,0.61,07/08/2020
G,PBX1,HGNC:8632,1q23.3,1:164528421-164855284,1:164559184-164886047,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.86,1,0.26,09/05/2019
G,PC,HGNC:8636,11q13.2,11:66615891-66725854,11:66848420-66958383,"30 (Autosomal Recessive)","pyruvate carboxylase deficiency disease",MONDO:0009949,"Not Yet Evaluated",'-,'-,,,23.85,0.01,0.44,08/22/2016
G,PCARE,HGNC:34383,2p23.2,2:29284561-29297389,2:29061695-29074523,"30 (Autosomal Recessive)","retinitis pigmentosa 54",MONDO:0013263,"0 (No Evidence)",'-,'-,,,84.18,0,1.11,09/25/2014
G,PCCA,HGNC:8653,13q32.3,13:100741347-101182689,13:100089093-100530435,"30 (Autosomal Recessive)","propionic acidemia",MONDO:0011628,"0 (No Evidence)",'-,'-,,,19.12,0,0.91,08/22/2016
G,PCDH15,HGNC:14674,10q21.1,10:55562531-57387702,10:53802771-55627942,"30 (Autosomal Recessive)","Usher syndrome type 1F",MONDO:0011186,"0 (No Evidence)",'-,'-,,,23.23,0,0.79,08/22/2016
G,PCDH19,HGNC:14270,Xq22.1,X:99546642-99665271,X:100291644-100410273,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.65,1,0.13,02/14/2023
G,PCDH9,HGNC:8661,13q21.32,13:66876966-67804468,13:66302834-67230336,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.79,0.81,0.37,06/08/2012
G,PCDHGA8,HGNC:8706,5q31.3,5:140772200-140892542,5:141392633-141512975,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,54.62,0,1.35,02/02/2021
G,PCSK9,HGNC:20001,1p32.3,1:55505221-55530525,1:55039548-55064852,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,73.06,0,1.34,12/17/2015
G,PCYT1A,HGNC:8754,3q29,3:195961239-196014597,3:196234368-196287726,"30 (Autosomal Recessive)","spondylometaphyseal dysplasia-cone-rod dystrophy syndrome",MONDO:0012160,"0 (No Evidence)",'-,'-,,,18.96,0,0.86,08/22/2016
G,PDE4D,HGNC:8783,5q11.2-q12.1,5:58264865-59792113,5:58969038-60522128,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.24,1,0.21,02/02/2018
G,PDE6C,HGNC:8787,10q23.33,10:95372294-95425767,10:93612537-93666010,"30 (Autosomal Recessive)","cone dystrophy 4",MONDO:0013129,"0 (No Evidence)",'-,'-,,,40.7,0,0.87,08/22/2016
G,PDHA1,HGNC:8806,Xp22.12,X:19362045-19379836,X:19343927-19361718,"3 (Sufficient Evidence)","pyruvate dehydrogenase deficiency",MONDO:0019169,"0 (No Evidence)",'-,'-,,,35.05,0.99,0.27,09/27/2022
G,PDHX,HGNC:21350,11p13,11:34937677-35017675,11:34915920-34996128,"30 (Autosomal Recessive)","pyruvate dehydrogenase E3-binding protein deficiency",MONDO:0009503,"Not Yet Evaluated",'-,'-,,,6.33,0,0.72,08/22/2016
G,PDP1,HGNC:9279,8q22.1,8:94929151-94938296,8:93916923-93926068,"30 (Autosomal Recessive)","pyruvate dehydrogenase phosphatase deficiency",MONDO:0012120,"Not Yet Evaluated",'-,'-,,,16.05,0.45,0.49,08/22/2016
G,PDSS2,HGNC:23041,6q21,6:107473766-107780768,6:107152562-107459564,"30 (Autosomal Recessive)","coenzyme Q10 deficiency, primary, 3",MONDO:0013838,"Not Yet Evaluated",'-,'-,,,16.76,0,1.13,08/22/2016
G,PDX1,HGNC:6107,13q12.2,13:28494137-28500450,13:27920000-27926313,"30 (Autosomal Recessive)","pancreatic agenesis 1",MONDO:0024547,"0 (No Evidence)",'-,'-,,,15,0.02,1.05,08/22/2016
G,PEG10,HGNC:14005,7q21.3,7:94285637-94299007,7:94656325-94669695,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.78,0.87,0.43,08/22/2012
G,PEG3,HGNC:8826,19q13.43,19:57321450-57352094,19:56810082-56840726,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,77.96,0,0.51,05/17/2012
G,PEPD,HGNC:8840,19q13.11,19:33877856-34012697,19:33386950-33521791,"30 (Autosomal Recessive)","prolidase deficiency",MONDO:0008221,"Not Yet Evaluated",'-,'-,,,20.61,0,1.26,08/22/2016
G,PEX1,HGNC:8850,7q21.2,7:92116339-92157834,7:92487025-92528520,"30 (Autosomal Recessive)","peroxisome biogenesis disorder",MONDO:0019234,"Not Yet Evaluated",'-,'-,,,50.89,0,0.66,08/22/2016
G,PEX11B,HGNC:8853,1q21.1,1:145516372-145523732,1:145911348-145918717,"30 (Autosomal Recessive)","peroxisome biogenesis disorder 14B",MONDO:0013967,"0 (No Evidence)",'-,'-,,,35.29,0,1.08,08/22/2016
G,PEX14,HGNC:8856,1p36.22,1:10535007-10690815,1:10474950-10630758,"30 (Autosomal Recessive)","peroxisome biogenesis disorder 13A (Zellweger)",MONDO:0013952,"0 (No Evidence)",'-,'-,,,19.48,0.23,0.52,08/22/2016
G,PEX16,HGNC:8857,11p11.2,11:45931214-45939428,11:45909663-45918822,"30 (Autosomal Recessive)","peroxisome biogenesis disorder",MONDO:0019234,"0 (No Evidence)",'-,'-,,,39.61,0,0.83,08/22/2016
G,PEX26,HGNC:22965,22q11.21,22:18560756-18588162,22:18077990-18105396,"30 (Autosomal Recessive)","peroxisome biogenesis disorder",MONDO:0019234,"0 (No Evidence)",'-,'-,,,72.53,0.93,0.37,08/22/2016
G,PEX3,HGNC:8858,6q24.2,6:143771942-143811753,6:143450805-143490616,"30 (Autosomal Recessive)","peroxisome biogenesis disorder 10B",MONDO:0054549,"0 (No Evidence)",'-,'-,,,27.6,0.02,0.56,08/22/2016
G,PEX7,HGNC:8860,6q23.3,6:137143730-137235072,6:136822592-136913934,"30 (Autosomal Recessive)","peroxisome biogenesis disorder 9B",MONDO:0013945,"Not Yet Evaluated",'-,'-,,,31.61,0,1.42,08/22/2016
G,PGAP3,HGNC:23719,17q12,17:37827375-37844310,17:39671122-39688057,"30 (Autosomal Recessive)","hyperphosphatasia with intellectual disability syndrome 4",MONDO:0014318,"Not Yet Evaluated",'-,'-,,,44.26,0,0.83,08/22/2016
G,PGK1,HGNC:8896,Xq21.1,X:77359745-77384792,X:78104248-78129295,"2 (Emerging Evidence)","glycogen storage disease due to phosphoglycerate kinase 1 deficiency",MONDO:0010392,"0 (No Evidence)",'-,'-,,,2.46,0.77,0.47,05/26/2021
G,PGM1,HGNC:8905,1p31.3,1:64059082-64125916,1:63593411-63660245,"30 (Autosomal Recessive)","PGM1-congenital disorder of glycosylation",MONDO:0013968,"Not Yet Evaluated",'-,'-,,,20.5,0,1.32,08/22/2016
G,PGM3,HGNC:8907,6q14.1,6:83860447-83903619,6:83148705-83193900,"30 (Autosomal Recessive)","immunodeficiency 23",MONDO:0014353,"0 (No Evidence)",'-,'-,,,45.16,0,0.65,08/22/2016
G,PHC1,HGNC:3182,12p13.31,12:9067105-9094063,12:8913843-8941467,"30 (Autosomal Recessive)","microcephaly 11, primary, autosomal recessive",MONDO:0014173,"0 (No Evidence)",'-,'-,,,41.66,1,0.24,08/22/2016
G,PHEX,HGNC:8918,Xp22.11,X:22050443-22269427,X:22032325-22251310,"3 (Sufficient Evidence)","X-linked dominant hypophosphatemic rickets",MONDO:0010619,"0 (No Evidence)",'-,'-,,,6.97,1,0.14,06/28/2012
G,PHF2,HGNC:8920,9q22.31,9:96338866-96441869,9:93576584-93679587,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,54.82,1,0.18,02/27/2019
G,PHF21A,HGNC:24156,11p11.2,11:45950870-46143005,11:45929319-46121454,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,2.85,1,0.08,09/21/2023
G,PHF3,HGNC:8921,6q12,6:64345707-64435904,6:63635802-63726011,"1 (Little Evidence)","autism spectrum disorder",MONDO:0005258,"0 (No Evidence)",'-,'-,,,36.85,0.99,0.29,02/27/2019
G,PHF6,HGNC:18145,Xq26.2,X:133507342-133562820,X:134373312-134428790,"3 (Sufficient Evidence)","Borjeson-Forssman-Lehmann syndrome",MONDO:0010537,"0 (No Evidence)",'-,'-,,,8.85,1,0.17,02/24/2021
G,PHF8,HGNC:20672,Xp11.22,X:53963113-54071569,X:53936680-54048936,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Siderius type",MONDO:0010286,"0 (No Evidence)",'-,'-,,,17.8,1,0.26,08/26/2020
G,PHIP,HGNC:15673,6q14.1,6:79644136-79787971,6:78934419-79078254,"3 (Sufficient Evidence)","PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome",MONDO:0035133,"0 (No Evidence)",'-,'-,,,12.52,1,0.11,04/13/2022
G,PHKB,HGNC:8927,16q12.1,16:47495210-47735434,16:47461299-47701523,"30 (Autosomal Recessive)","glycogen storage disease IXb",MONDO:0009868,"0 (No Evidence)",'-,'-,,,27.2,0,0.84,08/22/2016
G,PHKG2,HGNC:8931,16p11.2,16:30759746-30772497,16:30748425-30761176,"30 (Autosomal Recessive)","glycogen storage disease IXc",MONDO:0013091,"Not Yet Evaluated",'-,'-,,,25.69,0,0.66,08/22/2016
G,PHLDA2,HGNC:12385,11p15.4,11:2949503-2950650,11:2928273-2929420,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,63.76,0.15,1.73,03/22/2012
G,PHYH,HGNC:8940,10p13,10:13319799-13342064,10:13277799-13300064,"30 (Autosomal Recessive)","adult Refsum disease",MONDO:0009958,"Not Yet Evaluated",'-,'-,,,73.67,0,1.12,08/22/2016
G,PIGA,HGNC:8957,Xp22.2,X:15337573-15353676,X:15319451-15335554,"2 (Emerging Evidence)","developmental and epileptic encephalopathy",MONDO:0100062,"0 (No Evidence)",'-,'-,,,26.91,0.96,0.3,11/09/2021
G,PIGN,HGNC:8967,18q21.33,18:59708397-59854289,18:62017615-62187056,"30 (Autosomal Recessive)","multiple congenital anomalies-hypotonia-seizures syndrome 1",MONDO:0013563,"Not Yet Evaluated",'-,'-,,,42.61,0,1.03,08/22/2016
G,PIGO,HGNC:23215,9p13.3,9:35088685-35096588,9:35088688-35096591,"30 (Autosomal Recessive)","hyperphosphatasia with intellectual disability syndrome 2",MONDO:0013882,"0 (No Evidence)",'-,'-,,,35.9,0,0.81,08/22/2016
G,PIGW,HGNC:23213,17q12,17:34890814-34895152,17:36534987-36539303,"30 (Autosomal Recessive)","hyperphosphatasia with intellectual disability syndrome 5",MONDO:0014457,"0 (No Evidence)",'-,'-,,,42.97,0,1.08,08/22/2016
G,PIK3CA,HGNC:8975,3q26.32,3:178866145-178957881,3:179148126-179240093,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.26,1,0.12,03/12/2015
G,PIK3R2,HGNC:8980,19p13.11,19:18263973-18281342,19:18153163-18170532,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.46,0.02,0.49,06/25/2015
G,PINK1,HGNC:14581,1p36.12,1:20959951-20978004,1:20633458-20651511,"30 (Autosomal Recessive)","autosomal recessive early-onset Parkinson disease 6",MONDO:0011613,"Not Yet Evaluated",'-,'-,,,41.91,0,1.14,08/22/2016
G,PIP5K1C,HGNC:8996,19p13.3,19:3630181-3700466,19:3630183-3700468,"30 (Autosomal Recessive)","lethal congenital contracture syndrome 3",MONDO:0012656,"Not Yet Evaluated",'-,'-,,,59.99,0.98,0.31,08/22/2016
G,PITPNA,HGNC:9001,17p13.3,17:1421012-1466086,17:1517718-1562792,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.09,0.97,0.33,06/07/2012
G,PITX2,HGNC:9005,4q25,4:111538579-111563279,4:110617423-110642123,"3 (Sufficient Evidence)","Axenfeld-Rieger syndrome",MONDO:0019187,"0 (No Evidence)",'-,'-,,,0.8,0.98,0.26,10/24/2022
G,PITX3,HGNC:9006,10q24.32,10:103989946-104001269,10:102230189-102241512,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,6.41,0.81,0.48,11/06/2013
G,PKD1,HGNC:9008,16p13.3,16:2138709-2185899,16:2088708-2135898,"3 (Sufficient Evidence)","polycystic kidney disease 1",MONDO:0008263,"0 (No Evidence)",'-,'-,,,28.17,1,0.18,06/10/2020
G,PKD2,HGNC:9009,4q22.1,4:88928787-88998929,4:88007635-88077777,"3 (Sufficient Evidence)","polycystic kidney disease 2",MONDO:0013131,"0 (No Evidence)",'-,'-,,,12.05,0,0.5,07/06/2012
G,PKP2,HGNC:9024,12p11.21,12:32943689-33049711,12:32790755-32896777,"3 (Sufficient Evidence)","arrhythmogenic right ventricular cardiomyopathy",MONDO:0016587,"0 (No Evidence)",'-,'-,,,58.3,0,1.06,05/10/2023
G,PLA2G6,HGNC:9039,22q13.1,22:38507502-38577837,22:38111495-38181830,"30 (Autosomal Recessive)","neurodegeneration with brain iron accumulation",MONDO:0018307,"Not Yet Evaluated",'-,'-,,,35.59,0,0.86,08/22/2016
G,PLAGL1,HGNC:9046,6q24.2,6:144261437-144385736,6:143940300-144064599,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,60.44,0.98,0.26,08/27/2012
G,PLCB1,HGNC:15917,20p12.3,20:8112913-8865547,20:8132266-8884900,"30 (Autosomal Recessive)","developmental and epileptic encephalopathy, 12",MONDO:0013389,"0 (No Evidence)",'-,'-,,,5.05,0.98,0.3,08/22/2016
G,PLEKHG5,HGNC:29105,1p36.31,1:6526152-6580152,1:6467122-6520092,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease recessive intermediate C",MONDO:0014154,"0 (No Evidence)",'-,'-,,,53.41,0,0.57,08/22/2016
G,PLOD1,HGNC:9081,1p36.22,1:11994774-12035594,1:11934717-11975537,"30 (Autosomal Recessive)","Ehlers-Danlos syndrome, kyphoscoliotic type 1",MONDO:0016002,"Not Yet Evaluated",'-,'-,,,29.26,0,0.94,08/22/2016
G,PLOD2,HGNC:9082,3q24,3:145787227-145878971,3:146069440-146161184,"30 (Autosomal Recessive)","Bruck syndrome 2",MONDO:0012217,"Not Yet Evaluated",'-,'-,,,31.58,0,0.64,08/22/2016
G,PLOD3,HGNC:9083,7q22.1,7:100849265-100860862,7:101205984-101217581,"30 (Autosomal Recessive)","bone fragility with contractures, arterial rupture, and deafness",MONDO:0012892,"0 (No Evidence)",'-,'-,,,51.13,0,0.82,08/22/2016
G,PLP1,HGNC:9086,Xq22.2,X:103031434-103047548,X:103776506-103792619,"3 (Sufficient Evidence)","Pelizaeus-Merzbacher disease",MONDO:0010714,"3 (Sufficient Evidence)","Pelizaeus-Merzbacher disease",MONDO:0010714,,,1.65,0.93,0.36,04/12/2021
G,PMM2,HGNC:9115,16p13.2,16:8891696-8943182,16:8797839-8849325,"30 (Autosomal Recessive)","PMM2-congenital disorder of glycosylation",MONDO:0008907,"0 (No Evidence)",'-,'-,,,40.44,0,1.88,08/22/2016
G,PMP22,HGNC:9118,17p12,17:15133096-15168643,17:15229779-15265326,"3 (Sufficient Evidence)","hereditary neuropathy with liability to pressure palsies",MONDO:0008087,"0 (No Evidence)","Charcot-Marie-Tooth disease type 1A",MONDO:0007309,,,40.48,0.91,0.39,07/12/2012
G,PMS2,HGNC:9122,7p22.1,7:6010556-6048737,7:5970925-6009106,"3 (Sufficient Evidence)","Lynch syndrome 4",MONDO:0013699,"0 (No Evidence)",'-,'-,,,59.43,0,1.27,11/16/2015
G,PNP,HGNC:7892,14q11.2,14:20937565-20945248,14:20469406-20477089,"30 (Autosomal Recessive)","purine nucleoside phosphorylase deficiency",MONDO:0013171,"0 (No Evidence)",'-,'-,,,47.87,0,1.15,08/22/2016
G,POGZ,HGNC:18801,1q21.3,1:151375200-151431970,1:151402724-151459494,"3 (Sufficient Evidence)","intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome",MONDO:0014606,"0 (No Evidence)",'-,'-,,,29.96,1,0.12,12/27/2017
G,POLD1,HGNC:9175,19q13.3,19:50887580-50921275,19:50384323-50418018,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,69.77,0,0.53,06/05/2020
G,POLE,HGNC:9177,12q24.33,12:133200348-133263928,12:132623762-132687342,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.06,0,0.64,12/16/2019
G,POLH,HGNC:9181,6p21.1,6:43543922-43588260,6:43576185-43620523,"30 (Autosomal Recessive)","xeroderma pigmentosum variant type",MONDO:0010214,"0 (No Evidence)",'-,'-,,,29.98,0,0.84,08/22/2016
G,POLL,HGNC:9184,10q24.32,10:103338639-103348027,10:101578882-101588270,"0 (No Evidence)",'-,'-,"0 (No Evidence)","split hand-foot malformation 3",MONDO:0009525,,,20.37,0,1.06,12/21/2011
G,POLR1D,HGNC:20422,13q12.2,13:28194880-28241548,13:27620743-27667411,"3 (Sufficient Evidence)","Treacher Collins syndrome 2",MONDO:0013385,"0 (No Evidence)",'-,'-,,,31.76,0.36,1.01,06/23/2021
G,POMP,HGNC:20330,13q12.3,13:29233267-29253096,13:28659130-28678959,"30 (Autosomal Recessive)","keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome",MONDO:0011169,"0 (No Evidence)",'-,'-,,,11.76,0.91,0.39,08/27/2015
G,POMT2,HGNC:19743,14q24.3,14:77741299-77787226,14:77274956-77320883,"30 (Autosomal Recessive)","muscular dystrophy-dystroglycanopathy",MONDO:0018276,"Not Yet Evaluated",'-,'-,,,44.09,0,0.8,08/22/2016
G,POR,HGNC:9208,7q11.23,7:75544473-75616173,7:75915155-75986855,"30 (Autosomal Recessive)","Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis",MONDO:0008726,"Not Yet Evaluated",'-,'-,,,68.94,0,0.84,08/22/2016
G,PORCN,HGNC:17652,Xp11.23,X:48367380-48379202,X:48508992-48520814,"3 (Sufficient Evidence)","focal dermal hypoplasia",MONDO:0010592,"0 (No Evidence)",'-,'-,,,12.63,1,0.14,08/23/2012
G,POU4F3,HGNC:9220,5q32,5:145718402-145721291,5:146338839-146341728,"3 (Sufficient Evidence)","autosomal dominant nonsyndromic hearing loss 15",MONDO:0011226,"0 (No Evidence)",'-,'-,,,8.21,0.92,0.37,11/29/2023
G,PPIB,HGNC:9255,15q22.31,15:64448016-64455221,15:64155817-64163022,"30 (Autosomal Recessive)","osteogenesis imperfecta type 9",MONDO:0009805,"0 (No Evidence)",'-,'-,,,18.75,0,1.6,08/22/2016
G,PPIP5K1,HGNC:29023,15q15.3,15:43825660-43882451,15:43533475-43590253,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 16",MONDO:0011364,"0 (No Evidence)",'-,'-,,,27.93,0,0.69,08/27/2012
G,PPM1D,HGNC:9277,17q23.3,17:58677554-58743641,17:60600193-60666280,"0 (No Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,14.25,0,1.1,03/28/2023
G,PPP1R9A,HGNC:14946,7q21.3,7:94536906-94925727,7:94907236-95296415,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,36.02,0,0.48,04/04/2012
G,PPP2R1A,HGNC:9302,19q13.41,19:52693305-52732771,19:52190052-52229518,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,23.46,0.98,0.3,12/06/2023
G,PPP2R5D,HGNC:9312,6p21.1,6:42952308-42980080,6:42984570-43012342,"1 (Little Evidence)","intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome",MONDO:0014602,"0 (No Evidence)",'-,'-,,,19.74,1,0.18,05/26/2021
G,PPT1,HGNC:9325,1p34.2,1:40537133-40562924,1:40071461-40097252,"30 (Autosomal Recessive)","neuronal ceroid lipofuscinosis 1",MONDO:0009744,"0 (No Evidence)",'-,'-,,,21.97,0,0.89,08/22/2016
G,PQBP1,HGNC:9330,Xp11.23,X:48755213-48760420,X:48897930-48903143,"3 (Sufficient Evidence)","Renpenning syndrome",MONDO:0010653,"0 (No Evidence)",'-,'-,,,39.11,0.79,0.5,04/09/2020
G,PRCD,HGNC:32528,17q25.1,17:74523668-74541458,17:76527586-76553580,"30 (Autosomal Recessive)","retinitis pigmentosa 36",MONDO:0012523,"0 (No Evidence)",'-,'-,,,64.9,0.02,1.58,08/22/2016
G,PRDM6,HGNC:9350,5q23.2,5:122424936-122529960,5:123089241-123194266,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,13.65,0.61,0.42,12/14/2017
G,PREPL,HGNC:30228,2p21,2:44544746-44589001,2:44317607-44361862,"30 (Autosomal Recessive)","myasthenic syndrome, congenital, 22",MONDO:0044299,"0 (No Evidence)",'-,'-,,,39.97,0,0.99,03/21/2012
G,PRG4,HGNC:9364,1q31.1,1:186265405-186283699,1:186296273-186314567,"30 (Autosomal Recessive)","camptodactyly-arthropathy-coxa vara-pericarditis syndrome",MONDO:0008828,"0 (No Evidence)",'-,'-,,,84.91,0,0.74,08/22/2016
G,PRKAG2,HGNC:9386,7q36.1,7:151253213-151574200,7:151556127-151877115,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,27.16,1,0.26,11/05/2015
G,PRKN,HGNC:8607,6q26,6:161768449-163148798,6:161347417-162727766,"30 (Autosomal Recessive)","autosomal recessive juvenile Parkinson disease 2",MONDO:0010820,"0 (No Evidence)",'-,'-,,,0.77,0,0.86,05/15/2018
G,PRODH,HGNC:9453,22q11.21,22:18900294-18924066,22:18912781-18936553,"30 (Autosomal Recessive)","hyperprolinemia type 1",MONDO:0009400,"0 (No Evidence)",'-,'-,,,45.38,0,1.1,11/08/2022
G,PROP1,HGNC:9455,5q35.3,5:177419236-177423243,5:177992235-177996242,"30 (Autosomal Recessive)","pituitary hormone deficiency, combined, 2",MONDO:0009878,"0 (No Evidence)",'-,'-,,,82.55,0.09,0.9,08/22/2016
G,PRPS1,HGNC:9462,Xq22.3,X:106871740-106894256,X:107628510-107651026,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,26.12,0.92,0.38,05/17/2012
G,PRR12,HGNC:29217,19q13.33,19:50094439-50129696,19:49591182-49626439,"3 (Sufficient Evidence)","neuroocular syndrome",MONDO:0859193,"0 (No Evidence)",'-,'-,,,71.51,1,0.05,11/29/2023
G,PRRT2,HGNC:30500,16p11.2,16:29823514-29827202,16:29812193-29815881,"3 (Sufficient Evidence)","self-limited familial infantile epilepsy",MONDO:0100024,"0 (No Evidence)",'-,'-,,,70.09,0.58,0.56,12/14/2021
G,PRSS1,HGNC:9475,7q34,7:142457323-142460923,7:142749472-142753072,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,78.46,0,1.86,10/29/2012
G,PSAT1,HGNC:19129,9q21.2,9:80912041-80945009,9:78297125-78330093,"30 (Autosomal Recessive)","neurometabolic disorder due to serine deficiency",MONDO:0018162,"Not Yet Evaluated",'-,'-,,,23.31,0,1.27,08/22/2016
G,PSD3,HGNC:19093,8p22,8:18384813-18871213,8:18527303-19084805,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,45.05,0.01,0.45,12/07/2016
G,PSORS1C2,HGNC:17199,6p21.33,6:31105311-31106843,6:31137534-31139066,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,68.42,0,1.74,02/02/2021
G,PSPH,HGNC:9577,7p11.2,7:56078757-56119137,7:56011064-56051444,"30 (Autosomal Recessive)","PSPH deficiency",MONDO:0013531,"0 (No Evidence)",'-,'-,,,44.89,0,1.19,08/22/2016
G,PTCH1,HGNC:9585,9q22.32,9:98205262-98279253,9:95442980-95516971,"3 (Sufficient Evidence)","nevoid basal cell carcinoma syndrome",MONDO:0007187,"0 (No Evidence)",'-,'-,,,0.48,1,0.08,07/01/2020
G,PTCHD1,HGNC:26392,Xp22.11,X:23352966-23422491,X:23334396-23404374,"3 (Sufficient Evidence)","autism, susceptibility to, X-linked 4",MONDO:0010440,"0 (No Evidence)",'-,'-,,,6.56,0.98,0.28,02/28/2018
G,PTEN,HGNC:9588,10q23.31,10:89623382-89731687,10:87863625-87971930,"3 (Sufficient Evidence)","PTEN hamartoma tumor syndrome",MONDO:0017623,"0 (No Evidence)",'-,'-,,,0.07,0.26,0.51,06/24/2020
G,PTHLH,HGNC:9607,12p11.22,12:28111017-28125666,12:27958084-27972733,"3 (Sufficient Evidence)","brachydactyly type E2",MONDO:0013244,"1 (Little Evidence)","mesomelic dysplasia",MONDO:0023599,,,5.78,0.81,0.48,01/25/2023
G,PTPN11,HGNC:9644,12q24.13,12:112856751-112947722,12:112418947-112509918,"3 (Sufficient Evidence)",metachondromatosis,MONDO:0007979,"0 (No Evidence)","Noonan syndrome 1",MONDO:0008104,,,1.58,1,0.14,09/08/2020
G,PTPRQ,HGNC:9679,12q21.31,12:80838015-81074052,12:80444235-80680273,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 84A",MONDO:0013249,"Not Yet Evaluated",'-,'-,,,43.92,0,0.7,08/22/2016
G,PTS,HGNC:9689,11q23.1,11:112097151-112104696,11:112226428-112233973,"30 (Autosomal Recessive)","BH4-deficient hyperphenylalaninemia A",MONDO:0009863,"0 (No Evidence)",'-,'-,,,20.05,0,1.69,08/22/2016
G,PUF60,HGNC:17042,8q24.3,8:144898514-144911485,8:143816344-143829315,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,24.05,1,0.25,01/09/2024
G,PURA,HGNC:9701,5q31.3,5:139493694-139505204,5:140114109-140125619,"3 (Sufficient Evidence)","PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation",MONDO:0014512,"0 (No Evidence)",'-,'-,,,9.4,0.94,0.34,06/07/2017
G,PXDN,HGNC:14966,2p25.3,2:1635659-1748287,2:1631887-1744901,"30 (Autosomal Recessive)","anterior segment dysgenesis 7",MONDO:0010015,"0 (No Evidence)",'-,'-,,,61.43,0,0.52,08/22/2016
G,PYCR1,HGNC:9721,17q25.3,17:79890267-79895176,17:81932391-81937300,"30 (Autosomal Recessive)","autosomal recessive cutis laxa type 2B",MONDO:0013051,"Not Yet Evaluated",'-,'-,,,44.04,0,1.26,08/22/2016
G,QDPR,HGNC:9752,4p15.32,4:17488018-17513713,4:17486395-17512090,"30 (Autosomal Recessive)","dihydropteridine reductase deficiency",MONDO:0009862,"Not Yet Evaluated",'-,'-,,,24.03,0,1.06,08/22/2016
G,QRICH1,HGNC:24713,3p21.31,3:49067140-49131806,3:49029707-49094373,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,11.67,1,0.28,11/15/2023
G,RAB27A,HGNC:9766,15q21.3,15:55495164-55582011,15:55202966-55289813,"30 (Autosomal Recessive)","Griscelli syndrome type 2",MONDO:0011872,"Not Yet Evaluated",'-,'-,,,5.04,0,1.65,08/22/2016
G,RAB28,HGNC:9768,4p15.33,4:13369348-13485964,4:13367724-13484340,"30 (Autosomal Recessive)","cone-rod dystrophy 18",MONDO:0014153,"Not Yet Evaluated",'-,'-,,,12.5,0.02,0.76,08/22/2016
G,RAB39B,HGNC:16499,Xq28,X:154487520-154493776,X:155258235-155264491,"3 (Sufficient Evidence)","intellectual disability, X-linked 72",MONDO:0010289,"0 (No Evidence)",'-,'-,,,21.75,0.83,0.52,05/29/2020
G,RAB3GAP1,HGNC:17063,2q21.3,2:135809862-135928280,2:135052292-135176396,"30 (Autosomal Recessive)","Warburg micro syndrome 1",MONDO:0010822,"Not Yet Evaluated",'-,'-,,,27.47,0,0.54,08/22/2016
G,RAB3GAP2,HGNC:17168,1q41,1:220321635-220445795,1:220148293-220272453,"30 (Autosomal Recessive)","multiple congenital anomalies/dysmorphic syndrome-intellectual disability",MONDO:0015159,"0 (No Evidence)",'-,'-,,,51.08,0.99,0.29,08/22/2016
G,RABL2A,HGNC:9799,2q14.1,2:114384843-114400969,2:113627266-113643392,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,74.97,0,1.62,02/02/2021
G,RAD21,HGNC:9811,8q24.11,8:117858173-117887015,8:116845934-116874776,"3 (Sufficient Evidence)","Cornelia de Lange syndrome",MONDO:0016033,"0 (No Evidence)",'-,'-,,,4.51,1,0.26,03/08/2022
G,RAD51C,HGNC:9820,17q22,17:56769934-56812972,17:58692573-58735611,"3 (Sufficient Evidence)","breast-ovarian cancer, familial, susceptibility to, 3",MONDO:0013253,"0 (No Evidence)",'-,'-,,,9.19,0,1.49,07/08/2020
G,RAD51D,HGNC:9823,17q12,17:33419240-33446879,17:35092221-35119860,"3 (Sufficient Evidence)","familial ovarian cancer",MONDO:0016248,"0 (No Evidence)",'-,'-,,,59.17,0,1.22,01/09/2024
G,RAF1,HGNC:9829,3p25.2,3:12625100-12705616,3:12583601-12664117,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,14.17,0.85,0.35,09/13/2018
G,RAG1,HGNC:9831,11p12,11:36531903-36601312,11:36510353-36579762,"30 (Autosomal Recessive)","recombinase activating gene 1 deficiency",MONDO:0000572,"Not Yet Evaluated",'-,'-,,,24.07,0,0.74,08/22/2016
G,RAG2,HGNC:9832,11p12,11:36613493-36619786,11:36590996-36598236,"30 (Autosomal Recessive)","Omenn syndrome",MONDO:0011338,"Not Yet Evaluated",'-,'-,,,3.71,0.02,0.79,08/22/2016
G,RAI1,HGNC:9834,17p11.2,17:17584772-17714767,17:17681458-17811453,"3 (Sufficient Evidence)","Smith-Magenis syndrome",MONDO:0008434,"0 (No Evidence)",'-,'-,,,47.54,1,0.12,10/13/2020
G,RALGAPB,HGNC:29221,20q11.23,20:37101486-37207501,20:38472843-38578858,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,12.23,1,0.11,02/27/2019
G,RARS2,HGNC:21406,6q15,6:88223656-88299705,6:87513938-87589987,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 6",MONDO:0012683,"0 (No Evidence)",'-,'-,,,21.71,0,0.92,04/09/2015
G,RASA1,HGNC:9871,5q14.3,5:86563700-86687733,5:87267883-87391916,"3 (Sufficient Evidence)","capillary malformation-arteriovenous malformation 1",MONDO:0020783,"0 (No Evidence)",'-,'-,,,2.57,1,0.13,04/22/2020
G,RAX,HGNC:18662,18q21.32,18:56934270-56940686,18:59267038-59273454,"30 (Autosomal Recessive)","isolated microphthalmia 3",MONDO:0012604,"Not Yet Evaluated",'-,'-,,,51.09,0.1,0.86,08/22/2016
G,RB1,HGNC:9884,13q14.2,13:48877887-49056026,13:48303751-48481890,"3 (Sufficient Evidence)","hereditary retinoblastoma",MONDO:0018160,"0 (No Evidence)",'-,'-,,,0.53,1,0.13,03/09/2021
G,RB1CC1,HGNC:15574,8q11.23,8:53535018-53626995,8:52622458-52714435,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,10.33,1,0.14,07/25/2018
G,RBBP8,HGNC:9891,18q11.2,18:20513291-20606449,18:22914139-23026486,"30 (Autosomal Recessive)","Seckel syndrome 2",MONDO:0011715,"Not Yet Evaluated",'-,'-,,,13.93,0,0.75,08/22/2016
G,RBP3,HGNC:9921,10q11.22,10:48381481-48390999,10:47348363-47357881,"30 (Autosomal Recessive)","retinitis pigmentosa 66",MONDO:0014093,"0 (No Evidence)",'-,'-,,,56.69,0,0.65,08/22/2016
G,RCAN1,HGNC:3040,21q22.12,21:35888740-35987412,21:34516442-34615113,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,38.75,0.02,1.07,04/27/2012
G,RDX,HGNC:9944,11q22.3,11:110045647-110167339,11:110174922-110296614,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 24",MONDO:0012602,"0 (No Evidence)",'-,'-,,,8.08,0.85,0.35,08/22/2016
G,RELN,HGNC:9957,7q22.1,7:103112236-103630105,7:103471789-103989658,"0 (No Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,1.1,1,0.18,12/14/2023
G,RET,HGNC:9967,10q11.21,10:43572517-43625799,10:43077069-43130351,"3 (Sufficient Evidence)","Hirschsprung disease, susceptibility to, 1",MONDO:0007723,"0 (No Evidence)",'-,'-,,,1.58,1,0.12,08/26/2020
G,RETREG1,HGNC:25964,5p15.1,5:16473162-16617106,5:16473053-16616997,"30 (Autosomal Recessive)","neuropathy, hereditary sensory and autonomic, type 2B",MONDO:0013142,"0 (No Evidence)",'-,'-,,,47.64,0,0.86,08/22/2016
G,RFX6,HGNC:21478,6q22.1,6:117198405-117253324,6:116877242-116932161,"30 (Autosomal Recessive)","hypoplastic pancreas-intestinal atresia-hypoplastic gallbalder syndrome",MONDO:0017400,"0 (No Evidence)",'-,'-,,,28.8,0,0.47,09/18/2015
G,RIMS1,HGNC:17282,6q13,6:72596253-73112847,6:71886550-72403145,"1 (Little Evidence)","autism spectrum disorder",MONDO:0005258,"0 (No Evidence)",'-,'-,,,9.51,0.99,0.29,01/24/2018
G,RIN2,HGNC:18750,20p11.23,20:19738902-19983100,20:19757599-20002456,"30 (Autosomal Recessive)","RIN2 syndrome",MONDO:0013115,"Not Yet Evaluated",'-,'-,,,39.64,0,0.55,08/22/2016
G,RIPK4,HGNC:496,21q22.3,21:43159533-43187212,21:41739373-41767052,"30 (Autosomal Recessive)","Bartsocas-Papas syndrome 1",MONDO:0009901,"0 (No Evidence)",'-,'-,,,43.77,0,0.59,08/22/2016
G,RMND1,HGNC:21176,6q25.1,6:151725897-151773261,6:151404762-151452126,"30 (Autosomal Recessive)","combined oxidative phosphorylation defect type 11",MONDO:0013969,"0 (No Evidence)",'-,'-,,,36.01,0,1.11,08/22/2016
G,RMRP,HGNC:10031,9p13.3,9:35657748-35658015,9:35657750-35658019,"30 (Autosomal Recessive)","cartilage-hair hypoplasia",MONDO:0009595,"Not Yet Evaluated",'-,'-,,,‐,‐,‐,08/22/2016
G,RNASEH2A,HGNC:18518,19p13.13,19:12917398-12924454,19:12806584-12813640,"30 (Autosomal Recessive)","Aicardi-Goutieres syndrome 4",MONDO:0012472,"Not Yet Evaluated",'-,'-,,,3.39,0,0.88,08/22/2016
G,RNF135,HGNC:21158,17q11.2,17:29298057-29326929,17:30958921-30999911,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,90.13,0,1.44,09/22/2021
G,RNF168,HGNC:26661,3q29,3:196195654-196230639,3:196468783-196503768,"30 (Autosomal Recessive)","RIDDLE syndrome",MONDO:0012764,"0 (No Evidence)",'-,'-,,,69.55,0,1.2,08/22/2016
G,RNF32,HGNC:17118,7q36.3,7:156433468-156469824,7:156640204-156677130,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,75.12,0,1.54,02/02/2021
G,ROBO1,HGNC:10249,3p12.3,3:78646389-79817148,3:78597239-79767998,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,3.33,0,0.6,09/25/2018
G,ROBO3,HGNC:13433,11q24.2,11:124735328-124751367,11:124865432-124881471,"30 (Autosomal Recessive)","gaze palsy, familial horizontal, with progressive scoliosis 1",MONDO:0020790,"0 (No Evidence)",'-,'-,,,48.29,0,0.71,08/22/2016
G,ROGDI,HGNC:29478,16p13.3,16:4846969-4852634,16:4796968-4802633,"30 (Autosomal Recessive)","amelocerebrohypohidrotic syndrome",MONDO:0009185,"0 (No Evidence)",'-,'-,,,47.95,0,1.42,02/12/2015
G,ROR2,HGNC:10257,9q22.31,9:94484883-94712510,9:91722601-91950228,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,53.78,0,0.56,03/27/2013
G,RP2,HGNC:10274,Xp11.3,X:46696478-46741793,X:46837043-46882358,"3 (Sufficient Evidence)","retinitis pigmentosa 2",MONDO:0010723,"0 (No Evidence)",'-,'-,,,33.66,0.96,0.31,10/04/2012
G,RPE65,HGNC:10294,1p31.3,1:68894505-68915637,1:68428822-68449954,"30 (Autosomal Recessive)","RPE65-related recessive retinopathy",MONDO:0100368,"0 (No Evidence)",'-,'-,,,17.78,0,1.11,01/09/2024
G,RPGRIP1,HGNC:13436,14q11.2,14:21748242-21819460,14:21280083-21351301,"30 (Autosomal Recessive)","Leber congenital amaurosis 6",MONDO:0013446,"0 (No Evidence)",'-,'-,,,59.78,0,0.88,08/22/2016
G,RPH3A,HGNC:17056,12q24.13,12:113013040-113336686,12:112575236-112898881,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,42.44,0,0.47,07/25/2018
G,RPL10,HGNC:10298,Xq28,X:153626406-153630680,X:154398065-154402339,"0 (No Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,36.48,0.91,0.39,10/24/2018
G,RPL15,HGNC:10306,3p24.2,3:23958036-23966122,3:23916545-23924631,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,21.68,0.97,0.27,07/16/2014
G,RPS17,HGNC:10397,15q25.2,15:83205501-83209208,15:82536750-82540457,"3 (Sufficient Evidence)","Diamond-Blackfan anemia 4",MONDO:0012924,"0 (No Evidence)",'-,'-,,,60.09,0.33,1.85,12/10/2015
G,RPS19,HGNC:10402,19q13.2,19:42364325-42376993,19:41860255-41872925,"3 (Sufficient Evidence)","Diamond-Blackfan anemia 1",MONDO:0007110,"0 (No Evidence)",'-,'-,,,23.95,0.92,0.37,03/24/2021
G,RPS24,HGNC:10411,10q22.3,10:79793621-79816564,10:78033863-78056806,"3 (Sufficient Evidence)","Diamond-Blackfan anemia 3",MONDO:0012529,"0 (No Evidence)",'-,'-,,,22.8,0.68,0.59,10/23/2019
G,RPS26,HGNC:10414,12q13.2,12:56435702-56438481,12:56041918-56044697,"3 (Sufficient Evidence)","Diamond-Blackfan anemia 10",MONDO:0013217,"0 (No Evidence)",'-,'-,,,45.57,0.85,0.48,10/23/2019
G,RPS6KA3,HGNC:10432,Xp22.12,X:20168029-20285027,X:20149911-20267097,"3 (Sufficient Evidence)","Coffin-Lowry syndrome",MONDO:0010561,"0 (No Evidence)",'-,'-,,,4.88,1,0.09,06/14/2022
G,RS1,HGNC:10457,Xp22.13,X:18657808-18690228,X:18639688-18672108,"3 (Sufficient Evidence)","X-linked retinoschisis",MONDO:0010725,"0 (No Evidence)",'-,'-,,,28.71,0.96,0.3,08/02/2021
G,RSPH1,HGNC:12371,21q22.3,21:43892596-43916334,21:42472486-42496224,"30 (Autosomal Recessive)","primary ciliary dyskinesia 24",MONDO:0014202,"Not Yet Evaluated",'-,'-,,,83.46,0,0.99,08/22/2016
G,RSPH4A,HGNC:21558,6q22.1,6:116937642-116954148,6:116616479-116632985,"30 (Autosomal Recessive)","primary ciliary dyskinesia 11",MONDO:0012978,"Not Yet Evaluated",'-,'-,,,69.78,0,0.94,08/22/2016
G,RSPO4,HGNC:16175,20p13,20:939095-982954,20:958452-1002311,"30 (Autosomal Recessive)","nonsyndromic congenital nail disorder 4",MONDO:0008798,"Not Yet Evaluated",'-,'-,,,64.82,0,1.59,08/22/2016
G,RTTN,HGNC:18654,18q22.2,18:67670267-67872923,18:70003031-70205687,"30 (Autosomal Recessive)","bilateral generalized polymicrogyria",MONDO:0013907,"Not Yet Evaluated",'-,'-,,,64.2,0,0.74,08/22/2016
G,RUNX1,HGNC:10471,21q22.12,21:36160098-36421599,21:34787801-35049302,"3 (Sufficient Evidence)","hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1",MONDO:0100083,"0 (No Evidence)",'-,'-,,,0.45,0.65,0.44,06/14/2023
G,RXFP2,HGNC:17318,13q13.1,13:32313663-32377526,13:31739526-31803389,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,32.97,0,1,07/06/2012
G,RYR1,HGNC:10483,19q13.2,19:38924331-39078204,19:38433691-38587564,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,15.43,0,0.46,11/12/2015
G,RYR2,HGNC:10484,1q43,1:237205484-237997288,1:237042184-237833988,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,14.03,1,0.25,11/06/2015
G,SACS,HGNC:10519,13q12.12,13:23902969-24007841,13:23328830-23433702,"30 (Autosomal Recessive)","Charlevoix-Saguenay spastic ataxia",MONDO:0010041,"0 (No Evidence)",'-,'-,,,35.26,0,0.54,08/22/2016
G,SALL1,HGNC:10524,16q12.1,16:51169893-51185181,16:51135982-51152334,"1 (Little Evidence)","Townes-Brocks syndrome 1",MONDO:0054581,"0 (No Evidence)",'-,'-,,,5.63,1,0.2,01/27/2021
G,SALL4,HGNC:15924,20q13.2,20:50398870-50419060,20:51782331-51802521,"3 (Sufficient Evidence)","Duane-radial ray syndrome",MONDO:0011812,"0 (No Evidence)",'-,'-,,,38.01,1,0.1,01/11/2021
G,SAMD9,HGNC:1348,7q21.2,7:92728831-92747292,7:93099518-93117979,"30 (Autosomal Recessive)","normophosphatemic familial tumoral calcinosis",MONDO:0012502,"Not Yet Evaluated",'-,'-,,,77.6,0,1.24,08/22/2016
G,SATB2,HGNC:21637,2q33.1,2:200134223-200335989,2:199269500-199471266,"3 (Sufficient Evidence)","SATB2 associated disorder",MONDO:0100147,"0 (No Evidence)",'-,'-,,,1.6,1,0.09,07/15/2020
G,SBF2,HGNC:2135,11p15.4,11:9800215-10315766,11:9778668-10303837,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 4B2",MONDO:0011475,"Not Yet Evaluated",'-,'-,,,9.49,0,0.47,08/22/2016
G,SCARB2,HGNC:1665,4q21.1,4:77079890-77134977,4:76158737-76234532,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,24.43,0,0.72,07/06/2012
G,SCARF2,HGNC:19869,22q11.21,22:20778874-20792112,22:20424584-20437825,"30 (Autosomal Recessive)","van den Ende-Gupta syndrome",MONDO:0010959,"0 (No Evidence)",'-,'-,,,70.17,1,0.19,08/22/2016
G,SCN1A,HGNC:10585,2q24.3,2:166841151-167005671,2:165984641-166149161,"3 (Sufficient Evidence)","developmental and epileptic encephalopathy, 6",MONDO:0100079,"0 (No Evidence)",'-,'-,,,9.08,1,0.07,07/06/2012
G,SCN1B,HGNC:10586,19q13.11,19:35521374-35531353,19:35030470-35040449,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.18,0.1,1.27,09/04/2019
G,SCN2A,HGNC:10588,2q24.3,2:166095924-166248814,2:165239414-165392304,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,4.08,1,0.13,04/22/2020
G,SCN5A,HGNC:10593,3p22.2,3:38589553-38691178,3:38548062-38649687,"3 (Sufficient Evidence)","Brugada syndrome 1",MONDO:0011001,"0 (No Evidence)",'-,'-,,,15.55,0.91,0.31,06/08/2021
G,SCN8A,HGNC:10596,12q13.13,12:51985017-52206648,12:51591233-51812864,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,5.53,1,0.13,02/14/2023
G,SDCCAG8,HGNC:10671,1q43-q44,1:243419343-243663393,1:243256041-243500091,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 16",MONDO:0014444,"0 (No Evidence)",'-,'-,,,19.89,0,0.78,08/22/2016
G,SDHAF1,HGNC:33867,19q13.12,19:36486090-36487214,19:35995188-35996312,"30 (Autosomal Recessive)","mitochondrial complex II deficiency, nuclear type 1",MONDO:0100294,"0 (No Evidence)",'-,'-,,,74.19,0.09,1.9,08/22/2016
G,SDHAF2,HGNC:26034,11q12.2,11:61197596-61214205,11:61430124-61446733,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,7.74,0,1.81,05/11/2022
G,SDHB,HGNC:10681,1p36.13,1:17345217-17380527,1:17018722-17054032,"3 (Sufficient Evidence)","hereditary pheochromocytoma-paraganglioma",MONDO:0017366,"0 (No Evidence)",'-,'-,,,11.22,0,0.83,07/22/2020
G,SDHC,HGNC:10682,1q23.3,1:161284171-161345130,1:161314381-161363206,"3 (Sufficient Evidence)","paragangliomas 3",MONDO:0011544,"0 (No Evidence)",'-,'-,,,47.07,0,1.26,10/13/2021
G,SDHD,HGNC:10683,11q23.1,11:111957597-111966518,11:112086873-112095794,"3 (Sufficient Evidence)","paragangliomas 1",MONDO:0008192,"0 (No Evidence)",'-,'-,,,39.67,0.34,0.73,08/11/2021
G,SDR42E1,HGNC:29834,16q23.3,16:82022460-82045075,16:81988855-82011470,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,72.19,0,1.86,02/02/2021
G,SEC14L4,HGNC:20627,22q12.2,22:30884889-30901682,22:30488902-30505695,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,74.07,0,1.13,02/02/2021
G,SEC23B,HGNC:10702,20p11.23,20:18488192-18542059,20:18507548-18561415,"30 (Autosomal Recessive)","congenital dyserythropoietic anemia type 2",MONDO:0009134,"0 (No Evidence)",'-,'-,,,45.77,0,0.98,08/22/2016
G,SEM1,HGNC:10845,7q21.3,7:96110938-96339158,7:96481626-96709846,"0 (No Evidence)","split hand-foot malformation 1 with sensorineural hearing loss",MONDO:0009080,"0 (No Evidence)",'-,'-,,,7.71,0.02,1.53,05/14/2012
G,SEMA3A,HGNC:10723,7q21.11,7:83585093-83824105,7:83955777-84492725,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.46,0.98,0.31,08/07/2017
G,SEPSECS,HGNC:30605,4p15.2,4:25121636-25162071,4:25120014-25160582,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 2D",MONDO:0013438,"Not Yet Evaluated",'-,'-,,,34.9,0,0.99,08/22/2016
G,SERAC1,HGNC:21061,6q25.3,6:158530551-158589294,6:158109519-158168262,"30 (Autosomal Recessive)","3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome",MONDO:0013875,"Not Yet Evaluated",'-,'-,,,61.2,0,0.63,08/22/2016
G,SERPINA1,HGNC:8941,14q32.13,14:94843084-94856972,14:94376747-94390635,"30 (Autosomal Recessive)","alpha 1-antitrypsin deficiency",MONDO:0013282,"0 (No Evidence)",'-,'-,,,88.1,0,1.63,05/09/2017
G,SERPINB6,HGNC:8950,6p25.2,6:2948393-2972027,6:2948159-2971793,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 91",MONDO:0013269,"0 (No Evidence)",'-,'-,,,69,0,1.12,08/22/2016
G,SERPINB7,HGNC:13902,18q21.33,18:61420291-61472604,18:63753057-63805370,"30 (Autosomal Recessive)","palmoplantar keratoderma, Nagashima type",MONDO:0014272,"0 (No Evidence)",'-,'-,,,63.85,0,1.31,11/13/2014
G,SERPINE1,HGNC:8583,7q22.1,7:100770385-100782528,7:101127104-101139247,"30 (Autosomal Recessive)","congenital plasminogen activator inhibitor type 1 deficiency",MONDO:0013227,"Not Yet Evaluated",'-,'-,,,6.47,0.04,0.69,08/22/2016
G,SERPINF1,HGNC:8824,17p13.3,17:1665354-1680859,17:1762060-1777565,"30 (Autosomal Recessive)","osteogenesis imperfecta type 6",MONDO:0013515,"Not Yet Evaluated",'-,'-,,,32.9,0,1.21,08/22/2016
G,SETBP1,HGNC:15573,18q12.3,18:42260038-42648475,18:44680073-45068510,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 29",MONDO:0014482,"0 (No Evidence)",'-,'-,,,4.67,1,0.11,05/23/2018
G,SETD1A,HGNC:29010,16p11.2,16:30969075-30995985,16:30957754-30984664,"3 (Sufficient Evidence)",schizophrenia,MONDO:0005090,"0 (No Evidence)",'-,'-,,,12.55,1,0.14,02/28/2018
G,SETD2,HGNC:18420,3p21.31,3:47057926-47205603,3:47016436-47164840,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,8.64,1,0.21,03/08/2022
G,SETD5,HGNC:25566,3p25.3,3:9439299-9519838,3:9397615-9478154,"3 (Sufficient Evidence)","intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency",MONDO:0014336,"0 (No Evidence)",'-,'-,,,12.88,1,0.23,11/06/2014
G,SF3B4,HGNC:10771,1q21.2,1:149895209-149899695,1:149923317-149927803,"3 (Sufficient Evidence)","Nager acrofacial dysostosis",MONDO:0007943,"0 (No Evidence)",'-,'-,,,25.11,0.99,0.21,07/17/2014
G,SGCE,HGNC:10808,7q21.3,7:94214292-94285445,7:94584980-94656133,"3 (Sufficient Evidence)","myoclonic dystonia 11",MONDO:0008044,"0 (No Evidence)",'-,'-,,,13.27,0.02,0.54,11/11/2021
G,SGCG,HGNC:10809,13q12.12,13:23734647-23899301,13:23160508-23325162,"30 (Autosomal Recessive)","autosomal recessive limb-girdle muscular dystrophy type 2C",MONDO:0009677,"0 (No Evidence)",'-,'-,,,55.59,0,1.05,08/22/2016
G,SGSH,HGNC:10818,17q25.3,17:78183075-78194132,17:80200673-80220333,"30 (Autosomal Recessive)","mucopolysaccharidosis type 3A",MONDO:0009655,"0 (No Evidence)",'-,'-,,,69.12,0,0.8,02/12/2015
G,SH2B1,HGNC:30417,16p11.2,16:28857927-28885526,16:28846606-28874205,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,32.53,0.97,0.32,07/13/2021
G,SH2D1A,HGNC:10820,Xq25,X:123480413-123507010,X:124346563-124373160,"3 (Sufficient Evidence)","X-linked lymphoproliferative disease due to SH2D1A deficiency",MONDO:0024551,"0 (No Evidence)",'-,'-,,,11.82,0.39,0.96,01/27/2021
G,SH3TC2,HGNC:29427,5q32,5:148361713-148442625,5:148982150-149063062,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 4C",MONDO:0011113,"Not Yet Evaluated",'-,'-,,,47.72,0,0.81,08/22/2016
G,SHANK1,HGNC:15474,19q13.33,19:51162512-51223059,19:50659255-50719802,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,76.11,1,0.18,03/27/2019
G,SHANK2,HGNC:14295,11q13.3-q13.4,11:70313959-70963623,11:70467854-71253228,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,45.57,0,0.46,10/26/2023
G,SHANK3,HGNC:14294,22q13.33,22:51111251-51171640,22:50672823-50733212,"3 (Sufficient Evidence)","Phelan-McDermid syndrome",MONDO:0011652,"0 (No Evidence)",'-,'-,,,60.1,1,0.12,08/14/2018
G,SHH,HGNC:10848,7q36.3,7:155592674-155605157,7:155799980-155812463,"3 (Sufficient Evidence)","holoprosencephaly 3",MONDO:0007733,"0 (No Evidence)",'-,'-,,,0.66,0.98,0.24,06/24/2020
G,SHOC2,HGNC:15454,10q25.2,10:112679128-112773423,10:110919370-111013665,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.7,1,0.14,09/25/2018
G,SHOX,HGNC:10853,"Xp22.33 and Yp11.32",Y:535079-570146,Y:624344-659411,"3 (Sufficient Evidence)","Leri-Weill dyschondrosteosis",MONDO:0007481,"0 (No Evidence)",'-,'-,,,76.05,0.67,0.52,10/15/2015
G,SHROOM4,HGNC:29215,Xp11.22,X:50334642-50557194,X:50575534-50814194,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,44.15,1,0.23,10/10/2012
G,SI,HGNC:10856,3q26.1,3:164696686-164796284,3:164978898-165157921,"30 (Autosomal Recessive)","congenital sucrase-isomaltase deficiency",MONDO:0009114,"Not Yet Evaluated",'-,'-,,,61.91,0,1.04,08/22/2016
G,SIGLEC5,HGNC:10874,19q13.41,19:52114213-52133654,19:51610960-51630401,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,97.84,0,0.98,02/02/2021
G,SIL1,HGNC:24624,5q31.2,5:138282413-138534057,5:138946724-139198368,"30 (Autosomal Recessive)","Marinesco-Sjogren syndrome",MONDO:0009567,"Not Yet Evaluated",'-,'-,,,17.56,0.01,0.64,08/23/2021
G,SIM1,HGNC:10882,6q16.3,6:100832885-100912797,6:100385009-100464921,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,2.5,1,0.25,04/25/2012
G,SIN3A,HGNC:19353,15q24.2,15:75661720-75748156,15:75369379-75455815,"3 (Sufficient Evidence)","chromosome 15q24 deletion syndrome",MONDO:0013256,"0 (No Evidence)",'-,'-,,,7.32,1,0.07,01/13/2020
G,SIX1,HGNC:10887,14q23.1,14:61110139-61116195,14:60643421-60649477,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.35,0.65,0.52,03/22/2012
G,SIX3,HGNC:10889,2p21,2:45168841-45173210,2:44941702-44946071,"3 (Sufficient Evidence)","holoprosencephaly 2",MONDO:0007999,"0 (No Evidence)",'-,'-,,,12.2,0.95,0.32,09/23/2020
G,SIX4,HGNC:10890,14q23.1,14:61176257-61191069,14:60709539-60724351,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,18.53,0.69,0.43,05/08/2012
G,SIX6,HGNC:10892,14q23.1,14:60975864-60979568,14:60509146-60512850,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.88,0.52,0.6,03/22/2012
G,SKI,HGNC:10896,1p36.33-p36.32,1:2159758-2241652,1:2228319-2310213,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,34.04,1,0.19,01/06/2012
G,SKIC3,HGNC:23639,5q15,5:94799598-94890681,5:95463894-95554977,"30 (Autosomal Recessive)","trichohepatoenteric syndrome 1",MONDO:0024541,"Not Yet Evaluated",'-,'-,,,22.59,0,0.78,08/22/2016
G,SLC12A1,HGNC:10910,15q21.1,15:48498499-48596275,15:48206302-48304078,"30 (Autosomal Recessive)","Bartter disease type 1",MONDO:0100344,"0 (No Evidence)",'-,'-,,,10.66,0,0.82,04/28/2012
G,SLC12A3,HGNC:10912,16q13,16:56899119-56949762,16:56865207-56915850,"30 (Autosomal Recessive)","Gitelman syndrome",MONDO:0009904,"0 (No Evidence)",'-,'-,,,41.42,0,1.2,02/23/2012
G,SLC13A5,HGNC:23089,17p13.1,17:6588038-6616688,17:6684719-6713369,"30 (Autosomal Recessive)","developmental and epileptic encephalopathy, 25",MONDO:0014392,"0 (No Evidence)",'-,'-,,,66.88,0,0.67,08/22/2016
G,SLC16A12,HGNC:23094,10q23.31,10:91190056-91295351,10:89430299-89556704,"1 (Little Evidence)","juvenile cataract-microcornea-renal glucosuria syndrome",MONDO:0012786,"0 (No Evidence)",'-,'-,,,29.69,0.49,0.48,12/21/2011
G,SLC16A2,HGNC:10923,Xq13.2,X:73641328-73753751,X:74421493-74533916,"3 (Sufficient Evidence)","Allan-Herndon-Dudley syndrome",MONDO:0010354,"0 (No Evidence)",'-,'-,,,25.73,0.99,0.22,06/28/2012
G,SLC17A5,HGNC:10933,6q13,6:74303102-74363715,6:73593379-73653992,"30 (Autosomal Recessive)","free sialic acid storage disease",MONDO:0019366,"0 (No Evidence)",'-,'-,,,19.72,0,1.04,08/22/2016
G,SLC17A8,HGNC:20151,12q23.1,12:100750852-100815833,12:100357074-100422055,"1 (Little Evidence)","autosomal dominant nonsyndromic hearing loss",MONDO:0019587,"0 (No Evidence)",'-,'-,,,31.37,0,0.61,02/08/2022
G,SLC22A14,HGNC:8495,3p22.2,3:38323785-38360066,3:38278832-38318575,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,95,0,1.26,02/02/2021
G,SLC22A18,HGNC:10964,11p15.4,11:2920921-2946476,11:2899691-2925246,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,68.74,0,1.16,03/22/2012
G,SLC24A1,HGNC:10975,15q22.31,15:65903688-65953340,15:65611350-65661002,"30 (Autosomal Recessive)","congenital stationary night blindness 1D",MONDO:0013450,"0 (No Evidence)",'-,'-,,,79.17,0,0.57,08/22/2016
G,SLC25A1,HGNC:10979,22q11.21,22:19163094-19166249,22:19175581-19178736,"30 (Autosomal Recessive)","D,L-2-hydroxyglutaric aciduria",MONDO:0014072,"Not Yet Evaluated",'-,'-,,,46.07,0.06,0.65,08/22/2016
G,SLC25A12,HGNC:10982,2q31.1,2:172639915-172750754,2:171783405-171894244,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,9.53,0.22,0.42,01/19/2012
G,SLC25A13,HGNC:10983,7q21.3,7:95749532-95951410,7:96120220-96322098,"30 (Autosomal Recessive)","neonatal intrahepatic cholestasis due to citrin deficiency",MONDO:0011601,"Not Yet Evaluated",'-,'-,,,25.1,0,1.24,08/22/2016
G,SLC25A19,HGNC:14409,17q25.1,17:73269073-73285514,17:75272992-75289433,"30 (Autosomal Recessive)","thiamine-responsive dysfunction syndrome",MONDO:0000152,"0 (No Evidence)",'-,'-,,,55.79,0.65,0.52,08/22/2016
G,SLC2A1,HGNC:11005,1p34.2,1:43391024-43424539,1:42925353-42958868,"3 (Sufficient Evidence)","childhood onset GLUT1 deficiency syndrome 2",MONDO:0012805,"0 (No Evidence)",'-,'-,,,9.56,0.99,0.24,03/24/2016
G,SLC2A10,HGNC:13444,20q13.12,20:45338288-45364986,20:46708320-46736347,"30 (Autosomal Recessive)","arterial tortuosity syndrome",MONDO:0008818,"0 (No Evidence)",'-,'-,,,71.82,0,1.39,02/01/2018
G,SLC30A10,HGNC:25355,1q41,1:220083787-220132440,1:219910445-219959098,"30 (Autosomal Recessive)","cirrhosis - dystonia - polycythemia - hypermanganesemia syndrome",MONDO:0013208,"0 (No Evidence)",'-,'-,,,73.7,0.98,0.25,08/22/2016
G,SLC34A1,HGNC:11019,5q35.3,5:176811435-176825849,5:177384434-177398848,"30 (Autosomal Recessive)","hypercalcemia, infantile, 2",MONDO:0014851,"Not Yet Evaluated",'-,'-,,,55.22,0,1.83,08/22/2016
G,SLC34A2,HGNC:11020,4p15.2,4:25657473-25680370,4:25655851-25678748,"30 (Autosomal Recessive)","pulmonary alveolar microlithiasis",MONDO:0009928,"0 (No Evidence)",'-,'-,,,70.96,0,1.09,08/22/2016
G,SLC35A2,HGNC:11022,Xp11.23,X:48760460-48769235,X:48903183-48911958,"3 (Sufficient Evidence)","SLC35A2-congenital disorder of glycosylation",MONDO:0010478,"0 (No Evidence)",'-,'-,,,32.21,0.72,0.56,01/24/2018
G,SLC35C1,HGNC:20197,11p11.2,11:45825623-45834567,11:45804072-45813016,"30 (Autosomal Recessive)","leukocyte adhesion deficiency type II",MONDO:0009953,"0 (No Evidence)",'-,'-,,,48.28,0.02,0.98,08/22/2016
G,SLC35D1,HGNC:20800,1p31.3,1:67465033-67519831,1:66972976-67054148,"30 (Autosomal Recessive)","schneckenbecken dysplasia",MONDO:0010013,"0 (No Evidence)",'-,'-,,,22.91,0,0.78,04/11/2016
G,SLC37A4,HGNC:4061,11q23.3,11:118894822-118901587,11:119024112-119030877,"30 (Autosomal Recessive)","glycogen storage disease I",MONDO:0002413,"0 (No Evidence)",'-,'-,,,31.13,0,0.88,08/22/2016
G,SLC38A5,HGNC:18070,Xp11.23,X:48316927-48328648,X:48458544-48470260,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,59.25,0.98,0.3,09/26/2012
G,SLC38A8,HGNC:32434,16q23.3,16:84043272-84076400,16:84009667-84043372,"30 (Autosomal Recessive)","foveal hypoplasia - optic nerve decussation defect - anterior segment dysgenesis syndrome",MONDO:0012216,"0 (No Evidence)",'-,'-,,,68.65,0,1.9,08/22/2016
G,SLC3A1,HGNC:11025,2p21,2:44502619-44548633,2:44275480-44322437,"30 (Autosomal Recessive)",cystinuria,MONDO:0009067,"0 (No Evidence)",'-,'-,,,61.26,0,1.62,03/21/2012
G,SLC4A10,HGNC:13811,2q24.2,2:162480926-162841780,2:161624416-161985270,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.94,0.13,0.38,04/11/2012
G,SLC52A3,HGNC:16187,20p13,20:740724-756628,20:760080-780033,"30 (Autosomal Recessive)","Brown-Vialetto-van Laere syndrome 1",MONDO:0024537,"Not Yet Evaluated",'-,'-,,,68.43,0.02,0.8,08/22/2016
G,SLC5A1,HGNC:11036,22q12.3,22:32439248-32509016,22:32043261-32113029,"30 (Autosomal Recessive)","glucose-galactose malabsorption",MONDO:0011731,"Not Yet Evaluated",'-,'-,,,41.69,0,0.77,08/22/2016
G,SLC6A1,HGNC:11042,3p25.3,3:11034434-11080933,3:10992748-11039247,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,15.39,1,0.15,09/25/2019
G,SLC6A18,HGNC:26441,5p15.33,5:1225496-1246304,5:1225381-1246189,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,69.67,0,1.47,02/02/2021
G,SLC6A3,HGNC:11049,5p15.33,5:1392909-1445555,5:1392794-1445440,"30 (Autosomal Recessive)","classic dopamine transporter deficiency syndrome",MONDO:0054835,"Not Yet Evaluated",'-,'-,,,18.93,1,0.25,08/22/2016
G,SLC6A4,HGNC:11050,17q11.2,17:28521337-28562715,17:30194319-30235697,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.68,0.25,0.43,05/11/2012
G,SLC6A8,HGNC:11055,Xq28,X:152953381-152962048,X:153687926-153696593,"3 (Sufficient Evidence)","creatine transporter deficiency",MONDO:0010305,"0 (No Evidence)",'-,'-,,,22.63,1,0.21,11/10/2020
G,SLC7A7,HGNC:11065,14q11.2,14:23242431-23289000,14:22773222-22819791,"30 (Autosomal Recessive)","lysinuric protein intolerance",MONDO:0009109,"Not Yet Evaluated",'-,'-,,,26.7,0,0.96,08/22/2016
G,SLC7A9,HGNC:11067,19q13.11,19:33321417-33360673,19:32830511-32869767,"30 (Autosomal Recessive)",cystinuria,MONDO:0009067,"0 (No Evidence)",'-,'-,,,61.03,0,1.12,08/23/2021
G,SLC9A6,HGNC:11079,Xq26.3,X:135067594-135129428,X:135973837-136047269,"3 (Sufficient Evidence)","Christianson syndrome",MONDO:0010278,"0 (No Evidence)",'-,'-,,,22.85,1,0.21,12/08/2020
G,SLURP1,HGNC:18746,8q24.3,8:143822367-143823824,8:142740949-142742406,"30 (Autosomal Recessive)","mal de Meleda",MONDO:0009552,"0 (No Evidence)",'-,'-,,,81.26,0.26,1.31,06/08/2017
G,SMAD2,HGNC:6768,18q21.1,18:45335328-45457243,18:47808957-47930872,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.33,1,0.26,06/29/2018
G,SMAD3,HGNC:6769,15q22.33,15:67357940-67487507,15:67065602-67195169,"3 (Sufficient Evidence)","aneurysm-osteoarthritis syndrome",MONDO:0013426,"0 (No Evidence)",'-,'-,,,1.24,0.8,0.4,04/22/2020
G,SMAD4,HGNC:6770,18q21.2,18:48556583-48611412,18:51030213-51085042,"3 (Sufficient Evidence)","juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome",MONDO:0008278,"0 (No Evidence)",'-,'-,,,0.21,1,0.22,12/16/2020
G,SMARCA2,HGNC:11098,9p24.3,9:2015347-2193624,9:2015347-2193624,"0 (No Evidence)","intellectual disability-sparse hair-brachydactyly syndrome",MONDO:0011053,"0 (No Evidence)",'-,'-,,,1.61,1,0.2,03/27/2013
G,SMARCA4,HGNC:11100,19p13.2,19:11071706-11172949,19:10961030-11062273,"2 (Emerging Evidence)","rhabdoid tumor predisposition syndrome 2",MONDO:0013224,"0 (No Evidence)",'-,'-,,,2.95,1,0.06,07/13/2022
G,SMARCB1,HGNC:11103,22q11.23,22:24129153-24180196,22:23786966-23838009,"3 (Sufficient Evidence)","rhabdoid tumor predisposition syndrome 1",MONDO:0012252,"0 (No Evidence)",'-,'-,,,8.07,1,0.22,04/22/2020
G,SMC1A,HGNC:11111,Xp11.22,X:53401070-53449677,X:53374149-53422728,"3 (Sufficient Evidence)","Cornelia de Lange syndrome 2",MONDO:0010370,"0 (No Evidence)",'-,'-,,,14.23,1,0.06,07/23/2018
G,SMOC1,HGNC:20318,14q24.1,14:70346133-70499083,14:69879416-70032366,"30 (Autosomal Recessive)","microphthalmia with limb anomalies",MONDO:0008800,"0 (No Evidence)",'-,'-,,,20.73,0.01,0.59,08/22/2016
G,SMOC2,HGNC:20323,6q27,6:168841864-169068672,6:168441184-168667992,"30 (Autosomal Recessive)","dentin dysplasia type I",MONDO:0007436,"0 (No Evidence)",'-,'-,,,55.41,0,0.62,08/22/2016
G,SMS,HGNC:11123,Xp22.11,X:21958827-22012955,X:21940709-21994837,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Snyder type",MONDO:0010664,"0 (No Evidence)",'-,'-,,,12.45,0.97,0.31,08/23/2012
G,SNAP29,HGNC:11133,22q11.21,22:21213295-21245502,22:20859007-20891214,"30 (Autosomal Recessive)","CEDNIK syndrome",MONDO:0012290,"Not Yet Evaluated",'-,'-,,,61.36,0.01,0.86,08/22/2016
G,SNORD107,HGNC:32771,15q11.2,15:25227141-25227215,15:24981994-24982068,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,04/25/2012
G,SNORD108,HGNC:32772,15q11.2,15:25232072-25232140,15:24986925-24986993,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,07/06/2012
G,SNORD109B,HGNC:32774,15q11.2,15:25523490-25523556,15:25278343-25278409,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,04/28/2012
G,SNORD64,HGNC:32725,15q11.2,15:25230247-25230313,15:24985100-24985166,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,07/06/2012
G,SNORD8,HGNC:20159,14q11.2,14:21865452-21865560,14:21397293-21397401,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/11/2015
G,SNORD9,HGNC:32705,14q11.2,14:21860310-21860412,14:21392151-21392253,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,03/11/2015
G,SNRPN,HGNC:11164,15q11.2,15:25068784-25223870,15:24823637-24978723,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,73,0.04,0.83,10/26/2012
G,SNURF,HGNC:11171,15q11.2,15:25200134-25223870,15:24954987-24978723,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,0.46,0.84,03/28/2023
G,SOBP,HGNC:29256,6q21,6:107811321-107982510,6:107490117-107661306,"30 (Autosomal Recessive)","intellectual disability, anterior maxillary protrusion, and strabismus",MONDO:0013353,"0 (No Evidence)",'-,'-,,,8.51,1,0.13,08/22/2016
G,SON,HGNC:11183,21q22.11,21:34915344-34949787,21:33543038-33577481,"3 (Sufficient Evidence)","ZTTK syndrome",MONDO:0014936,"0 (No Evidence)",'-,'-,,,3.75,1,0.12,04/24/2019
G,SOS1,HGNC:11187,2p22.1,2:39208690-39352009,2:38981549-39124868,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.03,1,0.14,03/30/2012
G,SOST,HGNC:13771,17q21.31,17:41831106-41836159,17:43753738-43758791,"30 (Autosomal Recessive)","sclerosteosis 1",MONDO:0010016,"0 (No Evidence)",'-,'-,,,25.59,0.87,0.45,08/22/2012
G,SOX10,HGNC:11190,22q13.1,22:38368319-38380562,22:37972312-37984555,"3 (Sufficient Evidence)","Waardenburg syndrome type 4C",MONDO:0013202,"0 (No Evidence)",'-,'-,,,2.77,0.99,0.21,07/18/2013
G,SOX11,HGNC:11191,2p25.2,2:5832516-5841517,2:5692384-5701385,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 27",MONDO:0014376,"0 (No Evidence)",'-,'-,,,20.02,0.86,0.44,03/16/2017
G,SOX2,HGNC:11195,3q26.33,3:181429713-181432224,3:181711925-181714436,"3 (Sufficient Evidence)","anophthalmia/microphthalmia-esophageal atresia syndrome",MONDO:0008799,"0 (No Evidence)",'-,'-,,,0.54,0.71,0.57,07/06/2012
G,SOX3,HGNC:11199,Xq27.1,X:139585150-139587234,X:140502985-140505069,"0 (No Evidence)",'-,'-,"2 (Emerging Evidence)","intellectual disability, X-linked, with panhypopituitarism",MONDO:0010252,,,7.65,0.45,0.86,01/10/2023
G,SOX5,HGNC:11201,12p12.1,12:23682438-24715425,12:23529504-24562650,"3 (Sufficient Evidence)","Lamb-Shaffer syndrome",MONDO:0014778,"0 (No Evidence)",'-,'-,,,0.74,1,0.19,08/19/2016
G,SOX6,HGNC:16421,11p15.2,11:15987995-16760024,11:15966449-16738477,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.59,1,0.22,03/22/2012
G,SOX8,HGNC:11203,16p13.3,16:1031770-1036979,16:981770-986979,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,50.08,0.67,0.51,02/22/2012
G,SOX9,HGNC:11204,17q24.3,17:70117161-70122557,17:72121020-72126416,"3 (Sufficient Evidence)","campomelic dysplasia",MONDO:0007251,"0 (No Evidence)",'-,'-,,,0.56,1,0.17,05/10/2023
R,"SOX9 upstream enhancer region",ISCA-46303,17q24.3,17:67892996-69792434,"17:69896855 -71796293","3 (Sufficient Evidence)","Cooks syndrome",MONDO:0007134,"1 (Little Evidence)","isolated Pierre-Robin syndrome",MONDO:0009869,,,‐,‐,‐,06/07/2021
G,SPAST,HGNC:11233,2p22.3,2:32288625-32382706,2:32063556-32157637,"3 (Sufficient Evidence)","hereditary spastic paraplegia 4",MONDO:0008438,"0 (No Evidence)",'-,'-,,,9.51,1,0.22,09/25/2019
G,SPATA7,HGNC:20423,14q31.3,14:88852001-88904804,14:88385657-88470350,"30 (Autosomal Recessive)","Leber congenital amaurosis 3",MONDO:0011415,"0 (No Evidence)",'-,'-,,,75.54,0,1.15,08/22/2016
G,SPEG,HGNC:16901,2q35,2:220299565-220358351,2:219434843-219493629,"30 (Autosomal Recessive)","myopathy, centronuclear, 5",MONDO:0014418,"0 (No Evidence)",'-,'-,,,37.41,0.92,0.29,08/22/2016
G,SPEN,HGNC:17575,1p36.21-p36.13,1:16174202-16266951,1:15847707-15940456,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,5.51,1,0.07,03/27/2019
G,SPG21,HGNC:20373,15q22.31,15:65255363-65282252,15:64963022-64989914,"30 (Autosomal Recessive)","mast syndrome",MONDO:0009568,"Not Yet Evaluated",'-,'-,,,18.22,0,0.83,08/22/2016
G,SPG7,HGNC:11237,16q24.3,16:89574796-89624176,16:89508388-89557768,"30 (Autosomal Recessive)","hereditary spastic paraplegia 7",MONDO:0011803,"Not Yet Evaluated",'-,'-,,,61.82,0,1.65,08/22/2016
G,SPINK1,HGNC:11244,5q32,5:147204145-147218759,5:147824582-147839196,"3 (Sufficient Evidence)","hereditary chronic pancreatitis",MONDO:0008185,"0 (No Evidence)",'-,'-,,,90,0.31,1.13,10/25/2021
G,SPINK5,HGNC:15464,5q32,5:147443543-147516945,5:148063980-148137382,"30 (Autosomal Recessive)","Netherton syndrome",MONDO:0009735,"Not Yet Evaluated",'-,'-,,,69.56,0,0.93,08/22/2016
G,SPP2,HGNC:11256,2q37.1,2:234959346-234985778,2:234050702-234077134,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,87.97,0,1.89,02/27/2019
G,SPRED1,HGNC:20249,15q14,15:38545037-38649450,15:38252836-38357249,"3 (Sufficient Evidence)","Legius syndrome",MONDO:0012669,"0 (No Evidence)",'-,'-,,,13.12,0.97,0.32,03/14/2013
G,SRCAP,HGNC:16974,16p11.2,16:30710492-30752730,16:30699171-30741409,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,34.43,1,0.1,05/31/2018
G,SRD5A2,HGNC:11285,2p23.1,2:31747550-31806007,2:31522480-31663009,"30 (Autosomal Recessive)","46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency",MONDO:0009923,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/22/2012
G,SRPX2,HGNC:30668,Xq22.1,X:99899196-99930785,X:100644199-100675788,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,16.71,0.05,0.54,07/25/2012
G,SRRM2,HGNC:16639,16p13.3,16:2802639-2821413,16:2752638-2771412,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,19.08,1,0.12,02/13/2024
G,SRY,HGNC:11311,Yp11.2,Y:2654896-2655723,Y:2786855-2787682,"3 (Sufficient Evidence)","46,XY sex reversal 1",MONDO:0020712,"0 (No Evidence)",'-,'-,,,37.61,0,0,12/22/2020
G,ST14,HGNC:11344,11q24.3,11:130029677-130080257,11:130159782-130210362,"30 (Autosomal Recessive)","autosomal recessive congenital ichthyosis 11",MONDO:0011218,"0 (No Evidence)",'-,'-,,,62.79,0.56,0.38,08/22/2016
G,ST3GAL5,HGNC:10872,2p11.2,2:86064243-86116157,2:85837120-85889034,"30 (Autosomal Recessive)","GM3 synthase deficiency",MONDO:0018274,"0 (No Evidence)",'-,'-,,,63.29,0,0.76,09/25/2014
G,STAG2,HGNC:11355,Xq25,X:123094410-123236506,X:123960560-124102656,"3 (Sufficient Evidence)","X-linked syndromic intellectual disability",MONDO:0020119,"0 (No Evidence)",'-,'-,,,9.67,1,0.09,01/25/2023
G,STARD9,HGNC:19162,15q15.2,15:42867804-43013196,15:42575606-42720998,"0 (No Evidence)",'-,'-,"Not Yet Evaluated",'-,'-,,,70.17,0,0.63,10/10/2023
G,STAT1,HGNC:11362,2q32.2,2:191833875-191878897,2:190969149-191014171,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.02,1,0.19,09/18/2013
G,STIL,HGNC:10879,1p33,1:47715811-47780568,1:47250139-47314896,"30 (Autosomal Recessive)","microcephaly 7, primary, autosomal recessive",MONDO:0012989,"Not Yet Evaluated",'-,'-,,,31.88,0.2,0.38,08/22/2016
G,STK11,HGNC:11389,19p13.3,19:1205777-1228430,19:1205778-1228431,"3 (Sufficient Evidence)","Peutz-Jeghers syndrome",MONDO:0008280,"0 (No Evidence)",'-,'-,,,15.32,0.99,0.25,11/10/2021
G,STRC,HGNC:16035,15q15.3,15:43891761-43910998,15:43599563-43618800,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 16",MONDO:0011364,"Not Yet Evaluated",'-,'-,,,40.85,0,0.88,08/22/2016
G,STS,HGNC:11425,Xp22.31,X:7065331-7272682,X:7147290-7354641,"3 (Sufficient Evidence)","recessive X-linked ichthyosis",MONDO:0010622,"0 (No Evidence)",'-,'-,,,40.89,0.81,0.44,09/14/2018
G,STT3A,HGNC:6172,11q24.2,11:125462747-125492986,11:125591769-125623091,"30 (Autosomal Recessive)","STT3A-congenital disorder of glycosylation",MONDO:0014270,"0 (No Evidence)",'-,'-,,,5.47,0,0.49,08/29/2014
G,STUB1,HGNC:11427,16p13.3,16:730410-732801,16:680410-682801,"30 (Autosomal Recessive)","autosomal recessive spinocerebellar ataxia 16",MONDO:0014339,"Not Yet Evaluated",'-,'-,,,25.33,0.02,0.68,08/22/2016
G,STX11,HGNC:11429,6q24.2,6:144471654-144513076,6:144139963-144191939,"30 (Autosomal Recessive)","familial hemophagocytic lymphohistiocytosis 4",MONDO:0011336,"Not Yet Evaluated",'-,'-,,,37.4,0,1.38,08/22/2016
G,STXBP1,HGNC:11444,9q34.11,9:130374191-130458308,9:127611912-127696029,"3 (Sufficient Evidence)","developmental and epileptic encephalopathy, 4",MONDO:0012812,"0 (No Evidence)",'-,'-,,,21.32,1,0.09,06/20/2013
G,SUCLG1,HGNC:11449,2p11.2,2:84650652-84686404,2:84423528-84459280,"30 (Autosomal Recessive)","mitochondrial DNA depletion syndrome 9",MONDO:0009504,"0 (No Evidence)",'-,'-,,,4.91,0,0.88,08/22/2016
G,SUMF1,HGNC:20376,3p26.1,3:4402830-4508953,3:4034486-4467269,"30 (Autosomal Recessive)",mucosulfatidosis,MONDO:0010088,"0 (No Evidence)",'-,'-,,,29.81,0,1.07,08/22/2016
G,SUPT16H,HGNC:11465,14q11.2,14:21819635-21852178,14:21351476-21384019,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,22.56,1,0.12,05/09/2012
G,SURF1,HGNC:11474,9q34.2,9:136218613-136223363,9:133351758-133356487,"30 (Autosomal Recessive)","Leigh syndrome",MONDO:0009723,"Not Yet Evaluated",'-,'-,,,65.94,0,1.72,08/22/2016
G,SUZ12,HGNC:17101,17q11.2,17:30264026-30328057,17:31937007-32001038,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,3.13,1,0.13,07/06/2012
G,SYN1,HGNC:11494,Xp11.3-p11.23,X:47431300-47479256,X:47571901-47619857,"3 (Sufficient Evidence)","X-linked complex neurodevelopmental disorder",MONDO:0100148,"0 (No Evidence)",'-,'-,,,9.89,0.99,0.25,07/12/2022
G,SYNE4,HGNC:26703,19q13.12,19:36494209-36499715,19:36003307-36008813,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 76",MONDO:0014237,"0 (No Evidence)",'-,'-,,,81.2,0,1.29,08/22/2016
G,SYNGAP1,HGNC:11497,6p21.32,6:33387842-33421466,6:33418167-33453689,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,19.65,1,0.05,11/09/2021
G,SYP,HGNC:11506,Xp11.23,X:49044268-49056652,X:49187815-49200193,"1 (Little Evidence)","intellectual disability, X-linked 96",MONDO:0010429,"0 (No Evidence)",'-,'-,,,3.93,0.92,0.39,09/26/2018
G,SYT14,HGNC:23143,1q32.2,1:210111562-210344734,1:209938217-210171389,"30 (Autosomal Recessive)","autosomal recessive spinocerebellar ataxia 11",MONDO:0013645,"Not Yet Evaluated",'-,'-,,,18.2,0.94,0.34,08/22/2016
G,TAB2,HGNC:17075,6q25.1,6:149539062-149732743,6:149217926-149411607,"1 (Little Evidence)","congenital heart defects, multiple types, 2",MONDO:0014000,"0 (No Evidence)",'-,'-,,,5.38,1,0.1,05/27/2020
G,TACSTD2,HGNC:11530,1p32.1,1:59041105-59042924,1:58575433-58577252,"30 (Autosomal Recessive)","gelatinous drop-like corneal dystrophy",MONDO:0008777,"0 (No Evidence)",'-,'-,,,66.49,0,1.53,08/22/2016
G,TAF13,HGNC:11546,1p13.3,1:109606762-109618625,1:109064140-109076003,"1 (Little Evidence)",schizophrenia,MONDO:0005090,"0 (No Evidence)",'-,'-,,,18.12,0.02,1.09,05/22/2019
G,TAF2,HGNC:11536,8q24.12,8:120743014-120845081,8:119730774-119832841,"30 (Autosomal Recessive)","microcephaly-thin corpus callosum-intellectual disability syndrome",MONDO:0014273,"0 (No Evidence)",'-,'-,,,15.82,0,0.42,08/22/2016
G,TAOK1,HGNC:29259,17q11.2,17:27717381-27878921,17:29390363-29551903,"3 (Sufficient Evidence)","syndromic intellectual disability",MONDO:0000508,"0 (No Evidence)",'-,'-,,,3.72,1,0.27,06/28/2023
G,TARDBP,HGNC:11571,1p36.22,1:11072711-11085549,1:11012654-11030528,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.94,0.99,0.28,09/25/2018
G,TBC1D20,HGNC:16133,20p13,20:416124-443177,20:435480-462533,"30 (Autosomal Recessive)","Warburg micro syndrome 4",MONDO:0014296,"0 (No Evidence)",'-,'-,,,34.62,0.93,0.36,08/22/2016
G,TBC1D5,HGNC:19166,3p24.3,3:17198654-17784123,3:17157162-17742631,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.84,0,0.97,10/30/2015
G,TBCE,HGNC:11582,1q42.3,1:235530742-235615756,1:235367427-235452443,"30 (Autosomal Recessive)","hypoparathyroidism-retardation-dysmorphism syndrome",MONDO:0009426,"0 (No Evidence)",'-,'-,,,28.98,0,0.81,05/17/2012
G,TBL1XR1,HGNC:29529,3q26.32,3:176737132-176915270,3:177019344-177201800,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 41",MONDO:0014842,"1 (Little Evidence)",'-,'-,,,6.88,1,0.11,03/27/2019
G,TBR1,HGNC:11590,2q24.2,2:162272808-162282381,2:161416297-161425870,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,2.97,1,0.19,01/24/2018
G,TBX1,HGNC:11592,22q11.21,22:19744226-19771116,22:19756703-19783593,"2 (Emerging Evidence)","velocardiofacial syndrome",MONDO:0008644,"0 (No Evidence)",'-,'-,,,4.92,0.84,0.43,04/12/2022
G,TBX2,HGNC:11597,17q23.2,17:59477204-59486827,17:61399843-61409466,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,5.16,0.99,0.25,08/08/2018
G,TBX20,HGNC:11598,7p14.2,7:35242042-35293711,7:35202430-35254100,"2 (Emerging Evidence)","heart disorder",MONDO:0005267,"0 (No Evidence)",'-,'-,,,5.83,0.97,0.32,05/10/2023
G,TBX22,HGNC:11600,Xq21.1,X:79270252-79287273,X:80014753-80031774,"3 (Sufficient Evidence)","cleft palate with or without ankyloglossia, X-linked",MONDO:0010560,"0 (No Evidence)",'-,'-,,,43.82,0.98,0.3,03/28/2023
G,TBX3,HGNC:11602,12q24.21,12:115108060-115121980,12:114670255-114684175,"3 (Sufficient Evidence)","ulnar-mammary syndrome",MONDO:0008411,"0 (No Evidence)",'-,'-,,,3.05,0.99,0.28,09/23/2020
G,TBX4,HGNC:11603,17q23.2,17:59529783-59562471,17:61452422-61485110,"3 (Sufficient Evidence)","coxopodopatellar syndrome",MONDO:0007841,"0 (No Evidence)",'-,'-,,,4.73,0.5,0.45,12/11/2019
G,TBX5,HGNC:11604,12q24.21,12:114791716-114846247,12:114353911-114408442,"3 (Sufficient Evidence)","Holt-Oram syndrome",MONDO:0007732,"0 (No Evidence)",'-,'-,,,1.67,1,0.14,07/29/2020
G,TCF12,HGNC:11623,15q21.3,15:57210288-57583508,15:56918090-57291310,"3 (Sufficient Evidence)","TCF12-related craniosynostosis",MONDO:0014128,"0 (No Evidence)",'-,'-,,,2.07,0.68,0.37,08/16/2023
G,TCF20,HGNC:11631,22q13.2,22:42556019-42679933,22:42160013-42343537,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,23.45,1,0.1,06/26/2019
G,TCF4,HGNC:11634,18q21.2,18:52889416-53303188,18:55222185-55635957,"3 (Sufficient Evidence)","Pitt-Hopkins syndrome",MONDO:0012589,"0 (No Evidence)",'-,'-,,,0.38,1,0.22,07/08/2020
G,TCF7L2,HGNC:11641,10q25.2-q25.3,10:114710006-114927437,10:112950247-113167678,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,0.77,1,0.27,03/27/2019
G,TCIRG1,HGNC:11647,11q13.2,11:67806492-67818362,11:68039025-68053762,"30 (Autosomal Recessive)","autosomal recessive osteopetrosis 1",MONDO:0009815,"0 (No Evidence)",'-,'-,,,62.47,0,0.87,08/22/2016
G,TCN2,HGNC:11653,22q12.2,22:31003161-31023258,22:30607174-30627271,"30 (Autosomal Recessive)","transcobalamin II deficiency",MONDO:0010149,"Not Yet Evaluated",'-,'-,,,66.38,0,0.93,08/22/2016
G,TCOF1,HGNC:11654,5q32-q33.1,5:149737260-149779856,5:150357697-150400293,"3 (Sufficient Evidence)","Treacher Collins syndrome 1",MONDO:0007944,"0 (No Evidence)",'-,'-,,,69.76,0.95,0.31,04/28/2021
G,TCTN1,HGNC:26113,12q24.11,12:111051934-111087235,12:110614129-110649430,"30 (Autosomal Recessive)","Joubert syndrome 13",MONDO:0013608,"0 (No Evidence)",'-,'-,,,75.52,0,1.23,03/23/2015
G,TCTN2,HGNC:25774,12q24.31,12:124155660-124192946,12:123671113-123708399,"30 (Autosomal Recessive)","Meckel syndrome, type 8",MONDO:0013482,"0 (No Evidence)",'-,'-,,,87.7,0,0.99,08/22/2016
G,TDP1,HGNC:18884,14q32.11,14:90422271-90511108,14:89954968-90044764,"30 (Autosomal Recessive)","spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1",MONDO:0011801,"0 (No Evidence)",'-,'-,,,48.95,0,1.11,08/22/2016
G,TECPR2,HGNC:19957,14q32.33,14:102829278-102968814,14:102362941-102502477,"30 (Autosomal Recessive)","hereditary spastic paraplegia 49",MONDO:0014016,"0 (No Evidence)",'-,'-,,,73.01,0.58,0.35,08/22/2016
G,TECTA,HGNC:11720,11q23.3,11:120971952-121062199,11:121101243-121191490,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 21",MONDO:0011351,"0 (No Evidence)",'-,'-,,,11.78,0,0.58,02/07/2018
G,TERT,HGNC:11730,5p15.33,5:1253282-1295183,5:1253167-1295068,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,18.57,0.99,0.29,11/17/2011
G,TEX26,HGNC:28622,13q12.3,13:31506793-31549637,13:30932656-30975500,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,89.11,0,1.4,02/03/2021
G,TFAP2B,HGNC:11743,6p12.3,6:50786584-50815332,6:50818355-50847619,"3 (Sufficient Evidence)","Char syndrome",MONDO:0008209,"0 (No Evidence)",'-,'-,,,2.98,0.99,0.26,04/11/2023
G,TFR2,HGNC:11762,7q22.1,7:100218043-100239175,7:100620420-100641552,"30 (Autosomal Recessive)","hemochromatosis type 3",MONDO:0011417,"0 (No Evidence)",'-,'-,,,46.16,0,0.77,08/22/2016
G,TGFBR1,HGNC:11772,9q22.33,9:101867395-101916474,9:99103647-99154192,"3 (Sufficient Evidence)","multiple self-healing squamous epithelioma",MONDO:0007566,"0 (No Evidence)",'-,'-,,,1.85,0.85,0.38,02/13/2024
G,TGFBR2,HGNC:11773,3p24.1,3:30647994-30735634,3:30606356-30694142,"2 (Emerging Evidence)","Loeys-Dietz syndrome 2",MONDO:0012427,"0 (No Evidence)",'-,'-,,,2.72,0.13,0.52,04/11/2012
G,TGIF1,HGNC:11776,18p11.31,18:3412007-3459976,18:3412009-3459978,"3 (Sufficient Evidence)","holoprosencephaly 4",MONDO:0007734,"0 (No Evidence)",'-,'-,,,30.39,0.01,0.91,05/10/2012
G,TGM1,HGNC:11777,14q12,14:24718320-24732383,14:24249114-24263177,"30 (Autosomal Recessive)","autosomal recessive congenital ichthyosis 1",MONDO:0009441,"Not Yet Evaluated",'-,'-,,,48.02,0,0.93,08/22/2016
G,TGM5,HGNC:11781,15q15.2,15:43524788-43559126,15:43232590-43266928,"30 (Autosomal Recessive)","acral peeling skin syndrome",MONDO:0012345,"Not Yet Evaluated",'-,'-,,,58.03,0,1.44,08/22/2016
G,THRA,HGNC:11796,17q21.1,17:38218446-38250120,17:40062193-40093867,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,3.21,0.33,0.45,08/22/2013
G,TIGD6,HGNC:18332,5q32,5:149372681-149380217,5:149993118-150000654,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,70.79,0,1.21,02/03/2021
G,TIMM8A,HGNC:11817,Xq22.1,X:100600649-100603730,X:101345661-101348742,"3 (Sufficient Evidence)","deafness dystonia syndrome",MONDO:0010578,"0 (No Evidence)",'-,'-,,,16.93,0.65,0.87,03/24/2021
G,TJP2,HGNC:11828,9q21.11,9:71736180-71870124,9:69121264-69255208,"30 (Autosomal Recessive)","cholestasis, progressive familial intrahepatic, 4",MONDO:0014381,"Not Yet Evaluated",'-,'-,,,31.7,0,0.64,08/22/2016
G,TLX3,HGNC:13532,5q35.1,5:170736252-170739143,5:171309248-171312139,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,16.47,0.26,0.82,09/25/2018
G,TMC6,HGNC:18021,17q25.3,17:76103478-76128508,17:78107397-78132427,"30 (Autosomal Recessive)","epidermodysplasia verruciformis",MONDO:0009176,"0 (No Evidence)",'-,'-,,,79.04,0,0.75,08/22/2016
G,TMC8,HGNC:20474,17q25.3,17:76126852-76139049,17:78130771-78142968,"30 (Autosomal Recessive)","epidermodysplasia verruciformis",MONDO:0009176,"0 (No Evidence)",'-,'-,,,81.31,0,1.12,08/22/2016
G,TMCO1,HGNC:18188,1q24.1,1:165693528-165738159,1:165724291-165768922,"30 (Autosomal Recessive)","craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome",MONDO:0031329,"Not Yet Evaluated",'-,'-,,,14.08,0,1.36,08/22/2016
G,TMEM127,HGNC:26038,2q11.2,2:96914252-96931735,2:96248514-96265997,"3 (Sufficient Evidence)","hereditary pheochromocytoma-paraganglioma",MONDO:0017366,"0 (No Evidence)",'-,'-,,,19.66,0.01,1.15,07/13/2021
G,TMEM135,HGNC:26167,11q14.2,11:86748976-87039866,11:87037934-87328824,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,17.19,0.78,0.39,11/02/2015
G,TMEM231,HGNC:37234,16q23.1,16:75570639-75590184,16:75536741-75556286,"30 (Autosomal Recessive)","Joubert syndrome and related disorders",MONDO:0015369,"0 (No Evidence)",'-,'-,,,40.93,0,1.21,08/22/2016
G,TMEM237,HGNC:14432,2q33.1,2:202484909-202508226,2:201620186-201643503,"30 (Autosomal Recessive)","Joubert syndrome 14",MONDO:0013745,"0 (No Evidence)",'-,'-,,,49.64,0,1.25,04/09/2015
G,TMEM43,HGNC:28472,3p25.1,3:14166552-14185180,3:14125052-14143680,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,43,0,1.28,11/08/2015
G,TMEM67,HGNC:28396,8q22.1,8:94767072-94831466,8:93754844-93832653,"30 (Autosomal Recessive)","Joubert syndrome and related disorders",MONDO:0015369,"0 (No Evidence)",'-,'-,,,39.26,0,0.94,08/22/2016
G,TMLHE,HGNC:18308,Xq28,X:154718672-154842613,X:155489011-155612952,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,63.26,0,1.18,08/01/2013
G,TMPRSS3,HGNC:11877,21q22.3,21:43791999-43816161,21:42371890-42396052,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 8",MONDO:0010987,"0 (No Evidence)",'-,'-,,,64.12,0,1.12,08/22/2016
G,TMPRSS6,HGNC:16517,22q12.3,22:37461476-37505753,22:37065436-37110536,"30 (Autosomal Recessive)","IRIDA syndrome",MONDO:0008788,"0 (No Evidence)",'-,'-,,,54.76,0,0.72,08/22/2016
G,TNFRSF11B,HGNC:11909,8q24.12,8:119935796-119964124,8:118923557-118951885,"30 (Autosomal Recessive)","juvenile Paget disease",MONDO:0009394,"Not Yet Evaluated",'-,'-,,,13.92,0.16,0.55,08/22/2016
G,TNNI3,HGNC:11947,19q13.42,19:55663135-55669100,19:55151767-55157732,"1 (Little Evidence)","cardiomyopathy, familial restrictive, 1",MONDO:0007270,"0 (No Evidence)",'-,'-,,,40.95,0.1,0.69,05/25/2023
G,TNNT1,HGNC:11948,19q13.42,19:55644066-55660574,19:55132698-55149206,"30 (Autosomal Recessive)","nemaline myopathy 5",MONDO:0011539,"0 (No Evidence)",'-,'-,,,44.99,0,1.48,08/22/2016
G,TNNT2,HGNC:11949,1q32.1,1:201328142-201346808,1:201359014-201377680,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,56.44,0,0.64,11/16/2015
G,TNRC6B,HGNC:29190,22q13.1,22:40440838-40731812,22:40044834-40335808,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,5.62,1,0.17,06/26/2019
G,TOP3B,HGNC:11993,22q11.22,22:22311397-22337184,22:21957025-21982787,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,15.87,0,0.54,07/13/2022
G,TP53,HGNC:11998,17p13.1,17:7571739-7590808,17:7668421-7687490,"3 (Sufficient Evidence)","Li-Fraumeni syndrome",MONDO:0018875,"0 (No Evidence)",'-,'-,,,0.2,0.53,0.47,11/10/2021
G,TP63,HGNC:15979,3q28,3:189314535-189615065,3:189596746-189897276,"1 (Little Evidence)","cleft lip/palate",MONDO:0016044,"0 (No Evidence)",'-,'-,,,1.11,1,0.27,05/10/2023
G,TP73,HGNC:12003,1p36.32,1:3569080-3652765,1:3652516-3736201,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,25.95,1,0.26,07/06/2012
G,TPK1,HGNC:17358,7q35,7:144149034-144533146,7:144451941-144836437,"30 (Autosomal Recessive)","childhood encephalopathy due to thiamine pyrophosphokinase deficiency",MONDO:0013761,"0 (No Evidence)",'-,'-,,,43.3,0.09,0.7,08/22/2016
G,TPM1,HGNC:12010,15q22.2,15:63334946-63364114,15:63042747-63071915,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.5,0,0.78,11/09/2015
G,TPO,HGNC:12015,2p25.3,2:1417235-1547445,2:1374047-1543673,"30 (Autosomal Recessive)","thyroid dyshormonogenesis 2A",MONDO:0010133,"Not Yet Evaluated",'-,'-,,,76.12,0,1.11,08/22/2016
G,TPRN,HGNC:26894,9q34.3,9:140086071-140095193,9:137191619-137200741,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 79",MONDO:0013215,"0 (No Evidence)",'-,'-,,,84.93,0.01,0.8,08/22/2016
G,TPSD1,HGNC:14118,16p13.3,16:1306070-1309009,16:1256069-1259008,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,94.69,0,1.85,02/03/2021
G,TRAPPC10,HGNC:11868,21q22.3,21:45432190-45526433,21:44012309-44106552,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,47.8,1,0.2,09/06/2012
G,TRAPPC2,HGNC:23068,Xp22.2,X:13730364-13752739,X:13712245-13734620,"3 (Sufficient Evidence)","spondyloepiphyseal dysplasia tarda, X-linked",MONDO:0010737,"0 (No Evidence)",'-,'-,,,21.53,0,1.75,01/16/2014
G,TRAPPC9,HGNC:30832,8q24.3,8:140739968-141468678,8:139727725-140458579,"30 (Autosomal Recessive)","intellectual disability, autosomal recessive 13",MONDO:0013173,"0 (No Evidence)",'-,'-,,,53.39,0,0.73,08/06/2015
G,TRDN,HGNC:12261,6q22.31,6:123537484-123958095,6:123216339-123636950,"30 (Autosomal Recessive)","catecholaminergic polymorphic ventricular tachycardia 5",MONDO:0014191,"Not Yet Evaluated",'-,'-,,,49.08,0,1.02,08/22/2016
G,TRHR,HGNC:12299,8q23.1,8:110098814-110133794,8:109086585-109121565,"30 (Autosomal Recessive)","hypothyroidism, congenital, nongoitrous, 7",MONDO:0032819,"Not Yet Evaluated",'-,'-,,,21.25,0.27,0.64,08/22/2016
G,TRIM2,HGNC:15974,4q31.3,4:154073315-154260469,4:153152163-153339317,"30 (Autosomal Recessive)","Charcot-Marie-Tooth disease type 2R",MONDO:0014208,"0 (No Evidence)",'-,'-,,,21.81,1,0.27,08/22/2016
G,TRIM32,HGNC:16380,9q33.1,9:119449584-119463578,9:116687305-116701299,"30 (Autosomal Recessive)","autosomal recessive limb-girdle muscular dystrophy type 2H",MONDO:0009683,"0 (No Evidence)",'-,'-,,,26.93,0,0.86,08/22/2016
G,TRIM37,HGNC:7523,17q22,17:57060010-57184241,17:58967201-59106880,"30 (Autosomal Recessive)","mulibrey nanism",MONDO:0009664,"0 (No Evidence)",'-,'-,,,2.79,0,0.64,08/22/2016
G,TRIO,HGNC:12303,5p15.2,5:14143451-14510313,5:14143342-14510204,"3 (Sufficient Evidence)","micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome",MONDO:0014892,"0 (No Evidence)",'-,'-,,,25.7,1,0.14,01/24/2018
G,TRIOBP,HGNC:17009,22q13.1,22:38093055-38172563,22:37697048-37776556,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 28",MONDO:0012355,"0 (No Evidence)",'-,'-,,,54.57,0,0.71,08/22/2016
G,TRIP12,HGNC:12306,2q36.3,2:230628553-230787902,2:229763837-229923186,"3 (Sufficient Evidence)","Clark-Baraitser syndrome",MONDO:0030914,"0 (No Evidence)",'-,'-,,,3.78,1,0.06,04/02/2018
G,TRIP4,HGNC:12310,15q22.31,15:64680035-64747502,15:64387836-64455303,"30 (Autosomal Recessive)","spinal muscular atrophy with congenital bone fractures 1",MONDO:0014806,"0 (No Evidence)",'-,'-,,,18.24,0,0.67,08/17/2018
G,TRMT10A,HGNC:28403,4q23,4:100467868-100485196,4:99546711-99564039,"30 (Autosomal Recessive)","microcephaly, short stature, and impaired glucose metabolism 1",MONDO:0000208,"0 (No Evidence)",'-,'-,,,53.48,0,1.18,08/22/2016
G,TRMU,HGNC:25481,22q13.31,22:46731611-46753237,22:46335714-46357340,"30 (Autosomal Recessive)","acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins",MONDO:0013111,"0 (No Evidence)",'-,'-,,,63.58,0,1.56,08/22/2016
G,TRPM1,HGNC:7146,15q13.3,15:31293268-31453363,15:31001065-31161160,"30 (Autosomal Recessive)","congenital stationary night blindness 1C",MONDO:0013183,"Not Yet Evaluated",'-,'-,,,57.82,0,1.07,08/22/2016
G,TRPS1,HGNC:12340,8q23.3,8:116420724-116681202,8:115408496-115668975,"3 (Sufficient Evidence)","trichorhinophalangeal syndrome type I",MONDO:0008596,"0 (No Evidence)",'-,'-,,,1.26,1,0.11,07/08/2020
G,TRRAP,HGNC:12347,7q22.1,7:98476155-98610864,7:98878532-99013241,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,19.5,1,0.06,04/24/2019
G,TSC1,HGNC:12362,9q34,9:135766736-135820003,9:132891349-132945378,"3 (Sufficient Evidence)","tuberous sclerosis 1",MONDO:0008612,"0 (No Evidence)",'-,'-,,,11.9,1,0.12,10/13/2020
G,TSC2,HGNC:12363,16p13.3,16:2097986-2139492,16:2047985-2089491,"3 (Sufficient Evidence)","tuberous sclerosis 2",MONDO:0013199,"0 (No Evidence)",'-,'-,,,10.92,1,0.07,06/10/2020
G,TSEN2,HGNC:28422,3p25.2,3:12525979-12581123,3:12480231-12539624,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 2B",MONDO:0012890,"0 (No Evidence)",'-,'-,,,85.38,0,1.14,08/22/2016
G,TSEN54,HGNC:27561,17q25.1,17:73512609-73520816,17:75516528-75524735,"30 (Autosomal Recessive)","pontocerebellar hypoplasia",MONDO:0020135,"Not Yet Evaluated",'-,'-,,,62.63,0,0.88,08/22/2016
G,TSPAN7,HGNC:11854,Xp11.4,X:38420795-38548172,X:38561542-38688918,"1 (Little Evidence)","X-linked intellectual disability",MONDO:0100284,"0 (No Evidence)",'-,'-,,,17.96,0.75,0.54,06/22/2022
G,TSPEAR,HGNC:1268,21q22.3,21:45917776-46131487,21:44497893-44711572,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 98",MONDO:0013929,"0 (No Evidence)",'-,'-,,,67.21,0,1.2,08/22/2016
G,TTC19,HGNC:26006,17p12,17:15903138-15932718,17:15999824-16045015,"30 (Autosomal Recessive)","mitochondrial complex III deficiency nuclear type 2",MONDO:0014063,"0 (No Evidence)",'-,'-,,,51.14,0,1.12,08/22/2016
G,TTC21B,HGNC:25660,2q24.3,2:166729872-166810286,2:165873362-165953776,"30 (Autosomal Recessive)","nephronophthisis 12",MONDO:0013442,"0 (No Evidence)",'-,'-,,,30.49,0,0.85,08/22/2016
G,TTC7A,HGNC:19750,2p21,2:47143005-47303262,2:46915866-47076123,"30 (Autosomal Recessive)","multiple intestinal atresia",MONDO:0009465,"0 (No Evidence)",'-,'-,,,45.91,0,1.29,08/22/2016
G,TTC8,HGNC:20087,14q31.3,14:89290497-89347423,14:88824153-88881079,"30 (Autosomal Recessive)","Bardet-Biedl syndrome 8",MONDO:0014436,"Not Yet Evaluated",'-,'-,,,23.34,0,0.74,08/22/2016
G,TTLL5,HGNC:19963,14q24.3,14:76127589-76421422,14:75661246-75955079,"30 (Autosomal Recessive)","cone-rod dystrophy 19",MONDO:0014372,"0 (No Evidence)",'-,'-,,,12.66,0,0.76,08/22/2016
G,TTN,HGNC:12403,2q31.2,2:179390716-179672150,2:178525989-178807423,"3 (Sufficient Evidence)","dilated cardiomyopathy 1G",MONDO:0011400,"0 (No Evidence)",'-,'-,,,25.39,0,0.35,08/02/2021
G,TUBA1A,HGNC:20766,12q13.12,12:49578578-49582863,12:49184795-49189080,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,4.83,0.97,0.32,04/14/2016
G,TUBB3,HGNC:20772,16q24.3,16:89988333-90002505,16:89921925-89936097,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,61.93,0,1.11,08/30/2017
G,TUBB4A,HGNC:20774,19p13.3,19:6494330-6502859,19:6494319-6502848,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,42.56,0.11,0.67,11/19/2014
G,TUBGCP6,HGNC:18127,22q13.33,22:50656123-50683452,22:50217694-50245023,"30 (Autosomal Recessive)","microcephaly and chorioretinopathy 1",MONDO:0009624,"0 (No Evidence)",'-,'-,,,77.41,0,0.93,08/22/2016
G,TUFM,HGNC:12420,16p11.2,16:28853732-28857669,16:28842411-28846348,"30 (Autosomal Recessive)","combined oxidative phosphorylation defect type 4",MONDO:0012534,"0 (No Evidence)",'-,'-,,,20.48,0,0.74,08/22/2016
G,TUSC3,HGNC:30242,8p22,8:15397596-15624158,8:15417188-15852091,"30 (Autosomal Recessive)","intellectual disability",MONDO:0001071,"Not Yet Evaluated",'-,'-,,,34.41,0,0.93,12/01/2021
G,TWIST1,HGNC:12428,7p21.1,7:19152670-19157259,7:19113047-19117636,"3 (Sufficient Evidence)","Saethre-Chotzen syndrome",MONDO:0007042,"0 (No Evidence)",'-,'-,,,5.34,0.34,1.06,12/16/2020
G,TWIST2,HGNC:20670,2q37.3,2:239756726-239832230,2:238848085-238910534,"30 (Autosomal Recessive)","focal facial dermal dysplasia type III",MONDO:0009203,"0 (No Evidence)",'-,'-,,,6.73,0.56,1.15,08/22/2016
G,TYMP,HGNC:3148,22q13.33,22:50964181-50968514,22:50525752-50530085,"30 (Autosomal Recessive)","mitochondrial DNA depletion syndrome 1",MONDO:0011283,"Not Yet Evaluated",'-,'-,,,67.24,0,0.92,08/22/2016
G,TYROBP,HGNC:12449,19q13.12,19:36395305-36399197,19:35904403-35908295,"30 (Autosomal Recessive)","polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1",MONDO:0020749,"0 (No Evidence)",'-,'-,,,59.61,0.2,0.92,08/22/2016
G,TYRP1,HGNC:12450,9p23,9:12693385-12710285,9:12693385-12710285,"30 (Autosomal Recessive)","oculocutaneous albinism type 3",MONDO:0008747,"Not Yet Evaluated",'-,'-,,,21.84,0,1.89,08/22/2016
G,UBE2A,HGNC:12472,Xq24,X:118708526-118718386,X:119574563-119584423,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Nascimento type",MONDO:0010461,"0 (No Evidence)",'-,'-,,,9.57,0.82,0.54,05/22/2019
G,UBE2T,HGNC:25009,1q32.1,1:202300785-202311064,1:202331657-202341936,"30 (Autosomal Recessive)","Fanconi anemia complementation group T",MONDO:0014638,"0 (No Evidence)",'-,'-,,,19.95,0,1.3,09/01/2020
G,UBE3A,HGNC:12496,15q11.2,15:25578875-25684203,15:25333728-25439056,"3 (Sufficient Evidence)","Angelman syndrome",MONDO:0007113,"0 (No Evidence)",'-,'-,,,2.11,1,0.21,08/23/2012
G,UBE3B,HGNC:13478,12q24.11,12:109915439-109974507,12:109477634-109547829,"30 (Autosomal Recessive)","oculocerebrofacial syndrome, Kaufman type",MONDO:0009485,"0 (No Evidence)",'-,'-,,,57.19,0,0.55,08/22/2016
G,UBN2,HGNC:21931,7q34,7:138915983-138992982,7:139231237-139330428,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,23.88,1,0.21,05/22/2019
G,UBR1,HGNC:16808,15q15.2,15:43235095-43398236,15:42942897-43106038,"30 (Autosomal Recessive)","Johanson-Blizzard syndrome",MONDO:0009479,"Not Yet Evaluated",'-,'-,,,21.91,0.01,0.35,08/22/2016
G,UNC93A,HGNC:12570,6q27,6:167704803-167729502,6:167269032-167316014,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,85.98,0,1.69,02/03/2021
G,UPB1,HGNC:16297,22q11.23,22:24891300-24924358,22:24495332-24528390,"30 (Autosomal Recessive)","beta-ureidopropionase deficiency",MONDO:0013164,"Not Yet Evaluated",'-,'-,,,65,0,1.26,08/22/2016
G,UPF2,HGNC:17854,10p14,10:11962021-12085169,10:11920022-12043170,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.07,1,0.1,02/13/2019
G,UPF3B,HGNC:20439,Xq24,X:118967985-118986926,X:119805311-119852963,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability 14",MONDO:0010398,"0 (No Evidence)",'-,'-,,,33.04,0.98,0.29,02/09/2021
G,UROS,HGNC:12592,10q26.2,10:127473549-127511827,10:125784980-125823258,"30 (Autosomal Recessive)","cutaneous porphyria",MONDO:0009902,"Not Yet Evaluated",'-,'-,,,69.16,0.03,0.73,08/22/2016
G,USH1C,HGNC:12597,11p15.1,11:17515447-17565963,11:17493900-17544416,"30 (Autosomal Recessive)","Usher syndrome type 1C",MONDO:0010171,"0 (No Evidence)",'-,'-,,,22.32,0,0.89,04/07/2012
G,USH1G,HGNC:16356,17q25.1,17:72912175-72919350,17:74916083-74923255,"30 (Autosomal Recessive)","Usher syndrome type 1G",MONDO:0011748,"0 (No Evidence)",'-,'-,,,45.67,0,1.09,08/22/2016
G,USH2A,HGNC:12601,1q41,1:215796233-216596790,1:215622891-216423448,"30 (Autosomal Recessive)","Usher syndrome type 2A",MONDO:0010169,"Not Yet Evaluated",'-,'-,,,4.18,0,0.86,08/22/2016
G,USP9X,HGNC:12632,Xp11.4,X:40944698-41095832,X:41085445-41236579,"3 (Sufficient Evidence)","intellectual disability, X-linked 99",MONDO:0010487,"0 (No Evidence)",'-,'-,,,3.82,1,0.05,03/28/2018
G,UVSSA,HGNC:29304,4p16.3,4:1340996-1381837,4:1342011-1395989,"30 (Autosomal Recessive)","UV-sensitive syndrome 3",MONDO:0013834,"Not Yet Evaluated",'-,'-,,,81.41,0,1.48,08/22/2016
G,VAMP7,HGNC:11486,"Xq28 and Yq12",Y:59214014-59276439,Y:57067865-57130289,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,56.22,0.01,0.86,09/06/2012
G,VCX3A,HGNC:18159,Xp22.31,X:6451659-6453159,X:6533618-6535118,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,94.12,0.31,1.87,10/12/2012
G,VEGFA,HGNC:12680,6p21.1,6:43737946-43754224,6:43770211-43786487,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,0.1,0,0.84,08/23/2023
G,VHL,HGNC:12687,3p25.3,3:10183462-10195351,3:10141778-10153667,"3 (Sufficient Evidence)","von Hippel-Lindau disease",MONDO:0008667,"0 (No Evidence)",'-,'-,,,45.43,0.08,0.93,05/11/2022
G,VLDLR,HGNC:12698,9p24.2,9:2621787-2660056,9:2621787-2660056,"30 (Autosomal Recessive)","cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1",MONDO:0024542,"Not Yet Evaluated",'-,'-,,,13.41,0,0.72,08/22/2016
G,VPS13A,HGNC:1908,9q21.2,9:79792450-80036453,9:77177534-77421537,"30 (Autosomal Recessive)",chorea-acanthocytosis,MONDO:0008695,"Not Yet Evaluated",'-,'-,,,33.87,0,0.48,08/22/2016
G,VPS13B,HGNC:2183,8q22.2,8:100025502-100889808,8:99013274-99877580,"30 (Autosomal Recessive)","Cohen syndrome",MONDO:0008999,"0 (No Evidence)",'-,'-,,,4.55,0,0.65,06/26/2013
G,VPS26C,HGNC:3044,21q22.13,21:38595721-38640409,21:37223420-37268108,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,53.11,0,1.06,04/25/2012
G,VPS37A,HGNC:24928,8p22,8:17104467-17190964,8:17246958-17333455,"30 (Autosomal Recessive)","hereditary spastic paraplegia 53",MONDO:0013962,"0 (No Evidence)",'-,'-,,,43.37,0,0.72,08/22/2016
G,VPS53,HGNC:25608,17p13.3,17:411908-618079,17:508668-714839,"30 (Autosomal Recessive)","pontocerebellar hypoplasia type 2E",MONDO:0014370,"Not Yet Evaluated",'-,'-,,,20.07,0,0.61,08/22/2016
G,WAC,HGNC:17327,10p12.1,10:28821708-28912041,10:28532779-28623112,"3 (Sufficient Evidence)","DeSanto-Shinawi syndrome due to WAC point mutation",MONDO:0014741,"0 (No Evidence)",'-,'-,,,9.64,1,0.08,02/28/2018
G,WDFY3,HGNC:20751,4q21.23,4:85590750-85887843,4:84669597-84966690,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,21.08,1,0.07,10/10/2023
G,WDPCP,HGNC:28027,2p15,2:63346694-63815611,2:63119559-63840826,"30 (Autosomal Recessive)","heart defect - tongue hamartoma - polysyndactyly syndrome",MONDO:0009008,"0 (No Evidence)",'-,'-,,,24.69,0,0.78,08/22/2016
G,WDR26,HGNC:21208,1q42.11-q42.12,1:224572848-224622499,1:224385146-224434797,"3 (Sufficient Evidence)","Skraban-Deardorff syndrome",MONDO:0054636,"0 (No Evidence)",'-,'-,,,10.72,1,0.09,04/27/2022
G,WDR35,HGNC:29250,2p24.1,2:20110024-20189866,2:19910263-19990105,"30 (Autosomal Recessive)","short-rib thoracic dysplasia 7 with or without polydactyly",MONDO:0013569,"0 (No Evidence)",'-,'-,,,44.05,0,0.82,06/19/2013
G,WDR45,HGNC:28912,Xp11.23,X:48932101-48958116,X:49074442-49101178,"3 (Sufficient Evidence)","neurodegeneration with brain iron accumulation 5",MONDO:0010476,"0 (No Evidence)",'-,'-,,,49.99,0.99,0.21,04/09/2015
G,WDR62,HGNC:24502,19q13.12,19:36545799-36596010,19:36054897-36111145,"30 (Autosomal Recessive)","microcephaly 2, primary, autosomal recessive, with or without cortical malformations",MONDO:0011435,"Not Yet Evaluated",'-,'-,,,51.08,0,0.86,08/22/2016
G,WDR72,HGNC:26790,15q21.3,15:53805938-54055075,15:53513741-53762878,"30 (Autosomal Recessive)","amelogenesis imperfecta hypomaturation type 2A3",MONDO:0013181,"0 (No Evidence)",'-,'-,,,39.26,0,1.07,08/22/2016
G,WFS1,HGNC:12762,4p16.1,4:6271577-6304992,4:6269850-6303265,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,33.79,0,1.93,02/08/2012
G,WHRN,HGNC:16361,9q32,9:117164360-117267753,9:114402080-114505473,"30 (Autosomal Recessive)","autosomal recessive nonsyndromic hearing loss 31",MONDO:0011767,"0 (No Evidence)",'-,'-,,,38.98,0,0.67,08/22/2016
G,WNT7A,HGNC:12786,3p25.1,3:13857755-13921568,3:13816258-13880071,"30 (Autosomal Recessive)","non-syndromic limb reduction defect",MONDO:0019713,"0 (No Evidence)",'-,'-,,,20.9,0.04,0.71,08/22/2016
G,WRAP53,HGNC:25522,17p13.1,17:7589389-7606820,17:7686071-7703502,"30 (Autosomal Recessive)","dyskeratosis congenita, autosomal recessive 3",MONDO:0013520,"0 (No Evidence)",'-,'-,,,65.51,0,0.69,12/15/2017
G,WRN,HGNC:12791,8p12,8:30891326-31033654,8:31033810-31176138,"30 (Autosomal Recessive)","Werner syndrome",MONDO:0010196,"0 (No Evidence)",'-,'-,,,17.41,0,0.95,03/25/2015
G,WT1,HGNC:12796,11p13,11:32409321-32457085,11:32387775-32435539,"3 (Sufficient Evidence)","Wilms tumor 1",MONDO:0008679,"0 (No Evidence)",'-,'-,,,1.09,1,0.25,01/25/2022
G,WWOX,HGNC:12799,16q23.1-q23.2,16:78133551-79246564,16:78099654-79212667,"30 (Autosomal Recessive)","autosomal recessive spinocerebellar ataxia 12",MONDO:0013687,"0 (No Evidence)",'-,'-,,,0.38,0,1.53,11/08/2017
G,XDH,HGNC:12805,2p23.1,2:31557187-31637608,2:31334321-31414742,"30 (Autosomal Recessive)","xanthinuria type I",MONDO:0010209,"0 (No Evidence)",'-,'-,,,44.11,0,0.86,08/22/2016
G,XIAP,HGNC:592,Xq25,X:122993558-123047822,X:123859708-123913972,"3 (Sufficient Evidence)","X-linked lymphoproliferative disease due to XIAP deficiency",MONDO:0010385,"0 (No Evidence)",'-,'-,,,3.36,0.92,0.37,07/27/2022
G,XIST,HGNC:12810,Xq13.2,X:73040486-73072588,X:73820651-73852753,"3 (Sufficient Evidence)","X inactivation, familial skewed, 1",MONDO:0026404,"0 (No Evidence)",'-,'-,,,‐,‐,‐,04/22/2020
R,"Xp11.22 region (includes HUWE1)",ISCA-46299,Xp11.22,X:53363456-53793054,"X:53334251 -53766556","0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","X-linked syndromic intellectual disability",MONDO:0020119,,,‐,‐,‐,11/20/2018
R,"Xp11.22p11.23 recurrent region (includes SHROOM4)",ISCA-46290,Xp11.22-p11.23,X:48306152-52103258,"X: 48447780-52444264","0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","chromosome Xp11.23-p11.22 duplication syndrome",MONDO:0010428,,,‐,‐,‐,12/14/2017
R,"Xp11.23 population region (DGV_Gold_Standard_June_2021_gssvL136075)",ISCA-46735,Xp11.23,X:47880294-47952112,X:48020900-48092718,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 population region (gnomAD-SV_v2.1_DEL_X_186156)",ISCA-46539,Xp11.23,X:49176299-49186050,X:49319820-49329571,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 population region (gnomAD-SV_v2.1_DUP_X_53149)",ISCA-46540,Xp11.23,X:49197299-49208400,X:49331318-49342419,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 population region (gnomAD-SV_v2.1_DUP_X_53151)",ISCA-46541,Xp11.23,X:49292999-49318650,X:49528396-49554047,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 population region (gnomAD-SV_v2.1_DUP_X_53155)",ISCA-46542,Xp11.23,X:49328999-49343400,X:49564396-49578797,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 population region (gnomAD-SV_v2.1_DUP_X_53157)",ISCA-46543,Xp11.23,X:49338999-49356900,X:49574396-49592297,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xp11.23 region (includes MAOA and MAOB)",ISCA-37468,Xp11.23,X:43514154-43741720,X:43654906-43882474,"3 (Sufficient Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,10/11/2017
R,"Xp21.2 region (includes NR0B1)",ISCA-46302,Xp21.2,X:30195000-30355000,"X:30176883 -30336883","0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","46,XY sex reversal 2",MONDO:0010226,,,‐,‐,‐,07/22/2020
R,"Xp22.31 recurrent region (includes STS)",ISCA-37417,Xp22.31,X:6455812-8124954,X:6537771-8156913,"3 (Sufficient Evidence)","recessive X-linked ichthyosis",MONDO:0010622,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,07/01/2021
G,XPA,HGNC:12814,9q22.33,9:100437191-100459622,9:97654398-97697340,"30 (Autosomal Recessive)","xeroderma pigmentosum group A",MONDO:0010210,"0 (No Evidence)",'-,'-,,,25.19,0,0.97,02/14/2024
G,XPC,HGNC:12816,3p25.1,3:14186647-14220101,3:14145147-14178601,"30 (Autosomal Recessive)","xeroderma pigmentosum group C",MONDO:0010211,"Not Yet Evaluated",'-,'-,,,63.33,0,0.78,08/22/2016
G,XPNPEP3,HGNC:28052,22q13.2,22:41253152-41328819,22:40857148-40932815,"30 (Autosomal Recessive)","nephronophthisis-like nephropathy 1",MONDO:0013163,"0 (No Evidence)",'-,'-,,,37.01,0,0.88,08/22/2016
R,"Xq21.1 population region (DGV_Gold_Standard_June_2021_gssvL136501)",ISCA-46736,Xq21.1,X:76137628-76141022,X:76917203-76920597,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq24 population region (DGV_Gold_Standard_June_2021_gssvG41158)",ISCA-46733,Xq24,X:120006512-120123897,X:120872658-120990043,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq24 population region (gnomAD-SV_v2.1_DEL_X_189262)",ISCA-46544,Xq24,X:120063234-120090000,:-,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq24 population region (gnomAD-SV_v2.1_DEL_X_189263)",ISCA-46545,Xq24,X:120077116-120120000,X:120943262-120986146,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq25 region (includes STAG2)",ISCA-46743,Xq25,X:123034319-123236519,"X:123900469 -124102669","3 (Sufficient Evidence)",'-,'-,"3 (Sufficient Evidence)","complex neurodevelopmental disorder",MONDO:0100038,,,‐,‐,‐,11/30/2022
R,"Xq26.3 population region (gnomAD-SV_v2.1_DEL_X_189886)",ISCA-46546,Xq26.3,X:134872199-134878900,X:135779496-135786197,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq26.3 population region (gnomAD-SV_v2.1_DEL_X_189893)",ISCA-46547,Xq26.3,X:134948399-134964600,X:135831689-135847890,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq27.3 population region (DGV_Gold_Standard_June_2021_gssvL137799)",ISCA-46737,Xq27.3,X:142601775-142800327,X:143513946-143712498,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq28 population region (DGV_Gold_Standard_June_2021_gssvG41365)",ISCA-46734,Xq28,X:153409846-153460630,X:154144372-154195156,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq28 population region (gnomAD-SV_v2.1_DEL_X_190688)",ISCA-46548,Xq28,X:152240999-152251200,X:153072616-153082817,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq28 population region (gnomAD-SV_v2.1_DEL_X_190749)",ISCA-46549,Xq28,X:153511999-153522000,X:154246526-154256527,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq28 population region (gnomAD-SV_v2.1_DEL_X_190964)",ISCA-46550,Xq28,X:155238299-155249500,X:156008634-156019835,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Xq28 recurrent region (includes GDI1)",ISCA-37439,Xq28,X:153624564-153783898,X:154396223-154555683,"0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","chromosome Xq28 duplication syndrome",MONDO:0010436,,,‐,‐,‐,05/26/2016
R,"Xq28 recurrent region (int22h1/int22h2-flanked) (includes RAB39B)",ISCA-37494,Xq28,X:154118603-154564401,X:154890328-155335092,"3 (Sufficient Evidence)",'-,'-,"3 (Sufficient Evidence)","chromosome Xq28 duplication syndrome",MONDO:0010436,,,‐,‐,‐,08/31/2018
R,"Xq28 region (includes MECP2)",ISCA-46304,Xq28,X:153273980-153375749,"X:154008529 -154110279","0 (No Evidence)",'-,'-,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Lubs type",MONDO:0010283,,,‐,‐,‐,02/22/2021
G,XYLT1,HGNC:15516,16p12.3,16:17195626-17564817,16:17101769-17470960,"30 (Autosomal Recessive)","Desbuquois dysplasia 2",MONDO:0014343,"0 (No Evidence)",'-,'-,,,36.69,0.92,0.34,08/22/2016
G,YAP1,HGNC:16262,11q22.1,11:101981178-102104155,11:102110447-102233424,"1 (Little Evidence)","uveal coloboma-cleft lip and palate-intellectual disability",MONDO:0007355,"0 (No Evidence)",'-,'-,,,9.76,1,0.19,11/13/2014
R,"Yq11.223 population region (DGV_Gold_Standard_June_2021_gssvL138419)",ISCA-46738,Yq11.223,Y:24361866-24465171,Y:22215719-22319024,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Yq11.223 population region (DGV_Gold_Standard_June_2021_gssvL138428)",ISCA-46739,Yq11.223,Y:25853189-26146959,Y:23707042-24000812,"40 (Dosage Sensitivity Unlikely)",'-,'-,"0 (No Evidence)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Yq11.223 population region (gnomAD-SV_v2.1_DUP_Y_55049)",ISCA-46551,Yq11.223,Y:23656999-23713300,Y:21495113-21551414,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
R,"Yq11.223 population region (gnomAD-SV_v2.1_DUP_Y_55057)",ISCA-46552,Yq11.223,Y:24024199-24070000,Y:21878052-21923853,"0 (No Evidence)",'-,'-,"40 (Dosage Sensitivity Unlikely)",'-,'-,,,‐,‐,‐,08/03/2021
G,YTHDC1,HGNC:30626,4q13.2,4:69176105-69215808,4:68310387-68350090,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,10.1,1,0.09,04/24/2019
G,YWHAE,HGNC:12851,17p13.3,17:1247569-1303516,17:1344275-1400222,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,1.8,0.98,0.24,06/19/2014
G,ZBTB18,HGNC:13030,1q44,1:244211955-244220778,1:244048491-244057476,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 22",MONDO:0012869,"0 (No Evidence)",'-,'-,,,8.38,1,0.18,04/24/2019
G,ZBTB24,HGNC:21143,6q21,6:109783797-109804422,6:109462594-109483219,"30 (Autosomal Recessive)","immunodeficiency-centromeric instability-facial anomalies syndrome 2",MONDO:0013553,"0 (No Evidence)",'-,'-,,,53.44,0,0.66,08/22/2016
G,ZC4H2,HGNC:24931,Xq11.2,X:64135687-64254621,X:64915807-65034741,"3 (Sufficient Evidence)","Wieacker-Wolff syndrome",MONDO:0010758,"0 (No Evidence)",'-,'-,,,20.36,0.91,0.39,04/22/2020
G,ZDHHC15,HGNC:20342,Xq13.3,X:74588262-74742872,X:75368427-75523037,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,20.85,0.84,0.43,07/25/2012
G,ZDHHC9,HGNC:18475,Xq26.1,X:128937264-128977862,X:129803288-129843886,"3 (Sufficient Evidence)","syndromic X-linked intellectual disability Raymond type",MONDO:0010427,"0 (No Evidence)",'-,'-,,,13.32,0.74,0.48,10/12/2021
G,ZEB2,HGNC:14881,2q22.3,2:145141648-145277686,2:144384081-144520119,"3 (Sufficient Evidence)","Mowat-Wilson syndrome",MONDO:0009341,"0 (No Evidence)",'-,'-,,,0.37,1,0.11,06/24/2020
G,ZFPM2,HGNC:16700,8q23,8:106330666-106816767,8:105318438-105804539,"1 (Little Evidence)","congenital diaphragmatic hernia",MONDO:0005711,"0 (No Evidence)",'-,'-,,,0.93,1,0.15,09/20/2021
G,ZFYVE26,HGNC:20761,14q24.1,14:68213239-68283307,14:67728892-67816590,"30 (Autosomal Recessive)","hereditary spastic paraplegia 15",MONDO:0010044,"Not Yet Evaluated",'-,'-,,,42.96,0,0.6,08/22/2016
G,ZIC1,HGNC:12872,3q24,3:147127152-147134506,3:147409365-147416719,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,7.94,0.93,0.36,07/19/2021
G,ZIC2,HGNC:12873,13q32.3,13:100634038-100639019,13:99981784-99986765,"3 (Sufficient Evidence)",holoprosencephaly,MONDO:0016296,"0 (No Evidence)",'-,'-,,,6.3,0.97,0.27,08/24/2022
G,ZIC3,HGNC:12874,Xq26.3,X:136648286-136659850,X:137566127-137577691,"3 (Sufficient Evidence)","heterotaxy, visceral, 1, X-linked",MONDO:0010607,"0 (No Evidence)",'-,'-,,,4.79,0.92,0.36,12/02/2020
G,ZIC4,HGNC:20393,3q24,3:147103833-147124330,3:147386046-147406543,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,12.76,0,0.87,08/25/2021
G,ZIM2,HGNC:12875,19q13.43,19:57285915-57352094,19:56774547-56840726,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,88.9,0,0.84,05/17/2012
G,ZMYM3,HGNC:13054,Xq13.1,X:70459474-70475047,X:71239624-71255290,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,26.32,1,0.11,07/25/2012
G,ZMYND11,HGNC:16966,10p15.3,10:176028-300577,10:130088-254637,"3 (Sufficient Evidence)","intellectual disability, autosomal dominant 30",MONDO:0014486,"0 (No Evidence)",'-,'-,,,16.99,1,0.12,03/28/2018
G,ZMYND15,HGNC:20997,17p13.2,17:4643128-4649414,17:4739833-4746119,"30 (Autosomal Recessive)","spermatogenic failure 14",MONDO:0014366,"0 (No Evidence)",'-,'-,,,52.22,0,0.89,08/22/2016
G,ZNF141,HGNC:12926,4p16.3,4:331603-378657,4:337814-384868,"30 (Autosomal Recessive)","polydactyly, postaxial, type A6",MONDO:0014090,"Not Yet Evaluated",'-,'-,,,89.36,0.1,1.25,08/22/2016
G,ZNF264,HGNC:13057,19q13.43,19:57702868-57734214,19:57191500-57222846,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,88.53,0,0.99,05/10/2012
G,ZNF292,HGNC:18410,6q14.3,6:87865283-87975661,6:87155565-87265943,"1 (Little Evidence)","complex neurodevelopmental disorder",MONDO:0100038,"0 (No Evidence)",'-,'-,,,26.56,1,0.14,10/25/2023
G,ZNF407,HGNC:19904,18q23,18:72265106-72777627,18:74597870-75065671,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,53.21,1,0.09,07/11/2012
G,ZNF41,HGNC:13107,Xp11.3,X:47304577-47342621,X:47445178-47483222,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,72.46,0.04,0.62,10/24/2012
G,ZNF462,HGNC:21684,9q31.2,9:109625447-109775915,9:106860158-107013634,"3 (Sufficient Evidence)","weiss-kruszka syndrome",MONDO:0032836,"0 (No Evidence)",'-,'-,,,5.96,1,0.09,01/16/2020
G,ZNF592,HGNC:28986,15q25.3,15:85291823-85349676,15:84748592-84806445,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,48.68,1,0.13,10/14/2021
G,ZNF674,HGNC:17625,Xp11.3,X:46357160-46404856,X:46497725-46545421,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,80.29,0,1.31,03/28/2023
G,ZNF711,HGNC:13128,Xq21.1,X:84498997-84528363,X:85243991-85273357,"2 (Emerging Evidence)","intellectual disability, X-linked 97",MONDO:0010430,"0 (No Evidence)",'-,'-,,,30.43,0.98,0.31,08/29/2013
G,ZNF81,HGNC:13156,Xp11.23,X:47696301-47785026,X:47836902-47925627,"0 (No Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,71.33,0.55,0.51,10/29/2012
G,ZWILCH,HGNC:25468,15q22.31,15:66797664-66842468,15:66505326-66550130,"1 (Little Evidence)",'-,'-,"0 (No Evidence)",'-,'-,,,35.84,0,1.02,04/24/2019
,,,,,,,,,,,,,,,,,
